�e International Association of Anthroposophic PharmacistsIAAP
ANTHROPOSOPHICPHARMACEUTICAL CODEXAPC
3rd EDITION2013
International Association of Anthroposophic PharmacistsGoetheanumMedical Section4143 DornachSwitzerland
www.iaap.org.ukemail: [email protected]
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
Introductory Note APC 3rd edition 2013
International Association of Anthroposophic Pharmacists, IAAP
�e IAAP is the international umbrella organization of the national associations of Anthroposophic Pharma-cists.
Its purpose, objective and tasks are, in detail:
• To represent anthroposophic pharmacists in the anthroposophic-medical movement and in public life on an international level: Anthroposophic pharmacy is understood as an extension of conventional phar-macy.
• To establish standards regarding education, further training and practice in anthroposophic pharmacy (including but not limited to retail pharmacists).
• To promote research in anthroposophic pharmacy.• To achieve international recognition by specialised
publications as well as training material for anthro-posophic pharmacists.
• To establish a cooperative network between anthro-posophic pharmacists to exchange information and best practice throughout the world.
• To initiate / coordinate international activities.
It is in respect of this last aim that the Board is pleased to publish the 3rd edition 2013 of the Anthroposophic Pharmaceutical Codex (APC).
Several de�nitions have been harmonised with the de�nitions in the Swiss and German Law, as well as in the monograph on anthroposophic preparations “Anthropo- sophische Zubereitungen” in the Swiss Pharmacopoeia.
Several manufacturing procedures have been worded more precisely and new manufacturing methods have been included. Where appropriate, the European Pharmacopoeia has been referred to. Also the lists of starting materials used have been updated to include new substances, nomenclature, references to o�cial pharmacopoeias as well as a literature reference which demonstrates that the substance is generally known in anthroposophic pharmacy / medicine.
�e most relevant change however is the inclusion of �ve monographs:• Cydonia oblonga, fruit• Cydonia oblonga, fruit, heat treated aqueous tincture
1:2.1• Cydonia oblonga, fruit, glycerol extract with heat
treatment 1:2.1• Cydonia oblonga, fruit, mother tincture obtained
by rhythmic application of heat and cold: Cydonia oblonga e fructibus ferm 33b
• Levico Water
�e APC is reviewed and updated by an anthropo-sophic pharmaceutical committee responsible to the IAAP board.
�e changes in summary:new texts Manufacturing methods3.3.1, 3.3.2, 3.9.3, 3.12.25.2.2, 5.2.37.2, 7.58.2 with 8.2.1 and 8.2.2
MonographsCydonia oblonga, fruitCydonia oblonga, fruit, heat treated aqueous tincture 1:2.1Cydonia oblonga, fruit, glycerol extract with heat treat-ment 1:2.1Cydonia oblonga, fruit, mother tincture obtained by rhythmic application of heat and cold: Cydonia oblonga e fructibus ferm 33bLevico Water
revised texts General chaptersAll textsManufacturing methodsAll methodsChanged numbers: 7.2 into 7.4AppendicesAll appendices
deleted textsManufacturing methods3.9.2
Members of the APC committee
Gabriele Jones, pharmacist, Germany
Herwig Judex, chemist, Germany
Judith Klahre Parker, pharmacist, United Kingdom, Chairperson of the British Association, BAAP, (British Association of Anthroposophic Pharmacists)
Andrea Kühn, pharmacist, Germany
Jakob Maier, pharmacist, Switzerland, Board Member of VAEPS and Member of the Committee on Comple-mentary Medicinal Products of the Swiss Pharmaco-poeia
Mónica Mennet-von Ei�, pharmacist, Switzerland, Presi-dent of the Swiss association VAEPS, Board Member of the IAAP; Member of the Working Group HOM on Homoeopathic Raw Materials and Stocks of the Euro-pean Pharmacopoeia
• Introductory N
ote
2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
Christiaan Mol, pharmacist, Germany, Chairman of the APC committee, Board Member of the IAAP; Member of the Committee on Manufacturing Methods of the German Homoeopathic Pharmacopoeia
Peter Pedersen, pharmacist, Denmark; Member of the Committee on Manufacturing Methods of the German Homoeopathic Pharmacopoeia
Nelly Segur, pharmacist, France
Marion Zeeck, pharmacist, Germany
�e APC is recognised by the following national anthro-posophic pharmaceutical associations:
the French Association AFERPA (Association Française d'étude et de recherche sur la pharmacie anthroposo-phique – French Association for Studies and Research on Anthroposophic Pharmacy);the British Association, BAAP (British Association of Anthroposophic Pharmacists) and its Associate, New Zealand;the Belgian/Dutch Association BNVAA (Belgisch – Ned-erlandse Vereniging van Antroposo�sch georiënteerde Apothekers – Belgian Dutch Association of Anthropo-sophic Pharmacists);the Brazilian Association Farmantropo (Associação Brasileira de Farmácia Antroposó�ca – Brazilian An-throposophic Pharmacy Association);the German Association GAPiD (Gesellscha� Anthro-posophischer Apotheker in Deutschland – Society of Anthroposophic Pharmacists in Germany);the Austrian Association ÖGAPh (Österreichische Ge-sellscha� anthroposophischer Pharmazeuten – Austrian Society of Anthroposophic Pharmacists);the Italian Association SOFAI (Società di farmacisti antroposo� in Italia – Society of Anthroposophic Phar-macists in Italy);the Swiss association VAEPS (Verband für Anthroposo-phisch Erweiterte Pharmazie in der Schweiz – Associa-tion for Anthroposophically Extended Pharmacy in Switzerland).
Dr. Manfred Kohlhase, President IAAP, 30.06.2013For full details of the IAAP Guidelines, see website www.iaap.org.uk
• In
trod
ucto
ry N
ote
3
• Introductory N
ote
4
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
Endorsement Universität Witten/Herdecke
As a professor for Anthroposophic Medicine I warmly welcome the third edition of the Anthroposphic Pharmaceutical Codex. Anthroposophic Medicine is an integrative system of medicine involving conventional medicine and a set of di�erentiated thera-peutic tools. A very important tool is its array of medicinal products. Anthroposophic Medicine claims a substance related e�ect as well as a dynamic or process related e�ect for its medicines, both of which are meant to activate self healing processes. �e task of the APC is to develop appropriate quality principles as well as quality standards in line with the characteristics and requirements of anthroposophic medicines. Substance related standards are well documented as well as manufacturing methods, which relate to the process characteristics of anthroposophic medicinal products.
Prof. Peter Heusser
Endorsement IVAA
�e International Federation of Anthroposophic Medical Associations (IVAA) is the international umbrella organisation representing 31 anthroposophic medical associa-tions worldwide in political and legal matters. As well as services provided to member organisations, the IVAA provides similar assistance to doctors in more than 30 ad-ditional countries throughout the world.
�e IVAA´s mission includes political e�orts to ensure legal and regulatory safeguards for the availability of Anthroposophic Medicinal Products (AMPs) in any country in the world where doctors practise the anthroposophic medical approach.
�e Anthroposophic Pharmaceutical Codex (APC) is an indispensable document for de�ning the anthroposophic medical system, and provides detailed insight into the di�erent types of medicinal products used in Anthroposophic Medicine, including source materials, pharmaceutical processes and standards.
�e APC makes it possible to relate knowledge of substances and pharmaceutical pro-cesses to insight into human health and illness. From a pharmaceutical point of view it o�ers a full description of Anthroposophic Medicine as a complex medical system founded on the interrelationship between these processes and insights.
On behalf of the IVAA I wish to acknowledge and endorse this achievement by the community of anthroposophic pharmacists a�liated within the IAAP. Successful compilation of the codex now gives Anthroposophic Pharmacy a �rm position within general medical culture.
Peter Zimmermann MD, PhDPresident IVAA
• In
trod
ucto
ry N
ote
5
IVAA International Federation of Anthroposophic Medical AssociationsRue du Trône 194B-1050 BruxellesPhone: +32 2 644 00 20email: [email protected]
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
Endorsement Escamp
With pleasure I have taken notice of the recently �nalised new version of the APC. �e development of the APC is very important for ESCAMP. �e aim of ESCAMP is to develop the scienti�c basis for a permanent regulatory framework for Anthroposophic Medicinal Products (AMPs) in Europe. �e ESCAMP strategy includes a description of Anthroposophic Medicine as a whole system and an evaluation of single AMP’s and AMP groups (see www.escamp.org). For this work the APC provides essential pharma-ceutical source material, including de�nitions of AMPs as well as descriptions of their starting materials, manufacturing processes and dosage forms. On behalf of ESCAMP I herewith endorse the relevant steps that have been under-taken to revise and expand the APC, in particular the inclusion of speci�c substance monographs with relevant quality standards.
Dr. Harald Johan HamreFreiburg im Breisgau
• Introductory N
ote
6
Harald Johan HamreScienti�c Director and President of the European Scienti�c Cooperative of Anthroposophic Medicinal Products (ESCAMP)
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
Dear Sir or Madam,
�e Anthroposophic Pharmaceutical Codex, APC is now available in its revised 3rd edition. ECHAMP is the international industrial association that has given itself a number of tasks with regard to the further development of anthroposophic and homoeopathic medicinal products. Article 2 of the Articles of Association quotes as follows:
“Active promotion of the harmonisation, legalisation, research and the respective in-tegration of homeopathic and anthroposophic medicinal products into o�cial phar-macopoeias, primarily in the European Union, with the purpose of further enabling e�ective access by representatives of the professional groups and the general public to these medicinal products.” (Italics by the author)
�e APC is an important document from this perspective, since it provides the pool of pharmaceutical information in pharmacopoiea language which makes such an objec-tive possible for the stakeholders active in the area.
We wish to express our congratulations to the International Association of Anthropo-sophic Pharmacists, IAAP, for this new step. As an association also representing the anthroposophic medicinal product industries, we fully endorse the APC and wish that it will provide guidance in any concerned regulation process.
Nand de Herdt, President of ECHAMP
• In
trod
ucto
ry N
ote
7
European Coalition on Homeopathic and Anthroposophic Medicinal Products E.E.I.G.Rue Gray 100, 1040 Brussels ,Belgium, Tel: +32-2-649.94.40, Fax: +32-2-649.41.77o�[email protected] , www.echamp.eu , VAT BE 0467 826 644 RPR Brussels
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
Endorsement ECHAMP
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Introductory N
ote
8
Endorsement Hogeschool Leiden
�e International Association of Anthroposophic Pharmacists, IAAP, is publishing the 3rd edition of the Anthroposophic Pharmaceutical Codex, APC. For me as an aca-demic in the �eld of Anthroposophic Medicine it is of paramount importance to rely on the e�orts of the joint disciplines making Anthroposophic Medicine a constantly developing reality, in this case the precious work of my colleague pharmacists. With enthusiasm therefore I have taken notice of the further developments, in particular of the inclusion of monographs of starting materials and preparations. �e APC gives the framework of what belongs to the pharmaceutical identity of Anthroposophic Medi-cine. With this edition this identity is further validated and applied to single important preparations. With anthroposophic preparations derived from the quince, Cydonia oblongata, now monographed in the APC I have had the pleasure to carry out clinical research1. I wish the IAAP further successful steps in further developing the APC.
Erik BaarsHogeschool Leiden Lectoraat Antroposo�sche Gezondheitszorg
1 Erik W. Baars, Miek Jong, Andreas F. M. Nierop, Inge Boers, and Huub F. J. Savelkoul, “Citrus/Cydonia Compositum Subcutaneous Injections versus Nasal Spray for Seasonal Allergic Rhinitis: A Randomized Controlled Trial on E�cacy and Safety,” ISRN Allergy, vol. 2011, Article ID 836051, 11 pages, 2011. doi:10.5402/2011/836051
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• In
trod
ucto
ry N
ote
9
Endorsement Eberhard Karls University, Tübingen
The quality of medicinal products is - besides their safety and efficacy - definitely an im-portant aspect of public health. Usually the required quality is defined by the relevant phar-macopeias and the proper drug quality is guaranteed by respective analytical procedures. However, the quality of an anthroposophic medicinal product represents usually much more than the sum of its analytical characteristics. Its unique quality is strictly related to the entire process chain involved, including the source material, pharmaceutical processes and standards. In this context, I am very pleased to hold in my hand the 3rd Edition of the Anthroposo-phic Pharmaceutical Codex. It looks and defines quality in its entirety and represents thus a huge step forward for anthroposophic medicinal products in the direction of an up to date quality understanding. The APC successfully helps to close the gap which exists between those medicinal products described in official pharmacopeias, e.g. the European Pharma-copeia and the German Homeopathic Pharmacopeia, and the traditional anthroposophic codices. It was a real challenge to develop the quality related tools in line with the special needs of anthroposophic medicinal products.
Congratulations to the IAAP for showing the courage to venture to do this and congratula-tions for having done it so successfully.
Prof. Rolf DanielsChair of Pharmaceutical Technology, Pharmaceutical Institute Eberhard Karls University, Tübingen
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
Endorsement Faculty of Pharmacy, Philipps-Universität Marburg
Anthroposophic medicinal products do have a long tradition in Germany and its neigh-bouring countries. �e pharmaceutical pro�le of these products is comparable to that of homoeopathic medicinal products and their quality is usually de�ned by the quality of the starting materials as well as the manufacturing processes, as required by regula-tion. Consequently, the quality and testing procedures of raw materials and stocks - like for example mother tinctures - used for the production of anthroposophic medicinal products should be de�ned by monographs in the relating pharmacopeias (e.g., German Homoeopathic Pharmacopoeia and also more and more the European Pharmacopoeia).
�erefore, I am very pleased that the 3rd Edition of the Anthroposophic Pharmaceutical Codex now includes four monographs on starting materials and the relating preparations. �is represents a huge step towards a state of the art quality understanding of anthro-posophic medicinal products. �e APC successfully helps to close the gap, which exists between those medicinal products and starting materials described in o�cial phar-macopeias as mentioned above, and those which have not been covered by any o�cial monograph so far. It is a real challenge to develop the quality related tools in line with the special needs of anthroposophic medicinal products.
Congratulations to the IAAP for e�ectively closing this quality gap for anthroposophic starting materials.
Prof. Michael KeusgenDean of the Faculty of Pharmacy, Philipps-Universität Marburg, Germany
• Introductory N
ote
10
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Fo
rew
ord
11
Foreword
Pharmacy extended by the principles of anthroposophy began to be developed at the beginning of the 20th century by Rudolf Steiner (founder of anthroposophy, 1861 – 1925) and Oskar Schmiedel (Austrian chemist, 1887 – 1959), in collaboration with a number of physi-cians. �eir aim was to reinterpret and complement the results of pharmaceutical and medical research with insights gained from anthroposophic research of the human being and nature.�e basis of the anthroposophic approach to pharmacy is the “holistic” knowledge of mankind and nature, which recognizes the notion that human beings and the kingdoms of nature are related through a common evolution1.�is perception leads to a comprehensive view of substances in their relationship to health, illness and to a speci�c approach to pharmacy.
�erefore anthroposophic pharmacy uses substances from the mineral, plant and animal kingdoms2,3.
Anthroposophic medicinal products have been on the market world-wide and prescribed by quali�ed medical practitioners since 1921.
�e range of anthroposophic medicinal products is partially determined by the physical characteristics of substances, whereby allopathic, phytotherapeutic and homoeopathic criteria are taken into considera-tion. Most particularly, anthroposophic medicinal products are characterised by their manufacturing processes involving speci�c anthroposophic and typi-cal homoeopathic pharmaceutical procedures. �e range of anthroposophic medicinal products includes potentised medicinal products, manufactured by using the methods of the o�cial homoeopathic pharma-copoeias, as well as concentrated mineral, herbal or animal substances or preparations and compounded medicinal products. Considering this diversity, anthroposophic medicinal products, cannot be de�ned under a single substance classi�cation.
1 Jos Verhulst: „Der Erstgeborene“ (�e �rst-born), publisher Verlag Freies Geistesleben, Stuttgart, D 2001.2 Rudolf Steiner/Ita Wegman: „Grundlegendes für eine Erweiter-ung der Heilkunst nach geisteswissenscha�lichen Erkenntnis-sen.“ GA 27, publisher Rudolf Steiner Verlag, Dornach, CH, 1992.In English: „Extending Practical Medicine – Fundamental Prin-ciples based on the Science of the Spirit“. Rudolf Steiner Press , London, GB, 19963 Rudolf Steiner: „Geisteswissenscha� und Medizin“, 20 Vorträge für Ärzte (1920), Rudolf Steiner Verlag, Dornach, CH 1985.In English: „Introducing Anthroposophical Medicine“ (previ-ously published as: Spiritual Science and Medicine). Twenty lectures to doctors. Dornach 21 March – 9 April 1920, GA 312. Anthroposophic Press, Hudson, NY, USA, 1999.
�e Anthroposophic Pharmaceutical Codex APC gives an overview of substances and methods used in the manufacture of anthroposophic medicinal products as well as of the related quality parameters.
Legal SituationToday the European Union Directive 2001/83/EEC and amendments contain the main legislation concerning medicinal products. �e legal status of anthroposophic medicinal products in the EU is closely related to that of homoeopathic medicinal products (see below).
Preamble of Directive 2001/83/EEC n° (22) refers to anthroposophic medicinal products as follows:“Anthroposophic medicinal products, which are described in an o�cial pharmacopoeia and prepared by a homoeo-pathic method are to be considered, as regards to regis-tration and marketing authorization, as homeopathic medicinal products.”
From a regulatory point of view anthroposophic medicinal products can be devided into two categories:• anthroposophic medicinal products manufactured
according to a homoeopathic manufacturing method within the meaning of Directive 2001/83/EEC, article 1, 5.: “Any medicinal product prepared from substances called homoeopathic stocks in accordance with a homoeopathic manufacturing procedure described by the European Pharmacopoeia or, in absence thereof, by the pharmacopoeias currently used o�cially in the Member States. (...)”
• anthroposophic medicinal products other than those manufactured by a homoeopathic manufacturing method.
�ese are equally important and have never been included in any pharmacopoeia.
�e de�nitions of anthroposophic medicinal products given in the Swiss and German Drug Laws take both cat-egories into account (translations by APC Committee):
Switzerland: Regulation of Swissmedic concerning the simpli�ed Authorisation of Complementary and Herbal Medicinal Products (Verordnung des Schweizerischen Heilmittelinstituts über die vereinfachte Zulassung von Komplementär- und Phytoarzneimitteln) Art. 4, 2 f: Anthroposophic medicinal product: Medicinal product, whose active substances are manu-factured by a homoeopathic manufacturing procedure, or according to an anthroposophic manufacturing procedure described in the German Homoeopathic
• Forew
ord
Pharmacopoeia or in the British Homoeopathic Pharmacopoeia or according to a special anthroposophic manufacturing procedure and that is formulated and developed according to the anthroposophic knowledge of man, animal, substance and nature and is meant to be used according to these principles.
Germany: Medicinal Products Act (Gesetz über den Verkehr mit Arzneimitteln) Art. 4, (33) An anthroposophic medicinal product is a medicinal product that has been developed according to the anthroposophic knowledge of man and nature and that is manufactured according to a homoeopathic manufacturing procedure described in the European Pharmacopoeia or in absence thereof in a pharma-copoeia o�cially used in the Member States or according to a special anthroposophic manufacturing procedure and that is meant to be used according to the anthro-posophic principles concerning man and nature.
In many EU countries, and also world-wide, medicinal products used for the anthroposophic therapeutics are thus partially integrated in legislation.
In Brazil as well as in Australia the APC has been of-�cially recognised as quality standard and reference for anthroposophic medicinal products (RESOLUÇÃO RDC No – 26, DE 30 DE MARÇO DE 2007; amend-ments to the Australian �erapeutic Goods Act, 2009).
In summary anthroposophic medicinal products as a whole are step by step gaining legal recognition in the EU as well as world-wide, and among other things this requires comprehensive publication of their pharma-ceutical quality.
�e publication of the Anthroposophic Pharmaceutical Codex is to provide transparency of anthroposophic pharmaceutical quality for pharmacists and bodies requiring an appreciation of anthroposophic medicinal products and pharmacy. Furthermore it provides a basis for the maintenance of existing and development of new anthroposophic medicinal products.
�e relationship of the APC to the European Pharmacopoeia, to other existing o�cial Pharma-copoeias and non o�cial pharmacopoeias
�e APC is published by the IAAP, an independent association of professional pharmacists, within the context of o�cial existing pharmacopoeias. It is the intention of the APC to refer where possible to existing pharmacopoeias. In fact anthroposophic medicinal products are o�en manufactured and controlled
12
according to existing speci�cations and standards.A part of the reference pharmacopoeias for the APC are published by o�cial Authorities, in particular�e European Pharmacopoeia�e French Pharmacopoeia�e German Homoeopathic Pharmacopoeia (which is a part of the German Pharmacopoeia);�e Swiss Pharmacopoiea has implemented two texts concerning anthroposophic pharmacy in the last four years:• in 2009 (Suppl. 10.1) with the general Ph.Helv.-mono-
graph “Praeparationes anthroposophicae (Anthropo-sophic Preparations)” (Ph.Helv. CH 306); it was the �rst time that anthroposophic preparations appeared as a monograph in an o�cial pharmacopeia. �is monograph includes the paragraphs de�nitions, starting materials, methods of preparation and dosa- ge forms, by analogy with the Ph.Eur.-monograph Homoeopathic preparations Ph.Eur. 1038.
• in September 2013 (Suppl. 11.1) the new Ph.Helv.-chapter “17.7 Manufacturing methods for anthropo-sophic preparations” came into force. �is chapter gives an overview on the general manufacturing processes and describes in more detail some manu-facturing methods which are more frequently used in anthroposophic pharmacy and had not been described in an o�cial pharmacopoeia before.
�e APC served as important basis to establish both of these Ph.Helv.-texts. �erefore it can be concluded, that the continuing work of the APC supports the establish-ment of the pharmaceutical quality standards and the regulation of anthroposophic medicinal products in Switzerland.
Further o�cial pharmacopoeias of reference:�e Austrian Pharmacopoeia�e British Pharmacopoeia
In particular the European Pharmacopoeia today represents and for the future will represent a reference of paramount importance for the APC.
�erefore in part IV of the APC containing the lists of the various substances used in anthroposophic phar-macy reference is made where possible to the European Pharmacopoeia and other o�cial pharmacopoeias.
Particularly important Ph.Eur. monographs are:Herbal drugs for homoeopathic preparations (2045)Homoeopathic preparations (1038)Methods of preparation of homoeopathic stocks and potentisation (2371)Minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products (50208)
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Fo
rew
ord
13
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
Mother tinctures for homoeopathic preparations (2029)Tinctures (chapter in 0765 Extracts)Viral safety (50107)Other pharmacopoeias referred to in the APC are not o�cially recognised. Nevertheless they provide reliable standards accepted e.g. by regulatory authorities, in particular the British Homoeopathic Pharmacopoeia.
�e IAAP understands its task to sustain anthro-posophic pharmaceutical activities at any level (e.g. manufacturing, quality control, regulatory a�airs), worldwide, that is, beyond the countries of the European Pharmacopoeia Convention. �erefore during the evolution of the APC other o�cial pharmacopoeias (or reliable private pharmacopoeias) will possibly be referred to, e.g. the Brazilian Pharmacopoeia.
• Table of C
ontent
Table of ContentStructure of the Anthroposophic Pharma ceutical Codex, APC .....................................................................................16List of Abbreviations and Symbols ......................................................................................................................................17Glossary .......................................................................................................................................................................18
PART I De�nitions ......................................................................................................................................................191. Anthroposophic medicinal product ...............................................................................................................................202. Starting materials, general information .........................................................................................................................20 2.1. Minerals, rocks, including natural waters ..............................................................................................................21 2.2. Starting material of botanical origin ......................................................................................................................21 2.3. Starting materials of zoological origin ...................................................................................................................21 2.4. Starting materials that can be described chemically ............................................................................................22 2.5. Starting materials that have undergone special treatment ..................................................................................22 2.6. Compositions (for further information see “Glossary”) ......................................................................................223. Vehicles and excipients ....................................................................................................................................................224. Active substances ..............................................................................................................................................................22 4.1. Starting materials ......................................................................................................................................................22 4.2. Preparations ...............................................................................................................................................................22
PART IIa General monographs of preparations and speci�c production methods (Pharmaceutical processes) ........... 231. SPECIAL TREATMENTS OF RAW MATERIALS .....................................................................................................28 1.1. Vegetabilisation methods (“vegetabilised metals“) ...............................................................................................282. METAL PREPARATIONS ...............................................................................................................................................29 2.1. Metal mirrors .............................................................................................................................................................293. TINCTURES, MOTHER TINCTURES, GLYCEROL MACERATES AND VISCOUS EXTRACTS ...................30 3.1. Cold treated mother tinctures and liquid preparations thereof ..........................................................................30 3.2. Tinctures and mother tinctures made by macerations with water or ethanol/water .......................................31 3.3. Glycerol macerates ....................................................................................................................................................32 3.4. Liquid preparations made by maceration with oil ................................................................................................33 3.5. Mother tinctures made by percolation ...................................................................................................................34 3.6. Bu�ered aqueous mother tinctures manufactured under exclusion of oxidative in�uence ............................35 3.7. Fermented mother tinctures ....................................................................................................................................35 3.8. Tinctures and mother tinctures made by digestion (Digestio) ...........................................................................36 3.9. Tinctures and mother tinctures made by infusion (Infusum) .............................................................................37 3.10. Tinctures and mother tinctures made by decoction (Decoction) ....................................................................39 3.11. Viscous extracts with heat treatment ....................................................................................................................40 3.12. Preparations made by distillation (Distillates) ....................................................................................................40 3.13. Mother tinctures obtained by rhythmic application of heat and cold .............................................................414. SOLID STARTING MATERIALS OBTAINED BY HEAT ..........................................................................................43 4.1. Toasted preparations – Tosta ....................................................................................................................................43 4.2. Carbons – Carbo .......................................................................................................................................................43 4.3. Ashes – Cinis .............................................................................................................................................................445. SOLID PREPARATIONS FROM PLANTS (DRYING ONTO A VEHICLE) ..........................................................44 5.1. Solid preparations from fresh plants ......................................................................................................................44 5.2. Solid preparations from liquids, plant juices or aqueous extracts ......................................................................456. LIQUID DILUTIONS ......................................................................................................................................................46
14
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Ta
ble
of C
onte
nt
15
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
7. COMPOSITIONS .............................................................................................................................................................46 7.1. Compositions made by treating two or more starting materials by one or more pharmaceutical processes ....................................................................................................................46 7.2. Compositions made by treating two or more extracts or mother tinctures of one plant by one or more pharmaceutical processes ...................................................................................................47 7.3. Compositions made by treating one or more starting materials with one or more mother tinctures which undergo one or more pharmaceutical processes together ................................................49 7.4. Compositions made by treating two or more extracts or mother tinctures and/or dilutions by one or more pharmaceutical processes ......................................................................49 7.5. Compositions made by co-potentising ..................................................................................................................498. POTENTISED PREPARATIONS ...................................................................................................................................49 8.1. Co-potentised preparations......................................................................................................................................50 8.2. Potentising in an ointment base ..............................................................................................................................51 8.3. Triturations .................................................................................................................................................................529. MIXTURES .......................................................................................................................................................................52
PART IIb Individual monographs of starting materials and preparations .......................................................................53CYDONIA OBLONGA, FRUIT .........................................................................................................................................54CYDONIA OBLONGA, FRUIT, HEAT TREATED AQUEOUS TINCTURE 1:2.1 ...................................................54CYDONIA OBLONGA, FRUIT, GLYCEROL EXTRACT WITH HEAT TREATMENT 1:2.1 ................................................................................................................55CYDONIA OBLONGA, FRUIT, MOTHER TINCTURE OBTAINED BY RHYTHMIC APPLICATION OF HEAT AND COLD CYDONIA OBLONGA E FRUCTIBUS FERM 33B ..............................56LEVICO WATER ..................................................................................................................................................................57
PART III Dosage forms ......................................................................................................................................................59
INDEX LIST OF TERMS OF PART I, II AND III ..........................................................................................................63
PART IV Appendices ......................................................................................................................................................66Note concerning appendix 2.3. ..........................................................................................................................................67References concerning nomenclature in appendices 2.1. to 2.6. ..................................................................................67Note concerning the references for usage in anthroposophic medicine in appendices 2.1. to 2.6. ..........................67References concerning the use in anthroposophic medicine in appendices 2.1. to 2.6. ............................................68IVAA statement concerning starting materials of animal origin not yet mentioned in published anthroposophic medical literature or in published o�cial regulatory documents concerning anthroposophic medicinal products ...................................................................................................................................69
Appendix 2.1. List of minerals, rocks and natural waters ...............................................................................................75Appendix 2.2. List of starting materials of botanical origin ...........................................................................................85Appendix 2.3. List of starting materials of zoological origin ...................................................................................... 127 Appendix 2.4 List of starting materials that can be described chemically ............................................................... 153Appendix 2.5. List of starting materials that have undergone special treatment ..................................................... 165Appendix 2.6. List of compositions ................................................................................................................................ 169Appendix II .................................................................................................................................................................... 181Correlation table: Ph.Eur. / HAB manufacturing methods used in anthroposophic pharmacy and corresponding manufacturing methods in the HPUS ........................................................................................... 181
• Structure of A
PC
Structure of the Anthroposophic Pharma ceutical Codex, APC
Part I “De�nitions” provides de�nitions and describes quality aspects as well as parameters related to an-throposophic medicinal products. �e di�erent stages incurred in the obtaining of a medicinal product, from the starting material to the dosage form, are described in this part.
Part IIa “General Monographs of speci�c production methods (Pharmaceutical processes)” contains general monographs concerning the types of preparations/ active substances that are prepared by speci�ed pro-cedures. Beneath the relevant general monograph(s), di�erent speci�c production methods by which a particular type of a starting material can be prepared are either quoted from other pharmacopoeias or an APC production method is set out.
In this way, the relationship between the APC and other pharmacopoeias, as well as the option to de�ne substances through their production methods are outlined.
Schematically the following order is applied:
General monographs
De�nition, Identi�cation, Tests, Assay, Storage, Recommended Designation
Speci�c production methods related to the particular general monograph
Ph.Eur. Methods
HAB Methods
Ph.fr. Methods
B.Hom.P. Methods 1, 2, 3, 4, 5a, 5b, 6,
8a, 12
APC Methods
16
Part IIb “Monographs of starting materials and prepa-rations” sets standards for speci�c starting materials and preparations. In their last section the monographs of the starting materials list a) Some existing anthroposophic preparations that utilise the starting material and/ or b) Manufacturing methods, described in the Ph.Eur., the HAB or the APC commonly used for the processing of the particular starting material. �at list is not meant to be exhaustive.
Part III, information about dosage forms in anthro-posophic pharmacy as well as production methods of speci�c dosage forms for anthroposophic medicinal products.
Part IV “Appendices”
In appendix I starting materials for the preparation of anthroposophic medicinal products are listed (not excipients and vehicles). �e appendices are numbered according to the related chapter in part I: 2.1., 2.2., 2.3., 2.4., 2.5., 2.6.
In appendix II a link to the HPUS is given:• Correlation table: Ph.Eur./HAB manufacturing
methods used in anthroposophic pharmacy and corresponding manufacturing in the HPUS.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• St
rucr
ure
of A
PC
17
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
List of Abbreviations and Symbols
* see p. 67
1 CH Symbol for the �rst centesimal potency, see also C1 and 1C
1 DH Symbol for the �rst decimal potency, see also D1 and 1X
1C Symbol for the �rst centesimal potency, see also 1 CH and C1
1X Symbol for the �rst decimal potency, see also 1 DH and D1
ABMA-Vademe-cum
Gardin NE, Schleier R: Medicamentos Antropo-só�cos: Vademecum. Associação Brasileira de Medicina Antroposó�ca. São Paolo:Editor João de Barro; 2009
aph ad preparationes homoeopathicae
APC Anthroposophic Pharmaceutical Codex
B.Hom.P. British Homoeopathic Pharmacopoeia
B.P. British Pharmacopoeia
Br1 Numbering of the production methods of the B.Hom.P.
C1 Symbol for the �rst centesimal potency, see also 1 CH and 1C
CVD Chemical Vapour Decomposition
D1 Symbol for the �rst decimal potency, see also 1 DH and 1X
DAB Deutsches Arzneibuch(German Pharmacopoeia)
DAC Deutscher Arzneimittel-Codex(German Codex of Medicinal Products)
EU European Union
�p for homoeopathic preparations
GHP German Homoeopathic Pharmacopoeia. Un-authorized translation of the HAB. In case of di�erences between the GHP and the HAB the latter is decisive
Gl Symbol for mother tinctures prepared by HAB method 41 using glycerol
H 2.2.6 Analytical method speci�ed in the HAB
HAB Deutsches Homöopathisches Arzneibuch(German Homoeopathic Pharmacopoeia)
HPUS �e Homœopathic Pharmacopœia of the United States
IAAP International Association of Anthroposophic Pharmacists
IVAAstatement 2013
see p. 69
KC Mono-graph
Monograph of the “Kommission C” (Commis-sion of the German Ministry of Health for the an-throposophic therapeutic system and substances), published in the o�cial Gazette of the German government (in German: “Bundesanzeiger”)
Liste HAS
Liste der Homöopathischen und Anthropo- sophischen Sto�e (Anhang 4 zurVerordnung des Schweizerischen Heilmittelinstituts über die vereinfachte Zulassung von Komplementär- und Phytoarzneimitteln (List of Homoeopathic and Anthroposophic Subtances (Appendix 4 in the Regulation of the Swissmedic concerning the simpli�ed Authorisation of Complementary and Herbal Medicinal Products in Switzerland))
LM Symbol for potencies prepared according to Ph.Eur. (2371) 5.2 dra�
MT Mother tincture
Ph.Eur. European Pharmacopoeia
Ph.Eur. (2371)
Ph.Eur. Monograph 2371 “Methods of prepara-tion of homoeopathic stocks and potentisation”
Ph.fr. Pharmacopée Française (french Pharma copoeia), including monographies de souches pour pré-parations homéopathiques (monographs of the stocks for homoeopathic preparations)
Ph.Helv. Pharmacopoea Helvetica(Swiss Pharmacopoeia)
Q Symbol for potencies dilutedby the ratio 1: 50 000
Rh Symbol for mother tinctures prepared by HAB methods 21 and 22 (rhythmic procedure)
• Structure of A
PC
Glossary
In this glossary only those terms are referred to, that need extra clari�cation prior to the de�nitions given in part I.
Composition De�nition given in the monograph “Anthroposophische Zubereitungen”, (Anthroposophic preparations), Swiss Pharmacopoeia, Supplement 10.2, (translation by Swissmedic): “Compositions are active substances which are obtained, when two or more starting materials or preparations, with or without excipients, are processed together in a pharmaceutical process of anthroposophic pharmacy (e.g. Ferrum-Quarz).”
Excipient Excipients are auxiliary substances, which may be used for the production of pharmaceutical dosage forms. Excipients may beused in the production of mixtures.
Pharmaceutical process General term for substance transformations at di�erent stages to obtain starting materials for medicinal products or a medicinal product.
Preparation/active substance
A class of processed starting material speci�ed in the monographs of part II.
Production method A general manufacturing procedure speci�ed in a pharmacopoeia (see e.g. HAB).
Raw material Substance which has not undergone any pharmaceutical process and meets a general quality characterisation, e.g. an optical identi�cation.
Starting material A substance or a composition that meets a speci�cation and can be used as active substance or can be further processed.
Vehicle Vehicles are auxiliary substances which may be used to produce an active substance. Vehicles may be used in the production of mixtures.
18
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• A
PC P
art I
19
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
ANTHROPOSOPHICPHARMACEUTICAL CODEXAPC
PART IDe�nitions
Table of ContentPart I1. Anthroposophic medicinal product .................. 202. Starting materials, general information ............ 20 2.1. Minerals, rocks, including natural waters . 21 2.2. Starting material of botanical origin .......... 21 2.3. Starting materials of zoological origin ....... 21 2.4. Starting materials that can be described chemically ........................................... 22 2.5. Starting materials that have undergone special treatment .............................. 22
2.6. Compositions (for further information see “Glossary”) .......... 223. Vehicles and excipients........................................ 224. Active substances ................................................. 22 4.1. Starting materials .......................................... 22 4.2. Preparations................................................... 22
• A
PC Part I
1. Anthroposophic medicinal product
definitionAn anthroposophic medicinal product is conceived, developed and produced in accordance with the anthroposophic knowledge of man, nature, substance and pharmaceutical processing1. �e application within anthroposophic medicine results from that knowledge2.
According to anthroposophic principles, active sub-stances may be starting materials which are used as such or starting materials which have been transformed into active substances by a process of anthroposophic pharmacy, including compositions.
An anthroposophic medicinal product can contain one or more active substances (see also part I, chapter 4).
An anthroposophic medicinal product can fundamen-tally be employed in every dosage form, including external (topical), internal and parenteral dosage forms (see also part III).
production�e active substances or dosage forms of anthroposophic medicinal products are produced:
• in accordance with classical homoeopathic or anthro-posophic-homoeopathic manufacturing methods as described in the Ph.Eur., HAB, Ph.fr., and B.Hom.P. (Methods 1, 2, 3, 4, 5a, 5b, 6, 8a, 12)
• in accordance with anthroposophic pharmaceutical codex production methods, i.e. “APC Methods”
1 See IAAP brochure: “Basic Information on the Working Prin-ciples of Anthroposophic Pharmacy”, 2005, http://www.iaap.org.uk/downloads/principles.pdf2 For clari�cation it has to be mentioned here, that anthroposo-phic medicine from the beginning includes “Over the Counter” products (OTC). A part of its medicinal products had been con-ceived right from the start for broad use for typical health disor-ders; see Chapter XX, “Typical Remedies”, in Rudolf Steiner/Ita Wegman: “Grundlegendes für eine Erweiterung der Heilkunst nach geisteswissenscha�lichen Erkenntnissen.” GA 27, publisher Rudolf Steiner Verlag, Dornach, CH, 1992.In English: “Extending Practical Medicine – Fundamental Prin-ciples based on the Science of the Spirit”. Rudolf Steiner Press , London, GB, 1996
20
and/or• in accordance with anthroposophic manufacturing
methods described in the individual monograph.
An anthroposophic medicinal product complies with the relevant speci�cations/ monographs set out in parts I and II.
recommended designation Concerning the designation of anthroposophic medici-nal products a reference to the APC is recommended.
2. Starting materials, general information
Starting materials for the production of anthroposophic medicinal products are:
2.1. Minerals, rocks, including natural waters
2.2. Starting materials of botanical origin Dried or fresh plants or parts of plants, including algae, fungi and lichens; Plant secretions, juices, extracts, oleoresins, essential oils or distillation products.
2.3. Starting materials of zoological origin Whole animals, organs, parts of organs dried or fresh; Animal secretions, extracts, blood products, calcareous products.
2.4. Starting materials that can be described chemically
2.5. Starting materials that have undergone special treatment
2.6. Compositions (for further information see “Glossary”)
Starting materials for the production of anthropo-sophic medicinal products comply with any relevant monograph in the European Pharmacopoeia or in the absence thereof, with the relevant monographs in national pharmacopoeias used in the Member States, or in absence thereof with the individual monograph.
Starting materials can be active substances themselves or can be processed into preparations (see also Part I, chapter 4).
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• A
PC P
art I
21
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
2.1. Minerals, rocks, including natural watersMinerals are solid, crystalline components of natural origin belonging to the earth’s crust and other celestial bodies. A mineral has a de�ned crystal system and crystal class. Minerals are chemically and physically homogeneous to a signi�cant extent. In reality, how-ever, there are always deviations from the theoretical mineral formula. Many minerals may show di�erences in their colours. Form and habitus may be signi�cantly di�erent within the same type.
Rocks are composed of one or more minerals having a geological de�nition and distribution in their natural deposit with a certain statistical homogeneity.
Pieces that will be used for production should be big enough to allow mineralogical identi�cation. If a powdered mineral is used, adequate documentation should ensure the quality and natural origin. In fact pieces used for production must be free from visible foreign matter. �ey have not undergone any unwanted mechanical or chemical treatment: in particular any chemical reaction, colouring, varnishing, heating and arti�cial radiation must be excluded. �e amount of foreign matter accepted a�er chemical analysis is speci�ed in the respective monograph.
Natural waters can come from a natural source (e.g. Levico), from the sea (e.g. aqua maris) or from mineral cavities (e.g. agate water).
List of minerals, rocks, including natural waters: see part IV, appendix 2.1.
2.2. Starting materials of botanical originStarting materials of botanical origin are:• Dried or fresh plants or parts of plants,
including algae, fungi and lichens;• Plant secretions, juices, extracts, oleoresins,
essential oils or distillation products.
Fresh plants should be used shortly a�er harvest. If this is not possible, the quality is guaranteed by appropriate measures, e.g. freezing.
If material from cultivated plants is used preference should be given to materials from plants cultivated by biodynamic cultivation (“Demeter” certi�ed) or by other certi�ed organic cultivation methods in accord-ance to the relevant European regulations ruling organic agricultural products (see also Council Directive (EEC) n° 2092/91).If wild plants are harvested protection of species according to relevant regulations is granted and special care is taken of the eco-system concerned.
Plants or parts of plants are, as far as possible, free from impurities such as soil, dust, dirt and other contami-nants such as fungal, insect and other animal contami-nations. �ey are not decayed.
Harvested plants or the mother tinctures made thereof are analysed for content of heavy metals and pesticides.�e range and frequency of this testing can occur ac-cording to a monitoring plan based on risk assessment.
Unless otherwise stated, the collecting or harvesting times are generally:
Whole plants with underground partsand plants without underground parts
at �owering time
Leaves and shoots when fully developed
Flowers shortly a�er opening
Bark throughout the year
Underground parts of annual plants
at seed ripening time
Underground parts of biennial and perennial plants
in spring
Fruits and seeds at the time of ripening
Fungi when the fruiting bod-ies are fully developed
Starting materials of botanical origin see part IV, appendix 2.2.
2.3. Starting materials of zoological originStarting materials of zoological origin are:• Whole animals, organs, parts of organs
dried or fresh;• Animal secretions, extracts, blood products,
calcareous products. Lower animals as well as warm-blooded animals are used.
Animal husbandry and keeping must be adequate for the animal species (see also Council Directive (EEC) n° 2092/91). In particular in the case of warm-blooded
• A
PC Part I
species animals from well-monitored “Demeter” or biodynamic herds are preferentially used.
�e starting materials of zoological origin must meet the requirements of the European and/ or relevant national pharmacopoeias regarding the preparation of medicinal products from materials of animal origin and with EU directives and/or national guidelines of the appropriate regulatory authorities.In particular the Ph.Eur. monographs on TSE safety (Ph.Eur. 50208), and viral safety (Ph.Eur. 50107) apply.
Animals must be healthy and in good hygienic condition. �e intervals given in legislation a�er the administration of drugs to animals must be observed before the animals are used.
Health requirements, animal keeping, protection of species and processing of animals must comply with the relevant guidelines of responsible national authorities and those of the European Union, where applicable.
List of starting materials of zoological origin see part IV, appendix 2.3.
2.4. Starting materials that can be described chemicallyStarting materials that can be described chemically are inorganic and organic substances.Organic substances are generally of natural origin, e.g. puri�ed fractions.
Preference should be given to clearly traceable sub-stances, that comply with the quality standards in 2.1, 2.2, 2.3.
List of starting materials that can be described chemically see part IV, appendix 2.4.
2.5. Starting materials that have undergone special treatmentStarting materials that have undergone a special treatment are: e.g. plants, parts of plants cultivated by special treatment (see part IIa, chapter 1.1. Vegetabilisation methods of substances used for mother tinctures).
List of starting materials that have undergone special treatment see part IV appendix 2.5.
22
2.6. CompositionsDi�erent starting materials described in 2.1, 2.2, 2.3, 2.4, 2.5 undergo one or more pharmaceutical processes that will lead to a substance that cannot be described as an addition of its ingredients. �e rationale for the synthesis is an anthroposophic formula, in accordance with the anthroposophic understanding of man and nature1.
List of compositions see part IV, appendix 2.6.
3. Vehicles and excipients
Vehicles are auxiliary substances, which may be used for the production of active substances (e.g. ethanol to obtain an extract or lactose monohydrate to obtain a potentised preparation). Vehicles are also used in the production of mixtures (see part IIa, chapter 9).
Excipients are auxiliary substances, which may be used for the production of the pharmaceutical dosage forms (e.g. NaCl to obtain an isotonic solution for parenteral preparations). Excipients are also used in the production of mixtures (see part IIa, chapter 9).
Vehicles and excipients used in the manufacture of anthroposophic medicinal products comply with the relevant requirements of the European Pharmacopoeia or of the national pharmacopoeias used in the EU Member States.
4. Active substances
4.1. Starting materialsActive substances can be starting materials themselves or preparations.Starting material used directly as active substances may be the �nal dosage form, e.g. a herbal tea.
4.2. PreparationsPreparations are obtained from one or more starting materials.
Preparations comply with the speci�cations described in part II or in the individual monograph.
Preparations can be the �nal dosage form or can be processed further, e.g. to obtain mixtures.
1 As an example see: “Biodoron/Kephalodoron” , in Persephone N° 12, M. Kohlhase editor; publisher Verlag am Goetheanum, Dornach, CH, 1998.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• A
PC P
art I
Ia
23
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
ANTHROPOSOPHICPHARMACEUTICAL CODEXAPC
PART IIaGeneral monographs of preparations and speci�c production methods (Pharmaceutical processes)
Table of Content Part IIa1. SPECIAL TREATMENTS OF RAW MATERIALS .........................................................28 1.1. Vegetabilisation methods ............................282. METAL PREPARATIONS ..................................29 2.1. Metal mirrors ................................................293. TINCTURES, MOTHER TINCTURES, GLYC- . EROL MACERATES, VISCOUS EXTRACTS .30 3.1. Cold treated mother tinctures and liquid preparations thereof .................................30 3.2. Tinctures and mother tinctures made by macerations with water or ethanol/water ....31 3.3. Glycerol macerates .......................................32 3.4. Liquid preparations made by maceration with oil ..............................................33 3.5. Mother tinctures made by percolation ......34 3.6. Bu�ered aqueous mother tinctures manufactured under exclusion of oxidative in�uence ...............................................35 3.7. Fermented mother tinctures .......................35 3.8. Tinctures and mother tinctures made by digestion (Digestio) .............................36 3.9. Tinctures and mother tinctures made by infusion (Infusum) .........................................37 3.10. Tinctures and mother tinctures made by decoction (Decoction) ........................39 3.11. Viscous extracts with heat treatment .......40 3.12. Preparations made by distillation .............40 3.13. Mother tinctures obtained by rhythmic application of heat and cold .........41
4. SOLID STARTING MATERIALS OBTAINED BY HEAT ........................................43 4.1. Toasted preparations – Tosta .......................43 4.2. Carbons – Carbo ...........................................43 4.3. Ashes – Cinis .................................................445. SOLID PREPARATIONS FROM PLANTS .....44 5.1. Solid preparations from fresh plants ..........44 5.2. Solid preparations from liquids, plant juices or aqueous extracts .........................456. LIQUID DILUTIONS .........................................467. COMPOSITIONS ................................................46 7.1. Compositions made by treating two or more starting materials by one or more pharmaceutical processes ...................................46 7.2. Compositions made by treating two or more extracts or mother tinctures of one plant by one or more pharmaceutical processes ........47 7.3. Compositions made by treating one or more starting materials with one or more mother tinctures which undergo one or more pharmaceutical processes together ..........49 7.4. Compositions made by treating two or more extracts or mother tinctures and/or dilutions by one or more pharmaceutical processes ........49 7.5. Compositions made by co-potentising ......498. POTENTISED PREPARATIONS ......................49 8.1. Co-potentised preparations9. MIXTURES ..........................................................52
• A
PC Part IIa
24
Introduction: Brief description of the main pharmaceutical processes applied in anthroposophic pharmacySeveral pharmaceutical processes are described in existing homoeopathic pharmacopoeias as “production methods”. �ese homoeopathic pharmacopoeial pro-duction methods can be seen as examples of the general anthroposophic pharmaceutical principle described in the general APC monographs of part IIa.
In anthroposophic pharmacy the treatment of the raw or starting materials can already be part of the pharma-ceutical processing, e.g. a plant can be cultivated under treatment with a metal or mineral preparation.
Metals can either be used as a concentrated starting material or undergo a pharmaceutical process depending on the rationale of the anthroposophic therapeutics.
Preparations can be di�erentiated according to the thermal condition or treatment in the pharmaceutical process. Hereby follows a scheme concerning the related pharmaceutical processes applied to plant material and the main sphere of action.
Preparations may be the �nal dosage form, be incor-porated into the �nal dosage form or be processed further, e.g. by potentisation.
Pharmaceutical process
Heat/cold degree
Starting material Main sphere of therapeutic action 1, 2
Cold maceration 2 – 8 °C fresh or dried plants, all parts System of nerves and senses throughout the whole organism
Maceration 15 – 25 °C fresh plants, all parts system of nerves and senses throughout the whole organism
Rhythmic processing
4/37 °C fresh plants, all parts rhythmic system
Digestion 37 °C fresh plants, leaves, �owers rhythmic system, circulation
Infusion 60 – 90 °C dried leaves, �owers metabolic system, any type of gland
Decoction ca 100 °C dried roots, barks, seeds metabolic system, digestive tract(stomach, intestine)
Distillation steam,ca 100 °C
fresh or dried plants, all parts metabolic system, digestion
Treatments in liquid phase
Pharmaceutical process
Heat degree Starting material Main sphere of therapeutic action 1, 2
Toasting 170 – 250 °C dried plants, all parts, dried zoological starting material
metabolic system, digestion (liver)
Carbonisation above 200 °C dried plants, all parts, zoo-logical starting material
metabolic system, kidney organisation
Ash process above 500 °C dried plants, all parts, zoo-logical starting material
region of the lungs (respiration)
Treatments in dry phase
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
A crucially important pharmaceutical process is potentisation:• Potentised preparations are gradually diluted sub-
stances, whereby at each diluting step a rhythmic succussion (liquid potencies) or trituration (solid potencies) has been carried out.
• During this process the surface of the vehicle and the substance to be potentised are expanded and the mixing is thorough. �e potentising time di�ers for solid and liquid potentised preparations. Astrono-mical aspects may be considered (e.g. solar or lunar eclipse). Anthroposophic pharmacy mainly uses decimal attenuations. For co-potentised preparations the ratio between active substances to vehicle may vary, di�ering from 1:10 for homoeopathic co-potentising methods (see also Part IIa, 8 ”Potentised Preparations“).
• A
PC P
art I
Ia
25
1General scheme for the correlation between spheres of therapeutic action/ degree of potentisation:
Mother tincture – D10 Metabolic system
D11-D20 Rhythmic system
>D20 System of nerves and senses
See also:International Federation of Anthroposophic Medical Associa-tions, “�e System of Anthroposophic Medicine”, pp. 26-28 at http://www.ivaa.info/user�les/�le/SystemAnthroposMedicine2011_Interaktiv.pdf
2 See IAAP brochure: “Basic Information on the Working Prin-ciples of Anthroposophic Pharmacy”, 2005, http://www.iaap.org.uk/downloads/principles.pdf
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• A
PC Part IIa
26
General method of the APC Related speci�c production method
Ph.Eur. (2371)
HAB Ph.Helv. B.Hom.P. APC
1. Special treatment of raw materials
1.1. Vegetabilisation methods of substances used for mother tinctures
17.7.1.1, 17.7.1.2
Br1 1.1.1, 1.1.2
2. Metal preparations
2.1. Metal mirrors 17.7.2.1 – 4
2.1.1, 2.1.2, 2.1.3, 2.1.4
3. Tinctures and viscous extracts
3.1. Cold treated mother tinctures and liquid preparations thereof
38 17.7.6
3.2. Tinctures made by maceration with water or ethanol/water
1.1.1 – 1.1.11
12b, c, m, n, o, p, q; 49
17.7.7.1 3.2.1, 3.2.2
3.3. Glycerol macerates 2.1.1 – 2.1.3 2.2.1 – 2.2.4
3.3.1, 3.3.2
3.4. Liquid preparations made by maceration with oil
3.4.1
3.5. Tinctures made by percolation 1.1.8 – 1.1.9 17.7.7.2 3.5.1
3.6. Bu�ered aqueous mother tinctures under exclusion of oxidative in�uence
32
3.7. Fermented tinctures 53 17.7.7.3 3.7.1
3.8. Tinctures made by digestion (Digestio) 18, 24b 17.7.8.1 3.8.1
3.9. Tinctures made by infusion (Infusum) 20, 24a; 17.7.8.3 3.9.1, 3.9.2, 3.9.3
3.10. Tinctures made by decoction (Decoction) 12k, l, 19, 23
17.7.8.4 3.10.1
3.11. Oil extracts with heat treatment 12d – g, 57
3.12. Preparations made by distillation 52 17.7.8.5 3.12.1, 3.12.2
Correlation table of general methods for the manufacturing of anthroposophic medicinal products – related speci�c production methods
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• A
PC P
art I
Ia
27
General method of the APC Related speci�c production method
Ph.Eur. (2371)
HAB Ph.Helv. B.Hom.P. APC
3.13. Tinctures obtained with rhythmic application of heat and cold
21 – 22, 33 – 37, 51
17.7.9 3.13.1, 3.13.2.
4. Solid starting materials obtained by heat
4.1. Toasted preparations (Tosta) 17.7.4.1
4.2. Carbons (Carbo) 17.7.4.2 Br4
4.3. Ashes (Cinis) 17.7.4.3 Br3
5. Solid preparations from plants (drying onto a vehicle)
5.1. Solid preparations from fresh plants 17.7.5.1 5.1.1
5.2. Solid preparations from liquids, plant juices or aqueous extracts
17.7.5.2 5.2.1, 5.2.2, 5.2.3
6. Liquid dilutions 3.1.1 – 3.1.3
7. Compositions 17.7.3 7.2.1 – 7.2.4
8. Potentised preparations
Potentising speci�cations in: 1 – 5
12j, 17
11, 15, 18, 19, 20 – 24, 32 – 38, 39a, 39b, 45, 51, 53
Br5 – 6 8.1.1, 8.1.2, 8.2.1, 8.2.2Other APC Methods8.3
9. Mixtures 12, 16
Note: anthroposophic medicinal products may also be manufactured in accordance with individual speci�cations or monographs, see also Part I, chapter 1.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• A
PC Part IIa
28
monograph; the �owers or/and the leaves with petioles, possibly with stalks, but no woody parts are included. �e plant material is mixed together with neutral plant-compost which activates the �rst composting processes. �is metal plant-compost mixture is stored in terracotta pots which are buried almost completely in the soil in the same �eld used in that growing sea-son. �e composting process is continued during the whole winter until the next spring.In spring the compost is completed and ready to be used to treat the plants of the next growing season, the second life cycle.
2nd life cycle:Seeds of the same species are sown in cultivation substrate or soil, which was treated with the compost, made from the plant of the 1st growing season. �ese plants (of the second life cycle) are also grown to their speci�c plant development stage (i.e. �owering). Compost is made from these plants, which is prepared in a way similar to the compost of the plants of the �rst life cycle. �is compost is stored in terracotta pots, buried in the soil, in the �eld of the plants of the second life cycle.
3rd life cycle:Seeds of the same species are sown in cultivation substrate or soil which was treated with compost made from the plants of the second vegetation period. �e plants of the third growing season (third vegetation period) are cultivated to their speci�ed harvest stage.
further processing�e harvested plants are processed into a mother tincture according to a manufacturing method of the Ph.Eur., HAB or the APC or are otherwise processed.
identification, tests, assayAccording to the relevant tincture monograph (See Part IIa, chapters in section 3) or dried herbal drug.
recommended designation �e designation states:• the fertilised plant,• the substance used,• the designation “cultum”, “culta”,• the reference pharmacopoeia/codex.
Examples: Tabacum Cupro cultum APC, Equisetum arvense Silicea cultum APC
Speci�c pharmacopoeia/APC production methods to produce vegetabilised substancesAPC Method 1.1.1 Vegetabilisation of substances of metallic origin (“vegetabilised metals”)
1. SPECIAL TREATMENTS OF RAW MATERIALS
In anthroposophic pharmacy treatment of the raw materials can be part of the pharmaceutically relevant processing, e.g. a plant can be cultivated under treatment with a preparation of a mineral, normally containing a speci�c metal.
1.1. Vegetabilisation methods (“vegetabilised metals“)
definitionVegetabilisation of substances can be considered as a particular kind of potentising process of metals or minerals taking place through nature. �e potentising process is carried out with plants and normally goes through three life cycles. �e life cycle means one vegetation period (growing season) for annual, and two growing seasons for biennial plants. �e substance and appropriate plant are chosen in accordance with the rationale of anthroposophic understanding of man and nature.
preparation of mineral substancesSee APC Method 1.1.1 and 1.1.2.
cultivation�e cultivation of vegetabilised metals is a three years process (for biennial plants 6 years), meaning three generations of plants are grown until the �nal plant can be further processed, for example to a mother tincture. �is process is basically the same for each speci�c metal (mineral)-plant combination. Important for the cultivation process is, that each plant grows in the cultivation substrate and �eld soil speci�-cally prepared for each vegetation period. �e following is a cultivation description for each of the three growing seasons or life cycles.Exemptions have to be prescribed in individual monographs (e.g. Bryophyllum, Equisetum arvense and �uja occidentalis).
1st life cycle: �e seeds are sown in soil, which has been treated with a diluted preparation of the concerned inorganic substance (approximately 50 – 200 g/m2). Alternatively, jars with cultivation substrate, mixed with 5 – 20 g di-luted preparation/L can be used. In this case, the young growing plants are transferred to soil, which has been treated as mentioned above.When the plants reach their full development, i.e. in the �owering stage, compost is made from these plants. For preparing that compost, the upper aerial parts of the speci�c plant are used as prescribed in the individual
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• A
PC P
art I
Ia
29
through di�erent states of aggregation.�e metals or metal salts can be brought through a liquid state (melted or as solution), gas state or plasmatic state to be subsequently (obtained again) condensed in solid state as the pure metal.Metal mirrors are deposits of metals in reduced state onto a surface by a speci�c method of production.
Metal mirrors, produced according to APC methods 2.1.1, 2.1.2 and 2.1.3 can be removed from the surface and may be potentised according to Ph.Eur. method 4.1.1 and 4.1.2 and HAB method 48.
tests�e following analytical tests are always carried out for the metal which is used as starting material to produce the mirror. �e metal mirror itself is only tested when it is produced by the method of reduction of metal salts (2.1.3), the method of chemical vapour decomposition (2.1.2) or the method of sputtering (2.1.4). �e metal mirror produced by the method of distillation (2.1.1) is tested a�er further processing as the �rst or second produced dilution.
identificationAt least one suitable identi�cation test is carried out.
testssee the individual monograph.
assayContent according to the individual monograph.
storageStore in a well-closed container.
recommended designation �e designation states:• the metal used,• the designation ”metallicum praeparatum” or in the
case of metal mirror foil the name of the metal follo-wed of the word “foil”,
• the reference pharmacopoeia/codex,Examples: Argentum metallicum praeparatum APC Cuprum mirror foil APC.
Speci�c pharmacopoeial/APC production methods to prepare metal mirrors
APC Method 2.1.1 Metal mirrors obtained by distillationMetal mirrors prepared by distillation are obtained from the pure metal.�e pure metal is heated in appropriate equipment under vacuum until it evaporates. �e temperature and
For the vegetabilisation of substances of metallic origin plants are treated with a diluted substance, prepared from either a naturally occurring metal or a metal containing mineral (ore).
preparation of metallic substance�e raw material for the manufacturing of the mineral substance is a naturally occurring metal or a metal containing mineral (ore). �is is treated during several steps with mineral acids and other substances, contain-ing the chemical elements C, H, N, O and S, to a com-plex composition containing the metal in a form whose chemical structure is not clearly de�ned. It is triturated with lactose monohydrate, the result being the metal substance D1: the content of the metal is 8 – 12 %. �e metal substance D1 is diluted with a neutral material, e.g. cellulose or sucrose, to form the diluted metal substance that is ready for use. �e calculated metal content of this diluted metal substance di�ers, according to the toxicity and natural abundance of the metal in the soil:Au, Ag, Pb, Sn, Hg: max. 100 ppmFe, Cu: max. 1000 ppm
APC Method 1.1.2 Vegetabilisation of silicatesFor the vegetabilisation of silicates plants are treated with appropriate mineral containing silica.
preparation of mineral substance�e raw material for the manufacturing of the mineral substance is a pulverised mineral silicate. �is is treated during several steps with mineral acids and other sub-stances, containing the chemical elements C, H, N, O and S, to a complex composition containing silicium in a form whose chemical structure is not clearly de�ned. It is triturated with lactose monohydrate; the result is the silica, particularly quartz substance D1: the content of silicium is 8 – 12 %, calculated as silicium dioxide .�e silica, particularly quartz substance D1 is diluted with a neutral material, e.g. cellulose or sucrose, to form the diluted silica, particularly quartz substance that is ready for use. �e calculated content is max. 1 % silicium dioxide.
2. METAL PREPARATIONS
Metals can either be used as a concentrated starting material or undergo a pharmaceutical process depend-ing on the rationale of the anthroposophic therapeutics.
2.1. Metal mirrors
definitionBy producing metal mirrors the metal is transformed
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• A
PC Part IIa
30
molecules. Ions of the inert gas impact then the surface of the metal and the result is an ejection of metal atoms from the surface. �e electric �eld leads to an ionisa-tion of the metal which goes into a plasma aggregation state (at 30 – 45 °C) and condensates as a metal mirror on the substrate, in this case a plastic foil (e.g. PET). A�er this process the metal mirror foil is stitched to a special cotton tissue directly over the metal mirror.�e metal mirror foils must not be further processed.
tests�ickness of the mirror.
recommended designation the reference pharmacopoeia/codex,for external use only.
3. TINCTURES, MOTHER TINCTURES, GLYCEROL MACERATES AND VISCOUS EXTRACTS
Tinctures, mother tinctures, glycerol macerates and viscous extracts are obtained from starting materials from botanical or zoological origin by pharmaceutical processes under cold condition (2 – 8 °C), at ambient temperature (15 – 25 °C), with heat treatment at dif-ferent temperatures, by rhythmic application of heat and cold, by fermentation as well as by destillation. If applicable, vehicles e.g. water, ethanol, water/ethanol mixtures, glycerol, oils may be used. �ey may be processed further.
3.1. Cold treated mother tinctures and liquid preparations thereof
definitionCold treated mother tinctures are prepared from fresh (frozen) or dried herbal drugs. �e maceration is carried out at a temperature of 2 – 8 °C using puri�ed water, water for injections or isotonic solution.
productionIf necessary, comminute the matter to be extracted. �e prescribed quantity of extraction solvent according to the individual monograph is added to the starting material. Mix thoroughly and allow to stand in a closed container, where applicable protected from light, for an appropriate time (at least 7 days). Shake or stir occa-sionally. Express and �lter.
identificationAt least one chromatographic identi�cation test is carried out.
the vacuum are to be chosen in such a way, that the metal is distilled. �e metal vapour condenses onto the surface of the cooler parts of the distillation equipment, producing a metal mirror. �e metal mirror is removed a�er cooling from the surface.�e exact conditions of the distillation are described in the individual monograph.
APC Method 2.1.2. Metal mirrors obtained by Chemical Vapour Decomposition, CVDMetal mirrors prepared by chemical vapour decompo-sition are obtained from a volatile metal compound.A volatile metal compound is distilled under vacuum in appropriate equipment. �e temperature and the vacuum are to be chosen in such a way, that the metal compound is distilled. �e vapour is further heated until decomposition of the metal compound. As a result, the pure metal condenses onto the surface of the distillation equipment, producing a metal mirror. A�er cooling the metal mirror is removed from the surface.
APC Method 2.1.3. Metal mirrors obtained by reductionMetal mirrors prepared by reduction are obtained from an appropriate metal salt.To a solution of a metal salt an appropriate reducing agent and reagents are added. �e pure metal precipi-tates onto the surface of the reaction vessel producing the metal mirror. �e metal mirror is removed from the surface, �ltered from the solution, washed with puri�ed water and ethanol (the concentration of ethanol depending of the nature of the used reagents), until foreign matters are no longer detectable in the rinsing water and then dried.
APC Method 2.1.4. Metal mirror foilMetal mirror foils are prepared by a process which transforms the processed metal into a plasma aggre-gation and �nally condenses as an approximate 55 – 65 nm thick metal mirror on to the substrate.To produce a metal mirror foil a process known as sputtering is used. In this vapour phase technique there is no melting of the metal. �e sputtering process is most commonly used for thin-�lm deposition of many di�erent metals. High energy ions impacting on the target can liberate sputtered atoms of the metal as well as positive ions and electrons. A metal target is put under the e�ect of a magnetrom. A magnetrom is comprised of a cathode (electron source) an anode (electron collector) and a combined electric and magnetic �eld. Vacuum conditions (0.5 – 5 x 10-3 mbar) are generated and an inert gas (e.g. Argon Ph.Eur.) is used as medium. �e process begins as a result of a collision and momentum transfer from an incoming particle which impacts the inert gas
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• A
PC P
art I
Ia
31
from light for an appropriate time. If necessary shake or stir occasionally. Express and �lter, if necessary.Adjustment of the content of constituents may be car-ried out, if necessary, either by adding the extraction solvent of suitable concentration or by adding another macerate of the herbal or animal starting material used. If prescribed in the individual monograph, the tincture can be adjusted to the speci�ed content by concentra-tion, carried out generally under vacuum.
identificationAt least one chromatographic identi�cation test is carried out.
testsDry residue (Ph.Eur. 2.8.16 or H 2.2.6). �e pre-paration complies with the limits prescribed in the individual monograph.Relative density (Ph.Eur. 2.2.5). Where applicable, the preparation complies with the limits prescribed in the individual monograph.Ethanol content (Ph.Eur. 2.9.10). Where applicable, the ethanol content complies with that prescribed in the individual monograph.Methanol and 2-propanol (Ph.Eur. 2.9.11). Maximum 0.05 per cent V/V of methanol and maximum 0.05 per cent V/V of 2-propanol, unless otherwise authorised by a national o�cial Pharmacopoeia, or another limit is justi�ed and authorised.
assayAn assay with quantitative limits is performed when starting materials with toxicologically or therapeuti-cally relevant substances are used.
storageStore in a well-closed container, protected from light.
recommended designation �e designation states:• the herbal or animal matter used,• where applicable, the fresh herbal or animal matter
used,• where applicable, the ethanol content in the pre-
paration,• where applicable, the ratio of starting material to ex-
traction liquid or of starting material to preparation,• the reference pharmacopoeia/codex.
Speci�c pharmacopoeial/APC production methods to produce tinctures and mother tinctures made by macerations with water or ethanol/water
Ph.Eur. (2371) Methods1.1.1 – 11
testspH (Ph.Eur. 2.2.3). Where applicable, the preparation complies with the limits prescribed in the individual monograph.Dry residue (Ph.Eur. 2.8.16 or H 2.2.6). �e pre-paration complies with the limits prescribed in the individual monograph.Relative density (Ph.Eur. 2.2.5). Where applicable, the preparation complies with the limits prescribed in the individual monograph.Methanol and 2-propanol (Ph.Eur. 2.9.11). Maximum 0.05 per cent V/V of methanol and maximum 0.05 per cent V/V of 2-propanol, unless otherwise authorised by a national o�cial Pharmacopoeia, or another limit is justi�ed and authorised.
assayAn assay with quantitative limits is performed when starting materials with toxicologically or therapeuti-cally relevant substances are used.
recommended designation �e designation states:• the herbal drug used,• where applicable, the fresh herbal drug used,• where applicable, the ethanol content in the
preparation,• where applicable, the ratio of starting material to ex-
traction liquid or of starting material to preparation,• the reference pharmacopoeia/codex.
Speci�c pharmacopoeial/APC production methods to produce mother tinctures obtained under cold conditions (2 – 8 °C)HAB Method 38
3.2. Tinctures and mother tinctures made by macerations with water or ethanol/water
definitionTinctures and mother tinctures made by maceration with water or ethanol/water are liquids and are ob-tained from fresh (frozen) or dried matter of botanical or zoological origin. �e maceration is carried out at a temperature not above 25 °C by using ethanol of a suitable concentration or puri�ed water.
productionIf necessary, comminute the matter to be extracted; animals are processed immediately a�er killing. �e pre-scribed quantity of extraction solvent according to the individual monograph is added to the starting material. Mix thoroughly and allow to stand in a closed container at the required temperature, where applicable protected
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• A
PC Part IIa
32
productionLower animals are killed immediately before process-ing; the parts of warm-blooded animals are processed immediately a�er being killed. Killing is carried out with respect for the animal su�ering.Comminute the matter to be extracted. Add the prescribed quantity of extraction solvent according to the individual monograph to the raw material. Mix thoroughly and allow to stand in a closed container at a temperature not above 25 °C, protected from light for an appropriate time. If necessary shake or stir occasionally. Express and �lter, if necessary.Adjustment of the content of constituents may be carried out, if necessary, either by adding the extraction solvent of suitable concentration or by adding another macera-te of the starting material of botanical or animal origin used.
identificationAt least one chromatographic or electrophoretic (animal matter) identi�cation test is carried out.
testsConductivity (Ph.Eur. 2.2.38). Where applicable, the preparation complies with the limits prescribed in the individual monograph.Relative density (Ph.Eur. 2.2.5). �e preparation com-plies with the limits prescribed in the individual mono-graph. Alternatively, the refractive index can be used.Refractive index (Ph.Eur. 2.2.6). Where applicable (preparations according to APC Methods 3.3.1 and 3.3.2), the refractive index of the preparation is mea-sured in appropriate equipment, this measure indicates the water content in the glycerol1, and this value is called ηm indicating the refractive index of the macerate. �is measure is used to calculate the proportion of glycerol of the macerate. �is calculation is made based on the following equation:
(eq.1)1
Electrophoresis (Ph.Eur. 2.2.31). Where applicable, the preparation complies with the characteristics prescribed in the individual monograph.Microbiological examination (Ph.Eur. 2.6.12, 2.6.13). Where applicable, the macerate complies with the limits prescribed.
assayAn assay with quantitative limits is performed when starting materials with toxicologically or therapeuti-cally relevant substances are used.
HAB Methods1 – 412b, c, m, n, o49
APC Method 3.2.1 (related to Ph.Eur. (2371) Method 1.1.8)Mother tinctures according to APC Method 3.2.1 are prepared using the maceration methods given in the Ph.Eur. monograph “Extracts” (0765). Use 1 part of dried plant or parts of plants to 20 parts of ethanol in suitable concentration (see HAB H 5.3), unless other-wise prescribed in the individual monograph.If adjustment to a given concentration is necessary, calculate the amount of ethanol required to obtain the concentration speci�ed or used for production from the equation given in Ph.Eur. (2371) Method 1.1.1. Mix the calculated amount of ethanol with the �ltrate. Allow to stand for not less than 5 days at a temperature not exceeding 20 °C, then �lter if necessary.
potentisation�e 2nd decimal dilution (D2) is made from2 parts of the mother tincture and8 parts of ethanol of the same concentration.
�e 3rd decimal dilution (D3) is made from1 part of 2nd decimal dilution and9 parts of ethanol of the same concentration.
Unless a di�erent ethanol concentration is speci�ed, use ethanol 30 per cent (m/m) for D4 and then 15 per cent (m/m) for subsequent dilutions from D5 onwards and proceed accordingly.
APC Method 3.2.2 (related to HAB Method 12a)Preparations according to APC Method 3.2.2 are tinc-tures for external use. �ey are prepared as follows:Use 1 part of dried plant or parts of plants to 10 parts of ethanol in suitable concentration (see HAB H 5.3), un-less otherwise prescribed in the individual monograph.Glycerol may be added up to 10 per cent.
3.3. Glycerol macerates
definitionGlycerol macerates comply with the de�nition in Ph.Eur. monograph 1038. �ey are prepared from fresh (frozen) or dried matter of botanical or zoologi-cal origin. �e maceration is carried out at the required temperature (not above 25 °C) using glycerol of a suitable concentration or a glycerol solution containing sodium chloride. 1 Miner, Carl S.& Dalton, N.N: (ed.). Glycerol, American Che-
mical Society, Monograph Series, n0 117. Reinhold Publishing Corp., New York 1953.
% Glycerol m⁄m = ηm – 1.3195
0.0016
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• A
PC P
art I
Ia
33
of the total mass, calculated based on the equation above (refractive index). Adjustment of the �nal content of glycerol to 85 % is carried out using measurement of refractive index, and adding glycerol.Adjustment of the content of constituents may be carried out, if necessary by adding another macerate of the herbal or animal starting material used.
3.4. Liquid preparations made by maceration with oil
definitionLiquid preparations prepared by maceration with oil are prepared from fresh (frozen) or dried matter of botanical or zoological origin. �e maceration is carried out at the required temperature (not above 25° C) mostly by using arachis oil or olive oil.
productionIf necessary, comminute the matter to be extracted. When animal matter is used, lower animals are killed immediately before processing, the parts of warm-blooded animals being processed immediately a�er killing. Killing is carried out with respect for the animal su�ering, e.g. according to HAB H 5.2.4.�e prescribed quantity of extraction solvent according to the individ-ual monograph is added to the starting material. Mix thoroughly and allow to stand in a closed container at the required temperature, protected from light for an appropriate time. If necessary shake or stir occasionally. Express and �lter, if necessary.Adjustment of the content of constituents may be car-ried out, if necessary, either by adding the extraction solvent of suitable concentration or by adding another macerate of the herbal or animal starting material used.
identificationAt least one chromatographic identi�cation test is carried out.
tests Relative density (Ph.Eur. 2.2.5). �e preparation complies with the limits prescribed in the individual monograph.Refractive index (Ph.Eur. 2.2.6). �e preparation complies with the limits prescribed in the individual monograph.Peroxide value (Ph.Eur. 2.5.5). Where applicable, the preparation complies with the limits prescribed in the individual monograph.
assayAn assay with quantitative limits is performed when starting materials with toxicologically or therapeuti-cally relevant substances are used.
storageStore in a well-closed container, protected from light.
recommended designation �e designation states:• the dried herbal drug or animal matter used,• where applicable, the fresh herbal drug or animal
matter used,• the glycerol content of the solvent used for the prepa-
ration,• where applicable, the ratio of starting material to ex-
traction liquid or of starting material to macerate,• the reference pharmacopoeia/codex.
Speci�c pharmacopoeial/APC production methods to produce glycerol maceratesPh.Eur. (2371) Methods2.1.1 – 2.1.3 (HAB Methods 42)2.2.1 – 2.2.4 (HAB Methods 41)
APC Method 3.3.1Glycerol macerates according to APC Method 3.3.1 are prepared from 3 parts of fresh (frozen) matter of botanical or zoological origin and 7 parts of glycerol by maceration.�e prescribed quantity of glycerol is added to the starting material. Mix thoroughly and allow to stand in a closed container for an appropriate time according to the individual monograph. If necessary, shake or stir occasionally. Express and �lter, if necessary.�e content of glycerol is determined using measure-ment of refractive index and should be 70–85 % (m/m) of the total mass, calculated based on the equation above (refractive index). Adjustment of the �nal content of glycerol to 85 % is carried out using measurement of refractive index, and adding glycerol.Adjustment of the content of constituents may be carried out, if necessary by adding another macerate of the herbal or animal starting material used.
APC Method 3.3.2Glycerol macerates according to APC Method 3.3.2 are prepared from 1 part of dried plants or parts of plants, 2 parts of puri�ed water and 7 parts of glycerol by maceration.�e prescribed quantity of puri�ed water is added to the starting material. Allow standing in a closed con-tainer for 6 hours. A�er that, the prescribed quantity of glycerol is added to the mixture. Mix thoroughly and allow to stand in a closed container for an appro-priate time according to the individual monograph. If necessary, shake or stir occasionally. Express and �lter, if necessary.�e content of glycerol is determined using measure-ment of refractive index and should be 75–85 % (m/m)
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• A
PC Part IIa
34
identificationAt least one chromatographic identi�cation test is carried out.
testsRelative density (Ph.Eur. 2.2.5). Where applicable, the preparation complies with the limits prescribed in the individual monograph.Dry residue (Ph.Eur. 2.8.16 or H 2.2.6). �e pre-paration complies with the limits prescribed in the individual monograph.Methanol and 2-propanol (Ph.Eur. 2.9.11). Maximum 0.05 per cent V/V of methanol and maximum 0.05 per cent V/V of 2-propanol, unless otherwise authorised by a national o�cial Pharmacopoeia, or another limit is justi�ed and authorised.
assayAn assay with quantitative limits is performed when starting materials with toxicologically or therapeutically relevant substances are used.
storageStore in a well-closed container, protected from light.
recommended designation �e designation states:• the fresh herbal drug used,• where applicable, the dried herbal drug used,• where applicable, the ethanol content in the
preparation,• where applicable, the ratio of starting material
to extraction liquid or of starting material to preparation,
• the reference pharmacopoeia/codex.
Speci�c pharmacopoeial/APC production methods to produce mother tinctures made by percolation
Ph.Eur. (2371), Methods 1.1.8, 1.1.9
HAB Methods 4
APC Method 3.5.1 (related to Ph.Eur. (2371) Method 1.1.8)
Mother tinctures according to APC Method 3.5.1 are prepared using the percolation methods given in the Ph.Eur. monograph “Extracts” (0765). Use 1 part of dried plant or parts of plants to 20 parts of ethanol in suitable concentration (see HAB H 5.3), unless other-wise prescribed in the individual monograph.If adjustment to a given concentration is necessary, calculate the amount of ethanol required to obtain the concentration speci�ed or used for production from
storageStore in a well-closed container, protected from light.
recommended designation �e designation states:• the dried herbal drug or animal matter used,• where applicable, the fresh herbal drug or animal
matter used,• where applicable, the solvent used for the preparation,• where applicable, the ratio of starting material to ex-
traction liquid or of starting material to preparation,
• the reference pharmacopoeia/codex.
Speci�c pharmacopoeial/APC production methods to produce liquid preparations made by maceration with oil
APC Method 3.4.1Preparations made according to APC Method 3.4.1 are oil extracts for external use prepared from 1 part of lower animals and 10 parts of arachis oil, re�ned (Ph.Eur.) as follows:
A�er having killed the animals with CO2, the animals are minced and mixed thoroughly with 10 parts of arachis oil, re�ned (Ph.Eur.). Protect the mixture from light. �e extraction time should not exceed 8 hours. �en �lter.
3.5. Mother tinctures made by percolation
definitionMother tinctures made by percolation are prepared from fresh (frozen) or dried herbal drugs. �e percolation is carried out at room temperature using ethanol of suitable concentration or puri�ed water.
productionIf necessary, comminute the herbal drug to be extracted to pieces of suitable size. Mix thoroughly with a potion of the prescribed extraction solvent and allow to stand for an appropriate time. Transfer to a percolator and allow the percolate to �ow slowly making sure that the matter to be extracted is always covered with the remaining extraction solvent. �e residue may be pressed out and the expressed liquid combined with the percolate.
Adjustment of the content of constituents may be carried out, if necessary, either by adding the extraction solvent of suitable concentration or by adding another percolate of the herbal drug used for the preparation.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• A
PC P
art I
Ia
35
Potentisation is generally carried out according to HAB Method 32.
Bu�ered aqueous mother tinctures and their liquid dilutions are exclusively intended for parenteral dosage forms. Before they are processed to �nished products, the mother tincture (D2) and the liquid dilution D3 must be stored for between 6 weeks and 1 year. Any eventual sediment must be excluded from the further processing.
identificationAt least one chromatographic identi�cation test is carried out.
testsLoss on drying (H 2.8.1). Loss on drying of the residue a�er �ltration.Sterility (Ph.Eur. 2.6.1). If bu�ered aqueous mother tinctures and their liquid dilutions are stored before further processing, they must comply with the test. Proportion of original extracts: Where applicable, the proportion of both extracts in the composition is determined e.g. by HPLC or by other suitable methods.Methanol and 2-propanol (Ph.Eur. 2.9.11). Maximum 0.05 per cent V/V of methanol and maximum 0.05 per cent V/V of 2-propanol, unless otherwise authorised by a national o�cial Pharmacopoeia or another limit is justi�ed and authorised.
assayAn assay with quantitative limits is performed when starting materials with toxicologically or therapeutically relevant substances are used.
storageStore in a well-closed, airtight container.
recommended designation �e designation states:• the herbal drug used,• the amount of herbal drug used,• the reference pharmacopoeia/codex.
Speci�c pharmacopoeial/APC production methods to produce bu�ered aqueous mother tinctures manufactured under exclusion of oxidative in�uence
HAB Method 32
3.7. Fermented mother tinctures
definitionFermented mother tinctures are aqueous preparations
the equation given in Ph.Eur. (2371) Method 1.1.1. Mix the calculated amount of ethanol with the �ltrate. Allow to stand for not less than 5 days at a temperature not exceeding 20 °C, then �lter if necessary.
�e 2nd decimal dilution (D2) is made from2 parts of the mother tincture and8 parts of ethanol of the same concentration.
�e 3rd decimal dilution (D3) is made from1 part of 2nd decimal dilution and9 parts of ethanol of the same concentration.
Unless a di�erent ethanol concentration is speci�ed, use ethanol 43 per cent (m/m) for subsequent dilutions from D4 onwards and proceed accordingly.
3.6. Bu�ered aqueous mother tinctures manufactured under exclusion of oxidative in�uence
definitionBu�ered aqueous mother tinctures manufactured under exclusion of oxidative in�uence are produced by exhaustive extraction of fresh (frozen) plants or parts of plants under the exclusion of atmospheric oxygen with a bu�er.
If the fresh plant material is not processed immediately, it must be stored in liquid nitrogen. �e loss on drying (H 2.8.1) must be determined before it is placed in liquid nitrogen.From 1 part of the plant material an amount of mother tincture, prescribed in the individual monograph, is produced according to HAB Method 32. �is amount is determined in a validation and depends on the loss on drying of the harvested plant material.�e mother tincture corresponds to the 2nd decimal dilution (mother tincture = D2).At �rst add a de�ned amount of ascorbate phosphate bu�er solution to the plant material and then �nely reduce this mixture to a slurry. Under further size reduction, add a quantity of ascorbate phosphate bu�er solution, su�cient for achieving the required amount of extract. Express, �lter and adjust to the required volume with ascorbate phosphate bu�er solution.
According to the individual monograph the production of the mother tincture may require the addition of a second extract from material of the same plant species harvested at a di�erent season. In this case mix the extracts in an appropriate apparatus to a composition (see Chapter 7) and then dilute in a de�ned proportion with ascorbate phosphate bu�er solution. �is compo-sition is the mother tincture (=D2).
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• A
PC Part IIa
36
HAB Method 53APC Methods 7.2.1, 7.2.3, 7.2.4
APC Method 3.7.1 (see also Compositions 7.2.1)Mother tinctures according to APC Method 3.7.1 are prepared from fresh plants or parts of plants following the procedure given below.Finely comminute the plants or parts of plants and mix 1 part of the plant mass with 1 part of puri�ed water. Leave to ferment at 20 to 24°C with the exclusion of air, ending the fermentation when the pH of the fermentation liquid has fallen to between 4 and 5. �en express and weigh the expressed liquid. �e weight of the expressed liquid is equal to 2 parts and is mixed with 1 part of a mixture of 0.95 parts of ethanol 94 per cent (m/m) and 0.05 parts of puri�ed water.�is tincture can together with another tincture of the same plant undergo a special pharmaceutical process leading to a composition according to method 7.2.1.
�is procedure is followed for plants harvested in the summer and for plants of the same species, harvested in the winter. �e mother tincture is produced by composing equal parts of the two tinctures.
potentisation�e 1st decimal dilution (D1) is made from3 parts of the mother tincture and7 parts of ethanol 30 per cent (m/m).
�e 2nd decimal dilution (D2) is made from1 part of the 1st decimal dilution and9 parts of ethanol 15 per cent (m/m).
Subsequent dilutions are produced as stated for D2.
recommended designation Preparations according to APC Method 3.7.1 carry the designation „ferm APC 3.7.1“.
3.8. Tinctures and mother tinctures made by digestion (Digestio)
definitionTinctures and mother tinctures made by digestion are liquids prepared from fresh (frozen) or dried plants or parts of plants with an additional heat treatment usually at 37 °C. �e digestion is carried out using ethanol of a suitable concentration or puri�ed water.
productionIf necessary, comminute the plant or parts of plants to be extracted. �e quantity of extraction liquid is
from fresh (frozen) or dried herbal drugs prepared by fermentation at room temperature.
productionIf necessary, comminute the herbal drug. Add puri�ed water according to the individual monograph and mix thoroughly. If stated in the individual monograph, add the prescribed fermenting agent. Allow to stand at room temperature for the time prescribed in the individual monograph protected from air, from light and, if necessary, from oxidation. Herea�er express and �lter, if necessary.
Adjustment of the content of constituents may be carried out with puri�ed water or by adding puri�ed water to the residue and expressing again.
identificationAt least one chromatographic identi�cation test is carried out.
testspH (Ph.Eur. 2.2.3). �e preparation complies with the limits prescribed in the individual monograph.Dry residue (Ph.Eur. 2.8.16 or H 2.2.6). �e preparation complies with the limits prescribed in the individual monograph.Relative density (Ph.Eur. 2.2.5). �e preparation complies with the limits prescribed in the individual monograph.Methanol and 2-propanol (Ph.Eur. 2.9.11). Maximum 0.05 per cent V/V of methanol and maximum 0.05 per cent V/V of 2-propanol, unless otherwise authorised by a national o�cial Pharmacopoeia, or another limit is justi�ed and authorised.
assayAn assay with quantitative limits is performed when starting materials with toxicologically or therapeutically relevant substances are used.
storageStore in a well-closed container, protected from light.
recommended designation �e designation states:• the fresh herbal drug used,• where applicable, the dried herbal drug used,• where applicable, the ratio of starting material to ex-
traction liquid or of starting material to preparation,• the reference pharmacopoeia/codex.
Speci�c pharmacopoeial/APC production methods to produce fermented mother tinctures
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• A
PC P
art I
Ia
37
• the designation “Digestio” or “ethanol. Digestio” if ethanol is used,
• the reference pharmacopoeia/codex.
Speci�c pharmacopoeial/APC production methods to produce tinctures and mother tinctures made by digestion
HAB Methods 18HAB Method 24b
APC Method 3.8.1Tinctures according to APC Method 3.8.1 are prepared from fresh plants with puri�ed water as follows:Comminute the plants or parts of plants unless other-wise prescribed in the monograph. �e amount of plants or parts of plants and puri�ed water are de�ned by the monograph. Introduce the amount of puri�ed water into a round-bottomed �ask, place in a water bath and heat up to 48 – 52 °C. Add the plants or parts of plants whereby the �ask should be a half to three quarters full, mix thoroughly. Close the �ask hermeti-cally. Keep the mixture at 48 – 52 °C for 6 hours. Allow to cool to 35 – 39 °C in the course of 20 – 24 hours and maintain this temperature for 64 – 72 hours with occasional stirring. Allow to cool. If prescribed in the individual monograph add the amount of ethanol 94 per cent (m/m) prescribed then express and �lter.Tinctures according to APC Method 3.8.1 which are prepared with puri�ed water only, are generally processed immediately to solid preparations (see method 5.2 “Solid preparations from liquids, plant juices or aqueous extracts”).
recommended designation Preparations made according to APC Method 3.8.1 carry the designation “Digestio APC 3.8.1”. �e same applies to preparations made from them. Preparations made according to APC Method 3.8.1 with addition of ethanol carry the designation “ethanol. stab. digestio APC 3.8.1”.
3.9. Tinctures and mother tinctures made by infusion (Infusum)
definitionTinctures and mother tinctures made by infusion are prepared from adequately prepared dried plant material by adding boiling puri�ed water. If ethanol (of the prescribed concentration) is used, the quantities of ethanol and puri�ed water are added separately.
productionIf necessary, comminute the plant material. Boiling
added according to the individual monograph. Mix thoroughly and warm to 35 – 39°C. �en keep at 35 – 39°C in a covered container. Allow to stand at this temperature for the time prescribed in the individual monograph, stirring occasionally. A�er cooling, allow to stand at room temperature in a well-closed container, protected from light for the time described in the individual monograph. Add ethanol of appropriate concentration if prescribed. If necessary shake or stir occasionally. Express and �lter, if necessary.Adjustment of the content of constituents may be carried out by diluting, either with the same liquid used for the digestion or with another digestion of the same raw material.If prescribed in the individual monograph, the tincture can be adjusted to the speci�ed content by concentration, carried out carefully and generally under vacuum.
identificationAt least one chromatographic identi�cation test is carried out.
testspH (Ph.Eur. 2.2.3). Where applicable the preparation complies with the limits prescribed in the individual monograph.Dry residue (Ph.Eur. 2.8.16 or H 2.2.6). �e preparation complies with the limits prescribed in the individual monograph.Relative density (Ph.Eur. 2.2.5). �e preparation complies with the limits prescribed in the individualmonograph.Methanol and 2-propanol (Ph.Eur. 2.9.11). Maximum 0.05 per cent V/V of methanol and maximum 0.05 per cent V/V of 2-propanol, unless otherwise authorised by a national o�cial pharmacopoeia, or another limit is justi�ed and authorised.
assayAn assay with quantitative limits is performed when starting materials with toxicologically or therapeutically relevant substances are used.
storageStore in a well-closed container, protected from light.
recommended designation �e designation states:• the dried herbal drug used,• where applicable, the fresh herbal drug used,• where applicable, the ethanol content in the
preparation,• where applicable, the ratio of starting material
to extraction liquid or of starting material to preparation,
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• A
PC Part IIa
38
HAB Method 20HAB Method 24a
APC Method 3.9.1 (related to HAB Method 20)Mother tinctures according to APC Method 3.9.1 are prepared from dried plants or parts of plants, using 1 part of the plant material and 10 parts of ethanol of the concentration, prescribed in the individual monograph as follows:Add the amounts of ethanol and puri�ed water required to obtain the prescribed ethanol concentration separately.Unless a degree of comminution is speci�ed in the monograph, comminute the herbal drug appropriately, add the total amount of boiling puri�ed water, cover and allow to stand until room temperature is reached, for not more than 12 h. Compensate any water loss by evaporation and add the required amount of ethanol. Allow to stand in a well-closed container for 24 – 36 h, stirring occasionally. Express and �lter.
potentisation�e mother tincture corresponds to the 1st decimal dilution (Ø = D1).�e 2nd decimal dilution (D2) is made from1 part of the mother tincture and9 parts of ethanol of the same concentration as calculated for the mother tincture.
Subsequent decimal dilutions are produced accordingly; in this process the ethanol concentration is reduced with each step in the succession – 43 – 30 – 15 per cent (m/m) until the 15 per cent level is reached.
recommended designation Preparations made according to APC Method 3.9.1 carry the designation “ethanol. stab. infusum”. �e same applies to preparations made from them.
APC Method 3.9.2 (related to HAB Method 20) deleted
APC Method 3.9.3Mother tinctures according to APC Method 3.9.3 are prepared from fresh or dried plants or parts of plants, using 1 part of the plant material and 10 parts of water (m/m) or according to the individual monograph.Comminute the starting material and add the total amount of boiling puri�ed water, cover and allow to stand until room temperature is reached, for not more than 12 h. Compensate any water loss. Allow to stand in a well-closed container for 24 – 36 h, stirring occasionally. Express and �lter.
puri�ed water is used for extraction. If ethanol of suitable concentration is used, the quantity of ethanol is either used prior to extraction for moistening the dried plant material for the time prescribed or added to the mixture a�er cooling. Allow to stand in a well-closed container for the time prescribed. If only puri�ed water is used as solvent, it is also used for moistening and to make up the �nal mass if prescribed. Express and �lter, if necessary. If only puri�ed water is used as solvent the preparation is processed further immediately.
identificationAt least one chromatographic identi�cation test is carried out.
testsDry residue (Ph.Eur. 2.8.16 or H 2.2.6). �e preparation complies with the limits prescribed in the individual monograph. Relative density (Ph.Eur. 2.2.5). �e preparation complies with the limits prescribed in the individual monograph.Methanol and 2-propanol (Ph.Eur. 2.9.11). Maximum 0.05 per cent V/V of methanol and maximum 0.05 per cent V/V of 2-propanol, unless otherwise authorised by a national o�cial Pharmacopoeia , or another limit is justi�ed and authorised.Sterility (Ph.Eur. 2.6.1). Applicable only if the infusion is a stored aqueous preparation.
assayAn assay with quantitative limits is performed when starting materials with toxicologically or therapeutically relevant substances are used.
storageStore in a well-closed container, protected from light, if the tincture contains ethanol.If aqueous tinctures made by infusion are stored they must meet the requirements of sterility (Ph.Eur. 2.6.1).
recommended designation �e designation states:• the herbal drug used,• where applicable, the ethanol content in the
preparation,• where applicable, the ratio of starting material to ex-
traction liquid or of starting material to preparation,• the designation “Infusum” or “ethanol. Infusum”, if
ethanol is used,• the reference pharmacopoeia/codex.
Speci�c pharmacopoeial/APC production methods to produce tinctures and mother tinctures made by infusion
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• A
PC P
art I
Ia
39
cent V/V of 2-propanol, unless otherwise authorised by a national o�cial pharmacopoeia, or another limit is justi�ed and authorised.
assayAn assay with quantitative limits is performed when starting materials with toxicologically or therapeutically relevant substances are used.
storageStore in a well-closed container, protected from light.
recommended designation �e designation states:• the herbal substance used,• where applicable, the fresh or dried herbal drug used,• where applicable, the ethanol content in the
preparation,• where applicable, the ratio of starting material to ex-
traction liquid or of starting material to preparation,• the designation “Decoctum” or “ethanol. Decoctum”,
if ethanol is used,• the reference pharmacopoeia/codex.
Speci�c pharmacopoeial/APC production methods to produce tinctures and mother tinctures made by decoction
HAB Methods 12k, 12l, 12qHAB Methods 19HAB Methods 23
APC Method 3.10.1 (related to HAB Method 19f)APC Method 3.10.1. is used for dried herbal drugs.Mother tinctures according to APC Method 3.10.1 are prepared by maceration with ethanol of an appropriate concentration as speci�ed in the individual monograph with additional heat treatment (decoction) as described below.1 part of dried herbal drug is macerated with 20 parts of ethanol of the appropriate concentration (anhydrous, 94 per cent m/m – 96 per cent V/V, 86 per cent m/m – 90 per cent V/V, 73 per cent m/m – 80 per cent V/V, 62 per cent m/m – 70 per cent V/V, 43 per cent m/m – 50 per cent V/V, 30 per cent m/m – 36 per cent V/V, 15 per cent m/m – 18 per cent V/V), unless otherwise prescribed in the individual monograph.
Unless otherwise prescribed, comminute the herbal drug, mix thoroughly with the total amount of ethanol of the appropriate concentration and heat to boiling under re�ux, maintaining at boiling temperature for 30 min unless otherwise speci�ed in the individual monograph.
potentisation�e mother tincture corresponds to the 1st decimal dilution (Ø= D1).�e 2nd decimal dilution (D2) is made from1 part of the mother tincture and9 parts of glycerol 85 % (m/m).
Subsequent dilutions are produced as stated for D2.
3.10. Tinctures and mother tinctures made by decoction (Decoction)
definitionTinctures and mother tinctures made by decoction are prepared from fresh or dried plants or parts of plants that have been allowed to boil with ethanol of a suitable concentration or puri�ed water or extracted with glycerol 85 % at 1000C.
productionIf necessary, comminute the plants or parts of plants, add the prescribed quantity of extraction solvent according to the individual monograph and mix thoroughly. Heat the mixture to boiling (in the case of glycerol 85 % to 1000C), if necessary under re�ux, maintaining at boiling temperature (in the case of glycerol 85 % at 1000C) for the time prescribed, usually 30 min. A�er cooling allow to stand in a well-closed container protected from light at room temperature for the time described in the individual monograph. If necessary, shake or stir occasionally. Express and �lter, if necessary.
Adjustment of the content of constituents may be carried out by diluting, either with the same liquid used for the decoction or with another decoction of the same raw material.If prescribed in the individual monograph, the tincture can be adjusted to the speci�ed content by concentration, carried out carefully and generally under vacuum.
identificationAt least one chromatographic identi�cation test is carried out.
testsDry residue (Ph.Eur. 2.8.16 or H 2.2.6). �e pre-paration complies with the limits prescribed in the individual monograph.Relative density (Ph.Eur. 2.2.5). �e preparation complies with the limits prescribed in the individual monograph.Methanol and 2-propanol (Ph.Eur. 2.9.11). Maximum 0.05 per cent V/V of methanol and maximum 0.05 per
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• A
PC Part IIa
40
Peroxide value (Ph.Eur. 2.5.5). Where applicable, the preparation made with a vegetable oil complies with the limits prescribed in the individual monograph.
assayAn assay with quantitative limits is performed when starting materials with toxicologically or therapeutically relevant substances are used.
storageStore in a well-�lled, airtight container, protected from light and heat. If necessary, the empty space in the container of oil extracts is �lled with an inert gas.
recommended designation �e designation states:• the fresh herbal drug used,• where applicable, the dried herbal drug used,• the extraction liquid used,• where applicable, the ratio of starting material to ex-
traction liquid or of starting material to preparation,• an indication of the extraction temperature,• the reference pharmacopoeia/codex.
Speci�c pharmacopoeial/APC production methods to produce viscous extracts with heat treatment
HAB Methods 12 d-gHAB Method 57
Individual Monographs:Cydonia oblonga, fruit, glycerol extract with heat treatment 1:2.1.
3.12. Preparations made by distillation (Distillates)
definitionDistillates are prepared from fresh plants or parts of plants or dried plants, organic or inorganic substances by steam distillation or water-and-steam distillation.�e distillation can be done in the presence of other substances that will not interfere with the �nal com-position of the distillate. �is process can be repeated several times in a rhythmic sequence of evaporation/condensation. Distillated preparations can be part of a more complex formulation that is composed by several fractions. Distillated preparations can be used as starting materials or �nished products and can be potentised.
productionAccording to the speci�c methods or the individual monograph.
Cool or allow to cool and leave the mixture to stand in a closed container for 12 – 36 h. Separate the residue from the ethanol and, if necessary, press out. In the latter case, combine the 2 liquids obtained.Adjust to the concentrations required in the individual monograph in accordance with Ph.Eur. (2371) Method 1.1.8.
potentisation�e 2nd decimal dilution (D2) is made from2 parts of the mother tincture and8 parts of ethanol of the same concentration.
�e 3rd decimal dilution (D3) is made from1 part of the 2nd decimal dilution and9 parts of ethanol of a reduced concentration as given below.
Subsequent decimal dilutions are produced accordingly; in this process the alcohol concentration is reduced with each step in the succession 94 – 86 – 73 – 62 – 43 – 30 – 15 per cent (m/m) until the 15 per cent level is reached.
3.11. Viscous extracts with heat treatment
definitionViscous extracts with heat treatment are prepared from fresh or dried herbal drugs using a fatty or mineral oil or glycerol 85 % as extraction liquid with heat.
productionIf necessary, comminute the herbal drug. Ethanol 94 per cent (m/m) may be added to moisten the plant material. �e prescribed quantity of the extraction liquid (mostly peanut, olive, sesame or sun�ower oil, liquid para�n, or glycerol 85 %) is added and mixed thoroughly with the herbal drug. �e mixture is heated at the prescribed temperature and allowed to stand in a closed container for an appropriate time. Extraction temperature and time are prescribed in the individual monograph. Finally express and �lter. If necessary, the empty space of the container is �lled with a protecting gas.
identificationAt least one chromatographic identi�cation test is carried out.
testsRelative density (Ph.Eur. 2.2.5). �e preparation complies with the limits prescribed in the individual monograph.Refractive index (Ph.Eur. 2.2.6). �e preparation complies with the limits prescribed in the individual monograph.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• A
PC P
art I
Ia
41
heat with �ame source, ending the distillation when 50 parts of distillated have been collected or according to the individual monograph.
�e aqueous distillation can be done in the presence of other substances that will not interfere with the �nal composition of the �nal distillate.
3.13. Mother tinctures obtained by rhythmic application of heat and cold
definitionMother tinctures obtained by rhythmic application of heat and cold are aqueous preparations from fresh or dried herbal drugs or saps from fresh herbal drugs, obtained by fermentation under cold and heat appli-cation.
productionComminute the herbal drug if necessary. Add puri�ed water. If stated in the individual monograph, add the prescribed fermenting agent.It is also possible to ferment the expressed plant sap or the �nely minced fresh plant without addition of puri�ed water. Treat rhythmically with application of heat (generally 37°C) and cold (generally 4°C). Where required, express and �lter a�er the time prescribed in the individual monograph. Salts, speci�c plant ashes, metals or minerals may be added according to the individual monograph.
identificationAt least one chromatographic identi�cation test is carried out.
testspH (Ph.Eur. 2.2.3). �e preparation complies with the limits prescribed in the individual monograph.Dry residue (Ph.Eur. 2.8.16 or H 2.2.6). �e preparation complies with the limits prescribed in the individual monograph.Relative density (Ph.Eur. 2.2.5). Where applicable, the preparation complies with the limits prescribed in the individual monograph.Methanol and 2-propanol (Ph.Eur. 2.9.11). Maximum 0.05 per cent V/V of methanol and maximum 0.05 per cent V/V of 2-propanol, unless otherwise authorised by a national o�cial pharmacopoeia, or another limit is justi�ed and authorised.
assayAn assay with quantitative limits is performed when starting materials with toxicologically or therapeutically relevant substances are used.
identificationAt least one chromatographic identi�cation test is carried out.
testsDry residue (Ph.Eur. 2.8.16 or H 2.2.6). �e preparation complies with the limits prescribed in the individual monograph.Relative density (Ph.Eur. 2.2.5). Where applicable, the preparation complies with the limits prescribed in the individual monograph.Methanol and 2-propanol (Ph.Eur. 2.9.11). Maximum 0.05 per cent V/V of methanol and maximum 0.05 per cent V/V of 2-propanol, unless otherwise authorised by a national o�cial pharmacopoeia or another limit is justi�ed and authorised.
recommended designation Distillates and derived dosage forms carry the designation „destillata“.
Speci�c pharmacopoeial/APC production methods to produce preparations made by distillation
APC Method 3.12.1 Preparations made by ethanolic distillation (related to HAB Method 52)
Distillates according to APC method 3.12.1 are prepared from fresh plants or parts of plants following the proce-dure given below.Comminute the plant material. Pour 8 parts of ethanol 86 per cent (m/m) over 100 parts of plant mass. Leave to stand in a closed container for at least 24 h, then steam distil, ending the steam distillation when 50 parts of distillate have been collected.
�e mother tincture is made from1 part of distillate and1 part of ethanol 15 per cent (m/m).
potentisation�e 1st decimal dilution (D1) is made from1 part of the mother tincture and9 parts of alcohol 15 per cent (m/m).Subsequent dilutions are produced as stated for D1.
APC Method 3.12.2 Preparations made by aqueous distillation
Distillates according to APC Method 3.12.2 are preparations of fresh or dried starting materials from mineral, vegetal and animal source, obtained by aqueous distillation.Comminute the material. To 1 part of material add water according to the individual monograph, then
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• A
PC Part IIa
42
�e 1st decimal dilution (D1) is made from1 part of Rh mother tincture and9 parts of water for injections.
Subsequent decimal dilutions are produced as stated for D1.
Ethanolic Dilutions �e 1st decimal dilution (D1) is made from1 part of Rh mother tincture and9 parts of ethanol 15 per cent (m/m).
Subsequent decimal dilutions are produced as stated for D1.
recommended designation Preparations made according to APC Method 3.13.1 carry the designation “Rh”; the same applies to prepa-rations made from them. If ethanol 15 per cent (m/m) is used from the 1st decimal dilution onwards, state this on the label.
APC Method 3.13.2 (related to HAB Method 22)Rh mother tinctures according to APC Method 3.13.2 are prepared from fresh plants, generally yielding distinctly less than 50 per cent of expressed liquid, as follows:
Comminute the plants immediately a�er harvesting. Subject the plant material to the diurnal hot-cold rhythm (“Rh”) for 7 – 10 days. Each morning, warm the plant material to approximately 35 – 39°C and maintain at this temperature. Each evening, cool the plant mate-rial to 2 – 6°C and maintain at this temperature.�en express. Transfer the expressed juice to containers and subject to the diurnal hot-cold rhythm (“Rh”) as described under method 3.13.1.
potentisationAqueous dilutions�e 1st decimal dilution (D1) is made from1 part of Rh mother tincture and9 parts of water for injections.
Subsequent decimal dilutions are produced as stated for D1.
Ethanolic dilutions�e 1st decimal dilution (D1) is made from1 part of Rh mother tincture and9 parts of ethanol 15 per cent (m/m).
storageStore in a well-closed container, protected from light, at 8 – 15°C.
recommended designation �e designation states:• the herbal drug used,• where applicable, the fresh herbal drug used,• where applicable, the name of the salt, metal or
mineral added,• where applicable, the ratio of starting material to ex-
traction liquid or of starting material to preparation,• the designation „ferm“ (with water and fermenting
agents) or „Rh“ (fermented plant sap without fermenting agents),
• the reference pharmacopoeia/codex.
Speci�c pharmacopoeial/APC production methods to produce mother tinctures obtained with rhythmic application of heat and cold
HAB Method 21HAB Method 22HAB Methods 33HAB Methods 34HAB Methods 35HAB Method 36HAB Methods 37HAB Methods 51
APC Method 3.13.1 (related to HAB Method 21)Rh mother tinctures according to APC Method 3.13.1 are prepared from fresh plants generally yielding more than 50 per cent of expressed liquid, as follows:
Comminute the plants immediately a�er harvesting and express. Transfer the expressed juice to containers and subject to the diurnal hot-cold rhythm (“Rh”) described below until fermentation is complete.Each morning, warm the expressed liquid to 35 – 39°C over a period of 30 – 90 min and maintain at this temperature. Each evening, cool the expressed liquid to 2 – 6°C over a period of 30 – 90 min and maintain at this temperature.Stir the liquid for 60 – 200 min during both temperature phases at the beginning, gradually decreasing to 10 min at the end of the fermentation process. Filter as soon as fermentation has ceased.
potentisationAqueous dilutions
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• A
PC P
art I
Ia
43
storageStore in a well-closed container.
recommended designation �e designation states:• the name of herbal or animal matter used,• the designation “tostus/a/um/”, example: Spongia
tosta,• the reference pharmacopoeia/codex.
Speci�c pharmacopoeial/APC production methods to produce toasted preparations.
According to the individual monograph.
4.2. Carbons – Carbo
definitionCarbons are obtained from dried plants or parts of plants or dried animal matter. �ey are dry, brittle, and generally black substances.�e plant or animal matter is heated to a temperature usually above 200 °C under reduced presence of oxygen to produce the carbonised deposit. �e carbonised substance is powdered.Carbons may be potentised according to Ph.Eur 4.1.1.
identification�e identi�cation is carried out according to the individual monograph.
tests�e tests are carried out according to the individual monograph, where applicable:• Acidity or Alkalinity,• Acid-soluble substances,• Adsorption power,• Alkali-soluble coloured matter,• Cyanide,• Ethanol-soluble substances,• Fluorescent substances,• Heavy metals (e.g. Ph.Eur. 2.4.8),• Loss on drying (Ph.Eur. 2.2.32),• Sulfated ash (Ph.Eur. 2.4.14),• Sul�de,• Total ash (Ph.Eur. 2.4.16),• Zinc.
assayAn assay is carried out according to the individual monograph, where applicable.
storageStore in a well-closed container.
Subsequent decimal dilutions are produced as stated for D1.
recommended designation Mother tinctures made according to APC Method 3.13.2 carry the designation “Rh”; the same applies to preparations made from them. If ethanol 15 per cent (m/m) is used from the 1st decimal dilution onwards, state this on the label.
4. SOLID STARTING MATERIALS OBTAINED BY HEAT
Heat treatment can be applied directly to solid starting materials from botanical or zoological origin without addition of a vehicle. �e heat treatment may be per-formed under presence or reduced presence of oxygen. Solid starting materials obtained by heat include toasted preparations (Tosta), carbons (Carbo) and ashes (Cinis).
4.1. Toasted preparations – Tosta
definitionToasted preparations are obtained from dried plants or parts of plants or solid, dried animal matter by toasting. Toasted preparations are dry, usually brownish and have an intense and characteristic odour.
�e substances to be toasted are crushed, if necessary, and are exposed to a heat source for the prescribed time. During the process water evaporates and the matter becomes brown or brownish. �is is achieved through control of the heat supply, usually 170 – 250 °C and by tossing the material during this procedure. �e toasted substance is powdered.Particle size of the raw material, temperature and heat-ing time are prescribed in the individual monograph.
Toasted substances may be potentised according to Ph.Eur. 4.1.1.
identificationAccording to the individual monograph.
tests�e tests are carried out according to the individual monograph, where applicable.
assayAn assay is carried out according to the individual monograph, where applicable.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• A
PC Part IIa
44
5. SOLID PREPARATIONS FROM PLANTS (DRYING ONTO A VEHICLE)
Solid preparations from plants are obtained either by drying fresh plants, plant juices or aqueous extracts onto a vehicle.
5.1. Solid preparations from fresh plants
definitionSolid preparations of fresh plants are prepared by drying fresh plant material onto suitable vehicles e.g. lactose monohydrate.
productionComminute the fresh plant material, and mix thoroughly with the vehicle in order to adsorb its liquid part. Dry the mixture gently and mill if necessary.�e preparation can be potentised according to Ph.Eur. (2371) Methods 4.1.1 and 4.1.2.
identificationAt least one chromatographic test is carried out.
testsLoss on drying (Ph.Eur. 2.2.32): �e solid preparation complies with the limits prescribed in the individual monograph.Microbiological quality (Ph.Eur. 5.1.4): (Non-aqueous preparations for oral use).
assayAn assay with quantitative limits is performed when raw materials with toxicologically or therapeutically relevant substances are used.
storageStore in a well-closed container, protected from light.
recommended designation �e designation states:• the name of the plant material used,• the quantity used,• the vehicle used,• the reference pharmacopoeia/codex.
Speci�c pharmacopoeial/APC production methods to produce solid preparations from fresh plants
Ph.Eur. (2371) Method4.1.1
APC Method 5.1.1Preparations according to APC Method 5.1.1 are solid preparations of fresh plants prepared by drying fresh
recommended designation �e designation states:• the name of the herbal or animal matter used,• the designation ”Carbo”, example: Carbo Gentianae,• the reference pharmacopoeia/codex.
Speci�c pharmacopoeial/APC production methods to produce carbons
B.Hom.P. Method Br4
4.3. Ashes – Cinis
definitionAshes are obtained from dried plants or parts of plants or dried animal matter. �ey are generally �ne, amorphous, white, grey, beige or brown powders.
�e herbal or animal matter is incinerated generally at a temperature above 500 °C.
Ashes may be potentised according to Ph.Eur. 4.1.1.
identification�e identi�cation is carried out according to the individual monograph.
tests�e tests are carried out according to the individual monograph, where applicable:• Acid insoluble substances,• Arsenic (e.g. Ph.Eur. 2.4.2),• Heavy metals (e.g. Ph.Eur. 2.4.8),• Loss on drying (Ph.Eur. 2.2.32).
assayWhere applicable the Cinis complies with the individual monograph.
storageStore in a well-closed container with a desiccant if necessary.
recommended designation �e designation states:• the name of the herbal or animal substance used,• the designation ”Cinis”, example: Cinis Tabaci,• the reference pharmacopoeia/codex.
Speci�c pharmacopoeial/APC production methods to produce ashes
B.Hom.P. Method Br3
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• A
PC P
art I
Ia
45
• the name of the plant material used,• the quantity used,• the vehicle used,• the reference pharmacopoeia/codex.
Speci�c pharmacopoeial/APC production methods to produce solid preparations from liquid extracts/ plant juicesPh.Eur. (2371) Methods (refer to potentisation)4.1.14.1.2
APC Method 5.2.1Preparations according to APC Method 5.2.1 are solid preparations from fresh plant juices prepared by drying the fresh plant juice onto lactose monohydrate or another excipient.Add 1 part of the expressed plant juice or aqueous extract to 1.9 parts of lactose monohydrate unless otherwise prescribed in the individual monograph to obtain a wet granulate. Dry the wet granulate gently until it reaches the dryness required. Mill, if necessary, then sieve as speci�ed in the individual monograph and remix thoroughly. For granulation it may be necessary to concentrate the plant juice under reduced pressure.
APC Method 5.2.2Preparations according to APC Method 5.2.2 are solid preparations from fresh plant juices prepared by drying the fresh plant juice onto lactose monohydrate or another excipient.�e expressed plant juice of 1 part of the fresh plant is added to 3 parts of lactose monohydrate unless other-wise prescribed in the individual monograph to obtain a wet granulate. Dry the wet granulate gently until it reaches the dryness required. Mill, if necessary, then sieve as speci�ed in the individual monograph and re-mix thoroughly. Before granulation it may be necessary to concentrate the plant juice under reduced pressure.
APC Method 5.2.3Preparations according to APC Method 5.2.3 are solid preparations from aqueous extracts prepared by drying aqueous extracts of fresh plants onto lactose monohydrate or another excipient.Mix 1 part of the comminuted fresh plants with 0.15 parts of puri�ed water. �en express the mixture. �e expressed aqueous extract is added to 4 parts of lactose monohydrate unless otherwise prescribed in the individual monograph to obtain a wet granulate. Dry the wet granulate gently until it reaches the dry-ness required. Mill, if necessary, then sieve as speci�ed in the individual monograph and remix thoroughly. Before granulation it may be necessary to concentrate the aqueous extract under reduced pressure.
herbal drugs onto lactose monohydrate.Comminute the plants or parts of plants. To 1 part of the plant material add the required amount of lactose mono hydrate, usually 2.9 parts unless otherwise pre-scribed in the individual monograph. Mix thoroughly. Dry the moist mixture gently until it reaches the dryness required. Mill, if necessary, then sieve as speci�ed in the individual monograph and remix thoroughly.
potentisation�e preparation can be potentised according to Ph.Eur. (2371) Methods 4.1.1 and 4.1.2.�e 1st decimal dilution (D1) is made from 3 parts of the solid preparation and7 parts of lactose monohydrate
5.2. Solid preparations from liquids, plant juices or aqueous extracts
definitionSolid preparations of liquids are prepared by drying plant juices, tinctures, aqueous extracts or solutions or their dilutions onto suitable vehicles e.g. lactose monohydrate. �e expressed juice or the tincture from the fresh plant material or the solution is mixed thoroughly with the vehicle. �e mixture is dried gently and milled if necessary.�e preparation can be potentised according to Ph.Eur. (2371) Methods 4.1.1 and 4.1.2.
productionAccording to the speci�c methods or the individual monograph.
identificationAt least one chromatographic test is carried out.
testsLoss on drying (Ph.Eur. 2.2.32). �e solid preparation complies with the limits prescribed in the individual monograph.Microbiological quality (Ph.Eur. 5.1.4). (Non-aqueous preparations for oral use)
assayAn assay with quantitative limits is performed when raw or starting materials with toxicologically or therapeutically relevant substances are used.
storageStore in a well-closed container, protected from light.
recommended designation �e designation states:
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• A
PC Part IIa
46
7. COMPOSITIONS
Compositions are active substances which are obtained when two or more starting materials and/or prepara-tions with or without excipients and/or vehicles are processed together in a pharmaceutical process that will lead to a new substance (unit). �e rationale for composing is the anthroposophic understanding of man, nature, substance and processing. Compositions may be directly used as an active substance or can be potentised or diluted for any dosage form.
7.1. Compositions made by treating two or more starting materials by one or more pharmaceutical processes
definitionCompositions made by treating two or more starting materials or preparations by one or more pharma-ceutical processes are prepared by combining starting materials in a de�ned ratio according to the individual monograph using a speci�ed process (e.g. speci�ed mixing, heat treatment, chemical process).
productionAccording to the speci�c methods or the individual monograph.
identification/testsAccording to the nature of the composition. �e components of the composition comply with the requirements of the relevant monographs.
recommended designation �e designation states:• the name of the composition,• the composition of the product
(quantity of the ingredients),• reference pharmacopoeia/codex.
Speci�c APC production methods to produce compositions according to 7.1
Examples (see appendix 2.6): Anis-Pyrit, Ferrum-Quarz, Hepar-Magnesium, Hepar sulfuris, Kalium aceticum comp., Plumbum mellitum, Solutio Sacchari comp. (mineral compositions according to the model of a plant).
6. LIQUID DILUTIONS
definitionLiquid dilutions are prepared by dissolving one or more starting materials in an appropriate vehicle. �e liquid obtained may be directly potentised.
production�e starting material is dissolved in the appropriate vehicle. Dissolution may require heating or stirring. �e separation of a residue may be necessary.
Where necessary, immediately a�er the dissolution the �rst potentisation step is carried out in accordance with the individual monograph.
identificationLiquid dilutions are identi�ed using a suitable method.
testsAppearance (Ph.Eur. 2.2.1, 2.2.2). Where applicable, the preparation complies with the limits described in the individual monograph.pH (Ph.Eur. 2.2.3). Where applicable, the preparation complies with the limits prescribed in the individual monograph.Dry residue (Ph.Eur. 2.8.16 or H 2.2.6). Where applicable, the liquid solution complies with the limits prescribed in the individual monograph.Relative density (Ph.Eur. 2.2.5). �e preparation complies with the limits prescribed in the individual monograph.
assayWhere applicable, liquid solutions of chemically de�ned starting materials are assayed.
storageStore in a well-closed container, protected from light.
recommended designation �e designation states:• the name of the substance dissolved,• the quantity dissolved,• where applicable, the degree of potentisation,• the reference pharmacopoeia/codex.
Speci�c pharmacopoeial/APC production methods to produce liquid dilutions
Ph.Eur. (2371) Methods3.1.13.1.2
HAB Methods 5
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• A
PC P
art I
Ia
47
�is procedure is followed for plants harvested in summer and for plants of the same species, harvested in winter.�e mother tincture is a composition, produced by unifying equal parts of the two tinctures.
�e mother tincture can be potentised as follows:
�e 1st decimal dilution (D1) is made from3 parts of the mother tincture and7 parts of alcohol 30 per cent (m/m).
�e 2nd decimal dilution (D2) is made from1 part of the 1st decimal dilution and9 parts of alcohol 15 per cent (m/m).Subsequent dilutions are produced as stated for D2.
recommended designation Preparations according to APC Method 7.2.1 carry the designation „ferm APC 7.2.1“.
APC Method 7.2.2 Compositions of aqueous extracts and liquid preparations thereofCompositions according to APC Method 7.2.2 are mother tinctures produced from fresh (frozen) plants or parts of plants by the following procedure.�e plants or parts of plants are comminuted in a grinder, pressed in appropriate boxes and frozen at – 10°C to – 30°C. �e plants or parts of plants are combined to a speci�c formulation: Plants and parts of plants from winter harvest with plants from spring harvest to give the so called winter formulation. Plants from summer harvest with plants from autumn harvest to give the so called summer formulation. 5 parts of frozen plants are extracted for 1 – 4 h at 10 – 20°C with 95 parts of 0.09 % sodium chloride solution in a container with stirring. �e coarse plants or plant parts are separated by centrifugation. �e centrifugate is �lled up to 100 parts with 0.09 percent sodium chloride solution and �ltered. �e winter formulation produces the so called winter extract, the summer formulation the so called summer extract. If the extract is to be stored, sterile �ltration must take place.�e composition is produced by composing three parts of winter extract and one part of summer extract as described below.�e winter extract is stirred in a specially constructed gilded mixing vessel. �e summer extract is allowed to drop from the top of the vessel into the vortex of the winter extract. �e osmolality is adjusted by adding sodium chloride and the pH is adjusted to 6.1 – 6.3 by adding sodium hydroxide solution. If the composition is to be stored, sterile �ltration must take place. �e composition (mother tincture) can be used directly or
7.2. Compositions made by treating two or more extracts or mother tinctures of one plant by one or more pharmaceutical processes
definitionCompositions made by treating two or more mother tinctures of one plant by pharmaceutical processes are prepared from extracts (mother tinctures) of the same plant species harvested at di�erent seasons, i.e. at di�erent stages of development. According to the individual monograph the extracts are combined in a de�ned ratio by a speci�c pharmaceutical process possibly using speci�c equipment. Adjustment of concentration, of pH, and of osmolality may be carried out.
productionAccording to the speci�c methods or the individual monograph.
identification/testsAccording to the nature of the composition. �e components of the composition comply with the requirements of the relevant monographs.
recommended designation �e designation states:• the name of the composition,• the composition of the product
(quantity of the ingredients),• reference pharmacopoeia/codex.
Speci�c pharmacopoeial APC production methods to produce compositions according to 7.2
HAB Method 32HAB Method 38See appendix 2.6, for example Viscum album compositions.
APC Method 7.2.1 (see also APC Method 3.7.1)Compositions according to APC Method 7.2.1 are produced from fresh plants or parts of plants by the following procedure:Finely comminute the plants or parts of plants and mix 1 part of the plant mass with 1 part of puri�ed water. Leave to ferment at 20 to 24°C with the exclusion of air, ending the fermentation when the pH of the fermenta-tion liquid has fallen to between 4 and 5. �en express and weigh the expressed liquid. �e weight of the expressed liquid is equal to 2 parts and is mixed with 1 part of a mixture of 0.95 parts of ethanol 94 per cent (m/m) and 0.05 parts of puri�ed water. �is tincture is stored until it will undergo another pharmaceutical process with a second tincture of the same plant.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• A
PC Part IIa
48
Method 7.2.3Mix two parts of summer extract with 3 parts of water for injections.Mix one part of winter extract of plant material and one part of extract of berries with 3 parts of water for injections.
Method 7.2.4Mix two parts of summer extract with 3 parts of water for injections. Mix one part of winter extract of plant material and one part of extract of berries with a mixture of 0.002 parts of a metal salt trituration from the D4 potentisation step and 2.998 parts of water for injections.
Methods 7.2.3 and 7.2.4Feed the mixture of the winter extracts continuously onto the centre of a rotating disk. At the same time, feed the summer extracts continuously onto the slightly raised edge of the disk. �e blended mixture �ows con-tinually o� over the edge of the disk. Filter the mixture; the �ltrate is the mother tincture. If the mother tincture is stored for further processing, it must comply with the test for sterility (Ph.Eur. 2.6.1).�e dilution series is (composition or dilution + water for injections): 1+9 (20 mg), 1+19 (10 mg, correspond-ing to a 1:20 dilution); 1+39 (5 mg); 1 + 99 (2 mg); 1 part 1:20 dilution + 9 parts water for injections (1:200 or 1 mg); 1 part 1:200 dilution + 9 parts water for injections (1:2,000 or 0.1 mg); 1 part 1:2,000 dilution + 9 parts water for injections (1:20,000 or 0.01 mg); 1 part 1:20,000 dilution + 9 parts water for injections (1:200,000 or 0.001 mg); 1 part 1:200,000 dilution + 9 parts water for injections (0.0001 mg). To prepare the �nal preparation, add sodium chloride to the water for injections to obtain an isotonic solution.
Compositions produced according to methods 7.2.3 and 7.2.4 may be potentised according to chapter 8.
recommended designation �e amount of herbal drug (fresh plant) which was extracted to achieve 1 mL of the �nal preparation.
storageStore the mother tincture in a well-closed container at 2 – 8°C.
can be used for further dilutions. �e addition of anti oxidants or substances for pH adjustment is allowed.
Dilutions are obtained by diluting the composition. At a temperature between 10°C and 25°C the necessary amount of 0.9 percent sodium chloride solution is stirred in a vessel; the composition is dropped from the top into the vortex. �e dilution series is: (Composition + sodium chloride solution) e.g. 3+2 (30 mg), 2+3 (20 mg), 1+4 (10 mg), 1+9 (5 mg), 1+49 (1mg), 1+499 (0.1 mg); 1+4999 (0.01 mg). If the dilution is to be stored, sterile �ltration must take place.
recommended designation �e amount of herbal drug (fresh plant) which was extracted to achieve 1 mL/2 mL of the �nal preparation.
APC Method 7.2.3 and 7.2.4 Compositions of fermented aqueous extracts and liquid preparations thereofCompositions according to APC Method 7.2.3 and 7.2.4 are mother tinctures produced from fresh plants or parts of plants by the following procedure.Finely comminute the plants or parts of plants and mix 1 part of the plant mass with 1.318 parts of water for injections, 0.03 parts of sucrose, and 0.002 parts of a Lactobacillus plantarum suspension, 109 – 1010 cfu/mL and mix thoroughly. Leave to ferment for 3 days at 20 to 27°C with the exclusion of air. �en express and weigh the expressed liquid. If (except for the berries) gentle pressure applied to the plant residue does not achieve a �nal mass of extract equal to 2 parts, pour a su�cient amount of water for injections over the plant residue and express gently. Use the resulting extract to make the extract up to 2 parts. If prescribed in the indi-vidual monograph, adjust the pH to 5.0 – 6.5 by adding sodium hydroxide.Follow the same procedure for plant material harvested in the summer and for plant material of the same species, harvested in the winter. However, for the winter harvest, process the berries and the other plant parts separately according to the method described above and use 1.328 parts of water for injections and 0.02 parts of sucrose. Also, leave the berry mixture to ferment for 4 days.If the extracts are stored for further processing, they must comply with the test for sterility (Ph.Eur. 2.6.1).
�e composition is produced by composing equal parts of the summer and the combined winter extracts as described below.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• A
PC P
art I
Ia
49
recommended designation �e designation states:• the name of the preparation,• the composition of the product
(quantity of the ingredients),• reference pharmacopoeia/codex.
Speci�c pharmacopoeial/APC production methods to produce compositions according to 7.4
Examples (see appendix 2.6): Onopordum acanthium, Folium rec., ethanol. Digestio (1:3.1) with 1 – 2 % Hyoscyamus niger, Herba rec. Ø, see also Plantago lanceolata and Primula.
7.5. Compositions made by co-potentising
definitionCompositions made by co-potentising are prepared from two or more starting materials and/or prepara-tions (e.g. mother tinctures, potencies) by co-poten-tising over one or more steps.
productionAccording to APC Method 8.1 or the individual monograph.
identification/testsAccording to the nature of the composition. �e components of the composition comply with the requirements of the relevant monographs.
recommended designation �e designation states:• the name, quantity and potency degree of each
ingredient,• how many potentising steps were carried out on the
mixture as a whole,• reference pharmacopoeia/codex.
Speci�c pharmacopoeial/APC production methods to produce compositions according to 7.5Ph.Eur. (2371) Methods5.1.15.1.25.1.5
8. POTENTISED PREPARATIONS
Potentised preparations are gradually diluted substances, whereby at each diluting step a rhythmic succussion (liquid potencies) or trituration (solid or semi-solid potencies) has been carried out for a de�ned time. �e
7.3. Compositions made by treating one or more starting materials with one or more mother tinctures which undergo one or more pharmaceutical processes together
definitionCompositions made by treating one or more starting materials with one or more mother tinctures are obtained by combining one or more starting materials with one or more stocks in a de�ned ratio according to the individual monograph.
productionAccording to the speci�c methods or the individual monograph.
identification/testsAccording to the nature of the composition. �e components of the composition comply with the requirements of the relevant monographs.
recommended designation �e designation states:• the name of the composition,• the composition of the product
(quantity of the ingredients),• reference pharmacopoeia/codex.
Speci�c pharmacopoeial/APC production methods to produce compositions according to 7.3
Examples (see appendix 2.6): Cinis e fructibus Avenae sativae cum Magnesio phosphorico (1:1), Cissus-Ossa.
7.4. Compositions made by treating two or more extracts or mother tinctures and/or dilutions by one or more pharmaceutical processes
definitionComposition made by treating two or more extracts or mother tinctures and/or dilutions by pharmaceutical processes are prepared according to an individual monograph prescribing the combination of the ingre-dients in a de�ned ratio by a speci�c pharmaceutical process using speci�c equipment.
productionAccording to the individual monograph.
identification/testsAccording to the nature of the composition. �e components of the composition comply with the requirements of the relevant monographs.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• A
PC Part IIa
50
B.Hom.P. Method Br5B.Hom.P. Method Br6
�e potentising speci�cations in Ph.Eur. monograph 2371 of Methods 1.1.1 – 1.1.11, 2.1.1, 2.1.2, 2.2.1 – 2.2.4 and 5.1.1 – 5.1.5.
�e potentising speci�cations in HAB methods5, 11, 15, 18, 19, 20, 21, 22, 23, 24, 32, 33, 34, 35, 36, 37, 38, 39a, 39b, 45, 51, 53.
�e potentising speci�cations in APC Methods.
8.1. Co-potentised preparations
definitionMethod 8.1 is used for preparing dilutions by co- potentising two or more stocks and/or dilutions thereof, where co-potentisation consists of mixing several stocks or dilutions of stocks then potentising them together in one or more potentisation steps.
productionCo-potentised compositions according to APC Method 8.1 may be prepared from starting materials and/or solutions, potentised preparations and mother tinctures whose method of production is speci�ed by a ratio of 1 part of starting material and 10 parts of extraction solvent.When a solid potency D4 shall be potentised with liquids, it can be potentised one step according to Ph.Eur. (2371) Methods 3.2, and then be used as D5 for co-potentisation or dilution to a �nal concentration of 1 ppm.
Co-potentised compositions may be used to produce all types of dosage forms. Co-potentisation of mixtures according to APC Method 8.1 to produce parenteral preparations or eye drops is carried out with water for injections or an isotonic solution as diluting agent.
identification, test, assayare carried out according to the individual monograph.
storageStore in a well-closed container.
recommended designation �e designation states:• the name of the potentised substance(s),• where applicable, the ethanol content,• the potentising ratio; decimal potencies may be
designated as D or DH or X,• the potency degree, example: D3 or 3 DH or 3X,• the reference pharmacopoeia/codex.
potentising time di�ers for solid and liquid potentised preparations. Astronomical aspects may be considered (e.g. solar or lunar eclipse ).�e preparations are de�ned by the number of liquid potentising or trituration steps respectively and by the ratio between the vehicle (diluting agent) and the substance to be potentised.
�e potentising ratio is usually:1 part of substance9 parts of vehicle.
�e potentising ratio for co-potentised preparations is usually:1 part of a mixture of equal parts of active substances9 parts of vehicle.
liquid potencies:�e substance or mixture to be potentised is dissolved in the vehicle in the chosen ratio. Usual vehicles for liquid potencies are water (puri�ed or water for injections), ethanol of various concentrations, glycerol or vegetable oils. Excipients might be necessary, for example to emulsify an aqueous substance into oil. A�er dissolution, rhythmic succussion is carried out. For the next poten-tising step one part of the �rst potency and the prescribed amount of vehicle are brought together and succussed. Further potentising is carried out in likewise manner.
solid potencies (triturations):Potencies of solid substances are prepared by trituration of the substance to be potentised usually with lactose monohydrate in the prescribed ratio in a mortar with a pestle or in an adequate trituration machine.Solid potencies can be further potentised in liquid phase, if they are soluble in a vehicle.
semi-solid potencies:Semi-solid potencies are prepared by trituration of a liquid or a solid substance to be potentised with an ointment base in the prescribed ratio in a mortar with a pestle or in an adequate trituration machine.
Speci�c pharmacopoeial/APC production methods to produce potentised preparationsPh.Eur. (2371) Methods3.2.1 – 34.1.1 – 24.2.1 – 25.1.1 – 5
HAB Method 12jHAB Method 17
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• A
PC P
art I
Ia
51
identification, tests, assayare carried out according to the individual monograph.
storageStore in a well-closed container.
recommended designation �e designation states:• the name of the potentised substance(s),• the potentising ratio; decimal potencies may be
designated as D or DH or X,• the potency degree in the ointment,• the reference pharmacopoeia/codex.
APC Method 8.2.1 (Ointments containing powdered solid starting materials, related to HAB Method 48)Ointments containing powdered solid starting materials are produced with 1 part of a powdered metal, powdered mineral or a composition containing minerals and 9 parts of an ointment base leading to a homogeneous ointment. �is potentising step in an ointment base results in the �rst decimal dilution (D1). �e particle size of the powdered solid starting material must be smaller than 100 mm.Ointments according to APC Method 8.2.1 must meet the requirements of the Ph.Eur. monograph "Semi-solid preparations for cutaneous application" (0132).Ointments according to APC Method 8.2.1 can be used further to produce ointments according to HAB Method 13.
recommended designation Ointments according to APC Method 8.2.1 carry the desigation “APC M” and the resulting decimal dilution “D1”.
APC-Method 8.2.2 Ointments containing solid or liquid dilutionsOintments containing solid or liquid dilutions are produced with 1 part of a decimal solid or liquid dilution (Dn) and 9 parts of an ointment base leading to a homogeneous ointment. �e resulting decimal dilution degree is (Dn+1).Ointments according to APC Method 8.2.2. must meet the requirements of the Ph.Eur. monograph “Semi-solid preparations for cutaneous application” (0132).
recommended designation Ointments according to APC Method 8.2.2 carry the designation of the resulting degree of decimal dilution. Example: D3 or 3 DH or 3X APC 8.2.2.
APC Method 8.1.1 (Ph.Eur. (2371) Method 5.1.5)Co-potentised preparations according to APC Method 8.1.1 are liquid dilutions potentised with a suitable vehicle from two or more (n) preparations, each making up 1 part of the �nal 10 parts. Consequently the vehicle is 10 minus n parts.
potentisationFor the �rst co-potentisation step combine and succuss 1 part of each of the n preparations with 10 minus n parts of water or ethanol of the appropriate concen-tration speci�ed under HAB H 5.3. For each further co-potentisation step the ratio is 1 part of the given composed potency and 9 parts of vehicle.
recommended designation �e designation of co-potentised compositions according to APC Method 8.1.1 and derived dosage forms states how many potentising steps were carried out on the mixture as a whole adding the expressions “rhythmically diluted”.
APC Method 8.1.2 (related to Ph.Eur. (2371) Methods 5.1.1 and 5.1.2)
Co-potentised preparations according to APC Method 8.1.2. are liquid dilutions potentised with a suitable vehicle from two or more (n) preparations, each making up 1/n part of the �nal 10 parts. Consequently the vehicle is 9 parts.
potentisationFor the �rst co-potentisation step combine and succuss 1/n part of each of the n preparations with 9 parts of water or ethanol of the appropriate concentration speci�ed under HAB H 5.3. For each further co-poten-tisation step the ratio is 1 part of the given composed potency and 9 parts of vehicle.
recommended designation �e designation of co-potentised compositions according to APC Method 8.1.2. and derived dosage forms states how many potentising steps were carried out on the mixture as a whole.
8.2. Potentising in an ointment base
definitionLiquid and solid starting materials can be potentised within an ointment base.
productionAccording to the speci�c methods or the individual monograph.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• A
PC Part IIa
52
9.2. Mixtures of preparations with a vehicle9.2a. Liquid preparations produced according to Ph.Eur., HAB or APC Methods in which the vehicle is added in a ratio other than 1 to 10 or 1 to 100.9.2b. Solid preparations produced according to Ph.Eur., HAB or APC Methods in which the vehicle is added in a ratio other than 1 to 10 or 1 to 100.9.2c. Liquid and solid preparations, produced according to Ph.Eur., HAB or APC Methods, resulting in a liquid preparation, in which the vehicle is added in a ratio other than 1 to 10 or 1 to 100.9.3. Mixtures of preparations with excipients and vehicles.9.3a. Liquid preparations produced according to Ph.Eur., HAB or APC Methods with an excipient(s).Vehicles may be added.9.3b. Liquid and solid preparations, produced according to Ph.Eur., HAB or APC Methods, resulting in a liquid preparation with an excipient(s). Vehicles may be added.9.4. Mixtures of starting materials used as active substances and mother tinctures or preparations with or without vehicles and/or excipients.
recommended labelling• the ingredients mixed and their quantity,• reference pharmacopoeia/codex.
Speci�c pharmacopoeial/APC production methods to produce mixturesHAB Method 12HAB Method 16
8.3. Triturations
definitionPreparations according to APC Method 8.3 are tritura-tions of solid substances with lactose monohydrate as potentising vehicle unless otherwise speci�ed in a ratio of 1:10.
productionTriturate using a machine that ensures even trituration. Suitable machines include mixers with rhythmic, pul sating spatial inversion (e.g. “Turbula”), in combination with a sealable mixing vessel and appropriate grinding balls as well as other machines with rotating movements such as the ball mill.Triturate the whole amount of vehicle with the substance to be potentised.�e trituration time depends on the machine and the chosen parameters. Trituration must be between 15 and 60 minutes. It has to be ensured, that the trituration is homogeneous and that particle size reduction is achieved.
testsare carried out according to the individual monograph.
recommended designation Preparations according to APC Method 8.3 carry the designation of the resulting degree of decimal dilution. Example: D3 or 3 DH or 3X APC 8.3.
9. MIXTURES
definitionMixtures are produced from usually two or more active substances.Vehicles and/or excipients may be added. Mixtures contain the sum of the active substances mixed together. Mixtures can also be produced from one active substance and a vehicle. A special manufacturing method is not needed (cf. compositions). Mixtures are used to facilitate the administration of more than one active substance in one single �nished product. �e mixture itself may be the �nal dosage form.
Mixtures can be classi�ed into four categories:9.1. Mixtures of preparations without a vehicle9.1a. Mixtures of liquid preparations produced according to Ph.Eur., HAB or APC Methods.9.1b. Mixtures of solid preparations produced according to Ph.Eur., HAB or APC Methods.9.1c. Liquid and solid preparations, produced according to Ph.Eur., HAB or APC Methods, resulting in a liquid preparation.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• A
PC P
art I
Ib
53
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
ANTHROPOSOPHICPHARMACEUTICAL CODEXAPC
PART IIbIndividual monographs of starting materials and preparations
Table of ContentPart IIbCYDONIA OBLONGA, FRUIT ............................ 54CYDONIA OBLONGA, FRUIT, HEAT TREATED AQUEOUS TINCTURE 1:2.1 ............ 54CYDONIA OBLONGA, FRUIT, GLYCEROL EXTRACT WITH HEAT TREATMENT 1:2.1 ..................................... 55
CYDONIA OBLONGA, FRUIT, MOTHER TINCTURE OBTAINED BY RHYTHMIC APPLICATION OF HEAT AND COLD CYDONIA OBLONGA E FRUCTIBUS FERM 33B ..................................... 56LEVICO WATER ..................................................... 57
• A
PC Part IIb
54
production�e heat treated aqueous tincture is prepared in a ratio of fresh fruits to puri�ed water 1:2.1 and by heat treatment at 65 – 70°C as follows:
�e whole fresh ripe fruit are cut into pieces (2 – 4 cm). To 1 part of the cut fruit add 2.1 parts of puri�ed water and mix thoroughly. Heat to 65 – 70°C in a closed container and keep at this temperature for one hour swirling repeatedly. A�er cooling to 40 – 45°C separate by straining the mixture through gauze, �lter the resulting liquid and process immediately.
charactersAppearance: light yellow, slightly turbid liquid.Odour: fruity.
identification�in-layer chromatography (Ph.Eur. 2.2.27).
Test solution. Apply 10 mL onto a cartridge �lled with octadecylsilylated silica gel RH (particle size 55 – 110 µm, 360 mg), preconditioned sequentially with 10 mL of methanol R and 10 mL of water R. Wash the cartridge with 10 mL of water R. Elute with 10 mL of methanol R. Evaporate the eluate to dryness under reduced pressure. Dissolve the residue in 1 mL of methanol R.
Reference solution. Dissolve 5 mg of rutin R, 5 mg of hyperoside R and 5 mg of scopoletin R in 10 mL of methanol R.
Plate: TLC silica gel plate R.
Mobile phase: anhydrous formic acid R, water R, ethyl acetate R (15:15:70 V/V/V).
Application: 20 µL as bands.
Development: over a path of 10 cm.
Drying: at 105 °C for 5 min.
Detection: spray the plate while still warm with a 10 g/L solution of diphenylboric acid aminoethyl ester R in methanol R. Subsequently spray with a 50 mL/L solu-tion of macrogol 400 R. Examine in ultraviolet light at 365 nm within 30 min.
Results: see below the sequence of the zones present in the chromatograms obtained with the reference solution and the test solution. Other faint zones may be present in the chromatogram obtained with the test solution.
CYDONIA OBLONGA, FRUITCydonia oblonga, FructusCydonia
definitionFresh, ripe fruit of Cydonia oblonga Mill. collected during late summer and autumn.
characters�e odour is characterised by a typical �owery scent.
identification�e pear-shaped variety (var. pyriformis) is yellow, fragrant, fuzzy, 7 – 15 cm in diameter. �e gentle so� pulp is golden yellow.�e apple-shaped variety (var. maliformis) is yellow to greenish yellow, fuzzy, 7-15 cm in diameter and less fragrant. �e pulp is characterised by stone cells.Both varieties obtain �ve oblong-ovate sepals with serrate margins which are located in a depression. �ey are completely adnate with the 5 carpels. �e 5 loculi of the core generally each contain 5 to 15 or sometimes more brown, cuneate seeds arranged in 2 vertical rows and stuck together with a mucilaginous coat.
testsForeign matter (Ph.Eur. 2.8.2).As low as possible. �e whole batch is checked during manufacture. Foreign matter is sorted out.
Adulteration.Fruits from Japanese quince [Choenomeles japonica (�unb.) Lindl. ex Spach, syn. Cydonia japonica Pers., Rosaceae] and Chinese quince [Choenomeles speciosa (Sweet) Nakai, Rosaceae] are 4 to 5 cm in diameter with a smooth peel and being devoid of stone cells.
preparations1. Heat treated aqueous preparation according to the individual monograph,2. Heat treated preparation with glycerol according to the individual monograph,3. Tincture obtained by rhythmic application of heat and cold according to APC method 3.13 and method HAB 33b.
CYDONIA OBLONGA, FRUIT, HEAT TREATED AQUEOUS TINCTURE 1:2.1
definition�e heat treated aqueous tincture is prepared from the fresh cut fruit of Cydonia oblonga Mill., see Cydonia oblonga, Fruit (Cydonia oblonga, Fructus; Cydonia) APC
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• A
PC P
art I
Ib
55
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
charactersAppearance: light yellow, slightly turbid, viscous liquid.Odour: fruity.
identification�in-layer chromatography (Ph.Eur. 2.2.27).
Test solution. To 5 mL add 15 mL of water R. Apply the mixture onto a cartridge �lled with octadecylsi-lylated silica gel RH (particle size 55 – 110 µm, 360 mg), preconditioned sequentially with 10 mL of methanol R and 10 mL of water R. Wash the cartridge with 10 mL of water R. Elute with 10 mL of methanol R. Evaporate the eluate to dryness under reduced pressure. Dissolve the residue in 0.5 mL of methanol R.
Reference solution. Dissolve 10 mg of rutin R, 10 mg of hyperoside R and 2 mg of scopoletin R in 10 mL of methanol R.
Plate: TLC silica gel plate R.
Mobile phase: anhydrous formic acid R, water R, ethylacetate R (15:15:70 V/V/V).
Application: 20 µL as bands.
Development: over a path of 10 cm.
Drying: at 105 °C for 5 min.
Detection: spray the plate while still warm with a 10 g/L solution of diphenylboric acid aminoethyl ester R in methanol R. Subsequently spray with a 50 mL/L solution of macrogol 400 R. Examine in ultraviolet light at 365 nm within 30 min.
Results: see below the sequence of the zones present in the chromatograms obtained with the reference solution and the test solution. Other faint zones may be present in the chromatogram obtained with the test solution.
Top of the plate
Scopoletin: a blue zone A blue zone
A blue zone
__________________ __________________
Hyperoside: an orange zone
A strong light blue zone
Rutin: an orange zone An orange zone
__________________ __________________
Reference solution Test solution
testsRelative density (Ph.Eur. 2.2.5): 1.002 to 1.022.pH (Ph.Eur. 2.2.3): 3.0 to 4.0.Dry residue (Ph.Eur. 2.8.16): min. 2.5 % (3 g initial weight and dry at 105 °C for 2 hours).
storageIf stored it must meet the requirements of sterility, store in well closed containers, protected from light.
CYDONIA OBLONGA, FRUIT, GLYCEROL EXTRACT WITH HEAT TREATMENT 1:2.1
definition�e glycerol extract with heat treatment is prepared from the fresh cut fruit of Cydonia oblonga Mill., see Cydonia oblonga, Fruit (Cydonia oblonga, Fructus; Cydonia) APC.
production�e glycerol extract with heat treatment is prepared in a ratio of fresh fruits to glycerol (85 per cent) 1:2.1 and by heat treatment at 65 – 70 C as follows:
�e whole fresh ripe fruit are cut into pieces (2 – 4 cm). To 1 part of the cut fruit add 2.1 parts of glycerol (85 per cent) and mix thoroughly. Heat to 60 – 70°C in a closed container and keep at this temperature for one hour swirling repeatedly. A�er cooling to 40 – 45°C separate the mixture by straining through gauze, then �lter if necessary.
• A
PC Part IIb
56
Test solution. Apply 2 mL of the tincture onto a cartridge �lled with octadecylsilylated silica gel RH (sorbens mass 500 mg, 3 mL reservoir) preconditioned sequen-tially with 2 mL of methanol R and 2 mL of water R. Wash the cartridge with 10 mL of water R. Elute with 10 mL of ether R. �e eluate is evaporated to dryness. Dissolve the residue in 0.5 mL of methanol R.
Reference solution. Dissolve 10 mg of ca�eic acid R and 10 mg of hyperoside R in 10 mL of methanol R.
Plate: TLC silica gel plate R.
Mobile phase: anhydrous formic acid R, water R, ethyl acetate R (10:10:80 V/V/V).
Application: 60 µL of test solution and 10 µL of reference solution, as bands.
Development: over a path of 8 cm.
Drying: in air.
Detection: spray with a 10 g/L solution of diphenylboric acid aminoethyl ester R in methanol R. Subsequently spray with a 50 g/L solution of macrogol 400 R in methanol R. Examine in ultraviolet light at 365 nm a�er 30 min.
Results: See below the sequence of the zones present in the chromatograms obtained with the reference solution and the test solution. Other faint zones may be present in the chromatogram obtained with the test solution.
Top of the plate
Scopoletin: a blue zone A blue zone
A blue zone
__________________ __________________
Hyperoside: an orange zone
A strong light blue zone
Rutin: an orange zone An orange zone
__________________ __________________
Reference solution Test solution
testsRelative density (Ph.Eur. 2.2.5): 1.170 to 1.185.pH (Ph.Eur. 2.2.3): 3.5 to 5.0.
storageProtected from light.
CYDONIA OBLONGA, FRUIT, MOTHER TINCTURE OBTAINED BY RHYTHMIC APPLICATION OF HEAT AND COLD CYDONIA OBLONGA E FRUCTIBUS FERM 33B
definition�e tincture obtained by rhythmic application of heat and cold is prepared from the fresh minced fruit of Cydonia oblonga Mill., see Cydonia oblonga, Fruit (Cydonia oblonga, Fructus; Cydonia) APC.
production�e tincture obtained by rhythmic application of heat and cold is prepared according to HAB method 33b (APC method 3.13).
charactersAppearance: slightly yellow liquid.Odour: sour, fruity.
identification�in-layer chromatography (Ph.Eur. 2.2.27)
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• A
PC P
art I
Ib
57
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
LEVICO WATER
Aqua LeviciLevico
definitionNaturally occurring spring water from the source Levico (Italy).Content:• Arsenic: 4 – 8 ppm• Iron: 1000 – 2500 ppm
charactersAppearance: colourless to yellowish-brown liquid, usually clear, a slight sediment may occur.Odour: almost odourless.
identificationA. Identi�cation of arsenic by atomic absorption spectrometry (Ph.Eur. 2.2.23), see Assay.Results: the absorbance obtained with the test solution is not below the absorbance obtained with the reference solution with the lowest concentration.B. Identi�cation of iron by atomic absorption spectrometry (Ph.Eur. 2.2.23), see Assay.Results: the absorbance obtained with the test solution is not below the absorbance obtained with the reference solution with the lowest concentration.C. Identi�cation of copper by atomic absorption spectrometry (Ph.Eur. 2.2.23, Method I).Test solution. To 1.0 mL add 0.200 mL nitric acid R and dilute to 10.0 mL with water R.Reference solution. Prepare the reference solutions (0.5, 1.0, 2.0 and 4.0 ppm Cu) using copper standard solution R, diluted as necessary with a 5 per cent (V/V) solution of nitric acid R. Alternatively, commercially available copper standard solutions for atomic absorption spectrometry can be used.Source: copper hollow-cathode lamp using a transmis-sion band preferably of 0.5 nm.Wavelength: 324.8 nm.Flame: air-acetylene.Results: the absorbance obtained with the test solution is not below the absorbance obtained with the reference solution with the lowest concentration.D. To 0.5 mL add 4.5 mL of water R. �e solution gives reaction a on sulfates (Ph.Eur. 2.3.1).
testsRelative density (Ph.Eur. 2.2.5): 1.004 to 1.015.pH (Ph.Eur. 2.2.3): 1.5 to 2.5.
assayArsenic: 4 ppm to 8 ppm.
Top of the plate
Ca�eic acid: a light blue zone A light blue zone
__________________ __________________
Hyperoside: an orange yellow zone A light blue zone
__________________ __________________
Reference solution Test solution
testsRelative density (Ph.Eur. 2.2.5): 1.001 to 1.013.Dry residue (based on Ph.Eur. 2.2.32 d): minimum 1.0 per cent, determined on 1.000 g of mother tincture by drying for 4 to 5 hours at 105 °C.Calculate the dry residue (per cent m/m) from the expression:
∙ 100(m3 - m1)m2∙
m1 = mass of the crucible used, in grams;m2 = mass of the mother tincture used, in grams;m3 = mass of the crucible containing the mother tincture a�er drying, in grams.pH (Ph.Eur. 2.2.3): 3.0 to 4.2.
storageIn a well closed container at a temperature of max 15 °C.
• A
PC Part IIb
58
preparationsAccording to Ph.Eur., monograph 2371 Methods3.1.1, 3.1.2.
Atomic absorption spectrometry (Ph.Eur. 2.2.23, Method I).Test solution. To 0.200 mL add 2.00 mL nitric acid R and dilute to 100 mL with water R.Reference solutions. Prepare the reference solutions (5.0, 10.0, 15.0 and 20.0 ppb As) using arsenic standard solution R, diluted as necessary with a 5 per cent (V/V) solution of nitric acid R. Alternatively, commercially available arsenic standard solutions for atomic absorp-tion spectrometry can be used.Source: arsenic hollow-cathode lamp using a trans-mission band preferably of 0.5 nm.Wavelength: 193.7 nm.Atomisation device: graphite furnace.Calculate the content of arsenic in mg/kg from the expression:
X [ppm] = ( ) /1000A1 ∙ F1
F2∙
A1: measured concentration of arsenic in µg/LF1: 100 mL (dilution factor) F2: 0.200 mL
Iron: 1000 ppm to 2500 ppm.Atomic absorption spectrometry (Ph.Eur. 2.2.23, Method I).Test solution. To 0.500 mL add 2.00 mL nitric acid R and dilute to 100 mL with water R.Reference solutions. Prepare the reference solutions (5.0, 10.0, 15.0 and 20.0 ppm Fe) using iron standard solution R, diluted as necessary with a 5 per cent (V/V) solution of nitric acid R. Alternatively, commercially available iron standard solutions for atomic absorption spectrometry can be used.Source: iron hollow-cathode lamp using a transmission band preferably of 0.2 nm.Wavelength: 372.0 nm. Flame: air-acetylene.Calculate the content of iron in mg/kg from the expression:
X [ppm] = A2 ∙ F1
F2∙
A2: measured concentration of iron in mg/LF1: 100 mL (dilution factor) F2: 0.500 mL
storageStore in a well-closed container, protected from light.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• A
PC P
art I
II
59
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
ANTHROPOSOPHICPHARMACEUTICAL CODEXAPC
PART IIIDosage forms
Table of ContentPart IIIDosage forms ............................................................ 60 Index list of terms of part I, II and III .................... 63
• A
PC Part III
60
Dosage formsPrincipally an anthroposophic medicinal product can be administered in every dosage form, including ex-ternal (topical), internal and parenteral dosage forms, with or without excipients.A dosage form of an anthroposophic medicinal product complies with any relevant dosage form monograph
Main dosage forms for oral use Relevant monograph(s) in (Monograph number):
Standard term Traditional name
Capsules Capsules Ph.Eur. (0016)
Granules Granules Ph.Eur. (0499)
Homoeopathic Pillules, coated
Globuli velati Ph.Eur. (1038, 2786 Dra�), HAB Method 39
Homoeopathic Pillules, impregnated
Pillules Ph.Eur. (1038, 2079), HAB Method 10
Tablets Tablets Ph.Eur. (1038, 0478), HAB Method 9
Powders, oral Trituration Ph.Eur. (1165)
Oral drops Oral drops Ph.Eur. (0672)
Syrups Syrups Ph.Eur. (0672)
Oral solution Mother tincture, Dilution
Ph.Eur. (0672)
Main dosage forms for cutaneous use Relevant monograph(s) in (Monograph number):
Standard term Traditional name
Creams Creams Ph.Eur. (0132)
Ointments Ointments Ph.Eur. (0132), HAB Methods 13 and 48
Gels Gels Ph.Eur. (0132), HAB Method 13
Lotions Lotions B.P., Ph.Eur. (0927)
Oils Oils HAB Methods 12, Ph.Eur. (0927)
and any relevant test for that dosage form as described in the European Pharmacopoeia or in pharmacopoeias currently used o�cially in the EU Member States.
Main dosage forms for anthroposophic medicinal products and concerning references to o�cial pharmacopoeias:
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• A
PC P
art I
II
61
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
Main dosage forms for cutaneous use Relevant monograph(s) in (Monograph number):
Liquid preparations (other)
Tinctures for external use, external emulsions, suspensions
Ph.Eur. (0927), HAB Methods 12
Powders Powders Ph.Eur. (1166)
Main dosage forms for auricular use Relevant monograph(s) in (Monograph number):
Standard term Traditional name
Ear drops Ear drops Ph.Eur. (0652)
Main dosage forms for ophthalmic use Relevant monograph(s) in (Monograph number):
Standard term Traditional name
Eye drops Eye drops Ph.Eur. (1163), HAB Method 15
Semi-solid eye preparations
Eye ointments Ph.Eur. (1163)
Main dosage forms for nasal use Relevant monograph(s) in (Monograph number):
Standard term Traditional name
Nasal drops, solution Nasal drops Ph.Eur. (0676), HAB Method 45
Nasal spray, solution Nasal spray Ph.Eur. (0676)
Main dosage forms for oromucosal use Relevant monograph(s) in (Monograph number):
Standard term Traditional name
Gels Gels Ph.Eur. (1807)
Solutions Solutions Ph.Eur. (1807)
Sprays Sprays Ph.Eur. (1807)
Pillules Pillules Ph.Eur. (1038, 2079, 2786 Dra�), HAB Methods 10 and 39
• A
PC Part III
62
Main dosage forms for vaginal use Relevant monograph(s) in (Monograph number):
Standard term Traditional name
Gels Gels Ph.Eur. (1164)
Semi-solid vaginal preparations
Globules Ph.Eur. (1164)
Vaginal tablets Vagitories Ph.Eur. (1164)
Main dosage forms for rectal use Relevant monograph(s) in (Monograph number):
Standard term Traditional name
Suppositories Suppositories Ph.Eur. (1145), HAB Method 14
Main dosage forms for parenteral use Relevant monograph(s) in (Monograph number):
Standard term Traditional name
Injections Liquid dilutions for injection, ampoules, Solutions for injection
Ph.Eur. (0520), HAB Method 11
APC Pillules containing lactose (related to HAB Method 10)APC Pillules containing lactose are pillules made by applying one or more potentised liquid preparations to saccharose pillules, which may contain up to 5 per cent of lactose. �e potentising ratio usually is 1:100 (v/m or m/m). �e ethanol concentration of the potentised liquid preparation(s) is at least 60 per cent (m/m). If this is not the case and interactions are excluded, the last potentisation step for decimal potentised prepa-rations must be carried out with ethanol of at least 62 per cent (m/m). In case incompatibilities are expected, use ethanol of lower concentration.Preformed pillule sizes Ph.Eur. 3 and 6:Ph.Eur. size 3: 110 to 130 pillules weigh 1 gPh.Eur. size 6: 20 to 28 pillules weigh 1 g.Dry the pillules a�er impregnation in air.
recommended designation the designation states:the amount of potentised preparation(s),the potency degree,the potentising ratio in case other than 1:100.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• In
dex
63
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
Cissus-Ossa 49Cold maceration 24Compositions 18, 20, 22, 27, 36, 46, 47, 48, 49, 50, 51, 52Composting process 28Contaminants 21Co-potentisation 50, 51Co-potentising 25, 49, 50Council Directive (EEC) 21Creams 60Crystal 21Cuprum mirror foil 29Cutaneous application 51Cydonia oblonga 2, 8, 40, 54, 55, 56
DDAB 17DAC 17Demeter 21, 22Digestion 24, 26, 36, 37Directive 2001/83/EEC 11Distillate 40, 41 Distillation 20, 21, 24, 26, 29, 30, 40, 41Distillation products 20, 21Dornach 11, 20, 22Dosage forms 6, 12, 16, 18, 20, 22, 35, 41, 50, 51, 60, 61, 62
EEar drops 61ECHAMP 7Equisetum arvense Silicea cultum 28ESCAMP 6Essential oils 20, 21European Pharmacopoeia 2, 11, 12, 13, 17, 20, 22, 60Excipient 16, 18, 22, 45, 46, 50, 52, 60Extracts
13, 20, 21, 26, 27, 30, 32, 34, 35, 37, 40, 44, 45, 47, 48, 49Eye drops 50, 61
FFarmantropo 3Ferm 2, 36, 42, 47, 56Fermentation 30, 36, 41, 42, 47Fermented tinctures 26Ferrum-Quarz 18, 46Flowers 21, 24, 28French Pharmacopoeia 12, 17Fungi 20, 21
GGAPiD 3Gels 60, 61, 62German Homoeopathic Pharmacopoeia 11, 12, 17German Pharmacopoeia 12, 17GHP 17Glossary 18Glycerol macerates 26, 30, 32, 33Granules 60Growing season 28
INDEX LIST OF TERMS OF PART I, II AND III
AAbbreviations, list of 17Active substances 11, 16, 18, 20, 22, 25, 46, 50, 52AFERPA 3Agate water 21Algae 20, 21Animal matter 31, 32, 33, 34, 43, 44Animal origin 22, 32Anis-Pyrit 46Anode 30Anthroposophic medicinal products
11, 12, 16, 20, 22, 26, 27, 60Anthroposophic Pharmaceutical Codex
2, 11, 12, 16, 17, 20Anthroposophic pharmacy
2, 3, 11, 12, 16, 18, 20, 24, 25, 28Anthroposophic preparations 2, 12, 16, 18APC 17APC committee 2, 3, 11Aqua maris 21Argentum metallicum praeparatum 29Argon 30Ascorbate phosphate bu�er solution 35Ash process 24Astronomical aspects 25, 50Austrian Pharmacopoeia 12
BBAAP 3Bark 21, 24Biennial 21, 28Biodoron 22Biodynamic cultivation 21Blood products 20, 21BNVAA 3Botanical origin, starting materials of 20, 21Brazilian Pharmacopoeia 13British Homoeopathic Pharmacopoeia 12, 13, 17British Pharmacopoeia 12, 17
CCalcareous products 20, 21Capsules 60Carbo 27, 43, 44Carbo Gentianae 44Carbonisation 24Carbons 27, 43, 44Cathode 30, 57, 58Chemical vapour decomposition 17, 29, 30Cinis 27, 43, 44, 49Cinis e fructibus Avenae sativae
cum Magnesio phosphorico 49Cinis Tabaci 44
• Index
64
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
HHeat treatment 2, 26, 30, 36, 39, 40, 43, 46, 53, 55Hepar-Magnesium 46Hepar sulfuris 46Herbal Medicinal Products 11, 17Homoeopathic stocks 11, 12, 17Homoeopathic manufacturing method 11Homoeopathic manufacturing procedure 11, 12Homoeopathic preparations 12, 13, 17HPUS 16, 17
IIAAP 2, 12, 13, 17, 20, 25Infusion 24, 26, 37, 38Infusum 26, 37, 38Injections 8, 30, 42, 48, 50, 62Isotonic solution 22, 30, 48, 50IVAA 5, 17, 25
JJuices 20, 21, 27, 37, 44, 45
KKalium aceticum comp. 46KC Monograph 17Kohlhase, Manfred 3, 22Kommission C 17
LLactobacillus plantarum suspension 48Leaves and shoots 21Levico 2, 21, 57Lichens 20, 21Life cycle 28Liquid dilutions 27, 35, 46, 51, 62Liquid potencies 25, 49, 50Liquid preparations 26, 30, 33, 34, 47, 48, 52, 61, 62Liquid solutions 46Lotions 60Lunar eclipse 25, 50
MMaceration 24, 26, 30, 31, 32, 33, 34, 39Magnetrom 30Medicinal Products Act 12Metabolic system 24, 25Metallicum praeparatum 29Metal mirrors 26, 29, 30Metal plant-compost 28Metal preparations 26, 29Metal salts 29Metal vapour 30Minerals 20, 21, 28, 41, 51Mineral substances 28Miner, Carl S. 32Mixtures 18, 22, 27, 30, 50, 52Mother tinctures 13, 17, 21, 22, 26, 30, 31,
32, 34, 35, 36, 37, 38, 39, 41, 42, 43, 47, 48, 49, 50, 52
NNasal drops 61Nasal spray 8, 61Nitrogen 35
OÖGAPh 3Oils 30, 50, 60
see also Vegetable oilsOintments 51, 60Oleoresins 20, 21Oral drops 60Oral solution 60Organs 20, 21
PParenteral preparations 22, 50Percolate 34Percolation 26, 34Perennial plants 26, 34Petioles 28Pharmaceutical process
16, 18, 20, 22, 24, 25, 29, 30, 36, 46, 47, 49Pharmaceutical quality 12Pharmacopoea Helvetica 17Pharmacopoeia 2, 11, 12, 13, 16, 17, 18, 20, 22, 24, 28, 29,
30, 31, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 49, 50, 51, 52, 60 see also Austrian Pharmacopoeia see also British Pharmacopoeia see also British Homoeopathic Pharmacopoeia see also Brazilian Pharmacopoeia see also European Pharmacopoeia see also French Pharmacopoeia see also German Pharmacopoeia see also German Homoeopathic Pharmacopoeia see also Swiss Pharmacopoeia
Ph.Helv. 12, 17, 26, 27Pillules 60, 61, 62Plant secretions 20, 21Plumbum mellitum 46Potentised preparation 22, 25, 27, 49, 50, 51, 62Powders 44, 60, 61Preparations 18, 22, 24
QQuartz 29
RRaw materials 18, 26, 28, 44Rh 17, 42, 43Rhythmically diluted 51Rhythmic application 2, 27, 30, 41, 42, 54, 56Rhythmic procedure 17Rhythmic processing 24Rhythmic succussion 25, 49, 50Rhythmic system 24, 25Rocks 20, 21Rotating disk 48
• In
dex
65
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
SSchmiedel, Oskar 11Semi-solid vaginal preparations 62Silica 29, 54, 55, 56Silicium 29SOFAI 3Solar or lunar eclipse 25, 50Solid or semi-solid potencies 25, 49, 50Solid preparations from plants 27, 44Solid starting materials obtained by heat 27, 43Solutions 45, 50, 57, 58, 61, 62Solutio Sacchari comp. 46Sprays 61Sputtering 29, 30Starting materials 2, 12, 16, 18, 20, 21, 22, 24, 27, 30, 31, 32,
33, 34, 35, 36, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 51, 52Steiner, Rudolf 11, 20Summer extract 47, 48Suppositories 62Swissmedic 11, 17, 18Swiss Pharmacopoeia 2, 3, 17, 18Syrups 60
TTabacum Cupro cultum 28Tablets 60, 62�uja 28Tincture 2, 13, 17, 25, 26, 28, 30, 31, 32, 36, 37, 38,
39, 45, 47, 54, 56, 61 see also Fermented tincture see also Mother tincture
Toasted preparations 27, 43Toasting 24, 43Tosta 27, 43Trituration 25, 48, 49, 50, 52, 60
VVAEPS 3Vaginal tablets 62Vapour decomposition 29, 30Vegetabilisation 22, 26, 28, 29Vegetabilised metals 28Vegetable oils 50 Vegetation period 28Vehicle 16, 18, 22, 25, 27, 30, 43, 44, 45, 46, 50, 51, 52 Viscous extracts 26, 30, 40
WWaters, natural 20, 21Wegman, Ita 11, 20
ZZoological origin, starting materials of
20, 21, 22, 30, 31, 32, 33, 43
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
ANTHROPOSOPHICPHARMACEUTICAL CODEXAPC
PART IVAppendices
• Appendix
66
Table of ContentPart IVNote concerning appendix 2.3. ......................................67References concerning nomenclature in appendices 2.1. to 2.6. .................................................67Note concerning the references for usage in anthro-posophic medicine in appendices 2.1. to 2.6. ...............67References concerning usage in anthroposophic medicine in appendices 2.1. to 2.6. ...............................68IVAA statement concerning starting materials of animal origin not yet mentioned in published anthroposophic medical literature or in published o�cial regulatory documents concerning anthroposophic medicinal products .............................69
Appendix 2.1. List of minerals, rocks and natural waters ....................75Appendix 2.2. List of starting materials of botanical origin ................85
Appendix 2.3. List of starting materials of zoological origin ............127Appendix 2.4. List of starting materials that can be described chemically .....................................................153Appendix 2.5. List of starting materials that have undergone special treatment ............................................................165Appendix 2.6. List of compositions ......................................................169
Appendix II .....................................................................181
Correlation table: Ph.Eur. / HAB manufacturing meth-ods used in anthroposophic pharmacy and correspond-ing manufacturing methods in the HPUS ..................181
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Ap
pend
ix
67
Jäger EJ (Hrsg.).In: Rothmaler W. Exkursions�ora von Deutschland. Heidelberg: Springer Spektrum; 2011.
Schindler H, Helma F. Tiere in der Pharmazie und Medizin. Stuttgart: Hippokrates-Verlag; 1961.
Schmeil O, Fitschen J. Flora von Deutschland und angrenzender Länder. Heidelberg: Quelle & Meyer Verlag; 2006.
Schweingruber FH. Anatomie europäischer Hölzer. Bern/ Stuttgart: Haupt; 1990
Bresinsky A, Körner C, Kadereit JW, Neuhaus G, Sonnewald U. Strasburger Lehrbuch der Botanik. Heidelberg: Springer Spektrum; 2008.
Teuscher E. Biogene Arzneimittel.Stuttgart: Wissenscha�liche Verlagsgesellscha� mbH; 1997.
Note concerning the references for usage in anthro-posophic medicine in appendices 2.1. to 2.6.�e references given in the columns to the right in the appendices 2.1 to 2.6 aim to provide evidence, that the particular starting material is known and has been part of the medicinal tradition in anthroposophic medicine.
Where available, the monographs of the Commission C for medicinal products for human use dealing with the anthroposophic therapeutic direction (accord-ing to §25 of the German Drug Law) published in the German Federal Gazette (Bundesanzeiger) have been referred to. Where more than one monograph could be referred to, only one has been included. Not all starting materials are mentioned in the Commission C mono-graphs, because on the one hand its work stopped in 1994 a�er the 5th amendment of the German Drug law prior to completion work. On the other hand a number of starting materials in the lists are only known in the anthroposophic medicine tradition in countries other than Germany. �e Commission C monographs also refer to speci�c and composed active substances as well as existing pharmaceutical products. A number of references from other sources may refer generically to particular raw or starting materials, sometimes without linking to speci�c active substances. �e latter refer-ences show that the raw or starting material has been considered in therapeutic and pharmaceutical grounds in anthroposophic medicine. �ey may however also refer to speci�c active substances.
Note concerning appendix 2.3.Animal substances marked with “*” belong to cat-egory A materials according to “Note for guidance on minimising the risk of transmitting animal spongi-form encephalopathy agents via human and veteri-nary medicinal products” if sourced e.g. from cattle Bos taurus L. �ough sourcing from animals below 6 months of age from herds not fed with meat bone meal has been practice up to now in the �eld of concerning anthroposophic quality management, pharmaceutical manufacturers must continuously adapt their sourcing to the requirements of the Note for guidance, such as changing the donor animal. �e APC Committee needs to re�ect the existing practice and will adapt to imple-mented changes.
References concerning nomenclature in appendices 2.1. to 2.6.Bertsch K. Flora von Südwest-Deutschland. Stuttgart: Wissenscha�liche Verlagsgesellscha� mbH; 1962.
Chmelar J, Meusel W. Die Weiden Europas. Wittenberg Lutherstadt: Ziemsen-Verlag; 2004.
Erhardt W, Götz E, Bödeker N, Seybold S. Zander: Handwörterbuch der P�anzennamen. Stuttgart: Eugen Ulmer; 2008.
HagerROM 2006. Hagers Handbuch der Drogen und Arzneisto�e. Heidelberg: Springer Medizin Verlag; 2006.
Harms H. Die Mistel und ihre Verbreitung in Ostwestfalen. Mitt. Dt. Dendrologischen Gesellscha�; 1973.
Hartmann �. Anatomische und morphologische Untersuchungen zum Wechselverhältnis von Mistelp�anzen und ihren Wirtsgehölzen am Beispiel der Tannenmistel und der Kiefermistel. [Dissertation]. Technische Universität Berlin; 1994.
Moberg R, Holmasen I. Flechten von Nord- und Mitteleuropa. Ein Bestimmungsbuch. Stuttgart: Gustav Fischer; 1992.
Roberts WL, Rapp GR Jr, Weber J. Encyclopedia of Minerals. New York: Van Nostrand; 1974.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Appendix
68
International Federation of Anthroposophic Medical Associations, IVAA. Statement concerning starting materials of animal origin not yet mentioned in published anthroposophic medical literature or in published o�cial regulatory documents concerning anthroposophic medicinal products. Brussels: printed in APC Appendix I; 2013.
Monographs of the Commission C for medicinal prod-ucts for human use dealing with the anthroposophic therapeutic direction (according to §25 of the German Drug Law) published in the German Federal Gazette (Bundesanzeiger). Publication as compilation: An-throposophische Arzneimittel, Au�ereitungsmonog-raphien der Kommission C, published by Gesellscha� Anthroposophischer Ärzte in Deutschland e.V. (Soci-ety of anthroposophic doctors in Germany registered association) on behalf of the Medical Section at the Goetheanum, Dornach/ Switzerland; 1999.
Gesellscha� Anthroposophischer Ärzte in Deutschland e.V. and Medizinische Sektion der Freien Hochschule für Geisteswissenscha� Dornach. Vademecum An-throposophische Arzneimittel. Filderstadt (Germany); 2011; 3rd edition 2013.
Where there is no reference, the particular starting material has not yet been presented or discussed in publications. However anthroposophic pharmaceutical manufacturers place medicinal products on the market obtained from those starting materials. �e IAAP sees it as its task to promote the writing of publications, to support the relevance of the starting material in anthro-posophic medicine. Much work still needs to be done.
References concerning the use in anthroposophic medicine in appendices 2.1. to 2.6.Der Merkurstab (Zeitschri� für anthroposophische Medizin – Journal of Anthroposophic Medicine). Filderstadt: Gesellscha� Anthroposophischer Ärzte in Deutschland (Society of anthroposophic doctors in Germany).
Gardin N Schleier R. Vademecum, medicamentos antroposo�cos. São Paulo-SP: João de Barra Editora Ltda; 2009. Portugese.
Glöckler M. Anthroposophische Arzneitherapie (Anthroposophic �erapy with Medicinal Products). Stuttgart: Publisher Wissenscha�liche Verlagsgesell-scha�; 2010.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Ap
pend
ix
69
Statement concerning starting materials of animal origin not yet mentioned in published anthroposophic medical literature or in published o�cial regulatory documents concerning anthroposophic medicinal products
Anthroposophic medicinal products containing preparations from starting materials of animal origin belong to the range of anthroposophic therapeutics.1
Most of these starting materials and/or the anthroposophic medicinal products concerned are mentioned in anthroposophic medical literature or in o�cial regulatory documents. A certain number of these however are not mentioned in such references, although belonging to the range of anthroposophically used starting materials of animal origin. �e anthroposophic medicinal products concerned are available to doctors.2
�is statement con�rms the anthroposophic therapeutic usage and relevance of these starting ma-terials.3
�e starting materials of animal origin are listed on the following papers.4
For the IVAA
Dr. Peter ZimmermannDr. Andreas Arendt
15.02.2013
1 Girke M. Innere Medizin. 2. edition. Berlin: Salumed Verlag; 2012.2 Jütte R. Organpräparate in der Geschichte der „Schulmedizin“, der Homöopathie und der Anthroposophischen Medizin. Der Merkurstab 2009; 1: 49–60.3 Roemer F. Sommer M. Zur Bedeutung der potenzierten Organpräparate in der anthroposophischen �erapierichtung. Der Merkurstab 1998; Sonderhe� Organpräparate.4 Gesellscha� Anthroposophischer Ärzte in Deutschland e.V. and Medizinische Sektion der Freien Hochschule für Geistes-wissenscha� Dornach. Vademecum Anthroposophische Arzneimittel. 2. edition. Filderstadt (Germany); 2011.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Appendix
70
Scientific name Scientific name of the animal
Abbreviated definition
Aorta Oryctolagus cuniculus L.
Aorta from the rabbit
Aranea avicularis Avicularia avicularia L Whole bird spiderArteria basilaris Bos taurus L. Arteria basilaris from the calfArteria brachialis Bos taurus L. Arteria brachialis from the calfArteria coeliaca see Truncus coeliacusArteria pulmonalis Bos taurus L. Arteria pulmonalis from the calfArteria renalis Bos taurus L. Arteria renalis from the calfArticulatio cubiti Bos taurus L. Elbow joint with parts from the bones that form the joint, joint
cartilage, parts of joint capsule, synovia and parts of the liga-ments from the calf
Articulatio radio-carpea
Bos taurus L. Radiocarpal joint with parts of the bones, cartilage, ligaments and joint capsule that form the proximal carpal joint from the calf
Articulatio tem-poromandibularis
Bos taurus L. Parts of the os mandibulare and of the os temporale in the joint area, of the joint capsule, of the ligaments, of cartilage, as well as synovia from the calf
Articulationes inter-carpeae
Bos taurus L. Parts of the bones forming the joint, of the cartilage like surface of the articulation, as well as synovia from the calf
Articulationes intervertebrales cervicales
Bos taurus L. Region of the cervix: Parts of the bone process that participate to the intervertebral joints, cartilage and joint capsules, as well as synovia from the calf
Articulationes inter-vertebrales lumbales
Bos taurus L. Region of the loin: Parts of the bone process that participate to the intervertebral joints, cartilage and joint capsules, as well as synovia from the calf
Asterias rubens Asterias rubens L. �e whole star�sh Atlas Bos taurus L. Parts of the Atlas (1. cervical) from the calfAxis Bos taurus L. Parts of the Axis (2. cervical) from the calfBlatta orientalis Blatta orientalis L �e whole fresh or dried animalCartilago articularis coxae
Bos taurus L. Cartilage of the hip joint from the calf
Cervix uteri Bos taurus L. Parts of the neck of the womb from the cowCirculus arteriosus cerebri
Bos taurus L. Circulus arteriosus cerebri of the pituitary sha� from the calf
Coccus cacti Dactylopius coccus Costa
�e dried, fertilized, female of Dactylopius coccus Costa
Columna anterior Bos taurus L. Parts of the columna anterior of the spinal chord from the calf
Columna posterior Bos taurus L. Parts of the columna posterior of di�erent parts of the spinal chord from the calf
Cornu Caprae ibecis Capra ibex L. Horn from the ibex
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
Scientific name Scientific name of the animal
Abbreviated definition
Dactylopius coccus see Coccus cactiDens Bos taurus L. Teeth from the calfDiencephalon Bos taurus L. Diencephalon from the calfDuctus deferens Bos taurus L. Ductus deferens from the calfDura mater en-cephali
Bos taurus L. Dura mater encephali from the calf
Elaps Micrurus corallinus Merrem
Poison from Micrurus corallinus Merrem
Endocardium Bos taurus L. Endocardium from the calfEpididymis Bos taurus L. Le� epididymis from the bullErytrocytes Equus przewalskii f.
caballus PoliakovErythrocytes from the blood of the horse
Favus Apis mellifera L. Honey combs with pollenFolliculi lymphatici aggregati
Sus scrofa domestica L. Parts of Peyers’s patch of the small intestine from the pig
Galea aponeurotica Bos taurus L. Parts of the super�cial fascia of the forehead from the calf Glandula parotis Bos taurus L. Glandular tissue of the body of the parotid gland
from the calfGlandula suprarena-lis (Cortex)
Bos taurus L. Glandula suprarenalis (cortex) from the calf
Glandula suprarena-lis (Medulla)
Bos taurus L. Medulla glandulae suprarenalis of both adrenal glands from the calf
Glucogenum Oryctolagus cuniculus L.
Glycogen from the rabbit liver
Gyrus cinguli Bos taurus L. Gyrus cinguli from the calfHepar Oryctolagus cuniculus
L.Liver from the rabbit
Jejunum Sus scrofa domestica L. Jejunum from the pigKeratinum Equi Equus przewalskii f.
caballus PoliakovHoof from the horse
Lac vaccae Bos taurus L. Fresh cow’s milkLigamentum longi-tudinale anterius
Bos taurus L. Parts of the ligamentum longitudinale anterius of thoracic and lumbar regions of the spine from the calf
Lingua Bos taurus L. Parts of the tongue muscles, mucous membrane and papillae from the calf
Liquor cerebrospi-nalis
Bos taurus L. Liquor cerebrospinalis from the calf
Mephitis putorius Mephitis mephitis Schreb.
Liquid secretion of anal glands from Mephitis mephitis Schreb.
Moschus Moschus moschiferus L. Secretion of bursa from male Moschus moschiferus L.
• Ap
pend
ix
71
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
72
Scientific name Scientific name of the animal
Abbreviated definition
Musculi glutaei Bos taurus L. Gluteal muscles from the calf Musculus soleus-Komplex
Bos taurus L. Parts of the musculus soleus-complex, musculus soleus, musculus �bularis (peronaeus) longus, musculus gastrocnemius from the calf
Mygale avicularis see Aranea avicularisNaja tripudians Naja naja L. Carefully dried poison from Naja naja L.Nervus abducens Bos taurus L. Nervus abducens from the calfNervus accessorius Bos taurus L. Nervus accessorius from the calfNervus femoralis Bos taurus L. Nervus femoralis from the calfNervus hypoglossus Bos taurus L. Nervus hypoglossus from the calfNervus pudendus Bos taurus L. Nervus pudendus from the calfNervus radialis Bos taurus L. Nervus radialis from the calfNervus tibialis Bos taurus L. Nervus tibialis from the calfNervus ulnaris Bos taurus L. Nervus ulnaris from the calfOesophagus Sus scrofa domestica L. Oesophagus from the pigOssa longa Bos taurus L. Ossa longa from the calfOssicula auditus Bos taurus L. Auditory bones from the calfPapillae duodeni Sus scrofa domestica L. Papilla duodeni region of the small intestine
from the pigPars pallida Bos taurus L. Parts of the base of the brain from the calfPatella Bos taurus L. Patella from the calfPelvis renalis (et Ureter)
Bos taurus L. Parts of the pelvis renalis and ureter from the calf
Penis Bos taurus L. Penis from the bullPia mater encephali Bos taurus L. Pia mater encephali from the calfPlexus lumbalis Bos taurus L. Plexus lumbalis from the calfPlexus rectalis see Plexus haemorr-
hoidalisPortio vaginalis Bos taurus L. Portio vaginalis from the cowRenes, regio pyelo-renalis
Bos taurus L. Parts of tissue from the pelvis renalis and medulla renalis from the calf
Sclera Bos taurus L. Sclera from the calfSinus cavernosus-Komplex
Bos taurus L. Parts of the sinus cavernosus-complex; sinus cavernosus, nervus opticus, nervus oculomotorius, nervus trochlearis, nervus trigeminus and nervus abducens from the calf
Tarantula hispanica Lycosa hispanica �e whole spider Lycosa tarantula L., Allocosa fasciiventris Duf., or Hogna hispanica Walck.
�rombocytes Equus przewalskii f. caballus Poliakov
�rombocytes from the blood of the horse
Tonsilla pharyngea Bos taurus L. Tonsilla pharyngea from the calf
• Appendix
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Ap
pend
ix
73
Scientific name Scientific name of the animal
Abbreviated definition
Trachea Bos taurus L. Trachea from the calfTruncus coeliacus Bos taurus L. Arteria coeliaca (Truncus coeliacus) from the calfTruncus encephali Bos taurus L. Brain stem from the calfTruncus encephali Bos taurus L. Hypothalamus, thalamus, corpora quadrigemina, pons,
medulla oblongata from the calfTunica mucosa intestini tenuis
Sus scrofa domestica L. Mucosa from the di�erent regions of the small intestine from the pig
Tunica mucosa recti Sus scrofa domestica L. Tunica mucosa recti from the pigTunica mucosa ventriculi
Sus scrofa domestica L. Mucosa from the di�erent regions of the stomach from the pig
Ureter Bos taurus L. Ureter from the calfVagina Bos taurus L. Vagina from the cowValva trunci pulmo-nalis
Bos taurus L. Valva trunci pulmonalis from the calf
Valvula aortae Bos taurus L. Valva aortae from the calfValvula mitralis Bos taurus L. Valva mitralis from the calfVena cava Bos taurus L. Parts of the vena cava cranialis and vena cava caudalis
from the calfVena portae Bos taurus L. Vena portae from the calfVena tibialis Bos taurus L. Vena tibialis from the calfVertebra cervicalis Bos taurus L. Vertebra cervicalis from the calfVertebra coccygea Bos taurus L. Vertebra coccygea from the calfVertebra lumbalis Bos taurus L. Vertebra lumbalis from the calf
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
74
• Appendix 2.1
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
75
• Ap
pend
ix 2
.1
APPENDIX 2.1
List of minerals, rocks and natural waters Additional Information, see p. 21
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Appendix 2.1
76
Engl
ish n
ame:
Ph
.Eur
. or s
cien
ti�c
Germ
an n
ame:
H
AB (a
nd/o
r Ger
man
)Fr
ench
nam
e or
oth
ers
Abbr
evia
ted
de�n
ition
Fu
rthe
r syn
onym
sRe
fere
nce
to S
tand
ard
Exem
plar
y ref
eren
ce fo
r use
in an
thro
poso
phic
m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Am
ber
Succ
inum
(Ber
nste
in)
Foss
ilize
d tr
ee re
sin
HA
BSu
ccin
um(0
7.04
.198
8)A
met
hyst
(Am
ethy
st)
A v
iole
t var
iety
of q
uart
z (S
iO2)
Trop
aeol
um co
mp.
(0
2.03
.199
1)A
ntim
onite
See
Stib
nite
Ant
imon
it (0
2.09
.198
7)
Apat
iteAp
atit
Apat
ite�
e na
tura
l min
eral
H
AB
Apat
it (0
5.12
.198
9)A
gate
wat
er
(Ach
atw
asse
r)W
ater
exi
stin
g in
side
an u
ndam
aged
A
gate
geo
deD
er M
erku
rsta
b 20
09;
62(6
): 60
5-61
9A
qua
mar
is(M
eerw
asse
r)Se
e Se
awat
erA
rago
nite
(Ara
goni
t)A
rago
nite
�e
natu
ral m
iner
al
(cal
cium
car
bona
te; c
hem
.: C
aCO
3)A
rand
isite
(Ara
ndisi
t)A
rand
isite
�e
natu
ral m
iner
al
(com
plex
tin
silic
ate)
Ara
ndist
(02.
03.1
991)
Arg
entit
eA
rgen
titA
rgen
tite
�e
natu
ral m
iner
al
HA
BA
rgen
tit (0
5.12
.198
9)A
rgen
tum
(Silb
er)
Arg
ent n
atif
�e
natu
ral m
iner
al (n
atur
ally
oc
curr
ing
silve
r with
trac
es o
f oth
er
elem
ents
)
Arg
entu
m m
etal
licum
(04.
06.1
986)
Arg
illac
eous
Sha
leLa
pis s
ectil
is,
(Ton
schi
efer
)La
pis s
ectil
is�
e na
tura
l ver
y �n
e-gr
aine
d cl
ayey
ro
ck (c
onsis
ting
of cl
ay m
iner
als,
quar
tz, f
elds
par,
mic
a, co
mm
only
ch
lorit
e, gr
aphi
te a
nd o
ther
s)A
rsen
opyr
iteA
rsen
opyr
itA
rsen
opyr
ite�
e na
tura
l min
eral
(ars
enic
-iron
su
l�de
)Va
dem
ecum
: A
rsen
opyr
itAu
rum
(Gol
d)O
r nat
if�
e na
tura
l min
eral
(n
atur
ally
occ
urrin
g go
ld w
ith tr
aces
of
oth
er el
emen
ts)
Auru
m m
etal
licum
(04.
06.1
986)
Bary
silite
Bary
silit
�e
natu
ral m
iner
al (L
ead
man
gane
se
silic
ate)
Bary
silit
(DA
Z N
r. 29
vom
21
.07.
1994
)Ba
salt
(Bas
alt)
�e
natu
rally
occ
urrin
g,
�ne-
grai
ned
dark
gra
y to
bla
ck
volc
anic
rock
(con
sistin
g of
pl
agio
clas
e, py
roxe
ne an
d ot
hers
)
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Ap
pend
ix 2
.1
77
Engl
ish n
ame:
Ph
.Eur
. or s
cien
ti�c
Germ
an n
ame:
H
AB (a
nd/o
r Ger
man
)Fr
ench
nam
e or
oth
ers
Abbr
evia
ted
de�n
ition
Fu
rthe
r syn
onym
sRe
fere
nce
to S
tand
ard
Exem
plar
y ref
eren
ce fo
r use
in an
thro
poso
phic
m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Bert
hier
iteBe
rthi
erit
Bert
hier
ite�
e na
tura
l min
eral
(a
ntim
ony-
iron
sul�
de; c
hem
.: Fe
Sb2S
4)Bo
lus a
lba
(Bol
us)
See
Kao
linite
Cal
cite
(Kal
zit)
Cal
cite
�e
natu
ral m
iner
al
(cal
cium
car
bona
te; c
hem
.: C
aCO
3)(C
alx
jura
ssic
a)(J
urak
alk)
�e
natu
ral r
ock
Lim
esto
ne fr
om Ju
ra
perio
d (m
ainl
y co
nsist
ing
of c
alci
te)
Car
nelia
n(K
arne
ol)
�e
natu
ral m
iner
al (a
red
varie
ty o
f sil
icic
aci
d w
ith tr
aces
of i
ron
oxid
e)C
assit
erite
(Kas
siter
it, Z
inns
tein
)C
assit
érite
�e
natu
ral m
iner
al
(tin
oxi
de; c
hem
.: Sn
O2)
Kas
siter
it(0
7.04
.198
8)C
hlor
argy
rite
(Chl
orar
gyrit
)�
e na
tura
l min
eral
(s
ilver
chlo
ride;
chem
.: A
gCl)
Car
tilag
o/H
orne
rz
com
p. (0
5.12
.198
9)C
erite
(Cer
it)�
e na
tura
l min
eral
(com
plex
silic
ate
of
rare
ear
th el
emen
ts (c
eriu
m, l
anth
anum
an
d ot
hers
) and
cal
cium
, mag
nesiu
m
and
iron)
Cor
/Cra
taeg
us co
mp.
(0
2.03
.199
1)
Cer
ussit
eC
erus
sit
Cér
usite
�e
natu
ral m
iner
alH
AB
Cer
ussit
(07.
04.1
988)
Cha
lced
ony
(Cha
lced
on)
(Cha
lzed
on)
�e
natu
ral m
iner
al
(sili
cic a
cid;
chem
.: Si
O2)
Cha
lcoc
ite(C
halk
osin
)C
halc
osin
e�
e na
tura
l min
eral
H
AB
�yr
eoid
ea co
mp.
(0
3.07
.199
2)C
halc
opyr
ite(C
halk
opyr
it)C
halc
opyr
ite�
e na
tura
l min
eral
(c
oppe
r-iro
n su
l�de
; che
m.:
CuFe
S 2)
Chr
ysol
ite(C
hrys
olith
)C
hrys
olith
e�
e na
tura
l min
eral
H
AB
Chr
ysol
ith co
mp.
(25.
10.1
994)
Chr
ysop
rase
(Chr
ysop
ras)
�e
natu
ral m
iner
al (s
ilici
c aci
d
with
smal
l am
ount
s of n
icke
l)C
inna
bar
(Zin
nobe
r)
Cin
naba
ritC
inna
baris
nat
ural
e�
e na
tura
l min
eral
H
AB
Zinn
ober
(02.
09.1
987)
Cupr
iteCu
prit
Cupr
ite�
e na
tura
l min
eral
H
AB
Cupr
it (0
2.03
.199
1)
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Appendix 2.1
78
Engl
ish n
ame:
Ph
.Eur
. or s
cien
ti�c
Germ
an n
ame:
H
AB (a
nd/o
r Ger
man
)Fr
ench
nam
e or
oth
ers
Abbr
evia
ted
de�n
ition
Fu
rthe
r syn
onym
sRe
fere
nce
to S
tand
ard
Exem
plar
y ref
eren
ce fo
r use
in an
thro
poso
phic
m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Dia
mon
d(D
iam
ant)
�e
natu
ral m
iner
al
(Car
bon;
chem
.: C
, mos
t with
trac
es o
f iro
n an
d ot
her e
lem
ents
)D
iasp
ore
(Dia
spor
)�
e na
tura
l min
eral
(alu
min
ium
oxi
de
hydr
oxid
e; ch
em.:
AlO
OH
)D
iopt
ase
Dio
ptas
Dio
ptas
e�
e na
tura
l min
eral
(cop
per s
ilica
te;
chem
.: Cu
6Si 6O
18·6
H2O
)H
AB
Dio
ptas
(1
2.09
.199
2)D
yscr
asite
Dys
kras
itD
yscr
asite
�e
natu
ral m
iner
al
HA
BD
ykra
sit (D
AZ
Nr.
29
vom
21.
07.1
994)
Emer
ald
(Sm
arag
d)A
gre
en v
arie
ty o
f ber
yl
(alu
min
ium
-ber
ylliu
m si
licat
e;
chem
.: A
l 2Be 3
(Si 6O
18),
colo
ured
by
trac
e am
ount
s of c
hrom
ium
and
so
met
imes
van
adiu
mFe
rrum
side
reum
(Met
eore
isen)
Ferr
um si
dere
umSe
e Ir
on m
eteo
rite
= m
eteo
ric ir
onFe
rrum
silic
icum
See
Non
tron
iteFl
int
(Flin
t, Fe
uers
tein
)Si
lex
�e
natu
ral m
iner
al
(che
m.:
silic
ic a
cid
SiO
2)
Lapi
s Can
cri/F
lints
tein
(07.
04.1
988)
Fluo
rite
Fluo
rit (F
luss
spat
)Fl
uorit
e�
e na
tura
l min
eral
H
AB
Fluo
rit (0
2.09
.198
7)G
alen
aG
alen
it (B
leig
lanz
)G
alèn
e�
e na
tura
l min
eral
H
AB
Blei
glan
z/Se
cale
com
p.
(12.
09.1
992)
Gar
net
(Gra
nat)
�e
natu
ral m
iner
al: A
lman
dine
(ir
on-a
lum
iniu
m si
licat
e; ch
em.:
Fe3A
l 2(Si
O4)
3 ) o
r oth
er v
arie
ties
Der
Mer
kurs
tab
2004
; 57
(1):
57-5
8
(Gla
cies
Mar
iae)
See
sele
nite
Gne
iss(G
neis)
�e
natu
ral p
ale
rock
(Gne
iss fr
om
Gas
tein
(A);
cons
istin
g of
qua
rtz,
feld
-sp
ar, m
ica
and
othe
rs);
syn.
: Lap
is al
bus
Gra
nite
(Gra
nit)
Gra
nit
�e
natu
ral r
ock
(con
sistin
g of
qua
rtz,
feld
spar
and
mic
a an
d ot
hers
)D
isci/R
hus t
oxi-
code
ndro
n co
mp.
(0
5.12
.198
9)G
raph
iteG
raph
ites (
Gra
phit)
Gra
phite
s�
e na
tura
l min
eral
H
AB
Gra
phite
s (07
.04.
1988
)
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Ap
pend
ix 2
.1
79
Engl
ish n
ame:
Ph
.Eur
. or s
cien
ti�c
Germ
an n
ame:
H
AB (a
nd/o
r Ger
man
)Fr
ench
nam
e or
oth
ers
Abbr
evia
ted
de�n
ition
Fu
rthe
r syn
onym
sRe
fere
nce
to S
tand
ard
Exem
plar
y ref
eren
ce fo
r use
in an
thro
poso
phic
m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Hem
atite
Häm
atit
Hém
atite
�e
natu
ral m
iner
al
HA
BFe
rrum
rosa
tum
/G
raph
ites (
03.0
7.19
92)
Hal
iteH
alit
�e
natu
ral m
iner
al
HA
BH
alit
(07.
04.1
988)
Hek
la L
ava
See
Lava
Hel
iotr
ope
(Hel
iotr
op)
A g
reen
var
iety
of c
halc
edon
y w
ith re
d in
clus
ions
(sili
cic a
cid;
chem
.: Si
O2
with
iron
oxi
de)
Hya
cint
h(H
yazi
nth)
See
Zirc
onH
ydra
rgyr
um(Q
ueck
silbe
r)Se
e M
ercu
rius v
ivus
nat
ural
isIr
on m
eteo
rite
Ferr
um si
dere
um
(Met
eore
isen)
Ferr
um si
dere
um�
e na
tura
l met
eoric
iron
HA
BFe
rrum
side
reum
(0
4.06
.198
6)Ja
sper
(Jas
pis)
A re
d va
riety
of c
halc
edon
y (s
ilici
c ac
id; c
hem
.: Si
O2 w
ith ir
on o
xide
)K
aolin
ite(K
aolin
, wei
ßer T
on)
�e
natu
ral m
iner
al (a
lum
iniu
m
silic
ate;
chem
.: A
l 4[(O
H) 8
/Si 4O
10];
syn.
: Chi
na cl
ay, K
aolin
um p
onde
rosu
m
Ph. E
ur.
Bolu
s alb
a co
mp.
(0
2.03
.199
1)
Kas
siter
iteSe
e C
assit
erite
Kat
optr
ite(K
atop
trit)
�e
natu
ral m
iner
al (c
ompl
ex
man
gane
se-a
ntim
ony-
iron
silic
ate)
Kie
serit
e(K
iese
rit)
Kie
sérit
e�
e na
tura
l min
eral
H
AB
Kie
serit
(12.
09.1
992)
Lapi
s alb
us(G
neiss
)Se
e G
neiss
Lapi
s sec
tilis
(Ton
schi
efer
)Se
e A
rgill
aceo
us S
hale
Lava
Hek
la L
ava
(Lav
a)H
ekla
lava
�e
natu
ral r
ock
from
vol
cano
Hek
la
(Ice
land
) (co
nsist
ing
of d
i�er
ent
silic
ates
of c
alci
um, m
agne
sium
, al
umin
ium
and
sodi
um)
Levi
co w
ater
Levi
coLe
vico
Min
eral
wat
er fr
om th
e so
urce
Lev
ico,
Ita
lyA
PCLe
vico
(04.
06.1
986)
Mag
nesit
eM
agne
sitM
agné
site
�e
natu
ral m
iner
al
HA
BM
agne
sit/M
amm
a co
mp.
(12.
09.1
992)
Mal
achi
teM
alac
hit
Mal
achi
te�
e na
tura
l min
eral
H
AB
Mal
achi
t (12
.09.
1992
)
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Appendix 2.1
80
Engl
ish n
ame:
Ph
.Eur
. or s
cien
ti�c
Germ
an n
ame:
H
AB (a
nd/o
r Ger
man
)Fr
ench
nam
e or
oth
ers
Abbr
evia
ted
de�n
ition
Fu
rthe
r syn
onym
sRe
fere
nce
to S
tand
ard
Exem
plar
y ref
eren
ce fo
r use
in an
thro
poso
phic
m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Mar
ble
(Mar
mor
)M
arbr
e�
e na
tura
l gra
ined
, whi
te ro
ck
(mai
nly
cons
istin
g of
cal
cite
)M
arm
or/S
tibiu
m(0
3.07
.199
2)M
ercu
rius v
ivus
na
tura
lis(Q
ueck
silbe
r,
gedi
egen
)M
ercu
rius v
ivus
Nat
ural
ly o
ccur
ring
mer
cury
with
tr
aces
of o
ther
elem
ents
Ph.fr
.M
ercu
rius v
ivus
(02.
09.1
987)
(Met
eore
isen)
See
Ferr
um si
dere
umN
ontr
onite
Non
tron
itN
ontr
onite
�e
natu
ral m
iner
al; s
yn.:
Fe
rrum
silic
icum
nat
ural
eH
AB
Ferr
um u
stum
com
p.
(04.
06.1
986)
Oliv
enite
Oliv
enit
Oliv
énite
�e
natu
ral m
iner
al
HA
BO
liven
it (0
2.09
.198
7)O
livin
eSe
e C
hrys
olite
O
nyx
Ony
xO
nyx
�e
natu
ral m
iner
al
HA
BO
nyx
(05.
12.1
989)
Opa
l(O
pal)
�e
natu
ral m
iner
al
(sili
cic a
cid,
cont
aini
ng w
ater
)D
er M
erku
rsta
b 20
09;
62(6
): 60
5-61
9O
rtho
clas
e(O
rtho
klas
)�
e na
tura
l min
eral
(pot
assiu
m-
alum
iniu
m si
licat
e; ch
em.:
KA
lSi 3O
8)O
rtho
klas
(07.
04.1
988)
Palla
site
(Pal
lasit
)St
one-
Iron
-Met
eorit
e (o
livin
e cr
ysta
ls in
an
iron-
nick
el m
atrix
)Ph
arm
acol
itePh
arm
akol
ithPh
arm
acol
ithe
�e
natu
ral m
iner
al
HA
BPh
arm
akol
ith (D
AZ
Nr.
29 v
om 2
5.10
.199
4)Ph
osph
oroc
alci
te(P
hosp
horo
chal
cit,
Pseu
dom
alac
hit)
Phos
phor
ocha
lcite
�e
natu
ral m
iner
al
(alk
alin
e co
pper
pho
spha
te;
chem
.: Cu
5[(O
H) 4
/(PO
4)2]
)Pl
atin
um(P
latin
) Pl
atin
a�
e na
tura
l min
eral
(nat
ural
ly
occu
rrin
g pl
atin
um w
ith tr
aces
of o
ther
el
emen
ts)
Pyra
rgyr
ite(P
yrar
gyrit
)Py
rarg
yrite
�e
natu
ral m
iner
al (s
ilver
-ant
imon
y su
l�de
; che
m.:
Ag 3
SbS 3
)Py
rite
Pyrit
Pyrit
e�
e na
tura
l min
eral
H
AB
Pyrit
(04.
06.1
986)
Pyro
lusit
ePy
rolu
sitPy
rolu
site
�e
natu
ral m
iner
al (m
anga
nese
di-
oxyd
e; ch
em.:
MnO
2)Py
rom
orph
itePy
rom
orph
itPy
rom
orph
ite�
e na
tura
l min
eral
H
AB
Pyro
mor
phit
(21.
07.1
994)
Qua
rtz
Qua
rzQ
uart
z�
e na
tura
l min
eral
H
AB
Qua
rz (0
4.06
.198
6)
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Ap
pend
ix 2
.1
81
Engl
ish n
ame:
Ph
.Eur
. or s
cien
ti�c
Germ
an n
ame:
H
AB (a
nd/o
r Ger
man
)Fr
ench
nam
e or
oth
ers
Abbr
evia
ted
de�n
ition
Fu
rthe
r syn
onym
sRe
fere
nce
to S
tand
ard
Exem
plar
y ref
eren
ce fo
r use
in an
thro
poso
phic
m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Real
gar
(Rea
lgar
)Ré
alga
r�
e na
tura
l min
eral
(a
rsen
ic su
l�de
; che
m.:
As 4
S 4)
Real
gar
(05.
12.1
989)
Rose
qua
rtz
(Ros
enqu
arz)
�e
natu
ral m
iner
al (s
ilici
c aci
d;
chem
.: Si
O2)
; syn
.: Q
uarz
rosa
eRu
belli
te(R
ubel
lit)
Pink
to re
d to
urm
alin
e (c
ompl
ex
silic
ate
with
alu
min
ium
, bor
on,
�uor
ine,
lithi
um, i
ron,
sodi
um a
nd
othe
r ele
men
ts)
Vade
mec
um:
Rube
llit
Ruby
(Rub
in)
�e
natu
ral r
ed co
rund
um
(alu
min
ium
oxi
de; c
hem
.: A
l 2O3
with
trac
es o
f Chr
omiu
m)
Sal M
aris
See
Sea
salt
Sapp
hire
(Sap
hir)
�e
natu
ral b
lue
(alu
min
ium
oxi
de;
chem
.: A
l 2O3 w
ith tr
aces
of i
ron
and/
or
tita
nium
)Sc
orod
iteSk
orod
itSc
orod
ite�
e na
tura
l min
eral
H
AB
Skor
odit
(04.
06.1
986)
Sea
salt
(Mee
rsal
z)N
atru
m m
uria
ticum
Sea
salt
(che
m.:
com
plex
mix
ture
w
ith ch
lorid
es a
nd su
lfate
s of m
ainl
y so
dium
, mag
nesiu
m, c
alci
um a
nd
pota
ssiu
m b
esid
e m
inor
com
pone
nts)
; sy
n.: S
al M
aris
Ph.fr
.
Seaw
ater
Aqu
a m
aris
Aqu
a m
aris
Oce
anic
wat
er (c
hem
.: di
ssol
ved
mix
-tu
re o
f chl
orid
es a
nd su
lfate
s of m
ainl
y so
dium
, mag
nesiu
m, c
alci
um a
nd
pota
ssiu
m b
esid
e m
inor
com
pone
nts)
Aqu
a m
aris/
Prun
ussp
inos
a, S
umm
itate
s(0
5.12
.198
9)
Der
Mer
kurs
tab
2009
; 62
(6):
605-
619
Sele
nite
(Gla
cies
mar
ias,
Gip
s, M
arie
ngla
s)�
e na
tura
l min
eral
: Tra
nspa
rent
, co
lour
less
, var
iety
of G
ypsu
m (c
alci
um
sulfa
te; c
hem
.: C
aSO
4·2H
2O);
sy
n.: G
laci
es M
aria
eSi
derit
eSi
derit
Sidé
rite
�e
natu
ral m
iner
al
HA
BSi
derit
(21.
07.1
994)
Sile
xSi
lex
See
Flin
t Si
licea
nat
ural
eSe
e Q
uart
zSm
arag
dSe
e Em
eral
d
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Appendix 2.1
82
Engl
ish n
ame:
Ph
.Eur
. or s
cien
ti�c
Germ
an n
ame:
H
AB (a
nd/o
r Ger
man
)Fr
ench
nam
e or
oth
ers
Abbr
evia
ted
de�n
ition
Fu
rthe
r syn
onym
sRe
fere
nce
to S
tand
ard
Exem
plar
y ref
eren
ce fo
r use
in an
thro
poso
phic
m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Stib
nite
Ant
imon
it (G
raus
-pi
eßgl
anz)
Stib
ine
�e
natu
ral m
iner
al
HA
BA
ntim
onit
(02.
09.1
987)
Succ
inum
See
Am
ber
Sulfu
rSu
lfur
Sulfu
r�
e na
tura
l min
eral
Su
lfur (
17.0
2.19
86)
Sulfu
r sel
enos
um(S
ulfu
r sel
enos
um)
Sulfu
r sel
enos
um�
e na
tura
l min
eral
cont
aini
ng a
co
lloid
al so
lutio
n of
sele
nium
Vade
mec
um:
Sulfu
r sel
enos
umSy
lvite
(Syl
vin)
�e
natu
ral m
iner
al
(pot
assiu
m ch
lorid
e; ch
em.:
KCl)
(Ter
ra m
edic
inal
is)(H
eile
rde)
Drie
d, �
nely
-div
ided
, nat
ural
ly o
ccur
-rin
g cl
ay a
nd si
lt w
ith a
var
ied
com
po-
sitio
n of
alu
min
ium
oxi
de, s
ilica
, iro
n ox
ide
and
limes
tone
; Ter
ra m
edic
inal
is
Plac
enta
/Tro
paeo
lum
(0
2.03
.199
1)
(Ter
ra ru
bra)
(Ter
ra ru
bra)
�e
natu
ral r
ed to
bro
wni
sh ro
ck fr
om
perio
d Ro
tlieg
end
(con
sistin
g of
dif-
fere
nt �
ne-g
rain
ed a
lum
iniu
m si
licat
es
and
iron
oxid
e)
�en
ardi
te(�
enar
dit)
�én
ardi
te�
e na
tura
l min
eral
(s
odiu
m su
lfate
; che
m.:
Na 2
SO4)
Topa
z(T
opas
)�
e na
tura
l min
eral
(alu
min
ium
-�uo
-rin
silic
ate;
chem
.: sil
icat
e of
alu
min
i-um
and
�uo
rine,
Al 2[
(F,O
H) 2
/SiO
4.)]
Tron
a(T
rona
)�
e na
tura
l min
eral
(sod
ium
car
-bo
nate
-hyd
roge
n ca
rbon
ate;
chem
.: N
a 3(C
O3)
(HC
O3)
·2H
2O
Solu
tio F
erri
com
p.(2
5.10
.199
4)
Tour
mal
ine
(Tur
mal
in)
�e
natu
ral m
iner
al T
ourm
alin
e (c
om-
plex
silic
ate
with
alu
min
ium
, bor
on,
�uor
ine
and
othe
r ele
men
ts).
Rube
llite
or
oth
er v
arie
ties.
See
Rub
ellit
eVa
nadi
nite
(Van
adin
it)�
e na
tura
l min
eral
(lea
d va
nada
te;
chem
.: Pb
5[C
l/(V
O4)
3]V
ivia
nite
Viv
iani
tV
ivia
nite
�e
natu
ral m
iner
al
HA
BV
ivia
nit (
DA
Z N
r. 29
vo
m 2
1.07
.199
4)
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Ap
pend
ix 2
.1
83
Engl
ish n
ame:
Ph
.Eur
. or s
cien
ti�c
Germ
an n
ame:
H
AB (a
nd/o
r Ger
man
)Fr
ench
nam
e or
oth
ers
Abbr
evia
ted
de�n
ition
Fu
rthe
r syn
onym
sRe
fere
nce
to S
tand
ard
Exem
plar
y ref
eren
ce fo
r use
in an
thro
poso
phic
m
edic
ine
KC M
onog
raph
(dat
e)O
ther
With
erite
With
erit
With
érite
�e
natu
ral m
iner
al
HA
BFo
rmul
aire
de
med
.an-
thr.
(201
2): N
ontr
onit
D20
, Sco
rodi
t D12
, W
ither
it D
6Zi
nnob
erSe
e C
inna
bar
Zirc
on(H
yazi
nth)
�e
natu
ral m
iner
al (z
ircon
ium
oxi
de;
chem
.: Zr
[SiO
4])
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
84
• Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
85
• Ap
pend
ix 2
.2
APPENDIX 2.2
List of starting materials of botanical origin Additional Information, see p. 21
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Appendix 2.2
86
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erA
bies
alb
a M
ill.
Fres
h to
ps o
f Abi
es a
lba
Mill
.Pe
tasit
es co
mp.
(1
2.09
.199
2)A
bies
pec
tinat
a (L
am.)
DC
.Yo
ung,
fres
h, le
afy
bran
ches
of A
bies
alb
a M
ill. (
Abi
es p
ectin
ata
(Lam
.) D
C)
Ph.fr
.Fo
rmul
aire
de
med
.an
thr.
(201
0)A
brot
anum
See
Art
emisi
a ab
rota
num
L.
Abs
inth
ium
See
Art
emisi
a ab
sinth
ium
L.
Ace
tum
Vin
iSe
e V
itis v
inife
ra L
.A
cetu
m V
ini d
estil
latu
mSe
e V
itis v
inife
ra L
.A
chill
ea m
illef
oliu
m L
.Fr
esh,
who
le �
ower
ing
plan
t of A
chill
ea m
illef
oliu
m L
.Ph
.fr.
Form
ulai
re d
e m
ed.
anth
r. (2
010)
Ach
illea
mill
efol
ium
L.
Fres
h, le
aves
of A
chill
ea m
illef
oliu
m L
., co
llect
ed in
Spr
ing
Mill
efol
ium
/ H
yper
i-cu
m (0
7.04
.198
8)A
chill
ea m
illef
oliu
m L
.Fr
esh
aeria
l par
ts o
f Ach
illea
mill
efol
ium
L.,
colle
cted
at �
ower
ing
time
HA
BC
anth
aris
com
p.
(04.
06.1
986)
Ach
illea
mill
efol
ium
L.
Who
le o
r cut
, drie
d �o
wer
ing
tops
of A
chill
ea m
illef
oliu
m L
. (ya
r-ro
w).
Ph.E
ur.
Ach
illea
mill
efol
ium
L.
Drie
d �o
wer
s of A
chill
ea m
illef
oliu
m L
.Ph
.Hel
v.C
apse
lla/M
ajor
ana
com
p. (0
4.06
.198
6)A
coni
tum
nap
ellu
s L.
Fres
h, w
hole
pla
nts o
f Aco
nitu
m n
apel
lus L
. col
lect
ed at
the
end
of
�ow
erin
g tim
e
Ph.fr
.Fo
rmul
aire
de
med
.an
thr.
(201
0)A
coni
tum
nap
ellu
s L.
Fres
h w
hole
pla
nts o
f Aco
nitu
m n
apel
lus L
., co
llect
ed at
the
star
t of
�ow
erin
gH
AB
Aco
nitu
m n
apel
lus
(04.
06.1
986)
Aco
nitu
m n
apel
lus L
.D
ried
tube
rs o
f Aco
nitu
m n
apel
lus L
.Ph
.Hel
v. V
IA
coni
tum
nap
ellu
s (0
4.06
.198
6)A
coni
tum
nap
ellu
s L.
Fres
h un
derg
roun
d pa
rts o
f Aco
nitu
m n
apel
lus L
.A
coni
tum
nap
ellu
s (0
2.03
.198
6)A
coru
s cal
amus
L.
Vola
tile
oil f
rom
the
unde
rgro
und
part
s of A
coru
s cal
amus
L.
Aco
rus c
alam
us L
.Pe
eled
, drie
d rh
izom
e of
Aco
rus c
alam
us L
., w
ith ro
ots a
nd le
af
resid
ues r
emov
ed.
HA
BC
alam
us, R
hizo
ma
(02.
03.1
991)
Aco
rus c
alam
us L
.Fr
esh
unde
rgro
und
part
s of A
coru
s cal
amus
L.
Berb
eris/
Juni
peru
s co
mp.
(03.
07.1
992)
Act
aea
race
mos
ase
e C
imic
ifuga
race
mos
a (L
.) N
utt.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Ap
pend
ix 2
.2
87
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erA
ctae
a sp
icat
a L.
Fres
h, u
nder
grou
nd p
arts
of A
ctae
a sp
icat
a L.
colle
cted
a�e
r sho
ts
have
em
erge
d, b
ut b
efor
e �o
wer
ing
HA
B
Ado
nis v
erna
lis L
.Fr
esh
aeria
l par
ts o
f Ado
nis v
erna
lis L
. col
lect
ed at
�ow
erin
g tim
e
HA
BA
doni
s/Sc
illa
com
p.
(25.
10.1
994)
Aes
culu
s hip
poca
stan
um L
.Fr
esh
bark
from
you
nger
bra
nche
s of A
escu
lus h
ippo
cast
anum
L.
Cal
endu
la/T
ropa
eolu
m
com
p. (0
2.03
.199
1)A
escu
lus h
ippo
cast
anum
L.
Fres
h bu
ds o
f Aes
culu
s hip
poca
stan
um L
.Sa
l Mar
is co
mp.
(0
4.06
.198
6)A
escu
lus h
ippo
cast
anum
L.
Fres
hly
peel
ed se
eds o
f Aes
culu
s hip
poca
stan
um L
.H
AB
Aes
culu
s, Se
men
(0
2.03
.199
1)A
escu
lus h
ippo
cast
anum
L.
Fres
h un
peel
ed se
eds o
f Aes
culu
s hip
poca
stan
um L
.Ph
.fr.
Form
ulai
re d
e m
ed.
anth
r. (2
010)
Aes
culu
s hip
poca
stan
um L
.D
ried
bark
from
bra
nche
s of A
escu
lus h
ippo
cast
anum
L.
HA
BA
escu
lus,
Cor
tex
(0
4.06
.198
6)A
escu
lus h
ippo
cast
anum
L.
Drie
d se
eds o
f Aes
culu
s hip
poca
stan
um L
.D
AB
/ USP
Aes
culu
s, Se
men
(0
2.03
.199
1)A
ethu
sa c
ynap
ium
L.
Fres
h w
hole
pla
nt o
f Aet
husa
cyn
apiu
m L
. at t
he e
nd o
f �ow
erin
g Ph
.fr.
Aga
ricus
bul
bosu
sse
e A
man
ita p
hallo
ides
(Fr.)
Lin
k.A
garic
us m
usca
rius
see
Am
anita
mus
caria
(L.)
Pers
.A
gnus
cas
tus
see
Vite
x ag
nus-
cast
us L
.A
grop
yron
repe
ns (L
.) P.
Bea
uv.
Who
le o
r cut
, was
hed
and
drie
d rh
izom
e of
Agr
opyr
on re
pens
(L.)
P. B
eauv
. (El
ymus
repe
ns [L
.] G
ould
); th
e ad
vent
itiou
s roo
ts a
re
rem
oved
(cou
ch g
rass
rhiz
ome)
Ph.E
ur.
Flor
es S
ambu
ci co
mp.
/Q
uarz
(07.
04.1
988)
Agr
opyr
on re
pens
see
Elym
us re
pens
(L.)
Gou
ldA
ilant
hus a
ltiss
ima
(Mill
.) Sw
ingl
eFr
esh
�ow
erin
g sh
oots
and
fres
h ba
rk fr
om th
e tr
unk
and
bran
ches
of
Aila
nthu
s alti
ssim
a (M
ill.)
Swin
gle
Aila
nthu
s gla
ndul
osa
see
Aila
nthu
s alti
ssim
aAj
uga
rept
ans L
.Fr
esh
who
le p
lant
s of A
juga
rept
ans L
. at �
ower
ing
time
Ph.fr
.A
lcea
rose
a L.
Drie
d, fu
lly d
evel
oped
�ow
ers w
ith c
alic
es o
f Alc
ea ro
sea
L.M
alva
com
p.
(03.
07.1
992)
Alc
hem
illa
xant
hoch
lora
Rot
hm.
Fres
h ae
rial p
arts
of A
lche
mill
a xa
ntho
chlo
ra R
othm
. at �
ower
ing
Alfa
lfase
e M
edic
ago
sativ
a L.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
88
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erA
llium
cepa
L.
Fres
h bu
lbs o
f Alli
um ce
pa L
.H
AB
/ Ph.
fr.A
llium
cepa
/Mer
curia
-lis
com
p. (0
2.03
.199
1)A
llium
sativ
um L
.Fr
esh
bulb
s of A
llium
sativ
um L
. (ga
rlic f
or h
omoe
opat
hic p
repa
ra-
tions
) H
AB
/ Ph.
Eur.
/ USP
Arc
hang
elic
a co
mp.
(04.
06.1
986)
Alli
um u
rsin
um L
. Fr
esh
who
le p
lant
s of A
llium
urs
inum
L. a
t the
star
t of �
ower
ing
HA
BA
loe
fero
x M
ill. a
nd o
ther
Alo
e sp
ecie
sC
once
ntra
ted
and
drie
d ju
ice
of th
e le
aves
of v
ario
us sp
ecie
s of
Alo
e, m
ainl
y A
loe
fero
x M
iller
and
its h
ybrid
s (al
oes,
Cap
e)
Ph.fr
., H
AB
/ Ph.
Eur.
Alth
aea
o�ci
nalis
L.
Peel
ed o
r unp
eele
d, w
hole
or c
ut, d
ried
root
of A
lthae
a o�
cina
lis L
. (m
arsh
mal
low
root
)Ph
.Eur
.Si
rupu
s �ym
i com
p.
(04.
06.1
986)
Am
anita
mus
caria
(L.)
Pers
.Fr
esh
frui
ting
bodi
es o
f Am
anita
mus
caria
(L.)
Pers
.A
garic
us m
usca
rius
(12.
09.1
992)
Am
anita
pha
lloid
es (F
r.) L
ink.
Fres
h fr
uitin
g bo
dies
of A
man
ita p
hallo
ides
(Fr.
Link
)H
AB
Am
aryl
lis b
ella
-don
na L
.Fr
esh,
who
le p
lant
of A
mar
yllis
bel
la-d
onna
L. a
t �ow
erin
gA
mm
i visn
aga
(L.)
Lam
.D
ried
ripe
frui
ts o
f Am
mi v
isnag
a (L
.) La
m.
HA
BA
mm
i visn
aga
com
p.
(02.
03.1
991)
Am
ygda
lae
amar
aese
e Pr
unus
dul
cis v
ar. a
mar
a (D
C.)
Buch
heim
Ana
card
ium
see
Sem
ecar
pus a
naca
rdiu
m L
.A
naga
llis a
rven
sis L
.Fr
esh
who
le p
lant
of A
naga
llis a
rven
sis L
. at �
ower
ing
Ph.fr
.A
naga
llis c
omp.
(0
2.03
.199
1)A
naga
llis a
rven
sis L
.Fr
esh
aeria
l par
ts o
f Ana
galli
s arv
ensis
L.,
colle
cted
at �
ower
ing
Ana
galli
s / M
alac
hit
com
p. (2
5.10
.199
4)A
naga
llis a
rven
sis L
.D
ried
aeria
l par
ts o
f Ana
galli
s arv
ensis
L.,
havi
ng b
een
colle
cted
at
�ow
erin
gA
naga
llis /
Mal
achi
t co
mp.
(25.
10.1
994)
Ana
mirt
a co
ccul
us W
ight
et A
rn.
Ripe
, drie
d fr
uits
of A
nam
irta
cocc
ulus
Wig
ht e
t Arn
.H
AB
/ Ph.
fr.C
occu
lus/
Ole
um P
etra
e co
mp.
(04.
06.1
986)
Ana
nas c
omos
us (L
.) M
err.
Fres
hly
pres
sed
juic
e of
frui
t of A
nana
s com
osus
(L.)
Mer
r.Re
sina
Laric
is co
mp.
(0
4.06
.198
6)A
nana
s com
osus
(L.)
Mer
r.Fr
esh
frui
t of A
nana
s com
osus
(L.)
Mer
r.A
nana
ssa
com
p.
(02.
03.1
991)
Ang
elic
a ar
chan
gelic
a L.
Ferm
ente
d ju
ice
from
root
s of A
ngel
ica
arch
ange
lica
L. o
btai
ned
by
fres
h pr
essin
gA
rcha
ngel
ica
(05.
12.1
989)
• Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
89
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erA
ngel
ica
arch
ange
lica
L.Fr
esh
root
s of A
ngel
ica
arch
ange
lica
L.H
AB
Arc
hang
elic
a/Py
rit
com
p. (0
2.03
.199
1)A
ngel
ica
arch
ange
lica
L.W
hole
or c
ut, c
aref
ully
drie
d rh
izom
e an
d ro
ot o
f Ang
elic
a ar
chan
-ge
lica
L. (s
yn. A
. o�
cina
lis H
o�m
.) (a
ngel
ica
arch
ange
lica
root
) Ph
.Eur
.Sp
iritu
s Mel
issae
com
p.(0
4.06
.198
6)
Anh
alon
ium
see
Loph
opho
ra w
illia
msii
Cou
lt.A
nisu
mse
e Pi
mpi
nella
ani
sum
L.
Ant
hylli
s vul
nera
ria L
.Fr
esh
aeria
l par
ts o
f Ant
hylli
s vul
nera
ria L
. at �
ower
ing
Cal
endu
la/T
ropa
eolu
m
com
p. (0
2.03
.199
1)Ap
ocyn
um c
anna
binu
m L
.Fr
esh
unde
rgro
und
part
s of A
pocy
num
can
nabi
num
L.
HA
BSc
illa
com
p.(2
5.10
.199
4)A
ralia
race
mos
a L.
Fres
h un
derg
roun
d pa
rts o
f Ara
lia ra
cem
osa
L.H
AB
Arc
tium
lapp
a L.
Drie
d w
hole
or c
ut ro
ots o
f Arc
tium
lapp
a L.
(A. m
ajor
Gae
rtn.
), A
. m
inus
(Hill
) Ber
nh. a
nd A
. tom
ento
sum
Mill
. also
rela
ted
spec
ies
or h
ybrid
s (A
ster
acea
e), c
olle
cted
in au
tum
n of
the
�rst
yea
r or
sprin
g of
the
seco
nd y
ear
DA
CA
rnic
a/La
ppa
com
p.
(02.
03.1
991)
Aris
aem
a tr
iphy
llum
(L.)
Torr
.Fr
esh
unde
rgro
und
part
s of A
risae
mia
trip
hyllu
m (L
.) To
rr.,
col-
lect
ed b
efor
e th
e le
aves
dev
elop
. (A
rum
trip
hyllu
m)
HA
B
Arm
orac
ia ru
stic
ana
Ph. G
ärtn
., B.
Mey
. et S
cher
b.Fr
esh
leav
es o
f Arm
orac
ia ru
stic
ana
Ph. G
aert
n., B
. Mey
. et S
cher
b.
Arm
orac
ia ru
stic
ana
Ph. G
ärtn
., B.
Mey
. et S
cher
b.Fr
esh
unde
rgro
und
part
s of A
rmor
acia
rust
ican
a Ph
. Gae
rtn.
, B.
Mey
et S
cher
b.Ph
.fr.
Coc
hela
ria a
rmor
acia
(1
2.09
.199
2)A
rnic
a m
onta
na L
.Vo
latil
e oi
l fro
m th
e un
derg
roun
d pa
rts o
f Arn
ica
mon
tana
L.
Vade
mec
um: C
alci
um
silic
icum
com
p.A
rnic
a m
onta
na L
.Fr
esh
�ow
er-h
eads
of A
rnic
a m
onta
na L
.A
rnic
a, F
los
(04.
06.1
986)
Arn
ica
mon
tana
L.
Who
le fr
esh
�ow
erin
g pl
ants
of A
rnic
a m
onta
na L
.H
AB
/ Ph.
fr.A
rnic
a, P
lant
a to
ta
(04.
06.1
986)
Arn
ica
mon
tana
L.
Fres
h un
derg
roun
d pa
rts o
f Arn
ica
mon
tana
L.
Arn
ica
(04.
06.1
986)
Arn
ica
mon
tana
L.
Who
le o
r par
tially
bro
ken,
drie
d �o
wer
-hea
ds o
f Arn
ica
mon
tana
L.
(arn
ica
�ow
er)
HA
B / P
h.Eu
r.A
rnic
a, F
los
(04.
06.1
986)
Arn
ica
mon
tana
L.
Drie
d un
derg
roun
d pa
rts o
f Arn
ica
mon
tana
L.
HA
BA
rnic
a (0
4.06
.198
6)
• Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
90
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erA
rtem
isia
abro
tanu
m L
.Fr
esh
youn
g sh
oots
and
leav
es o
f Art
emisi
a ab
rota
num
L.
HA
B / P
h.fr.
Abr
otan
um (D
AZ
Nr.
29 v
om 2
1.07
.199
4)A
rtem
isia
absin
thiu
m L
.Fr
esh
uppe
r sho
ots w
ith at
tach
ed le
aves
and
�ow
ers a
nd b
asal
le
aves
of A
rtem
isia
absin
thiu
m L
. sep
arat
ely
or a
s a m
ixtu
re.
HA
B C
icho
rium
/Tar
axac
um
com
p.(0
4.06
.198
6)A
rtem
isia
absin
thiu
m L
.Ba
sal l
eave
s or s
light
ly le
afy,
�ow
erin
g to
ps, o
r mix
ture
of t
hese
dr
ied,
who
le o
r cut
org
ans o
f Art
emisi
a ab
sinth
ium
L. (
wor
mw
ood)
HA
B / P
h.Eu
r.G
entia
na co
mp.
(1
2.09
.199
2)A
rum
mac
ulat
um L
.Fr
esh
unde
rgro
und
part
s of A
rum
mac
ulat
um L
., co
llect
ed b
efor
e th
e le
aves
dev
elop
.H
AB
Aru
m m
acul
atum
/Pt
erid
ium
aqu
ilinu
m
(02.
03.1
991)
Aru
m tr
iphy
llum
see
Aris
aem
a tr
iphy
llum
(L.)
Torr
.A
rund
o do
nax
L.Fr
esh
unde
rgro
und
part
s of A
rund
o do
nax
L.Ph
.fr.
Asa
foet
ida
see
Feru
la a
ssa-
foet
ida
L.A
saru
m e
urop
aeum
L.
Fres
h un
derg
roun
d pa
rts o
f phe
nylp
ropa
ne-c
onta
inin
g su
bspe
cies
of
Asa
rum
eur
opae
um L
.H
AB
Asp
erul
a od
orat
ase
e G
aliu
m o
dora
tum
Asp
idiu
m �
lix-m
asse
e D
ryop
teris
�lix
-mas
(L.)
Scho
tt.A
spid
ospe
rma
queb
rach
o-bl
anco
Sc
hlec
hten
d.D
ried
who
le o
r cut
crus
t of A
spid
ospe
rma
queb
rach
o-bl
anco
Sc
hlec
hten
d.D
AC
Ast
raga
lus e
xsca
pus L
.Fr
esh
�ow
erin
g an
d in
frui
t ros
ette
s of A
stra
galu
s exs
capu
s L.
Vade
mec
um: A
stra
ga-
lus e
xsca
pus
Atro
pa b
ella
-don
na L
.W
hole
or c
ut, d
ried
root
s and
rhiz
ome
from
3- t
o 4-
yea
r old
pla
nts
of A
trop
a be
lla-d
onna
L.,
colle
cted
at �
ower
ing
and
with
frui
tD
AC
Bella
donn
a (0
4.06
.198
6)At
ropa
bel
la-d
onna
L.
Fres
h fr
uits
of A
trop
a be
lla-d
onna
L.
Bella
donn
a (0
4.06
.198
6)At
ropa
bel
la-d
onna
L.
Who
le fr
esh
plan
ts o
f Atr
opa
bella
-don
na L
., w
ithou
t woo
dy lo
wer
st
em se
ctio
ns, c
olle
cted
at th
e en
d of
�ow
erin
gH
AB
Bella
donn
a (0
4.06
.198
6)At
ropa
bel
la-d
onna
L.
Fres
h w
hole
�ow
erin
g pl
ants
of A
trop
a be
lla-d
onna
L.
Ph.fr
.Fo
rmul
aire
de
med
.an
thr.
(201
0)At
ropa
bel
la-d
onna
L.
Fres
h ae
rial p
arts
of A
trop
a be
lla-d
onna
L. w
ithou
t woo
dy lo
wer
st
em se
ctio
ns, c
olle
cted
at th
e be
ginn
ing
of �
ower
ing
Bella
donn
a (0
4.06
.198
6)At
ropa
bel
la-d
onna
L.
Fres
h un
derg
roun
d pa
rts o
f Atr
opa
bella
-don
na L
.Be
llado
nna
(04.
06.1
986)
Aven
a sa
tiva
L.W
hole
fres
h pl
ants
of A
vena
sativ
a L.
, col
lect
ed w
hen
the
grai
n ha
s rip
ened
to th
e m
ilky
stag
eH
AB
Aven
a/Pa
ssi�
ora
com
p.
(03.
07.1
992)
• Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
91
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erAv
ena
sativ
a L.
Fres
h ae
rial p
arts
of A
vena
sativ
a L.
, col
lect
ed w
hen
the
grai
n ha
s rip
ened
to th
e m
ilky
stag
eH
yper
icum
/Pas
si�or
a co
mp.
(DA
Z N
r. 29
vo
m 2
1.07
.199
4)Av
ena
sativ
a L.
Fres
h ae
rial p
arts
of A
vena
sativ
a L.
, col
lect
ed at
�ow
erin
g tim
eH
AB
/ Ph.
fr.Av
ena
sativ
a (D
AZ
Nr.
29 v
om 2
1.07
.199
4)Av
ena
sativ
a L.
Ger
min
ated
frui
ts o
f Ave
na sa
tiva
L.
Mag
nesiu
m p
hosp
hori-
cum
cum
cine
re A
vena
e (0
2.03
.199
1)Av
ena
sativ
a L.
Drie
d m
illed
frui
ts o
f Ave
na sa
tiva
L.Ba
llota
nig
ra L
.Fr
esh
who
le p
lant
of B
allo
ta n
igra
L. a
t �ow
erin
gPh
.fr.
Balsa
mum
per
uvia
num
see
Myr
oxyl
on b
alsa
mum
(L.)
Har
ms
Bam
busa
see
Phyl
lost
achy
s viri
digl
auce
scen
s (C
arr.)
A. e
t C. R
iv.Ba
mbu
sa a
rund
inac
ea (R
etz.)
W
illd,
Bam
busa
vul
garis
Sch
rad.
ex
J. C
. Wen
dl.
Fres
h sh
oot j
oint
s of B
ambu
sa a
rund
inac
ea (R
etz.)
Will
d an
d/or
Ba
mbu
sa v
ulga
ris S
chra
d. e
x J.
C. W
endl
Bella
donn
ase
e At
ropa
bel
la-d
onna
L.
Belli
s per
enni
s L.
Who
le fr
esh
�ow
erin
g pl
ants
of B
ellis
per
enni
s L.
HA
B / P
h.fr.
Sym
phyt
um co
mp.
(1
2.09
.199
2)Be
llis p
eren
nis L
.Fr
esh
aeria
l par
ts o
f Bel
lis p
eren
nis L
. at �
ower
ing
Belli
s/Tr
opae
olum
(0
2.03
.199
1)Be
nzoe
see
Styr
ax to
nkin
ensis
(Pie
rre)
Cra
ib e
x H
artw
ich
Berb
eris
aqui
foliu
mse
e M
ahon
ia a
quifo
lium
(Pur
sh) N
utt.
Berb
eris
vulg
aris
L.Fr
esh
aeria
l par
ts o
f Ber
beris
vul
garis
L. a
t �ow
erin
gBe
rber
is/Pr
osta
ta co
mp.
(1
2.09
.199
2)Be
rber
is vu
lgar
is L.
Fres
h un
derg
roun
d pa
rts o
f Ber
beris
vul
garis
L.
Berb
eris/
Urt
ica
uren
s, H
erba
(03.
07.1
992)
Berb
eris
vulg
aris
L.W
hole
, ful
ly ri
pene
d be
rrie
s of B
erbe
ris v
ulga
ris L
. str
ippe
d o�
the
frui
t sta
lks
HA
BBe
rber
is, F
ruct
us
(07.
04.1
988)
Berb
eris
vulg
aris
L.Fr
esh
who
le p
lant
incl
udin
g be
rrie
s of B
erbe
ris v
ulga
ris L
.Be
rber
is, P
lant
a to
ta /
Urt
ica
uren
s (0
2.03
.199
1)Be
rber
is vu
lgar
is L.
Drie
d ba
rk o
f aer
ial a
nd u
nder
grou
nd p
arts
of B
erbe
ris v
ulga
ris L
.H
AB
Berb
eris,
Cor
tex
(03.
07.1
992)
• Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
92
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erBe
rber
is vu
lgar
is L.
Drie
d ba
rk o
f und
ergr
ound
par
ts o
f Ber
beris
vul
garis
L.
Ph.fr
.Fo
rmul
aire
de
med
.an
thr.
(201
0)Be
rber
is vu
lgar
is L.
Drie
d un
derg
roun
d pa
rts o
f Ber
beris
vul
garis
L.
Berb
eris/
Che
lidon
ium
co
mp.
(02.
03.1
991)
Beta
vul
garis
L.
Sacc
haru
m B
etae
(cru
de b
eet s
ugar
)Be
toni
case
e St
achy
s o�
cina
lis (L
.) Tr
ev.
Betu
la p
endu
la R
oth
Fres
h yo
ung
leav
es o
f Bet
ula
pend
ula
Roth
.H
AB
Betu
la, F
oliu
m
(04.
06.1
986)
Betu
la p
endu
la R
oth
Drie
d w
hite
par
ts o
nly
of b
ark
from
trun
k an
d br
anch
es o
f Bet
ula
pend
ula
Roth
HA
BBe
tula
, Cor
tex
(07.
04.1
988)
Betu
la p
endu
la R
oth,
Bet
ula
pu-
besc
ens E
hrha
rtW
hole
or f
ragm
ente
d dr
ied
leav
es o
f Bet
ula
pend
ula
Roth
and
/or
Betu
la p
ubes
cens
Ehr
h., a
s wel
l as h
ybrid
s of b
oth
spec
ies.
(Birc
h le
af)
Ph.E
ur.
Betu
la, F
oliu
m
(04.
06.1
986)
Betu
la p
endu
la R
oth,
Bet
ula
pu-
besc
ens E
hrha
rtFi
nal c
arbo
n re
mai
ning
from
bur
ning
Birc
h w
ood
HA
BC
arbo
Bet
ulae
(0
4.06
.198
6)Bo
ldo
see
Peum
us b
oldu
s Mol
.Bo
rago
o�
cina
lis L
.Fr
esh
leav
es o
f Bor
ago
o�ci
nalis
L.
Bora
go (0
2.03
.199
1)Bo
rago
o�
cina
lis L
.Fr
esh
aeria
l par
ts o
f Bor
ago
o�ci
nalis
L. a
t �ow
erin
gBo
rago
(02.
03.1
991)
Bosw
ellia
spec
ies,
part
icul
arly
Bo
swel
lia c
arte
ri Bi
rdw
ood
see
Bosw
ellia
spec
ies,
part
icul
arly
Bos
wel
lia sa
cra
Flue
ckig
er
Bosw
ellia
spec
ies,
part
icul
arly
Bo
swel
lia sa
cra
Flue
ckig
erSo
lidi�
ed g
um-r
esin
obt
aine
d fr
om in
cisio
ns in
the
shru
bs o
r tre
es
of m
embe
rs o
f the
gen
us B
osw
ellia
, par
ticul
arly
Bos
wel
lia c
arte
ri Bi
rdw
ood
(Syn
. Bos
wel
lia sa
cra
Flue
ckig
er) a
nd/o
r Bos
swel
lia
frer
eana
Bird
woo
d
(DA
C, P
h.Eu
r., B
. ser
-ra
ta)
Auru
m co
mp.
(0
5.12
.198
9)
Botr
ychi
um lu
naria
L.
Fres
h ae
rial p
arts
of B
otry
chiu
m lu
naria
L.
Bras
sica
nigr
a (L
.) W
.D.J.
Koc
hRi
pe d
ried
seed
s of B
rass
ica
nigr
a (L
.) Ko
ch (S
inap
is ni
gra)
DA
CA
escu
lus/
Cer
a co
mp.
(0
2.03
.199
1)Br
yoni
a cr
etic
a L.
ssp.
dio
ica
(Jac
q.) T
utin
Fres
h ro
ot o
f Bry
onia
cret
ica
L. ss
p. d
ioic
a (J
acq.
) Tut
in o
r Bry
onia
al
ba L
., ha
rves
ted
befo
re th
e pl
ant c
omes
into
�ow
erH
AB
Bryo
nia
(03.
07.1
992)
Bryo
nia
cret
ica
L. ss
p. d
ioic
a (J
acq.
) Tut
inFr
esh
root
of B
ryon
ia cr
etic
a L.
ssp.
dio
ica
(Jac
q.) T
utin
, har
vest
ed
befo
re sh
oots
are
pro
duce
dH
AB
Bryo
nia
(03.
07.1
992)
Bryo
nia
cret
ica
L. ss
p. d
ioic
a (J
acq.
) Tut
inFr
esh
unde
rgro
und
part
s of B
ryon
ia cr
etic
a L.
ssp.
dio
ica
(Jac
q.)
Tutin
or B
ryon
ia a
lba
L.Ph
.fr.
Form
ulai
re d
e m
ed.
anth
r. (2
010)
• Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
93
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erBr
yoph
yllu
m d
aigr
emon
tianu
m
(Ray
m.-H
amet
et H
. Per
rier)
A.
Berg
er a
nd B
ryop
hyllu
m p
inna
-tu
m (L
am.)
Oke
n
Fres
h le
aves
of B
ryop
hyllu
m d
aigr
emon
tianu
m (R
aym
.-Ham
et e
t H
. Per
rier)
A. B
erge
r and
Kal
anch
oe p
inna
ta (L
am.)
Pers
., ha
rves
t-ed
in th
e �r
st y
ear o
f gro
wth
HA
BBr
yoph
yllu
m
(04.
06.1
986)
Bryo
phyl
lum
pin
natu
m (L
am.)
Oke
nFr
esh
pres
sed
juic
e fr
om le
aves
of B
ryop
hyllu
m p
inna
tum
(Lam
.) O
ken
Bryo
phyl
lum
(0
4.06
.198
6)Br
yoph
yllu
m p
inna
tum
(Lam
.) O
ken
Fres
h le
aves
of B
ryop
hyllu
m p
inna
tum
(Lam
.) O
ken,
har
vest
ed in
th
e �r
st y
ear o
f gro
wth
HA
BBr
yoph
yllu
m
(04.
06.1
986)
Buxu
s sem
perv
irens
L.
Fres
h, y
oung
leaf
y br
anch
es o
f Bux
us se
mpe
rvire
ns L
.Ph
.fr.
Cac
tus g
rand
i�or
usSe
e Se
leni
cere
us g
rand
i�or
us (L
.) Br
itt. e
t Ros
eC
ajep
uti a
ethe
role
umSe
e M
elal
euca
leuc
aden
dra
(L.)
L.C
alam
usSe
e A
coru
s cal
amus
L.
Cal
endu
la o
�ci
nalis
L.
Fres
h �o
wer
hea
ds o
f Cal
endu
la o
�ci
nalis
L.
Cal
endu
la (0
4.06
.198
6)C
alen
dula
o�
cina
lis L
.Fr
esh
aeria
l par
ts o
f Cal
endu
la o
�ci
nalis
L.,
colle
cted
at �
ower
ing
time
HA
BC
alen
dula
(04.
06.1
986)
Cal
endu
la o
�ci
nalis
L.
Drie
d �o
wer
hea
ds o
f Cal
endu
la o
�ci
nalis
L.
Euph
rasia
com
p.
(02.
09.1
987)
Cal
endu
la o
�ci
nalis
L.
Who
le o
r cut
, drie
d, a
nd fu
lly o
pene
d �o
wer
s tha
t hav
e be
en
deta
ched
from
the
rece
ptac
le o
f the
cul
tivat
ed, d
oubl
e-�o
wer
ed
varie
ties o
f Cal
endu
la o
�ci
nalis
L. (
Cal
endu
la �
ower
s)
Ph.E
ur.
Cal
endu
la o
�ci
nalis
L.
Drie
d ae
rial p
arts
of C
alen
dula
o�
cina
lis L
., co
llect
ed at
�ow
erin
g tim
eA
rnic
a co
mp.
/Cup
rum
(0
4.06
.198
6)C
apse
lla b
ursa
-pas
toris
(L.)
Med
.D
ried
aeria
l par
ts o
f Cap
sella
bur
sa-p
asto
ris (L
.) M
edik
, col
lect
ed at
�o
wer
ing
time
HA
BC
apse
lla b
ursa
-pas
toris
(1
2.09
.199
2)C
apsic
um a
nnuu
m L
.D
ried
ripe
frui
ts o
f Cap
sicum
ann
uum
L.
HA
B / P
h.fr.
Kas
tani
en-H
aart
oni-
kum
(04.
06.1
986)
Car
amel
see
Sacc
haru
m o
�ci
naru
m L
.C
ardu
us b
ened
ictu
sse
e C
nicu
s ben
edic
tus L
.C
ardu
us m
aria
nus
see
Sily
bum
mar
ianu
m (L
.) G
aert
n.C
arex
are
naria
L.
Drie
d rh
izom
e of
Car
ex a
rena
ria L
., co
llect
ed in
sprin
gSo
ldne
r / S
tellm
ann
(201
1), I
ndiv
idue
lle
Pädi
atrie
, p. 1
90-1
98
• Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
94
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erC
arum
car
vi L
.O
il ob
tain
ed b
y st
eam
dist
illat
ion
from
the
dry
frui
ts o
f Car
um
carv
i L. (
cara
way
oil)
Ph.E
ur.
Ole
um la
ctag
ogum
(0
2.09
.198
7)C
arum
car
vi L
.W
hole
, dry
mer
icar
p of
Car
um c
arvi
L. (
cara
way
frui
t)H
AB
/ Ph.
Eur.
Car
um c
arvi
com
p.
(02.
03.1
991)
Car
yoph
yllu
sse
e Sy
zygi
um a
rom
atic
um (L
.) M
err.
et L
. M. P
erry
Cas
sia a
ngus
tifol
ia V
ahl.,
Cas
sia
senn
a L.
Drie
d le
a�et
s of C
assia
senn
a L.
(C. a
cutif
olia
Del
il) ,
know
n as
Al-
exan
dria
n or
Kha
rtou
m se
nna,
or C
assia
ang
ustif
olia
Vah
l, kn
own
as T
inne
velly
senn
a, o
r a m
ixtu
re o
f the
2 sp
ecie
s
Ph.fr
. Fo
rmul
aire
de
med
.an
thr.
(201
0)
Cas
sia a
ngus
tifol
ia V
ahl.,
Cas
sia
senn
a L.
Drie
d le
a�et
s of C
assia
senn
a L.
(C. a
cutif
olia
Del
ile),
know
n as
Al-
exan
dria
n or
Kha
rtou
m se
nna,
or C
assia
ang
ustif
olia
Vah
l., k
now
n as
Tin
neve
lly se
nna,
or a
mix
ture
of t
he tw
o sp
ecie
s. (s
enna
leaf
)
Ph.E
ur.
Cen
taur
ium
com
p.(0
4.06
.198
6)
Cas
sia se
nna
L.
(C. a
cutif
olia
Del
ile)
Drie
d fr
uit o
f Cas
sia se
nna
L. (s
enna
pod
s, al
exan
dria
n)Ph
.Eur
.A
rtem
isia
com
p.(0
2.03
.199
1)C
aulo
phyl
lum
thal
ictr
oide
s (L.
) M
ichx
.Fr
esh
unde
rgro
und
part
s of C
aulo
phyl
lum
thal
ictr
oide
s (L.
) Mi-
chx.
, har
vest
ed in
late
sum
mer
HA
B
Cau
loph
yllu
m th
alic
troi
des (
L.)
Mic
hx.
Drie
d un
derg
roun
d pa
rts o
f Cau
loph
yllu
m th
alic
troi
des (
L.) M
ich-
aux.
Ph.fr
.Fo
rmul
aire
de
med
.an
thr.
(201
0)C
eano
thus
am
eric
anus
L.
Drie
d le
aves
of C
eano
thus
am
eric
anus
L.
Ph.fr
. / H
AB
Form
ulai
re d
e m
ed.
anth
r. (2
010)
Cen
taur
ium
ery
thra
ea R
afn.
Fres
h w
hole
pla
nts o
f Cen
taur
ium
ery
thra
ea R
afn.
, col
lect
ed at
�o
wer
ing
time
Cen
taur
ium
ery
thra
ea R
afn.
Fres
h ae
rial p
arts
of C
enta
uriu
m e
ryth
raea
Raf
n.C
icho
rium
/Tar
axac
um
com
p. (0
4.06
.198
6)C
enta
uriu
m e
ryth
raea
Raf
n.W
hole
or f
ragm
ente
d dr
ied
�ow
erin
g ae
rial p
arts
of C
enta
uriu
m
eryt
hrae
a Ra
fn s.
l. in
clud
ing
C. m
ajus
(H. e
t L.)
Zeltn
er a
nd C
. suf
-fr
utic
osum
(Gris
eb.)
Ronn
. (sy
n.: E
ryth
raea
cent
auriu
m P
erso
on;
C. u
mbe
llatu
m G
ilibe
rt; C
. min
us G
ars.)
(cen
taur
y)
Ph.E
ur.
Cen
taur
ium
com
p.
(04.
06.1
986)
Cen
tella
asia
tica
(L.)
Urb
.D
ried,
frag
men
ted
aeria
l par
ts o
f Cen
tella
asia
tica
(L.)
Urb
anPh
.fr.
Cep
ase
e A
llium
cepa
L.
Cep
hael
is ip
ecac
uanh
ase
e Ps
ycho
tria
ipec
acua
nha
(Bro
t.) S
toke
s
• Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
95
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erC
epha
elis
ipec
acua
nha
(Bro
t.)
A. R
ich.
, Cep
hael
is ac
umin
ata
Kar
sten
Frag
men
ted
and
drie
d un
derg
roun
d or
gans
of C
epha
elis
ipec
acua
-nh
a (B
rot.)
A. R
ich.
, kno
wn
as M
atto
Gro
sso
ipec
acua
nha,
or o
f C
epha
elis
acum
inat
a K
arst
en, k
now
n as
Cos
ta R
ica
ipec
acua
nha,
or
of a
mix
ture
of b
oth
spec
ies.
(ipec
acua
nhae
root
)
Ph.fr
. / P
h.Eu
r.Fo
rmul
aire
de
med
.an
thr.
(201
0)
Cet
raria
isla
ndic
a (L
.) A
ch.
Who
le o
r cut
, drie
d th
allu
s of C
etra
ria is
land
ica
(L.)
Ach
ariu
s s.l.
(ic
elan
d m
oss)
HA
B / P
h.Eu
r.C
etra
ria is
land
ica
(04.
06.1
986)
Cha
mae
liriu
m lu
teum
(L.)
A.
Gra
yD
ried
unde
rgro
und
part
s of C
ham
aelir
ium
lute
um (L
.) A
. Gra
y
Cha
mom
illa
recu
tita
(L.)
Raus
cher
tse
e M
atric
aria
recu
tita
L.
Che
irant
hus c
heiri
L.
Fres
h w
hole
�ow
erin
g pl
ant o
f Che
irant
hus c
heiri
L.
Che
lidon
ium
maj
us L
.Fr
esh
rhiz
ome
and
adhe
rent
root
s of C
helid
oniu
m m
ajus
L.,
col-
lect
ed d
urin
g la
te au
tum
n or
on
the
appe
aran
ce o
f the
�rs
t sho
ots
HA
BC
helid
oniu
m
(12.
09.1
992)
Che
lidon
ium
maj
us L
.Fr
esh
�ow
ers o
f Che
lidon
ium
maj
us L
.H
AB
Che
lidon
ium
(1
2.09
.199
2)C
helid
oniu
m m
ajus
L.
Fres
h ae
rial p
arts
of C
helid
oniu
m m
ajus
L.,
colle
cted
at �
ower
ing
time
Che
lidon
ium
(1
2.09
.199
2)C
helid
oniu
m m
ajus
L.
Fres
h w
hole
�ow
erin
g pl
ants
of C
helid
oniu
m m
ajus
L.
Ph.fr
.C
him
aphi
la u
mbe
llata
(L.)
Bart
onD
ried
aeria
l par
ts o
f Chi
map
hila
um
bella
ta (L
.) Ba
rton
Ph.fr
.Fo
rmul
aire
de
med
.an
thr.
(201
0)C
hina
see
Cin
chon
a pu
besc
ens V
ahl
Chl
orop
hyce
aeFr
esh
�al
li of
alg
ae fr
om th
e ge
nus C
lado
phor
a or
Oed
ogon
ium
or
oth
er g
ener
a of
�la
men
tous
org
anise
d gr
een
alga
e fr
om th
e cl
ass
Chl
orop
hyce
ae.
Arg
entu
m n
itric
um
com
p. (0
2.03
.199
1)
Cho
ndod
endr
on to
men
tosu
m
Ruiz
et P
av.
Drie
d ro
ots o
f Cho
ndod
endr
on to
men
tosu
m R
uiz e
t Pav
.Ph
.fr.
Chr
ysos
plen
ium
alte
rnifo
lium
L.
Who
le fr
esh
plan
ts o
f Chr
ysos
plen
ium
alte
rnifo
lium
L.
Chr
ysos
plen
ium
com
p.
(25.
10.1
994)
Cic
horiu
m in
tybu
s L.
Who
le fr
esh
�ow
erin
g pl
ants
of C
icho
rium
inty
bus L
.H
AB
Cic
horiu
m (0
3.07
.199
2)C
icho
rium
inty
bus L
.D
ried
who
le p
lant
s of C
icho
rium
inty
bus L
. var
. int
ybus
and
Cic
ho-
rium
inty
bus L
. var
. sat
ivum
DC
, col
lect
ed at
�ow
erin
g tim
e. �
e to
ugh
mid
dle
stem
sect
ions
are
not
use
d.
HA
BC
icho
rium
(03.
07.1
992)
• Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
96
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erC
icho
rium
inty
bus L
.D
ried
root
of C
icho
rium
inty
bus L
. ssp
. int
ybus
and
Cic
horiu
m
inty
bus L
. ssp
. sat
ivum
(DC
) Jan
chen
, col
lect
ed at
�ow
erin
g tim
eC
icho
rium
(03.
07.1
992)
Cim
icifu
ga ra
cem
osa
(L.)
Nut
t.Fr
esh
rhiz
ome
and
adhe
rent
root
s of C
imifu
ga ra
cem
osa
(L.)
Nut
t.H
AB
Cim
icifu
ga co
mp.
(0
2.09
.198
7)C
inch
ona
pube
scen
s Vah
lW
hole
or c
ut, d
ried
bark
of C
inch
ona
pube
scen
s Vah
l (C
inch
ona
succ
irubr
a Pa
v.), o
f C. c
alisa
ya W
edd.
, of C
. led
geria
na M
oens
ex
Trim
en o
r of t
heir
varie
ties o
r hyb
rids (
cinc
hona
bar
k)
HA
B / P
h.Eu
r.A
coni
tum
/Chi
na co
mp.
(1
2.09
.199
2)
Cin
erar
ia m
ariti
ma
see
Sene
cio
bico
lor (
Will
d.) T
od.
Cin
nam
omum
ver
um J.
S. P
resl
Drie
d ba
rk, f
reed
from
the
oute
r cor
k an
d th
e un
derly
ing
pare
n-ch
yma,
of t
he sh
oots
gro
wn
on c
ut st
ock
of C
inna
mom
umve
rum
J.
S. P
resl
(cin
nam
on)
HA
B / P
h.Eu
r.Sp
iritu
s Mel
issae
com
p.
(04.
06.1
986)
Ciss
us g
ongy
lode
s (Ba
k.) B
urch
.Fr
esh
aeria
l roo
ts o
f Ciss
us g
ongy
lode
s (Ba
k.) B
urch
.C
issus
-Oss
a (0
3.07
.199
2)C
itrul
lus c
oloc
ynth
is (L
.) Sc
hrad
.D
ried
pulp
of C
itrul
lus c
oloc
ynth
is (L
.) Sc
hrad
.Ph
.fr.
Form
ulai
re d
e m
ed.
anth
r. (2
010)
Citr
ullu
s col
ocyn
this
(L.)
Schr
ad.
Fres
h pe
eled
unr
ipe
frui
t of C
itrul
lus c
oloc
ynth
is (L
.) Sc
hrad
. w
ithou
t see
dsC
oloc
ynth
is (0
7.04
.198
8)C
itrul
lus c
oloc
ynth
is (L
.) Sc
hrad
.D
ried
peel
ed fr
uit o
f Citu
llus c
oloc
ynth
is (L
.) Sc
hrad
. with
out s
eeds
HA
BC
oloc
ynth
is (0
7.04
.198
8)C
itrus
lim
on (L
.) Bu
rm. f
.Es
sent
ial o
il ob
tain
ed b
y su
itabl
e m
echa
nica
l mea
ns, w
ithou
t the
ai
d of
hea
t, fr
om th
e fr
esh
peel
of C
itrus
lim
on (L
.) Bu
rman
. �l.
(lem
on o
il)
Ph.E
ur.
Spiri
tus M
eliss
ae co
mp.
(0
4.06
.198
6)
Citr
us li
mon
(L.)
Burm
. f.
Fres
h pr
esse
d ju
ice
from
the
frui
t of C
itrus
lim
on (L
.) Bu
rman
. �l.
Citr
us/C
ydon
ia
(04.
06.1
986)
Citr
us li
mon
(L.)
Burm
. f.
Fres
h fr
uit o
f Citr
us li
mon
(L.)
Burm
an. �
l.C
itrus
/Cyd
onia
(0
4.06
.198
6)C
itrus
med
ica
var.
limon
umse
e C
itrus
lim
on (L
.) Bu
rman
. �l.
Cla
dina
rang
iferin
a (L
.) N
yl.
Drie
d th
allu
s of C
ladi
na ra
ngife
rina
(L.)
Nyl
.Li
chen
es co
mp.
(0
4.06
.198
6)C
lavi
ceps
pur
pure
a (F
r.) T
ul.
Drie
d sc
lero
tum
of C
lavi
ceps
pur
pure
a (F
ries)
Tul
asne
, gro
wn
on
rye
plan
ts (S
ecal
e ce
real
e L.
) and
drie
d at
a te
mpe
ratu
re n
ot e
xcee
d-in
g 40
°C (S
ecal
e co
rnut
um)
HA
BBl
eigl
anz/
Seca
le co
mp.
(1
2.09
.199
2)
Cle
mat
is re
cta
L.Fr
esh,
you
ng le
afy
bran
ches
of C
lem
atis
rect
a L.
, col
lect
ed at
�ow
-er
ing
time
Ph.fr
.
• Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
97
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erC
lem
atis
rect
a L.
Fres
h ae
rial p
arts
of o
f Cle
mat
is re
cta
L., c
olle
cted
at �
ower
ing
time
HA
BVa
dem
ecum
: Cle
mat
is re
cta
Cni
cus b
ened
ictu
s L.
Fres
h ae
rial p
arts
of C
nicu
s ben
edic
tus L
., co
llect
ed at
�ow
erin
g tim
eH
AB
Bora
go co
mp.
(1
2.09
.199
2)C
occu
lus
see
Ana
mirt
a co
ccul
us W
ight
et A
rn.
Coc
hlea
ria a
rmor
acia
see
Arm
orac
ia ru
stic
ana
Ph. G
ärtn
., B.
Mey
. et S
cher
b.C
ochl
earia
o�
cina
lis L
.Fr
esh
aeria
l par
ts o
f Coc
hlea
ria o
�ci
nalis
L.,
colle
cted
at th
e st
art
of �
ower
ing
time
HA
BC
ochl
earia
o�
cina
lis
(07.
04.1
988)
Coc
hlea
ria o
�ci
nalis
L.
Drie
d ae
rial p
arts
of C
ochl
earia
o�
cina
lis L
., co
llect
ed at
the
begi
n-ni
ng o
f the
�ow
erin
g tim
eLe
vist
icum
com
p.
(02.
09.1
987)
Co�
ea a
rabi
ca L
.D
ried
roas
ted
seed
s of C
o�ea
ara
bica
L.
Aven
a sa
tiva
com
p.
(04.
06.1
986)
Co�
ea a
rabi
ca L
., C
o�ea
can
epho
-ra
Pie
rre
ex F
roeh
ner a
nd th
eir
varie
ties.
Drie
d gr
ey-g
reen
seed
s of C
o�ea
ara
bica
L.,
de C
o�ea
can
epho
ra
Pier
re e
x Fr
oehn
er a
nd th
eir v
arie
ties.
Ph.fr
.
Co�
ea a
rabi
ca L
.Ri
pe, d
ried,
unr
oast
ed se
eds o
f Co�
ea a
rabi
ca L
. with
the
seed
coat
(s
ilver
skin
) lar
gely
rem
oved
HA
B
Col
chic
um au
tum
nale
L.
Fres
h co
rms o
f Col
chic
um au
tum
nale
L.
Ph.fr
.Fo
rmul
aire
de
med
.an
thr.
(201
0)C
olch
icum
autu
mna
le L
.Fr
esh
corm
s of C
olch
icum
autu
mna
le L
., co
llect
ed at
�ow
erin
g tim
e an
d fr
ee fr
om �
brou
s roo
tsH
AB
Col
chic
um (0
4.06
.198
6)
Col
chic
um au
tum
nale
L.
Fres
h w
hole
, �ow
erin
g pl
ant o
f Col
chic
um au
tum
nale
L.
Col
chic
um (0
4.06
.198
6)C
ollin
soni
a ca
nade
nsis
L.
Drie
d rh
izom
e of
Col
linso
nia
cana
dens
is L.
Ph.fr
.C
oloc
ynth
isse
e C
itrul
lus c
oloc
ynth
is (L
.) Sc
hrad
.C
omm
ipho
ra Ja
cq. S
peci
esG
um-r
esin
, har
dene
d in
air,
obt
aine
d by
inci
sion
or p
rodu
ced
by
spon
tane
ous e
xuda
tion
from
the
stem
and
bra
nche
s of C
omm
ipho
-ra
mol
mol
Eng
ler a
nd/o
r oth
er sp
ecie
s of C
omm
ipho
ra (m
yrrh
)
Ph.E
ur.
Auru
m co
mp.
(0
5.12
.198
9)
Con
ium
mac
ulat
um L
.Fr
esh
�ow
erhe
ads o
f Con
ium
mac
ulat
um L
., co
llect
ed at
the
end
of
�ow
erin
g tim
ePh
.fr.
Form
ulai
re d
e m
ed.
anth
r. (2
010)
Con
ium
mac
ulat
um L
.Fr
esh,
aer
ial p
arts
of t
he �
ower
ing,
but
not
yet
frui
ting
spec
imen
s of
Con
ium
mac
ulat
um L
.H
AB
Con
ium
mac
ulat
um
(02.
09.1
987)
• Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
98
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erC
onva
llaria
maj
alis
L.Fr
esh
aeria
l par
ts o
f Con
valla
ria m
ajal
is L.
, col
lect
ed at
�ow
erin
g tim
eH
AB
Con
valla
ria
(03.
07.1
992)
Con
valla
ria m
ajal
is L.
Fres
h w
hole
, �ow
erin
g p
lant
s of C
onva
llaria
maj
alis
L.C
onva
llaria
/Prim
ula
com
p. (1
2.09
.199
2)C
onva
llaria
maj
alis
L.Fr
esh
�ow
ers o
f Con
valla
ria m
ajal
is L.
Con
valla
ria
(03.
07.1
992)
Cor
iand
rum
sativ
um L
.D
ried
crem
ocar
p of
Cor
iand
rium
sativ
um L
. (co
riand
er)
Ph.E
ur.
Spiri
tus M
eliss
ae co
mp.
(0
4.06
.198
6)C
oryd
alis
cava
(L.)
Cla
irv.
Fres
h un
derg
roun
g pa
rts o
f Cor
ydal
is ca
va (L
.) C
lair
v.C
rata
egus
laev
igat
a (P
oir.)
DC
., C
rata
egus
mon
ogyn
a Ja
cq.
emen
d. L
indm
.
Fres
h le
aves
and
ripe
frui
t of C
rata
egus
laev
igat
a (P
oir.)
DC
. and
C
rata
egus
mon
ogyn
a Ja
cq. e
men
d. L
indm
anC
rata
egus
(02.
09.1
987)
Cra
taeg
us la
evig
ata
(Poi
r.) D
C.,
Cra
taeg
us m
onog
yna
Jacq
. em
end.
Lin
dm.
Fres
h rip
e fr
uits
of C
rata
egus
laev
igat
a (P
oir)
DC
., C
rata
egus
mo-
nogy
na Ja
cq. e
men
d. L
indm
., th
eir h
ybrid
s and
mix
ture
s the
reof
HA
BC
rata
egus
(02.
09.1
987)
Cra
taeg
us la
evig
ata
(Poi
r.) D
C.,
Cra
taeg
us m
onog
yna
Jacq
. em
end.
Lin
dm.
Who
le o
r cut
, drie
d �o
wer
-bea
ring
bran
ches
of C
rata
egus
mo-
nogy
na Ja
cq. (
Lind
m.),
C. l
aevi
gata
(Poi
r.) D
C. (
syno
nym
s: C
.oxy
acan
thoi
des �
uill.
; C. o
xyac
anth
a au
ct.)
or th
eir h
ybrid
s or
, mor
e ra
rely,
othe
r Eur
opea
n C
rata
egus
spec
ies i
nclu
ding
C.
pent
agyn
a W
alds
t. et
Kit.
ex
Will
d., C
. nig
ra W
alds
t. et
Kit.
and
C.
azar
olus
L. (
haw
thor
n le
af a
nd �
ower
)
Ph.E
ur.
Cra
taeg
us (0
2.09
.198
7)
Cro
cus s
ativ
us L
.D
ried
stig
mas
of C
rocu
s sat
iva
L., u
sual
ly jo
ined
by
the
base
to a
sh
ort s
tyle
. (sa
�ron
for h
omoe
opat
hic p
repa
ratio
ns)
HA
B / P
h.Eu
r.K
aliu
m a
cetic
um co
mp.
(0
3.07
.199
2)C
roto
n tig
lium
L.
Drie
d se
eds o
f Cro
ton
tigliu
m L
.Ph
.fr.
Cucu
rbita
pep
o L.
Fres
h �o
wer
s of C
ucur
bita
pep
o L.
Apat
it / P
hosp
horu
s co
mp.
(04.
06.1
986)
Cucu
rbita
pep
o L.
Drie
d pu
lp o
f pum
pkin
s of C
ucur
bita
max
ima
Duc
h.Va
dem
ecum
: Che
lido-
nium
/Cur
cum
a co
mp.
Cupr
essu
s sem
perv
irens
LFr
esh
leaf
y br
anch
es o
f Cup
ress
us se
mpe
rvire
ns L
. with
cone
sPh
.fr.
Curc
uma
xant
horr
hiza
Rox
b.D
ried
rhiz
ome,
cut i
n sli
ces,
of C
ucur
ma
xant
horr
hiza
Rox
b. (C
. xa
ntho
rrhi
za D
. Die
tric
h). (
turm
eric
, Jav
anes
e)Ph
.Eur
.C
helid
oniu
m/C
urcu
ma
(04.
06.1
986)
Cyd
onia
obl
onga
Mill
.Fr
esh
ripe
frui
ts o
f Cyd
onia
obl
onga
Mill
.C
ydon
ia, F
ruct
us
(02.
03.1
991)
• Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
99
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erC
ymbo
pogo
n w
inte
rianu
s Jow
ittO
il ob
tain
ed b
y st
eam
dist
illat
ion
from
the
fres
h or
par
tially
drie
d ae
rial p
arts
of C
ymbo
pogo
n w
inte
rianu
s Jow
itt (c
itron
ella
e oi
l)Ph
.Eur
.C
itron
ella
e ae
ther
o-le
um (0
2.03
.199
1)C
ynar
a sc
olym
us L
.Fr
esh
leav
es o
f Cyn
ara
scol
ymus
L.
Ph.fr
.Fo
rmul
aire
de
med
.an
thr.
(201
0)C
ytisu
s sco
pariu
s (L.
) Lin
k.Fr
esh
youn
g tip
s of s
hoot
s of C
ytisu
s sco
pariu
s (L.
) Lin
k. w
ith �
ow-
ers a
nd le
aves
Ph.fr
.Fo
rmul
aire
de
med
.an
thr.
(201
0)C
ytisu
s sco
pariu
s (L.
) Lin
k.Fr
esh
aeria
l par
ts o
f Cyt
isus s
copa
rius (
L.) L
ink
at �
ower
ing
time
Saro
tham
nus c
omp.
(0
3.07
.199
2)D
aphn
e m
ezer
eum
L.
Fres
h ba
rk fr
om th
e br
anch
es o
f Dap
hne
mez
ereu
m L
., co
llect
ed
prio
r to
�ow
erin
gH
AB
Mez
ereu
m (0
3.07
.199
2)
Dat
ura
stra
mon
ium
L.
Fres
h ae
rial p
arts
of D
atur
a st
ram
oniu
m L
., co
llect
ed at
�ow
erin
g tim
eH
AB
/ Ph.
fr.St
ram
oniu
m
(02.
03.1
991)
Del
phin
ium
stap
hisa
gria
L.
Drie
d rip
e se
eds o
f Del
phin
ium
stap
hisa
gria
L.
HA
B / P
h.fr.
Form
ulai
re d
e m
ed.
anth
r. (2
010)
Dig
italis
pur
pure
a L.
Fres
h le
aves
from
two-
year
-old
spec
imen
s of D
igita
lis p
urpu
rea
L.,
colle
cted
bef
ore
�ow
erin
g tim
eH
AB
Dig
italis
pur
pure
a (0
2.09
.198
7)D
olic
hos p
rurie
nsse
e M
ucun
a pr
urie
ns (L
.) D
C.
Dro
sera
rotu
ndifo
lia L
., D
rose
ra
inte
rmed
ia H
ayne
, Dro
sera
an-
glic
a H
uds.
Who
le fr
esh
plan
ts o
f Dro
sera
rotu
ndifo
lia L
., D
rose
ra in
term
edia
H
ayne
and
Dro
sera
ang
lica
Hud
s., si
ngle
spec
ies o
r mix
ed, c
ol-
lect
ed at
the
star
t of �
ower
ing
HA
BPl
anta
go co
mp.
(1
2.09
.199
2)
Dro
sera
rotu
ndifo
lia L
., D
rose
ra
inte
rmed
ia H
ayne
, Dro
sera
an-
glic
a H
uds.
Who
le d
ried
plan
ts o
f di�
eren
t Dro
sera
spec
ies,
mai
nly
Dro
sera
ro
tund
ifolia
L.,
Dro
sera
inte
rmed
ia H
ayne
and
Dro
sera
ang
lica
Hud
s. (D
. lon
gifo
lia L
.)
Ph.fr
.Fo
rmul
aire
de
med
.an
thr.
(201
0)
Dry
opte
ris �
lix-m
as (L
.) Sc
hott.
Fres
h rh
izom
e of
Dry
opte
ris �
lix-m
as (L
.) Sc
hott,
with
root
sA
quili
num
com
p.
(12.
09.1
992)
Dry
opte
ris �
lix-m
as (L
.) Sc
hott.
Fres
h ae
rial p
arts
of D
ryop
teris
�lix
-mas
(L.)
Scho
tt.A
spid
ium
/Sal
ix co
mp.
(0
4.06
.198
6)D
ryop
teris
�lix
-mas
(L.)
Scho
tt.Ri
pe sp
ores
of D
ryop
teris
�lix
-mas
(L.)
Scho
tt.A
garic
us co
mp.
/Pho
s-ph
orus
(05.
12.1
989)
Dul
cam
ara
see
Sola
num
dul
cam
ara
L.Ec
hina
cea
angu
stifo
lia D
C.,
Echi
-na
cea
palli
da (N
utt.)
Nut
t.W
hole
fres
h �o
wer
ing
plan
ts o
f Ech
inac
ea a
ngus
tifol
ia D
C. a
nd
Echi
nace
a pa
llida
(Nut
t.) N
utt.,
sing
le sp
ecie
s or m
ixed
HA
B
Echi
nace
a an
gust
ifolia
DC
.W
hole
fres
h �o
wer
ing
plan
ts o
f Ech
inac
ea a
ngus
tifol
ia D
C.
HA
BEc
hina
cea
(07.
04.1
988)
• Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
100
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erEc
hina
cea
palli
da (N
utt.)
Nut
t.Fr
esh
�ow
erin
g pl
ants
of E
chin
acea
pal
lida
(Nut
t.) N
utt.
HA
BEc
hina
cea/
Qua
rz co
mp.
(0
2.03
.199
1)Ec
hina
cea
palli
da (N
utt.)
Nut
t.Fr
esh
aeria
l par
ts o
f Ech
inac
ea p
allid
a (N
utt.)
Nut
t., co
llect
ed at
�o
wer
ing
time
Echi
nace
a (0
7.04
.198
8)
Echi
nace
a pa
llida
(Nut
t.) N
utt.
Fres
h un
derg
roun
d pa
rts o
f Ech
inac
ea p
allid
a (N
utt.)
Nut
t.A
rgen
tum
/Ech
inac
ea
(05.
12.1
989)
Echi
nace
a pu
rpur
ea (L
.) M
oenc
hW
hole
fres
h �o
wer
ing
plan
ts o
f Ech
inac
ea p
urpu
rea
(L.)
Moe
nch
HA
BEc
hina
cea
(07.
04.1
988)
Elym
us re
pens
(L.)
Gou
ldFr
esh
unde
rgro
und
part
s of E
lym
us re
pens
(L.)
Gou
ldH
AB
Agr
opyr
on co
mp.
(0
7.04
.198
8)Eq
uise
tum
arv
ense
L.
Fres
h, g
reen
, ste
rile
shoo
ts o
f Equ
isetu
m a
rven
se L
.H
AB
Equi
setu
m a
rven
se
(04.
06.1
986)
Equi
setu
m a
rven
se L
.W
hole
or c
ut, d
ried
ster
ile a
eria
l par
ts o
f Equ
isetu
m a
rven
se L
. (e
quise
tum
stem
)Ph
.Eur
.Eq
uise
tum
arv
ense
(0
4.06
.198
6)Eq
uise
tum
�uv
iatil
e L
see
Equi
setu
m li
mos
um L
. Eq
uise
tum
lim
osum
L.
Fres
h ae
rial p
arts
of E
quise
tum
lim
osum
L.
Sold
ner/
Ste
llman
n (2
011)
Indi
vidu
elle
Pä
diat
rie
Eryt
hrae
a ce
ntau
rium
see
Cen
taur
ium
ery
thra
ea R
afn.
Esch
scho
lzia
cal
iforn
ica
Cha
m.
Who
le fr
esh
�ow
erin
g pl
ants
of E
schs
chol
zia
calif
orni
ca C
ham
.Ph
.fr.
Euca
lypt
us g
lobu
lus L
abill
.Es
sent
ial o
il ob
tain
ed b
y st
eam
dist
illat
ion
and
rect
i�ca
tion
from
th
e fr
esh
leav
es o
r the
fres
h te
rmin
al b
ranc
hlet
s of v
ario
us sp
e-ci
es o
f Euc
alyp
tus r
ich
in 1
,8-c
ineo
le. �
e sp
ecie
s mai
nly
used
are
Eu
caly
ptus
glo
bulu
s Lab
ill.,
Euca
lypt
us p
olyb
ract
ea R
.T.B
aker
and
Eu
caly
ptus
smith
ii R.
T.Ba
ker (
euca
lypt
us o
il)
Ph.E
ur.
Euca
lypt
i aet
hero
leum
(0
2.09
.198
7)
Euca
lypt
us g
lobu
lus L
abill
.Fr
esh
leav
es o
f Euc
alyp
tus g
lobu
lus L
abill
.Cu
prum
sulfu
ricum
/Eu
caly
ptus
(25.
10.1
994)
Euca
lypt
us g
lobu
lus L
abill
.W
hole
or c
ut d
ried
leav
es o
f old
er b
ranc
hes o
f Euc
alyp
tus g
lobu
lus
Labi
ll. (e
ucal
yptu
s lea
f)H
AB
/ Ph.
Eur.
Bryo
nia/
Eupa
toriu
m
com
p. (0
4.06
.198
6)Eu
geni
a ca
ryop
hylla
tase
e Sy
zygi
um a
rom
atic
um (L
.) M
err.
et L
. M. P
erry
Eupa
toriu
m c
anna
binu
m L
.Fr
esh
�ow
erin
g ae
rial p
arts
of E
upat
oriu
m c
anna
binu
m L
.A
coni
tum
/Chi
na co
mp.
(1
2.09
.199
2)
• Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
101
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erEu
pato
rium
per
folia
tum
L.
Fres
h ae
rial p
arts
of E
upat
oriu
m p
erfo
liatu
m L
., co
llect
ed at
star
t of
�ow
erin
gH
AB
/ Ph.
fr.Br
yoni
a/Eu
pato
rium
co
mp.
(04.
06.1
986)
Euph
orbi
a re
sinife
ra O
. Ber
g.H
arde
ned
late
x fr
om E
upho
rbia
resin
ifera
O. B
erg
HA
BFo
rmul
aire
de
med
.an
thr.
(201
0)Eu
phra
sia st
ricta
Wol
� ex
F.J.
Lehm
. and
Eup
hras
ia o
�ci
nalis
L.
subs
p. ro
stko
vian
a (H
ayne
) Tow
ns
Who
le fr
esh
plan
ts o
f Eup
hras
ia st
ricta
Wol
� ex
F.J.
Lehm
. and
Eu
phra
sia o
�ci
nalis
L. s
ubsp
. ros
tkov
iana
(Hay
ne) T
owns
, the
ir hy
brid
s and
mix
ture
s the
reof
, col
lect
ed at
�ow
erin
g tim
e
HA
BEu
phra
sia (0
5.12
.198
9)
Euph
rasia
o�
cina
lis L
.W
hole
fres
h pl
ants
of E
uphr
asia
o�
cina
lis L
., co
llect
ed at
�ow
erin
g tim
ePh
.fr.
Form
ulai
re d
e m
ed.
anth
r. (2
010)
Fagu
s syl
vatic
a L.
Bran
ch a
nd tr
unk
woo
d of
Fag
us si
lvat
ica
L.A
grop
yron
com
p.
(07.
04.1
988)
Feru
la a
ssa-
foet
ida
L.D
ried
gum
resin
from
Fer
ula
spec
ies s
uch
as F
erul
a as
sa-fo
etid
a L.
an
d Fe
rula
foet
ida
(Bun
ge) R
egel
. (A
sa fo
etid
a)H
AB
Filip
endu
la u
lmar
ia (L
.) M
axim
.Fr
esh
aeria
l par
ts o
f Fili
pend
ula
ulm
aria
(L.)
Max
im. c
olle
cted
at
�ow
eing
tim
e.H
AB
Betu
la/M
andr
agor
a co
mp.
(25.
10.1
994)
Filip
endu
la u
lmar
ia (L
.) M
axim
.Fr
esh
in�o
rece
nce
of F
ilipe
ndul
a ul
mar
ia (L
.) M
axim
. (Sp
iraea
ul
mar
ia L
.)Ph
.fr.
Form
ulai
re d
e m
ed.
anth
r. (2
010)
Filix
-mas
see
Dry
opte
ris �
lix-m
as (L
.) Sc
hott.
Foen
icul
um v
ulga
re M
ill.
Esse
ntia
l oil
obta
ined
by
stea
m d
estil
latio
n fr
om th
e rip
e fr
uits
of
Foen
icul
um v
ulga
re M
iller
ssp.
vul
gare
var
. Vul
gare
(bitt
er-fe
nnel
fr
uit o
il)
Ph.E
ur.
Berb
eris/
Juni
peru
s co
mp.
(03.
07.1
992)
Foen
icul
um v
ulga
re M
ill.
Drie
d cr
emoc
arps
and
mer
icar
ps o
f Foe
nicu
lum
vul
gare
Mill
. sp.
vu
lgar
e (fe
nnel
, bitt
er)
HA
B/Ph
.Eur
.Sp
ecie
s Car
vi co
mp.
(0
4.06
.198
6)Fr
agar
ia v
esca
L.
Fres
h, ri
pe fa
lse-f
ruits
of F
raga
ria v
esca
LFr
agar
ia/U
rtic
a co
mp.
(0
3.07
.199
2)Fr
agar
ia v
esca
L.
Drie
d, w
hole
or c
ut le
aves
, col
lect
ed at
�ow
erin
g tim
e of
Fra
garia
ve
sca
L., F
raga
ria m
osch
ata
Wes
t., F
raga
ria v
iridi
s Wes
t., F
raga
ria
x an
anas
sa (D
uch.
) Gue
des (
Rosa
ceae
), th
eir h
ybrid
s as w
ell a
s hy
brid
s with
oth
er F
raga
ria sp
ecie
s or m
ixtu
res o
f the
m
DA
CFr
agar
ia/V
itis
(04.
06.1
986)
Fran
gula
aln
usse
e Rh
amnu
s fra
ngul
a L.
Frax
inus
am
eric
ana
L.D
ried
bark
from
bra
nche
s of F
raxi
nus a
mer
ican
a L.
Ph.fr
.Fu
cus v
esic
ulos
us L
.Fr
esh
thal
lus o
f Fuc
us v
esic
ulos
us L
.(P
h.fr.
)Tr
opae
olum
com
p.
(02.
03.1
991)
• Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
102
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erFu
cus v
esic
ulos
us L
., Fu
cus s
er-
ratu
s L.,
Asc
ophy
llum
nod
osum
Le
Jolis
. (Ke
lp)
Frag
men
ted
drie
d th
allu
s of F
ucus
ves
icul
osus
L.,
or F.
serr
atus
L.,
or A
scop
hyllu
m n
odos
um L
e Jo
lis. (
kelp
)Ph
.Eur
.
Fum
aria
o�
cina
lis L
.Fr
esh
aeria
l par
ts o
f Fum
aria
o�
cina
lis L
., co
llect
ed at
�ow
erin
g tim
eH
AB
Trop
aeol
um co
mp.
(0
2.03
.199
1)G
alan
thus
niv
alis
L.Fr
esh
who
le �
ower
ing
plan
t of G
alan
thus
niv
alis
L.Va
dem
ecum
(com
bina
-tio
n se
e H
ippo
cam
pus)
Gal
lae
turc
icae
Oak
appl
es p
rodu
ced
on y
oung
shoo
ts o
f Que
rcus
infe
ctor
ia O
l-iv
ier b
y th
e st
ing
of th
e dy
er’s
gall
was
p A
ndric
us g
alla
e tin
ctor
iae
Oliv
ier
HA
B
Gal
ium
odo
ratu
m (L
.) Sc
op.
Fres
h le
aves
of G
aliu
m o
dora
tum
(L.)
Scop
.G
else
miu
m se
mpe
rvire
ns (L
.) Ja
ume
St. -
Hil.
Fres
h un
derg
roun
d pa
rts o
f Gel
sem
ium
sem
perv
irens
(L.)
Jaum
e St
.-Hil.
HA
BG
else
miu
m
(02.
09.1
987)
Gel
sem
ium
sem
perv
irens
(L.)
Jaum
e St
. - H
il.Fr
esh
unde
rgro
und
part
s of G
else
miu
m se
mpe
rvire
ns (L
.) Ja
ume
St.-H
il.Ph
.fr.
Gel
sem
ium
(0
2.09
.198
7)G
else
miu
m se
mpe
rvire
ns (L
.) D
ried
unde
rgro
und
part
s of G
else
miu
m se
mpe
rvire
ns (L
.) G
else
miu
m
(02.
09.1
987)
Gen
ista
scop
aria
see
Cyt
isus s
copa
rius (
L.) L
ink.
Gen
tiana
lute
a L.
Fres
h un
derg
roun
d pa
rts o
f Gen
tiana
lute
a L.
HA
B / P
h.fr.
Gen
tiana
lute
a (0
4.06
.198
6)G
entia
na lu
tea
L.D
ried,
frag
men
ted
unde
rgro
und
orga
ns o
f Gen
tiana
lute
a L.
(gen
-tia
n ro
ot)
Ph.E
ur.
Gen
tiana
lute
a (0
4.06
.198
6)G
eran
iace
aese
e Pe
larg
oniu
m sp
ecie
sG
eum
urb
anum
L.
Fres
h un
derg
roun
d pa
rts o
f Geu
m u
rban
um L
.H
AB
Geu
m u
rban
um
(03.
07.1
992)
Gin
kgo
bilo
ba L
.Fr
esh
leav
es o
f Gin
kgo
bilo
ba L
.H
AB
/ Ph.
fr.G
inse
ngse
e Pa
nax
gins
eng
C.A
. Mey
.G
lech
oma
hede
race
a L.
Fres
h w
hole
�ow
erin
g pl
ant o
f Gle
chom
a he
dera
cea
L.Ph
.fr.
Gle
chom
a he
dera
cea
L.D
ried
�ow
erin
g pl
ant o
f Gle
chom
a he
dera
cea
L.G
naph
aliu
mse
e Le
onto
podi
um a
lpin
um C
ass.
Gra
min
eae
Drie
d in
�ore
scen
ce o
f sev
eral
Gra
min
eae
spec
ies o
btai
ned
from
ha
y (h
ay �
ower
s, ha
y bl
osso
ms)
• Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
103
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erH
amam
elis
virg
inia
na L
.Fr
esh
bark
and
leav
es o
f Ham
amel
is vi
rgin
iana
L.
Ham
amel
is (0
3.07
.199
2)H
amam
elis
virg
inia
na L
.Fr
esh
bark
of H
amam
elis
virg
inia
na L
.H
AB
Ham
amel
is (0
3.07
.199
2)H
amam
elis
virg
inia
na L
.Fr
esh
leav
es o
f Ham
amel
is vi
rgin
iana
L.
HA
BH
amam
elis
(03.
07.1
992)
Ham
amel
is vi
rgin
iana
L.
Fres
h �o
wer
ing
bran
ches
of H
amam
elis
virg
inia
na L
., co
llect
ed in
la
te au
tum
nH
AB
34H
amam
elis
dest
illat
a (2
5.10
.199
4)H
amam
elis
virg
inia
na L
.D
ried
bark
from
the
stem
s and
bra
nche
s of H
amam
elis
virg
inia
na
L.H
AB
Ham
amel
is (0
3.07
.199
2)H
amam
elis
virg
inia
na L
.D
ried
leav
es a
nd d
ried
bark
from
the
stem
s and
bra
nche
s of H
ama-
mel
is vi
rgin
iana
L.
Lotio
Pru
ni co
mp.
(0
4.06
.198
6)H
amam
elis
virg
inia
na L
.W
hole
or c
ut, d
ried
leaf
of H
amam
elis
virg
inia
na L
. (ha
mam
elis
leaf
)Ph
.Eur
.St
ibiu
m co
mp
(04.
06.1
986)
Har
pago
phyt
um p
rocu
mbe
ns
(Bur
ch.)
DC
Cut a
nd d
ried,
tube
rous
seco
ndar
y ro
ots o
f Har
pago
phyt
um p
ro-
cum
bens
DC
. and
/or H
arpa
goph
ytum
zeyh
eri D
ecne
(dev
il’s cl
aw
root
)
Ph.E
ur. /
Ph.
fr.H
arpa
goph
ytum
, Rad
ix
(03.
07.1
992)
Form
ulai
re d
e m
ed.
anth
r. (2
010)
Hel
iant
hus t
uber
osus
L.
Fres
h tu
bers
of H
elia
nthu
s tub
eros
us L
., co
llect
ed in
late
autu
mn
HA
BH
elle
boru
s nig
er L
.Fr
esh
who
le �
ower
ing
plan
ts o
f Hel
lebo
rus n
iger
L.
Hel
lebo
rus n
iger
(0
4.06
.198
6)H
elle
boru
s nig
er L
.Fr
esh
who
le p
lant
s of H
elle
boru
s nig
er L
.H
elle
boru
s nig
er
(04.
06.1
986)
Hel
lebo
rus n
iger
L.
Who
le fr
esh
plan
t col
lect
ed in
sum
mer
and
fres
h �o
wer
ing
shoo
ts
colle
cted
in w
inte
r of H
elle
boru
s nig
er L
.H
elon
ias d
ioic
ase
e C
ham
aelir
ium
lute
um (L
.) A
. Gra
yH
erac
leum
man
tega
zzia
num
So
mm
ier &
Lev
ier
Who
le fr
esh
plan
t of H
erac
leum
man
tega
zzia
num
Som
mie
r &
Levi
erH
ibisc
us sa
bdar
i�a
L.W
hole
or c
ut d
ried
caly
ces a
nd e
pica
lyce
s of H
ibisc
us sa
bdar
i�a
L.,
colle
cted
dur
ing
frui
ting
(ros
elle
)Ph
.Eur
.
Hip
poph
aë rh
amno
ides
L.
Fres
h br
anch
es o
f Hip
poph
aë rh
amno
ides
L. w
ith fr
uit
Hip
poph
aë rh
amno
ides
L.
Fres
h fr
uits
of H
ippo
phaë
rham
noid
es L
.
• Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
104
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erH
ippo
phaë
rham
noid
es L
.Fa
tty o
il ob
tain
ed fr
om th
e se
eds a
nd/o
r fru
it of
Hip
poph
aë rh
am-
noid
es L
.H
orde
um v
ulga
re L
.Ex
trac
t obt
aine
d fr
om d
ried
germ
inat
ed fr
uits
of H
orde
um v
ulga
re
L. (m
alt)
Siru
pus �
ymi c
omp.
(0
4.06
.198
6)H
oya
carn
osa
(L.f.
) R. B
r.N
ecta
r of t
he �
ower
s of H
oya
carn
osa
(L.f.
) R. B
r.C
enta
uriu
m co
mp.
(0
4.06
.198
6)H
umul
us lu
pulu
s L.
Fres
h cr
eepe
rs w
ith le
aves
and
frui
ts o
f Hum
ulus
lupu
lus L
.Av
ena/
Pass
i�or
a co
mp.
(0
3.07
.199
2)H
umul
us lu
pulu
s L.
Fres
h fe
mal
e in
�ore
scen
ces o
f Hum
ulus
lupu
lus L
., co
llect
ed b
efor
e th
e se
eds h
ave
ripen
ed a
nd co
ntai
ning
as f
ew se
eds a
s pos
sible
HA
BAv
ena
sativ
a co
mp.
(0
4.06
.198
6)H
umul
us lu
pulu
s L.
Drie
d, g
ener
ally
who
le, f
emal
e in
�ore
scen
ces o
f Hum
ulus
lupu
lus
L. (h
op st
robi
le)
Ph.E
ur.
Hyd
rast
is ca
nade
nsis
L.D
ried
unde
rgro
und
part
s of H
ydra
stis
cana
dens
is L.
Ph.
Eur.:
Who
le
or c
ut, d
ried
rhiz
ome
and
root
of H
ydra
stis
cana
dens
is L
HA
B / U
SP /
Ph.fr
.Ec
hina
cea
com
p.(0
4.06
.198
6)H
ydro
coty
le a
siatic
ase
e C
ente
lla a
siatic
a (L
.) U
rb.
Hyo
scya
mus
nig
er L
.Fr
esh
�ow
erin
g ae
rial p
arts
of H
yosc
yam
us n
iger
L.
Hyo
scya
mus
(0
4.06
.198
6)H
yosc
yam
us n
iger
L.
Who
le, f
resh
�ow
erin
g pl
ants
of H
yosc
yam
us n
iger
L (h
yosc
yam
us
for h
omoe
opat
hic p
repa
ratio
ns)
HA
B / P
h.Eu
r.H
yosc
yam
us
(04.
06.1
986)
Hyp
eric
um p
erfo
ratu
m L
.Fr
esh
�ow
ers o
f Hyp
eric
um p
erfo
ratu
m L
.H
yper
icum
(0
2.09
.198
7)H
yper
icum
per
fora
tum
L.
Fres
h ae
rial p
arts
of H
yper
icum
per
fora
tum
L.,
colle
cted
at �
ower
-in
g tim
eH
AB
Hyp
eric
um
(02.
09.1
987)
Hyp
ogym
nia
phys
odes
(L.)
Nyl
.D
ried
thal
lus o
f Hyp
ogym
nia
phys
odes
(L.)
Nyl
. (Pa
rmel
ia p
hy-
sode
s (L.
) Ach
.)Ig
natia
See
Stry
chno
s ign
atii
Berg
ius
Impe
rato
ria o
stru
thiu
mSe
e Pe
uced
anum
ost
ruth
ium
(L.)
W. D
. J. K
och
Ipec
acua
nha
See
Psyc
hotr
ia ip
ecac
uanh
a (B
rot.)
Sto
kes
Ipec
acua
nha
(Ipec
acua
nhae
radi
x)Se
e C
epha
elis
ipec
acua
nha
(Bro
t.) A
. Ric
h., C
epha
elis
acum
inat
a K
arst
enIr
is ge
rman
ica
L.Fr
esh
rhiz
ome
of Ir
is ge
rman
ica
L.Ir
is ge
rman
ica
L.D
ried
peel
ed rh
izom
e of
Iris
germ
anic
a L.
, Iris
ger
man
ica
var.
�ore
ntin
a L.
and
Iris
palli
da L
amar
ckLo
tio P
runi
com
p.
(04.
06.1
986)
• Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
105
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erIr
is ve
rsic
olor
L.
Fres
h un
derg
roun
d pa
rts (
rhiz
ome
incl
udin
g ro
ots)
of I
ris v
ersi-
colo
r L. c
olle
cted
at �
ower
ing
time
Ph.fr
.
Iris
vers
icol
or L
.Fr
esh
unde
rgro
und
part
s of I
ris v
ersic
olor
L.
HA
BJu
glan
s reg
ia L
.D
ried
oute
r mem
bran
e fr
om th
e se
ed o
f Jug
lans
regi
a L.
Car
pellu
m M
ali c
omp.
(2
5.10
.199
4)
Jugl
ans r
egia
L.
Drie
d le
aves
of J
ugla
ns re
gia
L.D
AC
Jugl
ans r
egia
L.
Fres
h le
aves
and
unr
ipe
frui
t of J
ugla
ns re
gia
L.Ju
glan
s reg
ia co
mp.
(25.
10.1
994)
Juni
peru
s com
mun
is L.
Esse
ntia
l oil
obta
ined
by
stea
m d
istill
atio
n fr
om th
e rip
e, no
n-fe
r-m
ente
d be
rry
cone
s of J
unip
erus
com
mun
is L.
(jun
iper
oil)
Ph.E
ur.
Berb
eris/
Juni
peru
s co
mp.
(03.
07.1
992)
Juni
peru
s com
mun
is L.
Fres
h rip
e co
ne b
erry
of J
unip
erus
com
mun
is L.
DA
B 9
Trop
aeol
um co
mp.
(0
2.03
.199
1)Ju
nipe
rus c
omm
unis
L.D
ried
tips o
f sho
ots o
f Jun
iper
us co
mm
unis
L.C
icho
rium
/Tar
axac
um
com
p. (0
4.06
.198
6)Ju
nipe
rus c
omm
unis
L.D
ried
ripe
cone
ber
ry o
f Jun
iper
us co
mm
unis
L. (j
unip
er)
HA
B / P
h.Eu
r. Be
tula
/Juni
peru
s (0
2.03
.199
1)Ju
nipe
rus s
abin
a L.
Fres
h, st
ill u
nlig
ni�e
d, g
row
ing
tips o
f tw
igs o
f Jun
iper
us sa
bina
L.,
with
adh
eren
t lea
ves
HA
BC
olch
icum
/Sab
ina
(04.
06.1
986)
Kal
anch
oe d
aigr
emon
tiana
see
Bryo
phyl
lum
dai
grem
ontia
num
(Ray
m.-H
amet
et H
. Per
rier)
A
. Ber
ger
Kal
anch
oe p
inna
tase
e Br
yoph
yllu
m p
inna
tum
(Lam
.) O
ken
Kal
mia
latif
olia
L.
Fres
h le
aves
of K
alm
ia la
tifol
ia L
.H
AB
/ Ph.
fr.K
ram
eria
tria
ndra
Rui
z et P
av.
Drie
d, u
sual
ly fr
agm
ente
d, u
nder
grou
nd o
rgan
s of K
ram
eria
tria
n-dr
a Ru
iz a
nd P
avon
. (rh
atan
y ro
ot)
HA
B / P
h.Eu
r.Ra
tanh
ia co
mp.
(03.
07.1
992)
Kre
osot
umse
e Fa
gus s
ilvat
ica
L.La
miu
m a
lbum
L.
Who
le fr
esh
�ow
erin
g pl
ant o
f Lam
ium
alb
um L
.Ph
.fr.
Form
ulai
re d
e m
ed.
anth
r. (2
010)
Lam
ium
alb
um L
.D
ried
�ow
ers o
f Lam
ium
alb
um L
.H
AB
Arg
entu
m/Q
uerc
us
com
p. (0
4.06
.198
6)La
ppa
maj
orse
e A
rctiu
m la
ppa
L.La
rix d
ecid
ua M
ill.
Balsa
m o
btai
ned
from
hol
es d
rille
d in
the
trun
ks o
f Lar
ix d
ecid
ua
Mill
. (Te
rebi
nthi
na la
ricin
a )
HA
BRe
sina
Laric
is (0
2.09
.198
7)La
urus
nob
ilis L
.Fr
esh
leav
es o
f Lau
rus n
obili
s L.
• Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
106
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erLa
vand
ula
angu
stifo
lia M
ill.
Esse
ntia
l oil
obta
ined
by
stea
m d
istill
atio
n fr
om th
e �o
wer
ing
tops
of L
avan
dula
ang
ustif
olia
Mill
. (La
vand
ula
o�ci
nalis
Cha
ix)
(lave
nder
oil)
Ph.E
ur.
Lave
ndel
öl (0
4.06
.198
6)
Lava
ndul
a an
gust
ifolia
Mill
.Fr
esh
�ow
ers o
f Lav
andu
la a
ngus
tifol
ia M
ill.
HA
BLa
vand
ula
angu
stifo
lia M
ill.
Fres
h �o
wer
ing
stem
s of L
avan
dula
ang
ustif
olia
Mill
.Ph
.fr.
Form
ulai
re d
e m
ed.
anth
r. (2
010)
Lava
ndul
a an
gust
ifolia
Mill
.D
ried
�ow
er o
f Lav
andu
la a
ngus
tifol
ia M
ill. (
L. o
�ci
nalis
Cha
ix)
(lave
nder
�ow
er)
HA
B / P
h.Eu
r. A
escu
lus/
Lava
ndul
a
sicca
ta (2
5.10
.199
4)Le
dum
pal
ustr
e L.
Drie
d tip
s of t
wig
s of L
edum
pal
ustr
e L.
HA
BLe
onto
podi
um a
lpin
um C
ass.
Who
le fr
esh
plan
ts o
f Leo
ntop
odiu
m a
lpin
um C
ass.
Apis
com
p.
(04.
06.1
986)
Leon
topo
dium
alp
inum
Cas
s.W
hole
drie
d �o
wer
ing
plan
ts o
f Leo
ntop
odiu
m a
lpin
um C
ass.
Gna
phal
ium
com
p.
(25.
10.1
994)
Leon
urus
car
diac
a L.
Fres
h ae
rial p
arts
of L
eonu
rus c
ardi
aca
L., c
olle
cted
at �
ower
ing
time
HA
BC
imic
ifuga
com
p.(0
2.09
.198
7)Le
ptan
dra
virg
inic
a (L
.) N
utt.
Drie
d un
derg
roun
d pa
rts o
f Lep
tand
ra v
irgin
ica
(L.)
Nut
t.Le
vist
icum
o�
cina
le W
. D. J
. Ko
chW
hole
or c
ut d
ried
rhiz
ome
and
root
of L
evist
icum
o�
cina
le K
och.
(lo
vage
root
)Ph
.Eur
.Le
vist
icum
(04.
06.1
986)
Levi
stic
um o
�ci
nale
W. D
. J.
Koch
Who
le fr
esh
plan
t of L
evist
icum
o�
cina
le W
. D. J
. Koc
h
Levi
stic
um o
�ci
nale
W. D
. J.
Koch
Fres
h un
derg
roun
d pa
rts o
f Lev
istic
um o
�ci
nale
W. D
. J. K
och
HA
BLe
vist
icum
(04.
06.1
986)
Levi
stic
um o
�ci
nale
W. D
. J.
Koch
Fres
h �o
wer
s of L
evist
icum
o�
cina
le W
. D. J
. Koc
hLe
vist
icum
(04.
06.1
986)
Levi
stic
um o
�ci
nale
W. D
. J.
Koch
Fres
h le
aves
of L
evist
icum
o�
cina
le W
. D. J
. Koc
hD
er M
erku
rsta
b 4/
2007
: p.
345
Liliu
m la
ncifo
lium
�un
b.W
hole
fres
h �o
wer
ing
plan
ts o
f Lili
um la
ncifo
lium
�un
b.Ph
.fr.
Form
ulai
re d
e m
ed.
anth
r. (2
010)
Liliu
m la
ncifo
lium
�un
b.Fr
esh
part
s of L
ilium
lanc
ifoliu
m �
unb.
, with
pout
bul
bs, c
olle
cted
at
�ow
erin
g tim
eH
AB
Arg
entu
m/Q
uerc
us
com
p. (0
4.06
.198
6)Li
lium
lanc
ifoliu
m �
unb.
Fres
h ae
rial p
arts
of L
ilium
lanc
ifoliu
m �
unb.
, col
lect
ed at
�ow
er-
ing
time
and
incl
udin
g bu
lbils
Maj
oran
a/�
uja
com
p.
(02.
03.1
991)
Liliu
m ti
grin
umSe
e Li
lium
lanc
ifoliu
m �
unb.
• Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
107
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erLi
num
usit
atiss
imum
L.
Fatty
oil
obta
ined
by
cold
exp
ress
ion
from
ripe
seed
s of L
inum
us
itatis
simum
L. (
linse
ed o
il, v
irgin
) Ph
.Eur
.
Linu
m u
sitat
issim
um L
.D
ried,
ripe
seed
s of L
inum
usit
atiss
imum
L. (
linse
ed)
Ph.E
ur.
Lits
ea c
ubeb
a Pe
rs.
Esse
ntia
l oil
obta
ined
by
stea
m d
istill
atio
n fr
om th
e fr
uit o
f Lits
ea
cube
ba P
ers.
Loba
ria p
ulm
onar
ia (L
.) H
o�m
.D
ried
thal
lus o
f Lob
aria
pul
mon
aria
(L.)
Ho�
m.
HA
B / P
h.fr.
Lich
enes
com
p.(0
4.06
.198
6)Lo
belia
in�a
ta L
.Fr
esh
�ow
erin
g ae
rial p
arts
of L
obel
ia in
�ata
L.
Ph.fr
.Fo
rmul
aire
de
med
.an
thr.
(201
0)Lo
belia
in�a
ta L
.W
hole
fres
h �o
wer
ing
plan
ts o
f Lob
elia
in�a
ta L
.H
AB
Lobe
lia in
�ata
(0
7.04
.198
8)Lo
phop
hora
will
iam
sii C
oult.
Who
le fr
esh
plan
ts o
f Lop
hoph
ora
will
iam
sii C
oult.
Lyco
pers
icon
lyco
pers
icum
(L.)
Kar
st. e
x Fa
rw.
Fres
h ae
rial p
arts
of L
ycop
ersic
on ly
cope
rsic
um (L
.) K
arst
. ex
Farw
., co
llect
ed at
�ow
erin
g tim
eH
AB
34D
er M
erku
rsta
b 4/
2005
: p.
271
Lyco
pers
icon
lyco
pers
icum
(L.)
Kar
st. e
x Fa
rw.
Fres
h rip
e fr
uits
of L
ycop
ersic
on ly
cope
rsic
um (L
.) K
arst
. ex
Farw
.
Lyco
podi
um cl
avat
um L
.W
hole
spor
e-be
arin
g pl
ant o
f Lyc
opod
ium
clav
atum
L.
Lyco
podi
um
(25.
10.1
994)
Lyco
podi
um cl
avat
um L
.D
ried
ripe
spor
es o
f Lyc
opod
ium
clav
atum
L.
HA
B / P
h.fr.
Lyco
podi
um
(25.
10.1
994)
Lyco
pus v
irgin
icus
L.
Fres
h ae
rial p
arts
of L
ycop
us v
irgin
icus
L.,
colle
cted
at �
ower
ing
time
HA
B / P
h.fr.
Lyco
pus v
irgin
icus
L.
Who
le fr
esh
plan
t of L
ycop
us v
irgin
icus
L.,
colle
cted
at �
ower
ing
time.
Der
Mer
kurs
tab
5/20
04:
p. 3
59Ly
simac
hia
num
mul
aria
L.
Fres
h �o
wer
ing
aeria
l par
ts o
f Lys
imac
hia
num
mul
aria
L.
Dul
cam
ara/
Lysim
achi
a (0
4.06
.198
6)M
ahon
ia a
quifo
lium
(Pur
sh) N
utt.
Drie
d ba
rk fr
om b
ranc
hes a
nd tw
igs a
nd d
ried
tips o
f tw
igs o
f Ma-
honi
a aq
uifo
lium
(Pur
sh) N
utt.
HA
B
Maj
oran
ase
e O
rigan
um m
ajor
ana
L.M
altu
mse
e H
orde
um v
ulga
re L
.M
alus
sylv
estr
is M
ill.
Cor
e fr
om fr
esh
frui
t of M
alus
sylv
estr
is M
ill. w
ithou
t ker
nel
Car
pellu
m M
ali c
omp.
(2
5.10
.199
4)
• Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
108
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erM
alus
sylv
estr
is M
ill.
Fres
h un
ripe
frui
t of M
alus
sylv
estr
is M
ill.
Mal
va sy
lves
tris
L.W
hole
fres
h �o
wer
ing
plan
t of M
alva
sylv
estr
is L.
Ph.fr
.Fo
rmul
aire
de
med
.an
thr.
(201
0)M
alva
sylv
estr
is L.
Who
le o
r fra
gmen
ted
drie
d �o
wer
of M
alva
sylv
estr
is L.
or i
ts c
ulti-
vate
d va
rietie
s. (m
allo
w �
ower
)H
AB
/ Ph.
Eur.
Phos
phor
us/M
alva
(25.
10.1
994)
Mal
va sy
lves
tris
L.D
ried
leav
es o
f Mal
va sy
lves
tris
L.
Mal
va/M
illef
oliu
m/
Oxa
lis(0
7.04
.198
8)M
andr
agor
a o�
cina
rum
L.
Fres
h ro
ot o
f Man
drag
ora
o�ci
naru
m L
.M
andr
agor
a (0
4.06
.198
6)M
andr
agor
a o�
cina
rum
L.
Drie
d ro
ots o
f Man
drag
ora
o�ci
naru
m L
. and
Man
drag
ora
autu
m-
nalis
Ber
tol.
HA
BM
andr
agor
a (0
4.06
.198
6)M
arru
bium
vul
gare
L.
Who
le o
r fra
gmen
ted
�ow
erin
g dr
ied
aeria
l par
ts o
f Mar
rubi
um
vulg
are
L., c
olle
cted
at �
ower
ing
time
(whi
te h
oreh
ound
)Ph
.Eur
.Si
rupu
s �ym
i com
p.
(04.
06.1
986)
Mar
um v
erum
see
Teuc
rium
mar
um L
.M
atric
aria
recu
tita
L.Fr
esh
�ow
er h
eads
of M
atric
aria
recu
tita
L. (C
ham
omill
a re
cutit
a (L
.) Ra
usch
ert)
Ana
galli
s/M
alac
hit
com
p. (2
5.10
.199
4)M
atric
aria
recu
tita
L.W
hole
fres
h �o
wer
ing
plan
ts o
f Mat
ricar
ia re
cutit
a L.
HA
B / P
h.fr.
Cha
mom
illa
(12.
09.1
992)
Mat
ricar
ia re
cutit
a L.
Fres
h un
derg
roun
d pa
rts o
f Mat
ricar
ia re
cutit
a L.
(Cha
mom
illa
recu
tita
(L.)
Raus
cher
t) be
fore
�ow
erin
g tim
eC
ham
omill
a, R
adix
(0
4.06
.198
6)M
atric
aria
recu
tita
L.D
ried
capi
tula
of M
atric
aria
recu
tita
L. (C
ham
omill
a re
cutit
a (L
.) Ra
usch
ert)
(mat
ricar
ia �
ower
)Ph
.Eur
. / U
SPC
ham
omill
a (1
2.09
.199
2)M
atric
aria
recu
tita
L.D
ried
root
of M
atric
aria
recu
tita
L. (C
ham
omill
a re
cutit
a (L
.) Ra
usch
ert)
Cha
mom
illa,
Rad
ix
(04.
06.1
986)
Med
icag
o sa
tiva
L.W
hole
fres
h pl
ants
of M
edic
ago
sativ
a L.
, col
lect
ed at
�ow
erin
g tim
ePh
.fr.
Mel
aleu
ca le
ucad
endr
a(L.
) L.
Rect
i�ed
ess
entia
l oil
obta
ined
from
fres
h le
aves
and
bra
nche
s of
di�e
rent
Mel
aleu
ca (s
ub)s
peci
es
(Ph.
Eur.
Tea
Tree
oil:
Ess
entia
l oil
obta
ined
by
stea
m d
istill
atio
n fr
om fo
liage
and
term
inal
bra
nchl
ets o
f Mel
aleu
ca a
ltern
ifolia
(M
aide
n an
d Be
tch)
Che
el, M
. lin
ariif
olia
Sm
ith, M
. diss
iti�o
ra F.
M
uelle
r and
/or o
ther
spec
ies o
f Mel
aleu
ca)
Berb
eris/
Euca
lyp-
tus/
Silic
ea co
mp.
(0
2.03
.199
1)
• Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
109
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erM
elilo
tus o
�ci
nalis
(L.)
Pall.
Fres
h ae
rial p
arts
of M
elilo
tus o
�ci
nalis
(L.)
Pall.
with
out l
igne
ous
stem
s col
lect
ed at
�ow
erin
g tim
eH
AB
/ Ph.
fr.
Mel
issa
indi
cum
see
Cym
bopo
gon
win
teria
nus J
owitt
and
oth
er C
ymbo
pogo
n sp
.M
eliss
a o�
cina
lis L
.Fr
esh
leav
es o
f Mel
issa
o�ci
nalis
L.
Mel
issa
Cupr
o cu
lta
(25.
10.1
994)
Mel
issa
o�ci
nalis
L.
Fres
h ae
rial p
arts
of M
eliss
a o�
cina
lis L
., be
fore
�ow
erin
g tim
ePh
.fr.
Form
ulai
re d
e m
ed.
anth
r. (2
010)
Mel
issa
o�ci
nalis
L.
Fres
h ae
rial p
arts
of M
eliss
a o�
cina
lis L
.M
eliss
a/Se
pia
com
p.
(02.
03.1
991)
Mel
issa
o�ci
nalis
L.
Drie
d le
af o
f Mel
issa
o�ci
nalis
L. (
mel
issa
leaf
)Ph
.Eur
.M
ajor
ana/
Mel
issa
(02.
09.1
987)
Mel
issa
o�ci
nalis
L.
Drie
d ae
rial p
arts
of M
eliss
a o�
cina
lis L
.M
eliss
a co
mp.
(0
3.07
.199
2)M
enth
a pi
perit
a L.
Esse
ntia
l oil
obta
ined
by
stea
m d
istill
atio
n fr
om th
e fr
esh
aeria
l pa
rts o
f the
�ow
erin
g pl
ant o
f Men
tha
x pi
perit
a L.
(pep
perm
int
oil)
Ph.E
ur.
Berb
eris/
Che
lidon
ium
co
mp.
(02.
03.1
991)
Men
tha
pipe
rita
L.W
hole
fres
h �o
wer
ing
plan
t of M
enth
a x
pipe
rita
L.M
enth
a pi
perit
a L.
Who
le o
r cut
drie
d le
aves
of M
enth
a x
pipe
rita
L.
(pep
perm
int l
eave
s)Ph
.Eur
.C
enta
uriu
m co
mp.
(04.
06.1
986)
Men
yant
hes t
rifol
iata
L.
Who
le fr
esh
�ow
erin
g pl
ant o
f Men
yant
hes t
rifol
iata
L.
Ph.fr
.M
ercu
rialis
per
enni
s L.
Fres
h ae
rial p
arts
of M
ercu
rialis
per
enni
s L.,
colle
cted
at �
ower
ing
time
HA
BM
ercu
rialis
/ Ro
-sa
e ae
ther
oleu
m
(02.
03.1
991)
Mer
curia
lis p
eren
nis L
.W
hole
fres
h �o
wer
ing
plan
t of M
ercu
rialis
per
enni
s L.
HA
BM
ercu
rialis
per
enni
s (0
2.03
.199
1)M
ercu
rialis
per
enni
s L.
Who
le d
ried
�ow
erin
g pl
ant o
f Mer
curia
lis p
eren
nis L
.C
alen
dula
/Mer
curia
lis
com
p. (0
7.04
.198
8)M
ezer
eum
See
Dap
hne
mez
ereu
m L
.M
illef
oliu
mSe
e A
chill
ea m
illef
oliu
m L
.M
omor
dica
bal
sam
ina
L.Fr
esh
frui
t of M
omor
dica
bal
sam
ina
L.M
onot
ropa
uni
�ora
L.
Who
le d
ried
plan
t of M
onot
ropa
uni
�ora
L.
• Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
110
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erM
ucun
a pr
urie
ns (L
.) D
CD
ried
hairs
from
the
frui
ts o
f Muc
una
prur
iens
(L.)
DC
(Ph.
fr.:
Dol
icho
s pru
riens
)H
AB
/ Ph.
fr.
Myr
istic
a fr
agra
ns V
an H
outte
Drie
d se
ed k
erne
l of M
yrist
ica
frag
rans
Van
Hou
ttePh
.fr.
Form
ulai
re d
e m
ed.
anth
r. (2
010)
Myr
istic
a fr
agra
ns H
outt.
Drie
d, u
sual
ly li
me-
trea
ted
seed
s of M
yrist
ica
frag
rans
Hou
tt., w
ith
aril
and
test
a re
mov
edH
AB
Spiri
tus M
eliss
ae co
mp.
(04.
06.1
986)
Myr
istic
a se
bife
rase
e V
irola
sebi
fera
Aub
l.M
yrox
ylon
bal
sam
um (L
.) H
arm
sBa
lsam
obt
aine
d fr
om th
e sc
orch
ed a
nd w
ound
ed tr
unk
of M
y-ro
xylo
n ba
lsam
um (L
.) H
arm
s var
. per
eira
e (R
oyle
) Har
ms (
peru
ba
lsam
)
Ph.E
ur.
Berb
eris/
Euca
lyp-
tus/
Silic
ea co
mp.
(0
2.03
.199
1)M
yrrh
ase
e C
omm
ipho
ra Ja
cq. s
peci
esN
astu
rtiu
m o
�ci
nale
R. B
r.W
hole
fres
h pl
ant o
f Nas
turt
ium
o�
cina
le R
. Br.
Nas
turt
ium
o�
cina
le R
. Br.
Fres
h ae
rial p
arts
of N
astu
rtiu
m o
�ci
nale
R. B
r., co
llect
ed at
�ow
-er
ing
time
HA
BN
astu
rtiu
m M
ercu
rio
cultu
m (2
5.10
.199
4)N
astu
rtiu
m o
�ci
nale
R. B
r.D
ried
aeria
l par
ts o
f Nas
turt
ium
o�
cina
le R
. Br.
Mer
curiu
s viv
us co
mp.
(0
2.09
.198
7)N
icot
iana
taba
cum
L.
Fres
h le
aves
of N
icot
iana
taba
cum
L.
HA
BTa
bacu
m (0
4.06
.198
6)N
icot
iana
taba
cum
L.
Drie
d fe
rmen
ted
leav
es o
f Nic
otia
na ta
bacu
m L
.Ta
bacu
m (0
4.06
.198
6)N
icot
iana
taba
cum
L.
Drie
d un
ferm
ente
d le
aves
of N
icot
iana
taba
cum
L.
HA
BTa
bacu
m (0
4.06
.198
6)N
ux m
osch
ata
see
Myr
istic
a fr
agra
ns V
an H
outte
Nux
vom
ica
see
Stry
chno
s nux
-vom
ica
L.O
cim
um b
asili
cum
L.
Fres
h ae
rial p
arts
of O
cim
um b
asili
cum
L.,
colle
cted
prio
r to
�ow
-er
ing
HA
BBa
silic
um co
mp.
(07.
04.1
988)
Oci
mum
bas
ilicu
m L
.D
ried
�ow
erin
g ae
rial p
arts
of O
cim
um b
asili
cum
L.
Sal M
aris
com
p.
(04.
06.1
986)
O
liban
umse
e Bo
swel
lia sp
ecie
sO
nopo
rdum
aca
nthi
um L
.Fr
esh
leav
es o
f Ono
pord
um a
cant
hium
L.
Che
lidon
ium
com
p.
(04.
06.1
986)
Ono
pord
um a
cant
hium
L.
Fres
h �o
wer
head
of O
nopo
rdum
aca
nthi
um L
.O
nopo
rdum
/Prim
ula
com
p. (2
5.10
.199
4)O
rchi
s spe
cies
or O
phry
deae
trib
eFi
lial t
uber
s of d
i�er
ent s
peci
es o
f the
gen
us O
rchi
s L. (
Orc
hida
-ce
ae) o
r oth
er su
itabl
e in
tra-
and
inte
rgen
eric
Orc
his-
Hyb
rids o
f th
e tr
ibe
Oph
ryde
ae, w
hich
hav
e be
en b
lanc
hed
in b
oilin
g w
ater
an
d dr
ied
Cer
ebel
lum
com
p.
(02.
03.1
991)
• Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
111
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erO
rigan
um m
ajor
ana
L.Fr
esh
aeria
l par
ts o
f Orig
anum
maj
oran
a L.
, col
lect
ed at
�ow
erin
g tim
eH
AB
Maj
oran
a (0
7.04
.198
8)
Orig
anum
maj
oran
a L.
Drie
d ae
rial p
arts
of O
rigan
um m
ajor
ana
L.M
ajor
ana
(07.
04.1
988)
Orig
anum
maj
oran
a L.
Ripe
frui
t of O
rigan
um m
ajor
ana
L.C
apse
lla/M
ajor
ana
com
p. (0
4.06
.198
6)
Orn
ithog
alum
um
bella
tum
L.
Who
le fr
esh
plan
t of O
rnith
ogal
um u
mbe
llatu
m L
.O
xalis
ace
tose
lla L
.Fr
esh
leav
es o
f Oxa
lis a
ceto
sella
L.
HA
BO
xalis
(02.
09.1
987)
Oxa
lis a
ceto
sella
L.
Who
le fr
esh
�ow
erin
g pl
ant o
f Oxa
lis a
ceto
sella
L.
Oxa
lis (0
2.09
.198
7)O
xalis
ace
tose
lla L
.D
ried
�ow
erin
g pl
ant o
f Oxa
lis a
ceto
sella
LO
xalis
(02.
09.1
987)
Paeo
nia
o�ci
nalis
L. e
men
d.
Will
d.Fr
esh
unde
rgro
und
part
s of P
aeon
ia o
�ci
nalis
L. e
men
d. W
illd.
, co
llect
ed d
urin
g sp
ring
HA
BH
irudo
com
p.
(25.
10.1
994)
Pana
x gi
nsen
g C
.A. M
eyer
Who
le o
r cut
drie
d ro
ot, d
esig
nate
d w
hite
gin
seng
; tre
ated
with
st
eam
and
then
drie
d, d
esig
nate
d re
d gi
nsen
g of
Pan
ax g
inse
ng
C.A
. Mey
er. (
gins
eng)
Ph.E
ur. /
USP
/ H
AB
Vade
mec
um: G
inse
ng
Papa
ver r
hoea
s L.
Fres
h �o
wer
s of P
apav
er rh
oeas
L.
HA
BPa
pave
r rho
eas
(02.
03.1
991)
Papa
ver s
omni
feru
m L
.Fr
esh
late
x ob
tain
ed fr
om in
cisio
ns in
unr
ipe
frui
t of P
apav
er
som
nife
rum
L.
Papa
ver s
omni
feru
m
(07.
04.1
988)
Papa
ver s
omni
feru
m L
.Fr
esh
unrip
e fr
uit o
f Pap
aver
som
nife
rum
L.
Papa
ver s
omni
feru
m
(07.
04.1
988)
Paris
qua
drifo
lia L
.W
hole
fres
h pl
ants
of P
aris
quad
rifol
ia L
., co
llect
ed w
hen
the
frui
ts
have
ripe
ned
HA
B
Parm
elia
see
Hyp
ogym
nia
phys
odes
(L.)
Nyl
.Pa
ssi�
ora
caer
ulea
L.
Fres
h ae
rial p
arts
of P
assi�
ora
caer
ulea
L. c
olle
cted
at �
ower
ing
time
Pass
i�or
a co
mp.
(2
5.10
.199
4)Pa
ssi�
ora
inca
rnat
a L.
Fres
h ae
rial p
arts
of P
assi�
ora
inca
rnat
a L.
HA
B / P
h.fr.
Aven
a sa
tiva
com
p.
(04.
06.1
986)
Peat
Fres
h m
oist
pea
t fro
m m
oorla
nd [e
.g. u
plan
d m
oor]
Solu
m u
ligin
osum
co
mp.
(02.
03.1
991)
Pela
rgon
ium
spec
ies
Esse
ntia
l oil
obta
ined
by
stea
m d
estil
latio
n fr
om th
e ae
rial p
arts
of
suita
ble
spec
ies o
f Pel
argo
nium
e.g.
Pel
argo
nium
gra
veol
ens A
it.Ro
sae
aeth
erol
eum
/Si
licea
collo
idal
is co
mp.
(0
3.07
.199
2)
• Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
112
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erPe
tasit
es h
ybrid
us (L
.) Ph
. Gae
rtn.
B.
Mey
. et S
cher
bFr
esh
rhiz
ome
of P
etas
ites h
ybrid
us (L
.) Ph
. Gae
rtn.
B. M
ey. e
t Sc
herb
. with
atta
ched
root
sPe
tasit
es co
mp.
(1
2.09
.199
2)Pe
tasit
es h
ybrid
us (L
.) Ph
. Gae
rtn.
B.
Mey
. et S
cher
b.W
hole
fres
h �o
wer
ing
plan
t of P
etas
ites h
ybrid
us (L
.) Ph
. Gae
rtn.
B.
Mey
. et S
cher
b.Pe
tasit
es, P
lant
a to
ta
(12.
09.1
992)
Petr
osel
inum
crisp
um (M
ill.)
Nym
. ex
A. W
. Hill
Who
le fr
esh
�ow
erin
g pl
ants
of P
etro
selin
um cr
ispum
(Mill
.) N
ym.
ex A
. W. H
ill co
nvar
. cris
pum
, col
lect
ed at
the
star
t of �
ower
ing
HA
B
Petr
osel
inum
crisp
um (M
ill.)
Nym
. ex
A. W
. Hill
Drie
d ro
ots o
f Pet
rose
linum
crisp
um (M
ill.)
Nym
. ex
A. W
. Hill
ssp.
tu
bero
sum
(Ber
nh. e
x Rc
hb.)
Peuc
edan
um o
stru
thiu
m (L
.) W
. D
. J. K
och
Fres
h rh
izom
e of
Peu
ceda
num
ost
ruth
ium
(L.)
W.D
.J. K
och
Cic
horiu
m/T
arax
acum
co
mp.
(04.
06.1
986)
Peum
us b
oldu
s Mol
.W
hole
or f
ragm
ente
d dr
ied
leaf
of P
eum
us b
oldu
s Mol
ina
(bol
do
leaf
)H
AB
/ Ph.
Eur.
/Ph.
fr.
Phyl
lant
hus n
iruri
hort
. non
L.
Drie
d un
derg
roun
d pa
rts o
f Phy
llant
hus n
iruri
hort
. non
L.
Phyl
litis
scol
open
driu
m (L
.) N
ewm
.Fr
esh
spor
e-be
arin
g le
aves
of P
hylli
tis sc
olop
endr
ium
(L.)
New
m.
Aqu
ilinu
m co
mp.
(1
2.09
.199
2)Ph
yllo
stac
hys v
iridi
glau
cesc
ens
(Car
r.) A
. et C
. Riv.
Nod
es fr
om th
e st
em o
f Phy
llost
achy
s spe
cies
, esp
ecia
lly P
hyllo
-st
achy
s viri
digl
auce
scen
s (C
arr.)
A. e
t C. R
iv., c
olle
cted
in su
mm
erBa
mbu
sa (0
2.03
.199
1)
Phyt
olac
ca a
mer
ican
a L.
Fres
h ro
ots o
f Phy
tola
cca
amer
ican
a L.
, col
lect
ed d
urin
g au
tum
nH
AB
Phyt
olac
ca co
mp.
(2
5.10
.199
4)Ph
ytol
acca
am
eric
ana
L.Fr
esh
ripe
frui
ts o
f Phy
tola
cca
amer
ican
a L.
HA
BPi
cea
abie
s (L.
) Kar
st.
Esse
ntia
l oil
obta
ined
by
stea
m d
istill
atio
n of
nee
dles
and
tips
of
bra
nche
s or b
ranc
hes o
f Pic
ea a
bies
(L.)
Kar
sten
and
of A
bies
sib
irica
Led
ebou
r or o
ther
spec
ies o
f the
gen
era
Abi
es a
nd P
icea
DA
BSa
lvia
e ae
ther
oleu
m
com
p. (0
7.04
.198
8)
Pice
a ab
ies (
L.) K
arst
.Fr
esh
youn
g tip
s of s
hoot
s of P
icea
abi
es (L
.) K
arst
.Pe
tasit
es/P
lant
ago
com
p. (1
2.09
.199
2)Pi
cea
nigr
a (L
.) Li
nkD
ried
resin
from
Pic
ea n
igra
(L.)
Link
Pim
pine
lla a
nisu
m L
.Es
sent
ial o
il ob
tain
ed b
y st
eam
dist
illat
ion
of th
e dr
y rip
e fr
uits
of
Pim
pine
lla a
nisu
m L
. (an
ise o
il)Ph
.Eur
.Li
chen
es co
mp.
(04.
06.1
986)
Pim
pine
lla a
nisu
m L
.W
hole
dry
crem
ocar
p of
Pim
pine
lla a
nisu
m L
. (an
iseed
)H
AB
/ Ph.
Eur.
Ferr
um si
licic
um co
mp.
(D
AZ
Nr.
29 v
om
21.0
7.19
94)
Pinu
s mug
o Tu
rra
Esse
ntia
l oil
obta
ined
by
stea
m d
istill
atio
n of
the
fres
h le
aves
and
tw
igs o
f Pin
us m
ugo
Turr
a. A
suita
ble
antio
xida
nt m
ay b
e ad
ded
(dw
arf p
ine
oil)
Ph.E
ur.
Berb
eris/
Juni
peru
s co
mp.
(03.
07.1
992)
• Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
113
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erPi
nus s
peci
esEs
sent
ial o
il ob
tain
ed b
y st
eam
dist
illat
ion,
follo
wed
by
rect
i�ca
-tio
n at
a te
mpe
ratu
re b
elow
180
°C, f
rom
the
oleo
resin
obt
aine
d by
ta
ppin
g Pi
nus p
inas
ter A
iton.
A su
itabl
e an
tioxi
dant
may
be
adde
d (tu
rpen
tine
oil,
Pinu
s pin
aste
r typ
e)
Ph.E
ur.
Pinu
s syl
vest
ris L
.Es
sent
ial o
il ob
tain
ed b
y st
eam
dist
illat
ion
of th
e fr
esh
leav
es a
nd
bran
ches
of P
inus
sylv
estr
is L.
A su
itabl
e an
tioxi
dant
may
be
adde
d (p
ine
sylv
estr
is oi
l)
Ph.E
ur.
Ole
um c
amph
orat
um
com
p. (0
3.07
.199
2)
Pipe
r nig
rum
L.
Drie
d fr
uit o
f Pip
er n
igru
m L
.Pi
per n
igru
m L
.Fr
uit o
f Pip
er n
igru
m L
., co
llect
ed a
nd d
ried
befo
re ri
peni
ngPh
.Eur
.G
entia
na/Z
ingi
ber
com
p. (0
2.03
.199
1)Pi
x be
tulin
aBi
rch
tar s
ee B
etul
a pe
ndul
a Ro
th, B
etul
a pu
besc
ens E
hrha
rtPl
anta
go la
nceo
lata
L.
Who
le o
r cut
drie
d he
rb o
f Pla
ntag
o la
nceo
lata
L. s
.l.D
AB
1999
Plan
tago
lanc
eola
ta L
.Fr
esh
leav
es o
f Pla
ntag
o la
nceo
lata
L.
Bron
chi/P
lant
ago
com
p. (1
2.09
.199
2)Pl
anta
go la
nceo
lata
L.
Who
le o
r fra
gmen
ted,
drie
d le
af a
nd sc
ape
of P
lant
ago
lanc
eola
ta L
. s.l
. (rib
wor
t pla
ntai
n)Ph
.Eur
.
Podo
phyl
lum
pel
tatu
m L
.D
ried
rhiz
ome
of P
odop
hyllu
m p
elta
tum
L.
Ph.fr
.Po
llen
Flow
er p
olle
nPo
lyga
la a
mar
a L.
Fres
h w
hole
�ow
erin
g pl
ant o
f Pol
ygal
a am
ara
L.
HA
B 34
Poly
gona
tum
odo
ratu
m (M
ill.)
Dru
ceFr
esh,
und
ergr
ound
par
ts o
f Pol
ygon
atum
odo
ratu
m (M
ill.)
Dru
ceVe
spa
crab
ro co
mp.
(0
2.03
.199
1)Po
lypo
dium
vul
gare
L.
Fres
h le
aves
of P
olyp
odiu
m v
ulga
re L
.A
spid
ium
/Sal
ix co
mp.
(0
4.06
.198
6)Po
lypo
dium
vul
gare
L.
Fres
h un
derg
roun
d pa
rts o
f Pol
ypod
ium
vul
gare
L.
Popu
lus t
rem
ula
L.Fr
esh
leav
es o
f Pop
ulus
trem
ula
L.Sa
bal/S
olid
ago
com
p. (
DA
Z N
r.29,
21
.07.
1994
)Po
tent
illa
erec
ta (L
.) Ra
eusc
h.W
hole
or c
ut, d
ried
rhiz
ome,
free
d fr
om th
e ro
ots,
of P
oten
tilla
er
ecta
(L.)
Raeu
sch.
(P. t
orm
entil
la S
toke
s) (t
orm
entil
)Ph
.Eur
.C
oral
lium
com
p.(0
2.09
.198
7)Po
tent
illa
erec
ta (L
.) Ra
eusc
h.Fr
esh
unde
rgro
und
part
s of P
oten
tilla
ere
cta
(L.)
Raeu
sch.
, col
-le
cted
dur
ing
sprin
gH
AB
Torm
entil
la
(03.
07.1
992)
Pote
rium
see
Sacr
opot
eriu
m sp
inos
um (L
.) Sp
ach.
Prim
ula
veris
L.
Fres
h �o
wer
s of P
rimul
a ve
ris L
.C
onva
llaria
/Prim
ula
com
p. (1
2.09
.199
2)
• Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
114
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erPr
imul
a ve
ris L
.D
ried
�ow
ers o
f Prim
ula
veris
L.
Ph.fr
.Pr
imul
a co
mp.
(0
2.03
.199
1)Pr
unus
dul
cis (
Mill
.) D
.A.W
ebb
var.
amar
a (D
C.)
Buch
heim
Drie
d, ri
pe se
eds o
f Pru
nus d
ulci
s (M
ill.)
D.A
.Web
b, v
ar. a
mar
a (D
C.)
Buch
heim
HA
B
Prun
us d
ulci
s (M
iller
) D. A
. Web
b va
r. du
lcis
and/
or a
mar
a (D
. C.)
Buch
heim
Fatty
oil
otai
ned
by co
ld e
xpre
ssio
n fr
om th
e rip
e se
eds o
f Pru
nus
dulc
is (M
iller
) D.A
. Web
b va
r. du
lcis
or P
runu
s dul
cis (
Mill
er) D
.A.
Web
b va
r. am
ara
(D.C
.) Bu
chhe
im o
r a m
ixtu
re o
f bot
h va
rietie
s (a
lmon
d oi
l, vi
rgin
)
Ph.E
ur.
Ole
um P
etra
e co
mp.
(0
3.07
.199
2)
Prun
us la
uroc
eras
us L
.Fr
esh
leav
es o
f Pru
nus l
auro
cera
sus L
.H
AB
/ Ph.
fr.Pr
unus
spin
osa
L.Ju
ice
from
the
frui
t of P
runu
s spi
nosa
L.
Lotio
Pru
ni co
mp.
(0
4.06
.198
6)Pr
unus
spin
osa
L.Fr
esh
�ow
ers a
nd y
oung
tips
of s
hoot
s of P
runu
s spi
nosa
L.
Prun
us sp
inos
a (0
5.12
.198
9)Pr
unus
spin
osa
L.Fr
esh
�ow
ers o
f Pru
nus s
pino
sa L
., co
llect
ed b
efor
e th
e pe
tals
drop
o�
HA
B
Prun
us sp
inos
a L.
Fres
h fr
uit o
f Pru
nus s
pino
sa L
.Pr
unus
spin
osa
(05.
12.1
989)
Prun
us sp
inos
a L.
Fres
h yo
ung
tips o
f sho
ots o
f Pru
nus s
pino
sa L
., co
llect
ed so
me
wee
ks a
�er �
ower
ing
HA
BPr
unus
spin
osa
(05.
12.1
989)
Prun
us sp
inos
a L.
Fully
ope
ned
drie
d �o
wer
s of P
runu
s spi
nosa
L.
DA
C
Prun
us sp
inos
a (0
5.12
.198
9)Ps
ycho
tria
ipec
acua
nha
(Bro
t.)
Stok
esD
ried
unde
rgro
und
orga
ns o
f Psy
chot
ria ip
ecac
uanh
a (B
rot.)
St
okes
.H
AB
Ipec
acua
nha
(02.
09.1
987)
Ptel
ea tr
ifolia
ta L
. Fr
esh
bark
from
you
ng b
ranc
hes o
f Pte
lea
trifo
liata
L.
Ph.fr
.Pt
erid
ium
aqu
ilinu
m (L
.) Ku
hnFr
esh
leav
es o
f Pte
ridiu
m a
quili
num
(L.)
Kuhn
Aqu
ilinu
m co
mp.
(1
2.09
.199
2)Pu
lmon
aria
o�
cina
lis L
.Fr
esh
aeria
l par
ts o
f Pul
mon
aria
o�
cina
lis L
., co
llect
ed at
�ow
erin
g tim
eH
AB
Pulsa
tilla
vul
garis
Mill
.W
hole
fres
h �o
wer
ing
plan
ts o
f Pul
satil
la v
ulga
ris M
ill.
HA
B / P
h.fr.
Pulsa
tilla
(04.
06.1
986)
Pulsa
tilla
vul
garis
Mill
.Fr
esh
�ow
ers o
f Pul
satil
la v
ulga
ris M
ill. w
ith ap
ical
leaf
hus
k.Pu
lsatil
la (0
4.06
.198
6)Py
rus m
alus
See
Mal
us sy
lves
tris
Mill
.Q
uebr
acho
See
Asp
idos
perm
a qu
ebra
cho-
blan
co S
chle
chte
nd.
Que
rcus
robu
r L. a
nd Q
uerc
us
petr
aea
(Mat
t.) L
iebl
.Fr
esh
bark
from
you
ng tw
igs,
bran
ches
and
shoo
ts o
f Que
rcus
ro
bur L
. and
Que
rcus
pet
raea
(Mat
t.) L
iebl
.Q
uerc
us, C
orte
x (0
2.03
.199
1)
• Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
115
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erQ
uerc
us ro
bur L
., Q
uerc
us p
e-tr
aea
(Mat
t.) L
iebl
. and
Que
rcus
pu
besc
ens W
illd.
Cut a
nd d
ried
bark
from
the
fres
h yo
ung
bran
ches
of Q
uerc
us ro
-bu
r L.,
Q. p
etra
ea (M
att.)
Lie
bl. a
nd Q
. pub
esce
ns W
illd.
(oak
bar
k)H
AB
/ Ph.
Eur.
Que
rcus
, Cor
tex
(02.
03.1
991)
Ranu
ncul
us b
ulbo
sus L
.W
hole
fres
h �o
wer
ing
plan
ts o
f Ran
uncu
lus b
ulbo
sus L
.H
AB
/ Ph.
fr.Ra
phan
us sa
tivus
L.
Fres
h un
derg
roun
d pa
rts o
f Rap
hanu
s sat
ivus
L. v
ar. n
iger
(Mill
.) S.
Ke
rner
.H
AB
Raph
anus
sativ
us L
.D
ried
root
of R
apha
nus s
ativ
us L
. var
. nig
er (M
iller
) Ker
ner
Ph.fr
.Ra
tanh
iase
e K
ram
eria
tria
ndra
Rui
z. et
Pav
.Ra
uvol
�a se
rpen
tina
(L.)
Bent
h.W
hole
or c
ut, d
ried
root
s of R
auvo
l�a
serp
entin
a (L
.) Be
ntha
m e
x Ku
rzH
AB
/ DA
BRa
uwol
�a se
rpen
tina
(02.
09.1
987)
Resin
a La
ricis
see
Larix
dec
idua
Mill
.Rh
amnu
s fra
ngul
a L.
Fres
h ba
rk o
f the
stem
s and
bra
nche
s of R
ham
nus f
rang
ula
L.H
AB
Trop
aeol
um co
mp.
(0
2.03
.199
1)Rh
amnu
s pur
shia
na D
.C.
Drie
d, w
hole
or f
ragm
ente
d ba
rk o
f Rha
mnu
s pur
shia
na D
.C.
(Fra
ngul
a pu
rshi
ana
(DC
.) A
. Gra
y ex
J.G
. Coo
per)
(cas
cara
)Ph
.Eur
.
Rheu
m o
�ci
nale
Bai
ll., R
heum
pa
lmat
um L
.W
hole
or c
ut, d
ried
unde
rgro
und
part
s of R
heum
pal
mat
um L
. or
Rheu
m o
�ci
nale
Bai
llon
or o
f hyb
rids o
f the
se tw
o sp
ecie
s or o
f a
mix
ture
. �e
unde
rgro
und
part
s are
o�e
n di
vide
d; th
e st
em a
nd
mos
t of t
he b
ark
with
the
root
lets
are
rem
oved
(rhu
barb
)
Ph.E
ur. /
Ph.
fr.
Rheu
m rh
apon
ticum
L.
Who
le o
r cut
, drie
d un
derg
roun
d pa
rts o
f Rhe
um rh
apon
ticum
L.
Vade
mec
um: R
heum
rh
apon
ticum
Rh
odod
endr
on ch
rysa
nthu
m P
all.
Drie
d le
afy
twig
s of R
hodo
dend
ron
cam
pylo
carp
um H
ook.
f.
or R
hodo
dend
ron
chry
sant
hum
Pal
l., th
eir h
ybrid
s, or
mix
ture
s th
ereo
f
HA
B
Rhod
oden
dron
ferr
ugin
eum
L.
Fres
h le
afy
twig
s of R
hodo
dend
ron
ferr
ugin
eum
L.
Ph.fr
.Fo
rmul
aire
de
med
.an
thr.
(201
0)Rh
odod
endr
on fe
rrug
ineu
m L
.Fr
esh
�ow
erin
g le
afy
twig
s of R
hodo
dend
ron
ferr
ugin
eum
L.
Rhus
toxi
code
ndro
n L.
Fres
h, y
oung
leaf
y br
anch
es o
f Rhu
s to
xico
dend
ron
L., c
olle
cted
at
the
end
of su
mm
erPh
.fr.
Form
ulai
re d
e m
ed.
anth
r. (2
010)
Rhus
toxi
code
ndro
n L.
Fres
h, y
oung
, not
yet
lign
i�ed
shoo
ts o
f Tox
icod
endr
on q
uerc
ifo-
lium
(Mic
hx.)
Gre
ene,
with
leav
esH
AB
/ BP
Rhus
toxi
code
ndro
n (0
5.12
.198
9)Ri
bes n
igru
m L
.Fr
esh
leav
es o
f Rib
es n
igru
m L
.Ph
.fr.
Rici
nus c
omm
unis
L.Fa
tty o
il ob
tain
ed b
y co
ld e
xpre
ssio
n fr
om th
e se
eds o
f Ric
inus
co
mm
unis
L. (c
asto
r oil,
virg
in)
Ph.E
ur.
Berb
eris/
Che
lidon
ium
co
mp.
(02.
03.1
991)
• Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
116
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erRi
cinu
s com
mun
is L.
Drie
d se
eds o
f Ric
inus
com
mun
is L.
Ph.fr
.Ro
bini
a ps
eudo
acac
ia L
.Fr
esh
bark
from
you
ng b
ranc
hes o
f Rob
inia
pse
udo-
acac
ia L
.H
AB
/ Ph.
fr.Ro
bini
a co
mp.
(1
2.09
.199
2)Ro
bini
a ps
eudo
acac
ia L
.Fr
esh
bark
of R
obin
ia p
seud
oaca
cia
L.Ro
sa c
anin
a L.
Rose
hip
s mad
e up
by
the
rece
ptac
le a
nd th
e re
mai
ns o
f the
drie
d se
pals
of R
osa
cani
na L
., R.
pen
dulin
a L.
and
oth
er R
osa
spec
ies,
with
the
ache
nes r
emov
ed (d
og ro
se)
Ph.E
ur.
Rosa
cent
ifolia
L.
Fres
h pe
tals
of R
osa
cent
ifolia
L.
Rosa
, Flo
s (02
.03.
1991
)Ro
sa L
.Es
sent
ial o
il ob
tain
ed b
y st
eam
des
tilla
tion
from
fres
h �o
wer
s of
suita
ble
spec
ies o
f the
gen
us R
osa,
par
ticul
arly
Ros
a ga
llica
L.,
Rosa
da
mas
cena
Mill
. and
Ros
a ce
ntifo
lia L
.
Rosa
, Flo
s (02
.03.
1991
)
Rosa
L.
Subs
tanc
e ob
tain
ed b
y st
epw
ise e
xtra
ctio
n w
ith p
etro
leth
er a
nd
alco
hol f
rom
fres
h �o
wer
s of R
osa
dam
asce
na L
. and
Ros
a ce
ntifo
-lia
L.
Auru
m/L
avan
dula
e ae
ther
oleu
m/R
osa
(04.
06.1
986)
Rosa
L.
Fres
h �o
wer
s of s
uita
ble
spec
ies o
f the
gen
us R
osa
L., p
artic
ular
ly
dark
red
tea
hybr
ids
Rosa
, Flo
s (02
.03.
1991
)
Rosa
L.
Drie
d bu
ds a
nd p
etal
s of s
uita
ble
spec
ies o
f the
gen
us R
osa
L., p
ar-
ticul
arly
Ros
a ga
llica
L.,
Rosa
cent
ifolia
L.,
Rosa
dam
asce
na M
ill. a
s w
ell a
s dar
k re
d te
a hy
brid
s
Rosa
, Flo
s (02
.03.
1991
)
Rosm
arin
us o
�ci
nalis
L.
Esse
ntia
l oil
obta
ined
by
stea
m d
istill
atio
n fr
om th
e �o
wer
ing
aeria
l pa
rts o
f Ros
mar
inus
o�
cina
lis L
. (ro
sem
ary
oil)
Ph.E
ur.
Rosm
arin
öl(0
4.06
.198
6)Ro
smar
inus
o�
cina
lis L
.Fr
esh
leav
es o
f Ros
mar
inus
o�
cina
lis L
.H
AB
Rosm
arin
us(0
2.09
.198
7)Ro
smar
inus
o�
cina
lis L
.Fr
esh
�ow
erin
g tw
igs o
f Ros
mar
inus
o�
cina
lis L
.Ph
.fr.
Form
ulai
re d
e m
ed.
anth
r. (2
010)
Rosm
arin
us o
�ci
nalis
L.
Who
le d
ried
leaf
of R
osm
arin
us o
�ci
nalis
L. (
rose
mar
y le
af)
HA
B / P
h.Eu
r.Ro
smar
inus
(02.
09.1
987)
Rum
ex cr
ispus
L.
Fres
h un
derg
roun
d pa
rts o
f Rum
ex cr
ispus
L.,
harv
este
d at
the
end
of th
e ve
geta
tion
perio
dH
AB
Ruta
gra
veol
ens L
.Fr
esh
aeria
l par
ts o
f Rut
a gr
aveo
lens
L.,
colle
cted
at th
e st
art o
f �o
wer
ing
HA
BC
helid
oniu
m/T
ereb
in-
thin
a la
ricin
a co
mp.
(0
2.03
.199
1)Ru
ta g
rave
olen
s L.
Fres
h, a
eria
l, un
ligni
�ed
part
s of R
uta
grav
eole
ns L
. bef
ore
�ow
er-
ing
Ph.fr
.Fo
rmul
aire
de
med
.an
thr.
(201
0)
• Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
117
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erSa
badi
llase
e Sc
hoen
ocau
lon
o�ci
nale
(Cha
m. e
t Sch
lech
tend
.) A
. Gra
ySa
bal s
erru
latu
mse
e Se
reno
a re
pens
(Bar
tr.) S
mal
l.Sa
bina
see
Juni
peru
s sab
ina
L.Sa
ccha
rum
o�
cina
rum
L.
Car
amel
obt
aine
d th
roug
h th
e ro
astin
g of
Sac
char
um o
�ci
naru
m
L.Sa
ccha
rum
tost
umse
e Sa
ccha
rum
o�
cina
rum
L.
Salix
alb
a ss
p. v
itelli
na (L
.) A
r-ca
ng.
Fres
h ba
rk a
nd le
aves
of S
alix
alb
a ss
p. v
itelli
na (L
.) A
rcha
ng.
Rhus
/Sal
ix co
mp.
(2
5.10
.199
4)Sa
lix sp
ecie
sFr
esh
leav
es o
f Sal
ix a
lba,
ssp.
alb
a L.
and
/or s
sp. v
itelli
na (L
.) A
r-ca
ng. a
nd/o
r Sal
ix p
urpu
rea
L. a
nd/o
r Sal
ix v
imin
alis
L.A
spid
ium
/Sal
ix co
mp.
(0
4.06
.198
6)Sa
lix p
urpu
rea
L.Fr
esh
bark
and
leav
es o
f Sal
ix p
urpu
rea
L.Rh
us/S
alix
com
p.
(25.
10.1
994)
Salix
spec
ies
Who
le o
r fra
gmen
ted
drie
d ba
rk o
f you
ng b
ranc
hes o
r who
le d
ried
piec
es o
f cur
rent
-yea
r tw
igs o
f var
ious
spec
ies o
f gen
us S
alix
incl
ud-
ing
S. p
urpu
rea
L., S
. dap
hnoi
des V
ill. a
nd S
. fra
gilis
L. (
will
ow
bark
)
Ph.E
ur.
Salix
vim
inal
is L.
Fres
h ba
rk a
nd le
aves
of S
alix
vim
inal
is L.
Rhus
/Sal
ix co
mp.
(2
5.10
.199
4)Sa
lvia
o�
cina
lis L
.�
ujon
e-ric
h es
sent
ial o
il ob
tain
ed b
y st
eam
dist
illat
ion
from
the
aeria
l par
ts o
f Sal
via
o�ci
nalis
L.
DA
CM
ajor
ana/
�uj
a co
mp.
(0
2.03
.199
1)Sa
lvia
o�
cina
lis L
.Fr
esh
leav
es o
f Sal
via
o�ci
nalis
L.
HA
BA
rcha
ngel
ica/
Pyrit
co
mp.
(02.
03.1
991)
Salv
ia o
�ci
nalis
L.
Who
le o
r cut
drie
d le
aves
of S
alvi
a o�
cina
lis L
. (sa
ge le
af)
Ph.E
ur.
Frag
aria
/Urt
ica
com
p.
(03.
07.1
992)
Sam
bucu
s nig
ra L
.Fr
esh
pith
from
bra
nche
s of S
ambu
cus n
igra
L.
Sam
bucu
s com
p.
(05.
12.1
989)
Sam
bucu
s nig
ra L
.D
ried
pith
from
bra
nche
s of S
ambu
cus n
igra
L.
Sam
bucu
s com
p.
(05.
12.1
989)
Sam
bucu
s nig
ra L
.Fr
esh
in�o
resc
ence
of S
ambu
cus n
igra
L.
Ph.fr
.Fo
rmul
aire
de
med
.an
thr.
(201
0)Sa
mbu
cus n
igra
L.
Fres
h in
�ore
scen
ces o
f Sam
bucu
s nig
ra L
.Sa
mbu
cus c
omp.
(0
5.12
.198
9)
• Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
118
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erSa
mbu
cus n
igra
L.
Drie
d �o
wer
s of S
ambu
cus n
igra
L. (
elde
r �ow
er)
Ph.E
ur.
Mal
va co
mp.
(0
3.07
.199
2)Sa
mbu
cus n
igra
L.
Drie
d in
�ore
scen
ce o
f Sam
bucu
s nig
ra L
.Fl
ores
Sam
buci
com
p./
Qua
rz (0
7.04
.198
8)Sa
mbu
cus n
igra
L.
Equa
l par
ts o
f fre
sh le
aves
and
in�o
resc
ence
s of S
ambu
cus n
igra
L.
HA
BSa
mbu
cus/
Teuc
rium
co
mp.
(25.
10.1
994)
Sang
uina
ria c
anad
ensis
L.
Drie
d un
derg
roun
d pa
rts o
f San
guin
aria
can
aden
sis L
., co
llect
ed in
au
tum
nH
AB
Oxa
lis co
mp.
(04.
06.1
986)
Sani
cula
eur
opae
a L.
Fres
h w
hole
�ow
erin
g pl
ant o
f San
icul
a eu
ropa
ea L
.Ph
.fr. /
HA
BC
icho
rium
com
p.(0
3.07
.199
2)Fo
rmul
aire
de
med
.an
thr.
(201
0)Sa
nicu
la e
urop
aea
L.Fr
esh
aeria
l par
ts o
f San
icul
a eu
ropa
ea L
., co
llect
ed at
�ow
erin
g tim
eH
AB
Sapo
naria
o�
cina
lis L
. Fr
esh
who
le �
ower
ing
plan
t of S
apon
aria
o�
cina
lis L
.Ph
.fr.
Sarc
opot
eriu
m sp
inos
um (L
.) Sp
ach.
Drie
d ba
rk fr
om th
e ro
ots o
f Sar
copo
teriu
m sp
inos
um (L
.) Sp
ach.
Saro
tham
nus s
copa
rius
see
Cyt
isus s
copa
rius (
L.) L
ink.
Sars
apar
illa
see
Smila
x re
gelii
Kill
. et C
. V. M
orto
n, S
mila
x m
edic
a Sc
hlec
hten
d.
et C
ham
. etc
.Sc
hoen
ocau
lon
o�ci
nale
(Cha
m.
et S
chle
chte
nd.)
A. G
ray
Drie
d rip
e se
eds o
f Sch
oeno
caul
on o
�ci
nale
(Cha
m. e
t Sch
lech
-te
nd.)
A. G
ray.
HA
B / P
h.fr.
Ferr
um p
hosp
horic
um
com
p. (0
4.06
.198
6)Sc
illa
see
Urg
inea
mar
itim
a (L
.) Ba
k. s.
l.Sc
olop
endr
ium
see
Phyl
litis
scol
open
driu
m (L
.) N
ewm
.Sc
roph
ular
ia n
odos
a L.
Fr
esh
who
le �
ower
ing
plan
t of S
crop
hula
ria n
odos
a L.
Ph.fr
.Sc
utel
laria
late
rifol
ia L
. D
ried
who
le �
ower
ing
plan
t of S
cute
llaria
late
rifol
ia L
.Se
cale
corn
utum
see
Cla
vice
ps p
urpu
rea
(Fr.)
Tul
.Se
dum
acr
e L.
Fres
h ae
rial p
arts
of S
edum
acr
e L.
, col
lect
ed at
�ow
erin
g tim
eH
AB
Sedu
m a
cre
L.Fr
esh
aeria
l par
ts o
f Sed
um a
cre
L.Se
dum
tele
phiu
m L
.Fr
esh,
aer
ial p
arts
of �
ower
ing
Sedu
m te
leph
ium
L. (
Sedu
m p
ur-
pure
um L
.)Se
dum
pur
pure
um
(07.
04.1
988)
Sele
nice
reus
gra
ndi�
orus
(L.)
Britt
. et R
ose
Fres
h yo
ung
stem
and
�ow
ers o
f Sel
enic
ereu
s gra
ndi�
orus
(L.)
Britt
. et R
ose.
(Cac
tus)
HA
BC
actu
s gra
ndi�
orus
(1
2.09
.199
2)
• Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
119
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erSe
mec
arpu
s ana
card
ium
L.
Drie
d fr
uit o
f Sem
ecar
pus a
narc
ardi
um L
. (A
naca
rdiu
m o
rient
ale
L.) (
orie
ntal
cas
hew
for h
omoe
opat
hic p
repa
ratio
ns)
HA
B / P
h.Eu
r.
Sene
cio
bico
lor (
Will
d.) T
od.
Fres
h ae
rial p
arts
of S
enec
io b
icol
or (W
illd.
) Tod
., co
llect
ed b
efor
e �o
wer
ing
Cin
erar
ia m
ariti
ma
(12.
09.1
992)
Sene
cio
jaco
baea
L.
Fres
h ae
rial p
arts
of S
enec
io ja
coba
ea L
., co
llect
ed at
�ow
erin
g tim
eSe
neci
o co
mp.
(1
2.09
.199
2)Se
neci
o vu
lgar
is L.
Fres
h w
hole
�ow
erin
g pl
ant o
f Sen
ecio
vul
garis
L.
Sene
gase
e Po
lyga
la se
nega
L.
Senn
ase
e C
assia
ang
ustif
olia
Vah
l.Se
reno
a re
pens
(Bar
tr.) S
mal
lD
ried
ripe
frui
t of S
eren
oa re
pens
(Bar
tr.) S
mal
l.U
SP /
Ph.fr
.Sa
bal/S
olid
ago
com
p.(D
AZ
Nr.2
9,
21.0
7.19
94)
Sere
noa
repe
ns (B
artr.
) Sm
all
Fres
h rip
e fr
uits
of S
eren
oa re
pens
(Bar
tr.) S
mal
l. (S
abal
serr
ula-
tum
)H
AB
Sily
bum
mar
ianu
m (L
.) G
aert
n.M
atur
e fr
uit,
devo
id o
f the
pap
pus,
of S
ilybu
m m
aria
num
(L.)
Gae
rtne
r (m
ilk-t
hist
le fr
uit)
HA
B / P
h.Eu
r. / P
h.fr.
/ U
SPC
ardu
us m
aria
nus
(04.
06.1
986)
Smila
x sp
ecie
sD
ried
unde
rgro
und
part
s of S
mila
x ar
istol
ochi
ifolia
Mill
. S. m
edic
a Sc
hlec
hten
d. e
t Cha
m) a
nd re
late
d sp
ecie
sPh
.fr.
Sola
num
dul
cam
ara
L.Fr
esh
�ow
ers o
f Sol
anum
dul
cam
ara
L.D
ulca
mar
a/Ly
simac
hia
(04.
06.1
986)
Sola
num
dul
cam
ara
L.Fr
esh
shoo
ts o
f Sol
anum
dul
cam
ara
L., c
olle
cted
prio
r to
�ow
erin
gH
AB
Sola
num
dul
cam
ara
L.Fr
esh
youn
g le
afy
bran
ches
of S
olan
um d
ulca
mar
a L.
Sola
num
dul
cam
ara
L.D
ried,
lign
i�ed
stem
s of S
olan
um d
ulca
mar
a L.
(Dul
cam
ara,
Stip
i-te
s)D
AB6
Erg
.B.
Siru
pus �
ymi c
omp.
(0
4.06
.198
6)So
lanu
m ly
cope
rsic
umSe
e Ly
cope
rsic
on ly
cope
rsic
um (L
.) K
arst
. ex
Farw
.So
lidag
o vi
rgau
rea
L.Fr
esh
in�o
resc
ence
of S
olid
ago
virg
aure
a L.
Ph.fr
. / H
AB
Form
ulai
re d
e m
ed.
anth
r. (2
010)
Solid
ago
virg
aure
a L.
Fres
h ae
rial p
arts
of S
olid
ago
virg
aure
a L.
, col
lect
ed at
�ow
erin
g tim
eSo
lidag
o vi
rgau
rea
(D
AZ
Nr.
29 v
om
21.0
7.19
94)
Solu
m u
ligin
osum
se
e pe
at
• Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
120
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erSp
artiu
m sc
opar
ium
See
Cyt
isus s
copa
rius (
L.) L
ink.
Spig
elia
ant
helm
ia L
.D
ried,
who
le �
ower
ing
plan
t of S
pige
lia a
nthe
lmia
L.
Ph.fr
.Sp
igel
ia a
nthe
lmia
L.
Drie
d ae
rial p
arts
of S
pige
lia a
nthe
lmia
L.
HA
BSp
inac
ia o
lera
cea
L.Fr
esh
unde
rgro
und
part
s of S
pina
cia
oler
acea
L.
Sene
cio
com
p.
(12.
09.1
992)
Spira
ease
e Fi
lipen
dula
ulm
aria
(L.)
Max
im.
Spiri
to e
x vi
noSe
e V
itis v
inife
ra L
.St
achy
s o�
cina
lis (L
.) Tr
ev.
Fres
h ae
rial p
arts
of S
tach
ys o
�ci
nalis
(L.)
Trev
., co
llect
ed at
�ow
-er
ing
time
HA
BBe
toni
ca/R
osm
arin
us(1
2.09
.199
2)St
aphi
sagr
iase
e D
elph
iniu
m st
aphi
sagr
ia L
.St
ella
ria m
edia
(L.)
Fres
h w
hole
pla
nt o
f Ste
llaria
med
ia (L
.)St
icta
see
Loba
ria p
ulm
onar
ia (L
.) H
o�m
.St
ram
oniu
mse
e D
atur
a st
ram
oniu
m L
.St
roph
anth
us k
ombe
Oliv
.Fa
tty o
il fr
om th
e se
eds o
f Str
opha
nthu
s kom
be O
liv.
Ole
um S
trop
hant
hi
(03.
07.1
992)
Stro
phan
thus
kom
be O
liv.
Drie
d rip
e se
eds o
f Str
opha
nthu
s kom
bé O
liv.
Stro
phan
thus
kom
bé
(02.
09.1
987)
Stry
chno
s ign
atii
Berg
ius
Drie
d rip
e se
eds o
f Str
ychn
os ig
natii
Ber
gius
.H
AB
/ Ph.
fr.Ig
natia
(02.
09.1
987)
Stry
chno
s nux
-vom
ica
L.D
ried
ripe
seed
s of S
tryc
hnos
nux
-vom
ica
L.H
AB
/ Ph.
fr.N
ux v
omic
a (0
4.06
.198
6)St
yrax
tonk
inen
sis (P
ierr
e) C
raib
ex
Har
twic
hBa
lsam
obt
aine
d th
roug
h in
cisio
ns m
ade
into
the
trun
k of
Sty
rax
tonk
inen
sis (P
ierr
e) C
raib
ex
Har
twic
h (S
tyra
cace
ae)
DA
C
Sym
phyt
um o
�ci
nale
L.
Fres
h un
derg
roun
d pa
rts o
f Sym
phyt
um o
�ci
nale
L.
Ph.fr
. / B
PSt
annu
m/S
ymph
ytum
co
mp.
(12.
09.1
992)
Sym
phyt
um o
�ci
nale
L.
Fres
h ae
rial p
arts
of S
ymph
ytum
o�
cina
le L
., co
llect
ed at
�ow
erin
g tim
eC
alen
dula
/Urt
ica
com
p.
(12.
09.1
992)
Syzy
gium
aro
mat
icum
(L.)
Mer
r. et
L. M
. Per
ryEs
sent
ial o
il ob
tain
ed b
y st
eam
dist
illat
ion
from
the
drie
d �o
wer
bu
ds o
f Syz
ygiu
m a
rom
atic
um (L
.) M
erill
et L
. M. P
erry
(syn
. Eug
e-ni
a ca
ryop
hyllu
s [C
. Spr
eng.
] Bul
lock
et S
.G. H
arris
on) (
clov
e oi
l)
Ph.E
ur.
Rata
nhia
com
p.(0
3.07
.199
2)
Syzy
gium
aro
mat
icum
(L.)
Mer
r. et
L. M
. Per
ryW
hole
�ow
er b
uds o
f Syz
ygiu
m a
rom
atic
um (L
.) M
erill
et L
.M.
Perr
y (s
yn. E
ugen
ia c
aryo
phyl
lus [
C. S
pren
g.] B
ullo
ck e
t S.G
. Har
-ris
on) d
ried
until
they
bec
ome
redd
ish-b
row
n (c
love
)
Ph.E
ur.
Abs
inth
ium
/ C
aryo
phyl
li co
mp.
(02.
09.1
987)
Syzy
gium
jam
bos (
L.) A
lston
Drie
d se
eds o
f Syz
ygiu
m ja
mbo
s (L.
) Alst
on
• Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
121
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erTa
bacu
mSe
e N
icot
iana
taba
cum
L.
Tana
cetu
m v
ulga
re L
.Fr
esh
aeria
l par
ts o
f Tan
acet
um v
ulga
re L
., co
llect
ed at
�ow
erin
g tim
e, w
ithou
t ste
ms
HA
B
Tara
xacu
m o
�ci
nale
agg
. F.H
. W
igg.
Who
le fr
esh
�ow
erin
g pl
ants
of T
arax
acum
o�
cina
le a
gg. F
.H.
Wig
g.H
AB
/ Ph.
fr.Ta
raxa
cum
(2
5.10
.199
4)Ta
raxa
cum
o�
cina
le a
gg. F
.H.
Wig
g.Fr
esh
unde
rgro
und
part
s of T
arax
acum
o�
cina
le a
gg. F
.H. W
igg.
co
llect
ed in
autu
mn
(aut
umna
le) o
r spr
ing
(ver
nale
)Ta
raxa
cum
(2
5.10
.199
4)Ta
rtar
us cr
udus
See
Viti
s vin
ifera
L.
Teuc
rium
mar
um L
.Fr
esh
�ow
erin
g, a
eria
l par
ts o
f Teu
criu
m m
arum
L.
Teuc
rium
mar
um L
.Fr
esh
aeria
l par
ts o
f Teu
criu
m m
arum
L.,
with
out l
igni
�ed
sect
ions
of
twig
sH
AB
Teuc
rium
scor
odon
ia L
.Fr
esh
aeria
l par
ts o
f �ow
erin
g pl
ants
of T
eucr
ium
scor
odon
ia L
.H
AB
/ Ph.
fr.K
aliu
m/T
eucr
ium
co
mp.
(25.
10.1
994)
Teuc
rium
scor
odon
ia L
.D
ried
aeria
l par
ts o
f �ow
erin
g pl
ants
of T
eucr
ium
scor
odon
ia L
.Sp
ecie
s pul
mon
ales
(0
7.04
.198
8)�
uja
occi
dent
alis
L.Fr
esh
leaf
y br
anch
es o
f �uj
a oc
cide
ntal
is L.
, col
lect
ed p
refe
rabl
y in
sp
ring
Ph.fr
.Fo
rmul
aire
de
med
.an
thr.
(201
0)�
uja
occi
dent
alis
L.Fr
esh,
leaf
y, on
e-ye
ar-o
ld tw
igs o
f �uj
a oc
cide
ntal
is L.
HA
B�
uja
occi
dent
alis
(07.
04.1
988)
�ym
us se
rpyl
lum
L. e
men
d. M
ill.
Drie
d, w
hole
or c
ut, �
ower
ing
aeria
l sho
ots o
f �
ymus
serp
yllu
m
L. se
nsu
latio
reD
AB
Siru
pus �
ymi c
omp.
(04.
06.1
986)
�ym
us v
ulga
ris L
.Es
sent
ial o
il ob
tain
ed b
y st
eam
dist
illat
ion
from
the
fres
h �o
wer
ing
aeria
l par
ts o
f �ym
us v
ulga
ris L
., T.
zygi
s L. o
r a m
ixtu
re o
f bot
h sp
ecie
s. (t
hym
e oi
l, th
ymol
type
)
Ph.E
ur.
�ym
i aet
hero
leum
(2
5.10
.199
4)
�ym
us v
ulga
ris L
.Fr
esh
aeria
l par
ts o
f �ym
us v
ulga
ris L
., co
llect
ed at
�ow
erin
g tim
eH
AB
�ym
us v
ulga
ris L
.W
hole
leav
es a
nd �
ower
s sep
arat
ed fr
om th
e pr
evio
usly
drie
d st
ems
of �
ymus
vul
garis
L. o
r �ym
us zy
gis L
. or a
mix
ture
of b
oth
spe-
cies
. (th
yme)
Ph.E
ur.
Siru
pus �
ymi c
omp.
(04.
06.1
986)
Tilia
cord
ata
Mill
er, T
ilia
plat
y-ph
yllo
s Sco
poli
Fres
h in
�ore
scen
ce o
f Tili
a co
rdat
a M
iller
and
Tili
a pl
atyp
hyllo
s Sc
opol
iFl
ores
Sam
buci
/Qua
rz(0
7.04
.198
8)Ti
lia co
rdat
a M
iller
, Tili
a pl
aty-
phyl
los S
copo
liW
hole
, drie
d in
�ore
scen
ce o
f Tili
a co
rdat
a M
iller
, of T
ilia
plat
y-ph
yllo
s Sco
p., o
f Tili
a x
vulg
aris
Hey
ne o
r a m
ixtu
re o
f the
se (l
ime
�ow
er)
Ph.E
ur.
Mal
va co
mp.
(0
3.07
.199
2)
• Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
122
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erTo
rmen
tilla
see
Pote
ntill
a er
ecta
(L.)
Raeu
sch.
Toxi
code
ndro
nse
e To
xico
dend
ron
quer
cifo
lium
(Mic
hx.)
Gre
ene
Toxi
code
ndro
n qu
erci
foliu
m
(Mic
hx.)
Gre
ene
see
Rhus
toxi
code
ndro
n L.
Triti
cum
aes
tivum
L.
Fatty
oil
obta
ined
from
the
germ
of t
he g
rain
of T
ritic
um a
estiv
um
L. b
y co
ld e
xpre
ssio
n or
oth
er su
itabl
e m
echa
nica
l mea
ns (w
heat
-ge
rm o
il)
Ph.E
ur.
Triti
cum
aes
tivum
L. e
men
d. F
iori
et P
aol.
Fres
h �o
wer
s of T
ritic
um a
estiv
um L
. em
end.
Fio
ri et
Pao
l.
Triti
cum
aes
tivum
L. e
men
d. F
iori
et P
aol.
Fres
h ge
rmin
ated
frui
t of T
ritic
um a
estiv
um L
. em
end.
Fio
ri et
Pa
ol.
Ph.fr
.H
irnst
amm
/Trit
icum
(2
8. S
erie
) (D
AZ
Nr.
29
vom
21.
07.1
994)
Triti
cum
aes
tivum
L. e
men
d. F
iori
et P
aol.
Fres
h pa
rts p
roje
ctin
g ou
t of t
he in
�ore
senc
e sp
ikel
et o
f Trit
icum
ae
stiv
um L
. em
end.
Fio
ri et
Pao
l.Tr
iticu
m a
estiv
um L
. em
end.
Fio
ri et
Pao
l.D
ried
germ
of t
he g
rain
of T
ritic
um
aest
ivum
L. e
men
d Fi
ori e
t Pao
l. (w
heat
-ger
m)
Levi
stic
um co
mp.
(0
2.09
.198
7)Tr
iticu
m a
estiv
um L
. em
end.
Fio
ri et
Pao
l.W
heat
glu
ten
Triti
cum
repe
nsse
e El
ymus
repe
ns (L
.) G
ould
Tric
itum
vul
gare
Drie
d in
�ore
scen
ces o
f Trit
icum
aes
tivum
L. e
men
d. F
iori
et P
aol.
Flor
es T
ritic
i com
p.
(12.
9.19
92)
Trop
aeol
um m
ajus
L.
Fres
h ae
rial p
arts
of T
ropa
eolu
m m
ajus
L.,
colle
cted
at �
ower
ing
time
Trop
aeol
um co
mp.
(0
2.03
.199
1)Tu
lipa
silve
stris
L.
Fres
h w
hole
�ow
erin
g pl
ant o
f Tul
ipa
silve
stris
L.
Vade
mec
um: T
ulip
aU
rgin
ea m
ariti
ma
(L.)
Bak.
Fres
h, �
eshy
scal
e le
aves
of t
he re
d-sc
aled
subs
peci
es o
f Urg
inea
m
ariti
ma
(L.)
Bak.
sens
u la
tiore
(e.g
. Urg
inea
num
idic
a [J
ord.
et
Four
r.] G
rey)
with
a cl
early
det
ecta
ble
scill
irosid
e co
nten
t
HA
B
Urg
inea
mar
itim
a va
r. ru
bra
(L.)
Bake
rFr
esh
bulb
of U
rgin
ea m
ariti
ma
var.
rubr
a (L
.) Ba
ker
Ado
nis/
Scill
a co
mp.
(2
5.10
.199
4)U
rtic
a di
oica
L.
Fres
h le
aves
of U
rtic
a di
oica
L.
Urt
ica
dioi
ca
(02.
09.1
987)
Urt
ica
dioi
ca L
.W
hole
,fres
h, �
ower
ing
plan
ts o
f Urt
ica
dioi
ca L
. (C
omm
on st
ing-
ing
nettl
e fo
r hom
oeop
athi
c pre
para
tions
) H
AB
/ Ph.
Eur.
Urt
ica
dioi
ca
(02.
09.1
987)
• Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
123
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erU
rtic
a di
oica
L.
Fres
h ae
rial p
arts
of U
rtic
a di
oica
L.
Urt
ica
dioi
ca
(02.
09.1
987)
Urt
ica
dioi
ca L
.W
hole
or c
ut d
ried
leav
es o
f Urt
ica
dioi
ca L
., U
rtic
a ur
ens L
., or
a
mix
ture
of t
he 2
spec
ies (
nettl
e le
af)
Ph.E
ur.
Urt
ica
dioi
ca L
.D
ried
leav
es o
f Urt
ica
dioi
ca L
.U
rtic
a di
oica
L.
Drie
d �o
wer
s of U
rtic
a di
oica
L.
Cap
sella
/Maj
oran
a co
mp.
(04.
06.1
986)
Urt
ica
dioi
ca L
.D
ried,
aer
ial p
arts
with
max
imum
3 m
m th
ick
stem
s of U
rtic
a di
o-ic
a L.
, col
lect
ed sh
ortly
bef
ore
�ow
erin
gU
rtic
a di
oica
(0
2.09
.198
7)U
rtic
a ur
ens L
.Fr
esh,
who
le �
ower
ing
plan
t of U
rtic
a ur
ens L
.Ph
.fr.
Berb
eris,
Pla
nta
tota
/ U
rtic
a ur
ens
(02.
03.1
991)
Form
ulai
re d
e m
ed.
anth
r. (2
010)
Urt
ica
uren
s L.
Fres
h, w
hole
pla
nt o
f Urt
ica
uren
s L.
Urt
ica
uren
s L.
Fres
h, �
ower
ing
aeria
l par
ts o
f Urt
ica
uren
s L.
HA
B / B
PA
rnic
a/U
rtic
a ur
ens
(04.
06.1
986)
Urt
ica
uren
s L.
Drie
d, a
eria
l par
ts o
f Urt
ica
uren
s L.
Usn
ea b
arba
ta (L
.) W
igg.
Drie
d th
allu
s fro
m U
snea
P. B
r. ex
Ada
ns. s
peci
es, e
spec
ially
Usn
ea
barb
ata
(L.)
Wig
g.Li
chen
es co
mp.
(0
4.06
.198
6)Va
ccin
ium
myr
tillu
s L.
Drie
d rip
e fr
uit o
f Vac
cini
um m
yrtil
lus L
. (bi
lber
ry fr
uit,
drie
d)
Ph.E
ur.
Vacc
iniu
m v
itis-
idae
a L.
Leaf
y tw
igs w
ith fr
esh
frui
ts o
f Vac
cini
um v
itis-
idae
a L.
Vale
riana
o�
cina
lis L
.Fr
esh
�ow
ers o
f Val
eria
na o
�ci
nalis
L.
Vale
riana
o�
cina
lis L
.Fr
esh,
und
ergr
ound
par
ts o
f Val
eria
na o
�ci
nalis
L.
Ph.fr
.Fo
rmul
aire
de
med
.an
thr.
(201
0)Va
leria
na o
�ci
nalis
L.
Fres
h un
derg
roun
d pa
rts o
f Val
eria
na o
�ci
nalis
L. s
ensu
latio
reH
AB
Vale
riana
com
p.
(03.
07.1
992)
Vale
riana
o�
cina
lis L
.D
ried,
who
le o
r fra
gmen
ted
unde
rgro
und
part
s of V
aler
iana
of-
�cin
alis
L. s.
l., in
clud
ing
the
rhiz
ome
surr
ound
ed b
y th
e ro
ots a
nd
stol
ons (
vale
rian
root
)
Ph.E
ur. /
USP
Vauc
heria
DC
spec
ies
Fres
h, w
hole
org
anism
of V
auch
eria
DC
spec
ies
Vauc
heria
(25.
10.1
994)
Vera
trum
alb
um L
.C
aref
ully
drie
d rh
izom
e w
ith at
tach
ed ro
ots o
f Ver
atru
m a
lbum
L.
HA
BD
rose
ra/Ip
ecac
uanh
a co
mp.
(04.
06.1
986)
Vera
trum
alb
um L
.Fr
esh,
und
ergr
ound
par
ts o
f Ver
atru
m a
lbum
L.
Ph.fr
.Ve
ratr
um a
lbum
(0
4.06
.198
6)
• Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
124
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erVe
rbas
cum
den
si�or
um B
erto
l.Fr
esh,
unr
ipe
frui
ts o
f Ver
basc
um d
ensi�
orum
Ber
tol.
Verb
ascu
m co
mp.
(1
2.09
.199
2)Ve
rbas
cum
den
si�or
um B
erto
l.Fr
esh
aeria
l par
ts o
f Ver
basc
um d
ensi�
orum
Ber
tol.
with
out w
oody
st
ems,
colle
cted
at �
ower
ing
time
HA
B
Verb
ascu
m d
ensi�
orum
Ber
tol.
Drie
d fr
uit o
f Ver
basc
um d
ensi�
orum
Ber
tol.
Vero
nica
o�
cina
lis L
.D
ried
aeria
l par
ts o
f Ver
onic
a o�
cina
lis L
., co
llect
ed at
�ow
erin
g tim
eH
AB
Vero
nica
o�
cina
lis
(25.
10.1
994)
Vin
ca m
inor
L.
Fres
h, w
hole
�ow
erin
g pl
ant o
f Vin
ca m
inor
L.
Ph.fr
.V
inum
see
Viti
s vin
ifera
L.
Vio
la tr
icol
or L
.Fr
esh,
who
le �
ower
ing
plan
t of V
iola
tric
olor
L. a
nd /
or V
iola
ar
vens
is M
urra
yPh
.fr.
Vio
la tr
icol
or L
.Fr
esh
aeria
l par
ts o
f Vio
la tr
icol
or L
., co
llect
ed at
�ow
erin
g tim
eH
AB
Trop
aeol
um co
mp.
(0
2.03
.199
1)V
iola
tric
olor
L.
Drie
d, �
ower
ing
aeria
l par
ts o
f Vio
la a
rven
sis M
urra
y an
d/or
Vio
la
tric
olor
L. (
wild
pan
sy �
ower
ing
aeria
l par
ts)
Ph.E
ur.
Viro
la se
bife
ra A
ubl.
Fres
h ju
ice
of V
irola
sebi
fera
Aub
l. ob
tain
ed b
y in
cisin
g th
e ba
rk,
and
pres
erve
d w
ith a
n ap
prox
imat
ely
equa
l vol
ume
of E
than
ol (9
6 pe
r cen
t) (P
h.Eu
r.)
HA
BM
yrist
ica
sebi
fera
co
mp.
(07.
04.1
988)
Visc
um a
lbum
L.
Fres
h pl
ant i
nclu
ding
frui
t and
hau
stor
ium
of V
iscum
alb
um L
. ssp
. ab
ietis
(Wie
sb.)
Abr
om. (
Hos
t tre
e: A
bies
spec
ies)
Visc
um a
lbum
(0
4.06
.198
6)V
iscum
alb
um L
.Fr
esh
plan
t exc
ludi
ng h
aust
oriu
m o
f Visc
um a
lbum
ssp.
abi
etis
(Bec
k) (W
iesb
.) A
brom
. (H
ost t
ree:
Abi
es a
lba
Mill
. (A
bies
pec
ti-na
ta (L
am.)
DC
); �r
)
Visc
um a
lbum
(0
4.06
.198
6)
Visc
um a
lbum
L.
Fres
h pl
ant i
nclu
ding
frui
t and
hau
stor
ium
of V
iscum
alb
a L.
ssp.
al
bum
(Hos
t tre
es: P
opul
us sp
ecie
s)V
iscum
com
p.
(25.
10.1
994)
Visc
um a
lbum
L.
Fres
h pl
ant i
nclu
ding
frui
t and
hau
stor
ium
of V
iscum
alb
um L
. ssp
. au
stria
cum
(Wie
sb.)
Vollm
. (H
ost t
ree:
Pin
us sp
ecie
s)V
iscum
alb
um
(04.
06.1
986)
Visc
um a
lbum
L.
Fres
h pl
ant e
xclu
ding
hau
stor
ium
of V
iscum
alb
um ss
p. a
lbum
L.
(Hos
t tre
e: M
alus
dom
estic
a Bo
ekh.
; App
le tr
ee)
Visc
um a
lbum
(0
4.06
.198
6)V
iscum
alb
um L
.Fr
esh
plan
t exc
ludi
ng h
aust
oriu
m o
f Visc
um a
lbum
ssp.
aust
riacu
m
(Wie
sb.)
Vollm
. (H
ost t
ree:
Pin
us sy
lves
tris
L.; P
ine)
V
iscum
alb
um
(04.
06.1
986)
• Appendix 2.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
125
Nam
e of t
he o
rigi
nal p
lant
Abbr
evia
ted
de�n
ition
of t
he p
art u
sed
Refe
renc
e to
Stan
dard
sEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic
med
icin
eKC
mon
ogra
ph (d
ate)
Oth
erV
iscum
alb
um L
.Fr
esh
plan
t exc
ludi
ng h
aust
oriu
m o
f Visc
um a
lbum
ssp.
alb
um L
. (H
ost t
ree:
Que
rcus
robu
r L.,
Que
rcus
pet
raea
(Mat
t.) L
iebl
.; O
ak)
Visc
um a
lbum
(0
4.06
.198
6)V
iscum
alb
um L
.Fr
esh
plan
t exc
ludi
ng h
aust
oriu
m o
f Visc
um a
lbum
ssp.
alb
um L
. (H
ost t
ree:
Ulm
us c
aprin
ifolia
Gle
d. [U
lmus
cam
pest
ris L
.], U
lmus
gl
abra
Hud
s.; E
lm)
Visc
um a
lbum
(0
4.06
.198
6)
Visc
um a
lbum
L.
Fres
h le
afy
shoo
ts a
nd fr
uits
of V
iscum
alb
um L
.H
AB
Visc
um a
lbum
L.
Fres
h ha
usto
rium
of V
iscum
alb
um L
ssp.
alb
um (H
ost t
ree:
Mal
us
spec
ies)
Visc
um a
lbum
(0
4.06
.198
6)V
iscum
alb
um L
.Fr
esh
shoo
ts co
llect
ed in
sum
mer
and
�ow
ers c
olle
cted
in w
inte
r of
Visc
um a
lbum
L. s
sp. a
lbum
(Hos
t tre
e: S
alix
alb
a)V
iscum
alb
um L
.Fr
esh
aeria
l par
ts in
clud
ing
frui
t of V
iscum
alb
um L
. (H
ost t
rees
: Ap
ple,
Birc
h, F
ir, P
ine,
Lim
e)V
iscum
alb
um L
.D
ried
plan
t inc
ludi
ng fr
uit o
f Visc
um a
lbum
L. s
sp. a
lbum
(Hos
t tr
ees:
Oak
spec
ies)
with
out h
aust
oriu
m.
Visc
um a
lbum
L.
Drie
d pl
ant i
nclu
ding
frui
t and
hau
stor
ium
of V
iscum
alb
um L
. ssp
. al
bum
(Hos
t tre
es: C
rata
egus
spec
ies)
V
iscum
alb
um
(04.
06.1
986)
Visc
um a
lbum
L.
Drie
d pl
ant i
nclu
ding
frui
t and
hau
stor
ium
of V
iscum
alb
um L
. ssp
. al
bum
(Hos
t tre
es: S
alix
spec
ies)
Visc
um a
lbum
(0
4.06
.198
6)V
iscum
alb
um L
.D
ried
bran
ches
with
leav
es, �
ower
s and
frui
t of V
iscum
alb
um L
. ss
p. a
lbum
(Hos
t tre
es: M
alus
spec
ies)
Visc
um a
lbum
(0
4.06
.198
6)V
itex
agnu
s-ca
stus
L.
who
le, r
ipe,
drie
d fr
uits
of V
itex
agnu
s-ca
stus
L. (
agnu
s cas
tus f
ruit)
HA
B / P
h.Eu
r. / U
SP /
Ph.fr
.M
eliss
a/Ph
osph
orus
co
mp.
(03.
07.1
992)
Viti
s vin
ifera
L.
Dist
illed
red
win
e vi
nega
r (ac
etum
vin
i des
tilla
tum
)K
aliu
m a
cetic
um co
mp.
(0
3.07
.199
2)V
itis v
inife
ra L
.Re
d w
ine
vine
gar (
acet
um v
ini)
Viti
s vin
ifera
L.
Drie
d le
aves
of V
itis v
inife
ra L
.V
itis c
omp.
(0
4.06
.198
6)V
itis v
inife
ra L
.D
istill
ate
of w
ine
Viti
s vin
ifera
L.
Cre
am o
f tar
tar (
Tart
arus
crud
us)
Viti
s vin
ifera
L.
Whi
te w
ine
Zea
may
s L.
Fres
h st
igm
a an
d st
yle
of Z
ea m
ays L
.Ph
.fr.
Zing
iber
o�
cina
le R
osc.
Drie
d, w
hole
or c
ut rh
izom
e of
Zin
gibe
r o�
cina
le R
osco
e, w
ith th
e co
rk re
mov
ed, e
ither
com
plet
ely
or fr
om th
e w
ide,
�at s
urfa
ces o
nly
(gin
ger)
HA
B / P
h.Eu
r. / U
SPG
entia
na/Z
ingi
ber
com
p. (0
2.03
.199
1)
• Ap
pend
ix 2
.2
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
126
• Appendix 2.3
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
127
APPENDIX 2.3
List of starting materials of zoological originAdditional Information, see p. 21 and pp. 67-73 Abbreviation *: p. 67
• Ap
pend
ix 2
.3
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Appendix 2.3
128
Scie
nti�
c nam
e Sc
ient
i�c n
ame o
f the
anim
alAb
brev
iate
d de
�niti
onRe
fere
nce t
o St
anda
rdEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Aci
dum
For
mic
ae
(Aci
dum
form
icic
um e
fo
rmic
a; A
cidu
m F
or-
mic
ae v
enen
um)
Seve
ral s
peci
es o
f woo
d an
ts
of th
e Sub
genu
s For
mica
s.
str. (
e.g. F
orm
ica lu
gu-
bris
ZETT
., F.
polyc
tena
FÖ
RSTE
R., F
. par
alug
ubris
SE
IFER
T or
F. ru
fa L
.)
Aqu
eous
solu
tion
of th
e se
cret
ion
of w
ood
ants
of t
he S
ubge
nus F
orm
ica
s. st
r.,
cont
aini
ng n
ot le
ss th
an 1
,2%
m/m
of
form
ic a
cid
List
e H
AS
(10.
2012
)
Am
bra
grise
aPh
yset
er ca
todo
n L.
(Phy
sete
r m
acro
ceph
alus
L.)
Subs
tanc
e pr
oduc
ed in
the d
iges
tive s
yste
m
of th
e sp
erm
wha
leH
AB
/ Ph.
Fr.
Zinc
um v
aler
iani
cum
co
mp.
(25.
10.1
994)
Am
nion
Bos t
auru
s L.
Am
nion
from
the
bovi
ne fo
etus
Va
dem
ecum
: Am
nion
Anu
sBo
s tau
rus L
.A
nus f
rom
the
calf
Prun
us/R
osm
arin
us co
mp.
(0
2.03
.199
1)A
orta
Bos t
auru
s L.
Di�
eren
t sec
tions
of t
he a
orta
from
the
calf
Vade
mec
um [m
entio
ned
unde
r: At
ropa
bel
lado
nna
e ra
dice
]A
orta
Ory
ctol
agus
cu
nicu
lus L
.A
orta
from
the
rabb
itIV
AA
stat
emen
t 201
3
Apis
mel
li�ca
Apis
mell
ifera
L.
Who
le w
orke
r bee
HA
B / P
h. F
r. / P
h.
Eur.
Apis
mel
li�ca
(07.
04.1
988)
Apis
regi
naAp
is m
ellife
ra L
.W
hole
que
en ce
ll
with
larv
ae a
nd
nour
ishin
g sa
p
Apis
regi
na/A
urum
com
p.
(02.
03.1
991)
Apisi
num
Apis
mell
ifera
L.
Drie
d po
ison
from
the
hone
y be
eH
AB
/ Ph.
Fr.
Zinn
ober
com
p.
(02.
09.1
987)
Appe
ndix
ve
rmifo
rmis
Ory
ctol
agus
cuni
culu
s L.
Verm
iform
pro
cess
of t
he b
lind
gut f
rom
th
e ra
bbit
Der
Mer
kurs
tab:
So
nder
he�
1999
Ara
nea
avic
ular
isAv
icula
ria
avicu
laria
L.
Who
le b
ird sp
ider
IVA
A st
atem
ent 2
013
Ara
nea
diad
ema
Aran
eus d
iade
mat
us
CLER
CKW
hole
dia
dem
spid
erVa
dem
ecum
: Ara
nea
Art
eria
bas
ilaris
*Bo
s tau
rus L
.A
rter
ia b
asila
ris fr
om th
e ca
lf IV
AA
stat
emen
t 201
3A
rter
ia b
rach
ialis
Bos t
auru
s L.
Art
eria
bra
chia
lis fr
om th
e ca
lf IV
AA
stat
emen
t 201
3A
rter
ia c
arot
is co
mm
u-ni
s et s
inus
car
otic
usBo
s tau
rus L
.Pa
rts f
rom
the
Art
eria
car
otis
com
mun
is de
xtra
and
sini
stra
from
the
calf
Vade
mec
um: A
rter
ia
caro
tis co
mm
unis
et si
nus
caro
ticus
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Ap
pend
ix 2
.3
129
Scie
nti�
c nam
e Sc
ient
i�c n
ame o
f the
anim
alAb
brev
iate
d de
�niti
onRe
fere
nce t
o St
anda
rdEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Art
eria
cere
bri m
edia
*Bo
s tau
rus L
. A
rter
ia c
arot
is ce
rebr
alis
and
its ra
mi�
ca-
tions
from
the
calf
Vade
mec
um:
Art
eria
cere
bri m
edia
Art
eria
coel
iaca
se
e Tr
uncu
s coe
liacu
sIV
AA
stat
emen
t 201
3A
rter
ia co
rona
riaBo
s tau
rus L
. A
rter
ia co
rona
ria fr
om th
e ca
lf Va
dem
ecum
: A
rter
ia co
rona
ria
Art
eria
fem
oral
isBo
s tau
rus L
. A
rter
ia fe
mor
alis
from
the
calf
Vade
mec
um [m
entio
ned
unde
r: Se
cale
/Ble
igla
nz
com
p.]
Art
eria
oph
thal
mic
a*Bo
s tau
rus L
. A
rter
ia o
phth
alm
ica
exte
rna
from
the
calf
Vade
mec
um:
Art
eria
oph
thal
mic
aA
rter
ia p
oplit
eaBo
s tau
rus L
.A
rter
ia p
oplit
ea fr
om th
e ca
lfBl
eigl
anz/
Seca
le co
mp.
(1
2.09
.199
2)A
rter
ia p
ulm
onal
isBo
s tau
rus L
. A
rter
ia p
ulm
onal
is fr
om th
e ca
lf IV
AA
stat
emen
t 201
3A
rter
ia re
nalis
Bos t
auru
s L.
Art
eria
rena
lis fr
om th
e ca
lf IV
AA
stat
emen
t 201
3A
rter
iae*
Bos t
auru
s L.
Part
s of A
rter
ia b
asila
ris, A
rter
ia b
rach
ia-
lis, A
rter
ia co
rona
ria, A
rter
ia fe
mor
alis,
A
rter
ia m
esen
teric
a, A
rter
ia p
ulm
onal
is an
d A
rter
ia re
nalis
from
the
calf
Vade
mec
um: A
rter
iae
Art
icul
atio
Bos t
auru
s L.
�e
follo
win
g ar
ticul
atio
ns: c
ubits
, gen
us,
hum
eri,
radi
ocar
pa, s
acro
iliac
a, su
btal
aris,
ta
locr
ural
is, te
mpo
rom
andi
bula
ris
List
e H
AS
(10.
2012
) A
BMA-
Vade
mec
um:
Art
icul
atio
-Arg
entu
m
Sirim
im P
. 49
Art
icul
atio
coxa
eBo
s tau
rus L
.H
ip jo
int w
ith e
qual
par
ts fr
om th
e ac
etab
-ul
um, C
aput
fem
oris,
join
t car
tilag
e an
d Li
gam
entu
m c
apiti
s fem
oris
from
the
calf
Art
icul
atio
coxa
e (2
5.10
.199
4)
Art
icul
atio
cub
itiBo
s tau
rus L
. El
bow
join
t with
par
ts fr
om th
e bo
nes t
hat
form
the
join
t, jo
int c
artil
age,
part
s of j
oint
ca
psul
e, sy
novi
a an
d pa
rts o
f the
liga
men
ts
from
the
calf
IVA
A st
atem
ent 2
013
Art
icul
atio
gen
usBo
s tau
rus L
. K
nee
join
t with
par
ts fr
om th
e bo
nes t
hat
form
the
join
t, m
enisc
us, j
oint
cap
sule
, lig
amen
ts, c
artil
age
and
syno
via
from
the
calf
Art
icul
atio
gen
us
(25.
10.1
994)
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Appendix 2.3
130
Scie
nti�
c nam
e Sc
ient
i�c n
ame o
f the
anim
alAb
brev
iate
d de
�niti
onRe
fere
nce t
o St
anda
rdEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Art
icul
atio
hum
eri
Bos t
auru
s L.
Shou
lder
join
t with
par
ts o
f the
bon
es th
at
form
the
join
t, ca
rtila
ge, p
arts
of t
he jo
int
caps
ule
and
the
Burs
a in
tert
uber
cula
ris
from
the
calf
Vade
mec
um
[men
tione
d un
der:
Aco
nit
Schm
erzö
l]
Art
icul
atio
in
terp
hala
ngea
Bos t
auru
s L.
Part
s of t
he to
e jo
int f
rom
the
fore
ex
trem
ities
from
the
calf
Car
tilag
o/Ec
hina
cea
com
p.
(25.
10.1
994)
Art
icul
atio
ra
dioc
arpe
aBo
s tau
rus L
.Ra
dioc
arpa
l joi
nt w
ith p
arts
of t
he b
ones
, ca
rtila
ge, l
igam
ents
and
join
t cap
sule
that
fo
rm th
e pr
oxim
al c
arpa
l joi
nt fr
om th
e ca
lf
IVA
A st
atem
ent 2
013
Art
icul
atio
sa
croi
liaca
Bos t
auru
s L.
Part
s of I
lium
and
sacr
um fr
om th
e jo
int
area
, joi
nt c
apsu
le a
nd li
gam
ents
from
the
calf
Der
Mer
kurs
tab:
So
nder
he�
1999
Art
icul
atio
subt
alar
isBo
s tau
rus L
. Pa
rts o
f the
car
tilag
e, jo
int c
apsu
le a
nd
syno
via
of th
e pa
rt d
istal
to th
e O
s cen
tro-
quar
tale
of t
he jo
int l
ike
unio
n be
twee
n Ta
lus a
nd C
alca
neus
from
the
calf
Art
icul
atio
talo
crur
alis
com
p. (1
2.09
.199
2)
Art
icul
atio
ta
locr
ural
isBo
s tau
rus L
.Pa
rts o
f the
bon
es fo
rmin
g th
e jo
int,
Tibi
a an
d Ta
lus,
of th
e jo
int c
apsu
le, l
igam
ents
as
wel
l as s
ynov
ia o
f the
ank
le jo
int f
rom
th
e ca
lf
Art
icul
atio
talo
crur
alis
com
p. (1
2.09
.199
2)
Art
icul
atio
te
mpo
rom
andi
bula
risBo
s tau
rus L
.Pa
rts o
f the
Os m
andi
bula
re a
nd o
f the
O
s tem
pora
le in
the
join
t are
a, o
f the
join
t ca
psul
e, of
the
ligam
ents
, of c
artil
age,
as
wel
l as s
ynov
ia fr
om th
e ca
lf
IVA
A st
atem
ent 2
013
Art
icul
atio
nes
inte
rcar
peae
Bos t
auru
s L.
Part
s of t
he b
ones
form
ing
the
join
t, of
the
cart
ilage
like
surf
ace
of th
e ar
ticul
atio
n, a
s w
ell a
s syn
ovia
from
the
calf
IVA
A st
atem
ent 2
013
Art
icul
atio
nes i
nter
ver-
tebr
ales
cerv
ical
esBo
s tau
rus L
.Re
gion
of t
he ce
rvix
: Par
ts o
f the
bon
e pr
o-ce
ssus
that
par
ticip
ate
to th
e in
terv
erte
bral
jo
ints
, car
tilag
e an
d jo
int c
apsu
les,
as w
ell
as sy
novi
a fr
om th
e ca
lf
IVA
A st
atem
ent 2
013
Art
icul
atio
nes i
nter
ver-
tebr
ales
lum
bale
sBo
s tau
rus L
.Re
gion
of t
he lo
in: P
arts
of t
he b
one
pro-
cess
us th
at p
artic
ipat
e to
the
inte
rver
tebr
al
join
ts, c
artil
age
and
join
t cap
sule
s, as
wel
l as
syno
via
from
the
calf
IVA
A st
atem
ent 2
013
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Ap
pend
ix 2
.3
131
Scie
nti�
c nam
e Sc
ient
i�c n
ame o
f the
anim
alAb
brev
iate
d de
�niti
onRe
fere
nce t
o St
anda
rdEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Asc
idia
Seve
ral s
peci
es o
f pro
to-
Cho
rdat
es o
f Asc
idia
gro
up�
e w
hole
hea
ring
orga
nA
BMA-
Vade
mec
um
Art
eria
e-Ba
rium
Siri
mim
P.
48
Ast
eria
s rub
ens
Aste
rias r
uben
s L.
�e
who
le st
ar�s
h IV
AA
stat
emen
t 201
3At
las*
Bos t
auru
s L.
Part
s of t
he A
tlas (
1. ce
rvic
al) f
rom
the
calf
IVA
A st
atem
ent 2
013
Audi
tum
Bos t
auru
s L.
�e
who
le h
earin
g or
gan
ABM
A-Va
dem
ecum
Au
ditu
m-A
rgen
tum
Si
rimim
P. 5
1Au
ditu
m in
tern
umBo
s tau
rus L
.In
tern
al h
earin
g or
gan
ABM
A-Va
dem
ecum
La
byrin
thus
-Mer
curiu
s Si
rimim
P. 1
61A
xis*
Bos t
auru
s L.
Part
s of t
he A
xis (
2. ce
rvic
al) f
rom
the
calf
IVA
A st
atem
ent 2
013
Badi
aga
Seve
ral s
peci
es o
f fre
sh w
a-te
r spo
nges
and
Eph
ydat
ia
�uvi
atili
s L.
�e
who
le fr
esh
anim
alA
BMA-
Vade
mec
um
Lary
nx-M
anga
num
Sir-
imim
P. 1
63Bl
atta
orie
ntal
isBl
atta
orie
ntal
is L.
�e
who
le fr
esh
or d
ried
anim
al
IVA
A st
atem
ent 2
013
Both
rops
Both
rops
lanc
eola
tus
BON
ATER
REPo
ison
from
Bot
hrop
s lan
ceol
atus
Der
Mer
kurs
tab
1993
; 46
(3):
288-
297
Both
rops
jara
cara
see
Lach
esis
lanc
eola
tus
Bron
chi
Bos t
auru
s L.
Bron
chi f
rom
the
calf
Bron
chi/P
lant
ago
com
p.
(12.
09.1
992)
Bron
chi
Ory
ctol
agus
cuni
culu
s L.
Bron
chi f
rom
the
rabb
itBr
onch
i/Pla
ntag
o co
mp.
(1
2.09
.199
2)Bu
fo ra
naBu
fo b
ufo
L.
Skin
of t
he b
ack
from
the
toad
Der
Mer
kurs
tab
2000
; 53
(4):
259-
260
Bulb
us o
lfact
oriu
s*Bo
s tau
rus L
.Bu
lbus
olfa
ctor
ius o
f bot
h he
misp
here
s of
the
cere
brum
from
the
calf
Vade
mec
um: B
ulbu
s ol
fact
oriu
s Bu
rsae
art
icul
atio
nis
hum
eri-K
ompl
exBo
s tau
rus L
.Pa
rts o
f Bur
sa m
uscu
li in
fras
pina
m a
nd
Burs
a in
tert
uber
cula
ris h
umer
i fro
m th
e ca
lf
Vade
mec
um: B
ursa
e ar
ticul
atio
nis h
umer
i-Ko
mpl
exC
alca
rea
carb
onic
a os
trea
rum
see
Con
chae
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Appendix 2.3
132
Scie
nti�
c nam
e Sc
ient
i�c n
ame o
f the
anim
alAb
brev
iate
d de
�niti
onRe
fere
nce t
o St
anda
rdEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Cal
cium
car
boni
cum
H
ahne
man
nise
e C
onch
ae
Can
thar
isLy
tta v
esica
toria
L.
As f
ar a
s pos
sible
inta
ct sp
ecim
ens,
kille
d an
d dr
ied
at a
tem
pera
ture
not
exc
eedi
ng
40°C
HA
B C
anth
aris
(04.
06.1
986)
Vade
mec
um: C
anth
aris
Car
dia
Sus s
crof
a
dom
estic
a L.
Car
dia,
par
ts o
f the
wal
l of t
he st
omac
h in
th
e re
gion
of t
he e
ntra
nce
into
the
stom
ach
from
the
pig
Vade
mec
um: C
ardi
a
Car
tilag
o ar
ticul
aris
Bos t
auru
s L.
Car
tilag
e of
the
hip,
kne
e an
d sh
ould
er
join
ts fr
om th
e ca
lfC
artil
ago
com
p.
(12.
09.1
992)
Car
tilag
o ar
ticul
aris
coxa
eBo
s tau
rus L
.C
artil
age
of th
e hi
p jo
int f
rom
the
calf
IVA
A st
atem
ent 2
013
Car
tilag
o ar
ticul
aris
genu
sBo
s tau
rus L
.C
artil
age
of th
e kn
ee jo
int f
rom
the
calf
Der
Mer
kurs
tab:
So
nder
he�
1999
Cav
um ty
mpa
ni*
Bos t
auru
s L.
Part
s of t
he w
all o
f the
Cav
um ty
mpa
ni,
as w
ell a
s aud
itory
bon
es fr
om th
e ca
lfVa
dem
ecum
: C
avum
tym
pani
C
era
�ava
Apis
mell
ifera
L.
Bees
wax
obt
aine
d by
mel
ting
the
empt
y ho
neyc
ombs
, was
hing
and
elim
inat
ion
of
fore
ign
mat
ter
Ph. E
ur.
Plan
tago
com
p.
(12.
09.1
992)
Cer
ebel
lum
*Bo
s tau
rus L
.C
ereb
ellu
m fr
om th
e ca
lf C
ereb
ellu
m co
mp.
(0
2.03
.199
1)C
ereb
ellu
mO
ryct
olag
us cu
nicu
lus L
.C
ereb
ellu
m fr
om th
e ra
bbit
Cer
ebel
lum
com
p.
(02.
03.1
991)
Cer
ebru
mBo
s tau
rus L
.C
ereb
rum
from
the
calf
Arn
ica-
Cer
ebru
m
(12.
09.1
992)
Cer
ebru
m, r
egio
mo-
toric
a*Bo
s tau
rus L
.G
rey
mat
ter o
f the
Gyr
us p
raec
entr
alis
belo
ngin
g to
the
Lobu
s fro
ntal
is of
bot
h he
misp
here
s fro
m th
e ca
lf
Vade
mec
um:
Cer
ebru
m,
regi
o m
otor
ica
Cer
vix
uter
iBo
s tau
rus L
.Pa
rts o
f the
nec
k of
ute
rus f
rom
the
cow
IV
AA
stat
emen
t 201
3C
ircul
us a
rter
iosu
s ce
rebr
i*Bo
s tau
rus L
.C
ircul
us a
rter
iosu
s cer
ebri
of th
e pi
tuita
ry
sha�
from
the
calf
IVA
A st
atem
ent 2
013
Coc
cus c
acti
Dac
tylo
pius
co
ccus
CO
STA
�e
drie
d, fe
rtili
zed,
fem
ale
of D
acty
lopi
us
cocc
us C
osta
H
AB
/ Ph.
Fr.
IVA
A st
atem
ent 2
013
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Ap
pend
ix 2
.3
133
Scie
nti�
c nam
e Sc
ient
i�c n
ame o
f the
anim
alAb
brev
iate
d de
�niti
onRe
fere
nce t
o St
anda
rdEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Coc
hlea
*Bo
s tau
rus L
.Pa
rts o
f the
coch
lea
from
the
skel
etou
s as
wel
l as d
erm
al p
arts
of t
he in
ner e
ar fr
om
the
calf
Vade
mec
um: C
ochl
ea
Cod
live
r oil
(typ
e B)
see
jeco
ris a
selli
ole
um
Col
onSu
s scr
ofa
dom
estic
a L.
Col
on fr
om th
e pi
g C
olon
(25.
10.1
994)
Col
on si
gmoi
deum
Sus s
crof
a do
mes
tica
L.C
olon
sigm
oide
um, p
arts
of t
he �
nal t
ract
of
the
Col
on d
esce
nden
s fro
m th
e pi
g Va
dem
ecum
[men
tione
d un
der:
Er
ysid
oron
® 1;
Mer
curiu
s vi
vus n
atur
alis]
Col
umna
Bos t
auru
s L.
Spin
al co
rd o
btai
ned
from
foet
us o
f Bos
ta
urus
L.
ABM
A-Va
dem
ecum
: C
olum
na-A
rgen
tum
Si
rimim
P. 9
7C
olum
na a
nter
ior*
Bos t
auru
s L.
Part
s of t
he co
lum
na a
nter
ior o
f the
spin
al
chor
d fr
om th
e ca
lf IV
AA
stat
emen
t 201
3
Col
umna
pos
terio
r*Bo
s tau
rus L
.Pa
rts o
f the
colu
mna
pos
terio
r of d
i�er
ent
part
s of t
he sp
inal
chor
d fr
om th
e ca
lf IV
AA
stat
emen
t 201
3
Con
chae
Ostr
ea ed
ulis
L.
�e
inne
r par
ts o
f the
shel
ls of
the
oyst
er
HA
B / P
h. F
r. C
onch
ae (0
4.06
.198
6)Va
dem
ecum
: Con
chae
C
onju
nctiv
aBo
s tau
rus L
.C
onju
nctiv
a fr
om th
e ca
lf C
onju
nctiv
a co
mp.
(2
5.10
.199
4)C
onne
ctiv
e tis
sue
see
Text
us
conn
ectiv
usC
orBo
s tau
rus L
.C
or (h
eart
) fro
m th
e ca
lf C
or (2
5.10
.199
4)C
orBo
s tau
rus L
.Pa
rts o
f the
epi
card
ium
, myo
card
ium
, en
doca
rdiu
m a
nd th
e ar
teria
l mus
cula
ture
of
the
hear
t fro
m th
e ca
lf
Cor
(25.
10.1
994)
Cor
alliu
mSe
vera
l spe
cies
of r
ed C
oral
Secr
etio
n ob
tain
ed b
y tr
itura
tion
of fr
esh
anim
alA
BMA-
Vade
mec
um:
Cor
alliu
m ru
brum
P. 1
04C
oral
lium
rubr
umCo
ralli
um
rubr
um L
.Fr
agm
ente
d pa
rts o
f the
chal
k sk
elet
on
from
Cor
alliu
m ru
brum
, con
tain
ing
at
leas
t 82
per c
ent C
aCO
3 (M
r 100
,1)
HA
B K
aliu
m a
cetic
um co
mp.
(0
3.07
.199
2)
Cor
nea
Bos t
auru
s L.
Cor
nea
from
the
calf
Cor
nea/
Levi
stic
um co
mp.
(0
2.03
.199
1)C
ornu
Cap
rae
ibec
isCa
pra
ibex
L.
Hor
n fr
om th
e ib
ex
IVA
A st
atem
ent 2
013
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Appendix 2.3
134
Scie
nti�
c nam
e Sc
ient
i�c n
ame o
f the
anim
alAb
brev
iate
d de
�niti
onRe
fere
nce t
o St
anda
rdEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Cor
nu C
ervi
Cerv
us el
aphu
s L.
Ant
lers
from
the
deer
Li
ste
HA
S (1
0.20
12)
Cor
pora
qua
drig
emin
a*Bo
s tau
rus L
.Pa
rts o
f the
Lam
ina
tect
i with
the
Cor
pora
qu
adrig
emin
a fr
om th
e ca
lf A
rnic
a/Ep
iphy
sis/P
lum
-bu
m m
ellit
um co
mp.
(0
3.07
.199
2)C
orpu
s am
ygda
loi-
deum
*Bo
s tau
rus L
.Br
ain
mat
ter o
f the
regi
on o
f the
Cor
pus
amyg
dalo
ideu
m fr
om th
e ca
lfVa
dem
ecum
: C
orpu
s am
ygda
loid
eum
C
orpu
s lut
eum
Bos t
auru
s L.
Cor
pus l
uteu
m fr
om th
e ca
lf M
eliss
a/Ph
osph
orus
com
p.
(03.
07.1
992)
Cor
pus l
uteu
mSu
s scr
ofa
dom
estic
a L.
Cor
pus l
uteu
m fr
om th
e so
wM
eliss
a/Ph
osph
orus
com
p.
(03.
07.1
992)
Cor
pus s
tria
tum
*Bo
s tau
rus L
.C
orpu
s str
iatu
m fr
om th
e ca
lf Va
dem
ecum
[men
tione
d un
der:
Regi
o su
bsta
ntia
e ni
grae
]C
orpu
s vitr
eum
*Bo
s tau
rus L
.C
orpu
s vitr
eum
from
the
calf
Cor
pus v
itreu
m/H
orne
rz
com
p. (0
2.03
.199
1)C
orpu
s vitr
eum
Ory
ctol
agus
cuni
culu
s L.
Cor
pus v
itreu
m fr
om th
e ra
bbit
Cor
pus v
itreu
m/H
orne
rz
com
p. (0
2.03
.199
1)C
rota
lus h
orrid
usCr
otal
us h
orrid
us L
.Fr
eeze
drie
d po
ison
from
Cro
talu
s ho
rrid
us L
. H
AB
Der
Mer
kurs
tab
1993
; 46
(3):
288-
297
Cro
talu
s ter
ri�cu
sCr
otal
us d
uriss
us te
rri�
cus
LAU
REN
TI
Free
ze d
ried
poiso
n fr
om C
rota
lus d
uriss
us
terr
i�cu
s Lau
rent
i D
er M
erku
rsta
b 19
93;
46(3
): 28
8-29
7Cu
tis (f
eti)
Bos t
auru
s L.
�e
exte
rnal
skin
of a
3 to
9 m
onth
s old
bo
vine
foet
us
Cal
endu
la/T
ropa
eolu
m
com
p. (0
2.03
.199
1)Cu
tis (f
eti f
emin
i)Bo
s tau
rus L
.�
e ex
tern
al sk
in o
f a c
a. 5
mon
ths o
ld
fem
ale
bovi
ne fo
etus
Pr
unus
/Ros
mar
inus
com
p.
(02.
03.1
991)
Dac
tylo
pius
cocc
usse
e Co
ccus
cact
i D
ens
Bos t
auru
s L.
Teet
h fr
om th
e ca
lf IV
AA
stat
emen
t 201
3D
iaph
ragm
aBo
s tau
rus L
.M
uscu
lar a
nd te
ndin
ous p
arts
of t
he
diap
hrag
m fr
om th
e ca
lf Va
dem
ecum
[men
tione
d un
der:
Regi
o su
bsta
ntia
e ni
grae
]D
iaph
ragm
a pe
lvis
Bos t
auru
s L.
Part
s of t
he m
uscl
e an
d fa
scie
s clo
sing
the
pelv
is, in
clud
ing
conn
ectiv
e tis
sue
from
th
e ca
lf
Vade
mec
um: D
iaph
ragm
a pe
lvis
Die
ncep
halo
n*Bo
s tau
rus L
.D
ienc
epha
lon
from
the
calf
IVA
A st
atem
ent 2
013
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Ap
pend
ix 2
.3
135
Scie
nti�
c nam
e Sc
ient
i�c n
ame o
f the
anim
alAb
brev
iate
d de
�niti
onRe
fere
nce t
o St
anda
rdEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Disc
i int
erve
rteb
rale
s (c
ervi
cale
s)Bo
s tau
rus L
.Fi
broc
artil
age
of in
terv
erte
bral
disc
s of
cerv
ical
spin
e fr
om th
e ca
lf Va
dem
ecum
[men
tione
d un
der:
Disc
i int
erve
rte-
bral
es (f
eti)]
Disc
i int
erve
rteb
rale
s (c
ervi
cale
s, th
orac
ici e
t lu
mba
les)
Bos t
auru
s L.
Part
s of i
nter
vert
ebra
l disc
s of c
ervi
cal,
thor
acic
and
lum
bar s
pine
from
the
calf
Disc
i com
p. c
um
Arg
ento
(05.
12.1
989)
Disc
i int
erve
rteb
rale
s (fe
ti)Bo
s tau
rus L
.In
terv
erte
bral
disc
s of d
i�er
ent r
egio
ns o
f th
e sp
ine
from
a 3
to 9
mon
ths o
ld b
ovin
e fo
etus
Vade
mec
um:
Disc
i int
erve
rteb
rale
s (fe
ti)D
isci i
nter
vert
ebra
les
(lum
bale
s)Bo
s tau
rus L
.In
terv
erte
bral
disc
s of l
umba
r spi
ne fr
om
the
calf
Vade
mec
um [m
entio
ned
unde
r: D
isci i
nter
vert
e-br
ales
(fet
i)]D
uctu
s cho
ledo
chus
Sus s
crof
a
dom
estic
a L.
Duc
tus c
hole
doch
us fr
om th
e pi
g D
er M
erku
rsta
b:
Sond
erhe
� 19
99D
uctu
s def
eren
sBo
s tau
rus L
.D
uctu
s def
eren
s fro
m th
e ca
lf IV
AA
stat
emen
t 201
3D
uctu
s tho
raci
cus
Bos t
auru
s L.
Duc
tus t
hora
cicu
s fro
m th
e ca
lf Bo
rago
/Ren
es co
mp.
(1
2.09
.199
2)D
uode
num
Sus s
crof
a
dom
estic
a L.
Part
s of d
uode
num
from
the
pig
Vade
mec
um [m
entio
ned
unde
r: Pl
exus
gas
tric
us]
Dur
a m
ater
en
ceph
ali*
Bos t
auru
s L.
Dur
a m
ater
enc
epha
li fr
om th
e ca
lf IV
AA
stat
emen
t 201
3
Elap
sM
icrur
us co
ralli
nus
MER
REM
Poiso
n fr
om M
icru
rus c
oral
linus
Mer
rem
IVA
A st
atem
ent 2
013
Endo
card
ium
Bos t
auru
s L.
Endo
card
ium
from
the
calf
IVA
A st
atem
ent 2
013
Endo
met
rium
Bos t
auru
s L.
Endo
met
rium
from
the
cow
En
dom
etriu
m co
mp.
(2
5.10
.199
4)En
dom
etriu
mSu
s scr
ofa
do
mes
tica
L.En
dom
etriu
m fr
om th
e pi
gEn
dom
etriu
m co
mp.
(2
5.10
.199
4)Ep
idid
ymis
Bos t
auru
s L.
Le�
epid
idym
is fr
om th
e bu
ll IV
AA
stat
emen
t 201
3Ep
iphy
sis*
Bos t
auru
s L.
Part
s of t
he e
piph
ysis
from
the
calf
Epip
hysis
(12.
09.1
992)
Ep
iphy
sisO
ryct
olag
us cu
nicu
lus L
.Pa
rts o
f the
epi
phys
is fr
om th
e ra
bbit
Epip
hysis
(12.
09.1
992)
Er
ytro
cyte
sEq
uus p
rzew
alsk
ii f.
caba
llus
POLI
AKO
VEr
ythr
ocyt
es fr
om th
e bl
ood
of th
e ho
rse
IVA
A st
atem
ent 2
013
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Appendix 2.3
136
Scie
nti�
c nam
e Sc
ient
i�c n
ame o
f the
anim
alAb
brev
iate
d de
�niti
onRe
fere
nce t
o St
anda
rdEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Fasc
icul
us at
riove
n-tr
icul
aris
Bos t
auru
s L.
Part
s of t
he co
nduc
tion
syst
em o
f the
he
art,
His´
s bun
dle
and
Purk
inje
´s �
ber
from
the
calf
Vade
mec
um:
Fasc
icul
us at
riove
ntric
u-la
ris
Fasc
icul
us o
ptic
us*
Bos t
auru
s L.
Fasc
icul
us o
ptic
us fr
om th
e ca
lf Li
ste
HA
S (1
0.20
12)
Favu
sAp
is m
ellife
ra L
.ho
neyc
ombs
with
pol
len
IVA
A st
atem
ent 2
013
Fel p
iscis
Salm
o tr
utta
L.
Bile
from
pre
dato
ry �
sh, e
.g. t
rout
Der
Mer
kurs
tab
2004
; 57
(3):
224
Fel t
auri
Bos t
auru
s L.
Fres
h bi
le fr
om g
all b
ladd
er fr
om th
e ca
lf G
land
ulae
supr
aren
ales
co
mp.
(12.
09.1
992)
Fel
Ory
ctol
agus
cuni
culu
s L.
Bile
from
gal
l bla
dder
from
the
rabb
itG
land
ulae
su
prar
enal
es co
mp.
(1
2.09
.199
2)Fe
mur
Bos t
auru
s L.
Part
s of t
he d
iaph
ysis
of O
s fem
oris
from
th
e ca
lf Va
dem
ecum
: Fem
ur
Folli
culi
lym
phat
ici a
g-gr
egat
iSu
s scr
ofa
do
mes
tica
L.Pa
rts o
f Pey
ers’s
pat
ch o
f the
smal
l int
estin
e fr
om th
e pi
g IV
AA
stat
emen
t 201
3
Form
ica
Form
ica ru
fa L
., Fo
rmica
po
lyct
ena
FÖRS
TER
L.Li
ve w
orke
r ant
sH
AB
/ Ph.
Fr.
Form
ica
(07.
04.1
988)
Vade
mec
um: F
orm
ica
Form
ica
parv
aLa
sius n
iger
Live
wor
ker a
nts
List
e H
AS
(10.
2012
)Fu
nicu
lus u
mbi
lical
isBo
s tau
rus L
.Fu
nicu
lus u
mbi
lical
is fr
om a
bov
ine
foet
us
betw
een
the
third
and
nin
th m
onth
of
preg
nanc
y
Cal
endu
la/
Trop
aeol
um co
mp.
(0
2.03
.199
1)G
alea
apon
euro
tica
Bos t
auru
s L.
Part
s of t
he su
per�
cial
fasc
ia o
f the
fo
rehe
ad fr
om th
e ca
lf IV
AA
stat
emen
t 201
3
Gin
giva
Bos t
auru
s L.
Gin
giva
from
the
calf
Perio
dont
ium
/Sili
cea
com
p.
(12.
09.1
992)
Gla
ndul
a la
crim
alis
Bos t
auru
s L.
Lacr
imal
gla
nd fr
om th
e ca
lf Va
dem
ecum
: Gla
ndul
a la
crim
alis
Gla
ndul
a pa
rotis
Bos t
auru
s L.
Gla
ndul
ar ti
ssue
of t
he b
ody
of th
e pa
rotid
gl
and
from
the
calf
IVA
A st
atem
ent 2
013
Gla
ndul
a
supr
aren
alis
Bos t
auru
s L.
Supr
aren
al g
land
from
the
calf
Gla
ndul
a su
prar
enal
is (2
5.10
.199
4)G
land
ula
su
prar
enal
is (C
orte
x)
Bos t
auru
s L.
Supr
aren
al g
land
(Cor
tex)
from
the
calf
IVA
A st
atem
ent 2
013
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Ap
pend
ix 2
.3
137
Scie
nti�
c nam
e Sc
ient
i�c n
ame o
f the
anim
alAb
brev
iate
d de
�niti
onRe
fere
nce t
o St
anda
rdEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Gla
ndul
a su
prar
enal
is (M
edul
la)
Bos t
auru
s L.
Mar
row
of t
he su
prar
enal
gla
nd o
f bot
h ad
rena
l gla
nds f
rom
the
calf
IVA
A st
atem
ent 2
013
Gla
ndul
a su
prar
enal
is de
xtra
Bos t
auru
s L.
Righ
t sup
rare
nal g
land
from
the
calf
Cupr
um/G
land
ula
supr
are-
nalis
dex
tra
(02.
03.1
991)
Gla
ndul
a su
prar
enal
is sin
istra
Bos t
auru
s L.
Le�
supr
aren
al g
land
from
the
calf
Cupr
um/G
land
ula
supr
are-
nalis
sini
stra
(02.
03.1
991)
Gla
ndul
a �
ymus
see
�ym
us (G
land
ula)
G
land
ula
thyr
eoid
eaBo
s tau
rus L
.�
yroi
d gl
and
from
the
calf
Gla
ndul
a th
yreo
idea
(0
7.04
.198
8)G
land
ula
thyr
eoid
eaO
ryct
olag
us cu
nicu
lus L
.�
yroi
d gl
and
from
the
rabb
itG
land
ula
thyr
eoid
ea
(07.
04.1
988)
Gla
ndul
ae
para
thyr
eoid
eae
Bos t
auru
s L.
Para
thyr
oid
glan
d fr
om th
e ca
lf Pa
rath
yreo
idea
com
p.
(02.
03.1
991)
Gla
ndul
ae
para
thyr
eoid
eae
Sus s
crof
a do
mes
tica
L.Pa
rath
yroi
d gl
and
from
the
pig
Para
thyr
eoid
ea co
mp.
(0
2.03
.199
1)G
land
ulae
su
prar
enal
esse
e G
land
ula
supr
aren
alis
Glu
coge
num
Ory
ctol
agus
cuni
culu
s L.
Gly
coge
n fr
om th
e ra
bbit
liver
IV
AA
stat
emen
t 201
3G
yrus
cing
uli*
Bos t
auru
s L.
Gyr
us ci
ngul
i fro
m th
e ca
lf IV
AA
stat
emen
t 201
3H
epar
Bos t
auru
s L.
Pars
inte
rmed
ia o
f the
live
r fro
m th
e ca
lf H
epar
(25.
10.1
994)
Hep
arO
ryct
olag
us cu
nicu
lus L
.Li
ver f
rom
the
rabb
it IV
AA
stat
emen
t 201
3H
ippo
cam
pus*
Bos t
auru
s L.
Hip
poca
mpu
s fro
m th
e ca
lf Va
dem
ecum
: Hip
poca
m-
pus
Hiru
do e
x an
imal
eH
irudo
m
edici
nalis
L.
Leec
h im
med
iate
ly a
�er s
acri�
ce
Vesp
a cr
abro
com
p.
(02.
03.1
991)
Hyp
ophy
sis*
Bos t
auru
s L.
Hyp
ophy
sis fr
om th
e ca
lf H
ypop
hysis
(12.
09.1
992)
H
ypop
hysis
Ory
ctol
agus
cuni
culu
s L.
Hyp
ophy
sis fr
om th
e ra
bbit
Hyp
ophy
sis (1
2.09
.199
2)H
ypot
hala
mus
*Bo
s tau
rus L
.H
ypot
hala
mus
from
the
calf
Vade
mec
um:
Hyp
otha
lam
us
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Appendix 2.3
138
Scie
nti�
c nam
e Sc
ient
i�c n
ame o
f the
anim
alAb
brev
iate
d de
�niti
onRe
fere
nce t
o St
anda
rdEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Ieco
ris a
selli
ole
umG
adid
ae
Cod
live
r oil:
(typ
e A
or B
) Pur
i�ed
fatty
oi
l obt
aine
d fr
om th
e fr
esh
liver
s of G
adus
m
orhu
a L.
and
oth
er sp
ecie
s of G
adid
ae,
solid
subs
tanc
es b
eing
rem
oved
by
cool
ing
and
�lte
ring
Ph. E
ur.
Berb
eris/
Che
lidon
ium
co
mp.
(02.
03.1
991)
Ileum
Sus s
crof
a
dom
estic
a L.
Ileum
from
the
pig
Vade
mec
um
[men
tione
d un
der:
Nux
vo
mic
a/N
icot
iana
com
p.]
Iris
Bos t
auru
s L.
Iris
from
the
calf
Iris
bovi
s com
p.
(02.
03.1
991)
Jeco
ris o
leum
see
Ieco
ris a
selli
ole
umJe
junu
mSu
s scr
ofa
do
mes
tica
L.Je
junu
m fr
om th
e pi
g IV
AA
stat
emen
t 201
3
Kera
tinum
Equ
iEq
uus p
rzew
alsk
ii f.
caba
llus
POLI
AKO
VH
oof f
rom
the
hors
e IV
AA
stat
emen
t 201
3
Laby
rinth
us*
Bos t
auru
s L.
Coc
hlea
and
laby
rinth
from
the
calf
Arn
ica/
Epip
hysis
/Plu
m-
bum
mel
litum
com
p.
(03.
07.1
992)
Lac c
anin
umCa
nis l
upus
fam
iliar
is L.
Fr
esh
milk
from
the
fem
ale
dog
ABM
A-Va
dem
ecum
M
amm
a-A
rgen
tum
Sir-
imim
P. 1
69La
ches
isLa
ches
is m
elano
ceph
ala
SOLÒ
RZA
NO
& C
ERD
AS,
La
ches
is ste
noph
rys C
ope
or
Lach
esis
mut
a L.
Car
eful
ly d
ried
poiso
n fr
om L
ache
sis
mel
anoc
epha
la S
olòr
zano
& C
erda
s,
Lach
esis
sten
ophr
ys C
ope
or L
ache
sis
mut
a L.
HA
B La
ches
is (0
2.03
.199
1)Va
dem
ecum
: Lac
hesis
Lach
esis
lanc
eola
tus
Both
rops
jara
raca
WIE
D.
Poiso
n fr
om B
othr
ops j
arar
aca
Wie
d.
Der
Mer
kurs
tab
1993
; 46
(3):
288-
297
Lac v
acca
eBo
s tau
rus L
.Fr
esh
cow
’s m
ilk
IVA
A st
atem
ent 2
013
Lam
ina
qu
adrig
emin
a*Bo
s tau
rus L
.La
min
a qu
adrig
emin
a fr
om th
e ca
lfLa
min
a/Re
tina
com
p.
(25.
10.1
994)
Lath
rode
ctus
Lath
rode
ctus
mac
tans
Koc
hLi
ving
spid
er o
f Lat
hrod
ectu
s mac
tans
Ko
chA
BMA-
Vade
mec
um
Cor
-Ars
enic
um a
lbum
Si
rimim
P. 1
05La
pis c
ancr
iA
stacu
s asta
cus L
. �
e ga
stro
lithe
s fro
m th
e bo
dy c
avity
from
A
stac
us a
stac
us L
. or o
ther
cray
�sh
List
e H
AS
(10.
2012
)
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Ap
pend
ix 2
.3
139
Scie
nti�
c nam
e Sc
ient
i�c n
ame o
f the
anim
alAb
brev
iate
d de
�niti
onRe
fere
nce t
o St
anda
rdEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Lary
nxBo
s tau
rus L
.Pa
rts o
f the
lary
nx fr
om th
e ca
lfAp
is/La
rynx
com
p.
(25.
10.1
994)
Lens
crist
allin
aBo
s tau
rus L
.Le
ns cr
istal
lina
from
the
calf
Lens
crist
allin
a/V
is-cu
m co
mp.
cum
Sta
nno
(02.
03.1
991)
Lien
Bos t
auru
s L.
Sple
en fr
om th
e ca
lf Li
en co
mp.
(25.
10.1
994)
Liga
men
tum
long
itudi
-na
le a
nter
ius
Bos t
auru
s L.
Part
s of t
he L
igam
entu
m lo
ngitu
dina
le
ante
rius o
f tho
raci
c and
lum
bar r
egio
ns o
f th
e sp
ine
from
the
calf
IVA
A st
atem
ent 2
013
Liga
men
tum
long
itudi
-na
le p
oste
rius*
Bos t
auru
s L.
Liga
men
tum
long
itudi
nale
dor
sale
from
th
e ca
lf Va
dem
ecum
: Lig
a-m
entu
m lo
ngitu
dina
le
post
eriu
s Li
gam
entu
m v
ocal
eBo
s tau
rus L
.Pa
rts o
f the
voc
al ch
ords
incl
uded
the
mu-
cous
mem
bran
e of
the
lary
nx fr
om th
e ca
lf Va
dem
ecum
[m
entio
ned
unde
r: La
r-yn
x co
mp.
]Li
ngua
Bos t
auru
s L.
Part
s of t
he to
ngue
mus
cles
, muc
ous
mem
bran
e an
d pa
pilla
e fr
om th
e ca
lfIV
AA
stat
emen
t 201
3
Liqu
or
cere
bros
pina
lisBo
s tau
rus L
.C
ereb
rosp
inal
�ui
d fr
om th
e ca
lf IV
AA
stat
emen
t 201
3
Lobu
s fro
ntal
is*Bo
s tau
rus L
.Fr
onta
l lob
e of
cere
brum
from
the
calf
Glö
ckle
r, M
.: “A
nthr
opos
-op
hisc
he A
rzne
ither
apie”
(A
nthr
opos
ophi
c �er
apy
with
Med
icin
al P
rodu
cts)
, Pu
blish
er W
issen
scha
�li-
che
Verla
gsge
sells
cha�
, St
uttg
art 2
010
Lobu
s occ
ipita
lis*
Bos t
auru
s L.
Occ
ipita
l lob
e of
cere
brum
from
the
calf
Glö
ckle
r, M
.: “A
nthr
opos
-op
hisc
he A
rzne
ither
apie”
(A
nthr
opos
ophi
c �er
apy
with
Med
icin
al P
rodu
cts)
, Pu
blish
er W
issen
scha
�li-
che
Verla
gsge
sells
cha�
, St
uttg
art 2
010
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Appendix 2.3
140
Scie
nti�
c nam
e Sc
ient
i�c n
ame o
f the
anim
alAb
brev
iate
d de
�niti
onRe
fere
nce t
o St
anda
rdEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Lobu
s par
ieta
lis*
Bos t
auru
s L.
Parie
tal l
obe
of th
e ce
rebr
um fr
om th
e ca
lf G
löck
ler,
M.:
“Ant
hrop
os-
ophi
sche
Arz
neith
erap
ie”
(Ant
hrop
osop
hic �
erap
y w
ith M
edic
inal
Pro
duct
s),
Publ
isher
Wiss
ensc
ha�l
i-ch
e Ve
rlags
gese
llsch
a�,
Stut
tgar
t 201
0Lo
bus t
empo
ralis
*Bo
s tau
rus L
.Te
mpo
ral l
obe
from
the
calf
Glö
ckle
r, M
.: “A
nthr
opos
-op
hisc
he A
rzne
ither
apie”
(A
nthr
opos
ophi
c �er
apy
with
Med
icin
al P
rodu
cts)
, Pu
blish
er W
issen
scha
�li-
che
Verla
gsge
sells
cha�
, St
uttg
art 2
010
Mam
ma
Bos t
auru
s L.
Gla
ndul
ar ti
ssue
from
bov
ine
udde
r M
agne
sit/M
amm
a co
mp.
(1
2.09
.199
2)M
amm
a (d
extr
a)Bo
s tau
rus L
.G
land
ular
tiss
ue fr
om ri
ght p
art o
f bov
ine
udde
r Va
dem
ecum
: Mam
ma
Mam
ma
(sin
istra
)Bo
s tau
rus L
.G
land
ular
tiss
ue fr
om le
� pa
rt o
f bov
ine
udde
r Va
dem
ecum
: Mam
ma
Man
dibu
la (f
eti)
Bos t
auru
s L.
Man
dibl
e fr
om a
bov
ine
foet
us b
etw
een
3
and
9 m
onth
s Pe
riodo
ntiu
m/S
ilice
a co
mp.
(1
2.09
.199
2)M
arm
ot fa
tse
e M
arm
otta
e ol
eum
Mar
mot
tae
oleu
mM
arm
ota
spec
ies
Fat f
rom
bro
wn
adip
ose
tissu
e fr
om d
i�er
-en
t spe
cies
of m
arm
ota,
e.g.
Mar
mot
a m
ar-
mot
a L.
, Mar
mot
a bo
bak
sibiri
ca R
adde
, M
arm
ota
cam
tsch
atic
a Pa
llas
Sal M
aris
com
p.
(04.
06.1
986)
Max
illa
(feti)
Bos t
auru
s L.
Max
illa
from
a b
ovin
e fo
etus
bet
wee
n 3
and
9 m
onth
s Pe
riodo
ntiu
m/S
ilice
a co
mp.
(1
2.09
.199
2)M
edul
la o
blon
gata
*Bo
s tau
rus L
.M
edul
la o
blon
gata
from
the
calf
Arn
ica/
Epip
hysis
/Plu
m-
bum
mel
litum
com
p.
(03.
07.1
992)
Med
ulla
obl
onga
taO
ryct
olag
us cu
nicu
lus L
.M
edul
la o
blon
gata
from
the
rabb
itA
rnic
a/Ep
iphy
sis/P
lum
-bu
m m
ellit
um co
mp.
(0
3.07
.199
2)
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Ap
pend
ix 2
.3
141
Scie
nti�
c nam
e Sc
ient
i�c n
ame o
f the
anim
alAb
brev
iate
d de
�niti
onRe
fere
nce t
o St
anda
rdEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Med
ulla
oss
ium
(rub
ra)
Bos t
auru
s L.
Red
bone
mar
row
from
the
epip
hysis
of
tubu
lar b
ones
from
the
calf
Med
ulla
oss
ium
(2
5.10
.199
4)M
edul
la o
ssiu
m (r
ubra
)O
ryct
olag
us cu
nicu
lus L
.Re
d bo
ne m
arro
w fr
om th
e ep
iphy
sis o
f tu
bula
r bon
es fr
om th
e ra
bbit
Med
ulla
oss
ium
(2
5.10
.199
4)M
edul
la sp
inal
is to
ta*
Bos t
auru
s L.
Med
ulla
spin
alis
of d
i�er
ent s
ectio
ns fr
om
the
calf
Vade
mec
um: M
edul
la
spin
alis
tota
M
elAp
is m
ellife
ra L
.H
oney
Ph
. Eur
.A
escu
lus/
Cer
a co
mp.
(0
2.03
.199
1)M
embr
ana
sinus
fron
-ta
lisBo
s tau
rus L
.M
ucos
a of
Sin
us fr
onta
lis fr
om th
e ca
lf Li
ste
HA
S (1
0.20
12)
Mem
bran
a sin
us m
axil-
laris
Bos t
auru
s L.
Muc
osa
of S
inus
max
illar
is fr
om th
e ca
lf G
löck
ler,
M.:
“Ant
hrop
os-
ophi
sche
Arz
neith
erap
ie”
(Ant
hrop
osop
hic �
erap
y w
ith M
edic
inal
Pro
duct
s),
Publ
isher
Wiss
ensc
ha�l
i-ch
e Ve
rlags
gese
llsch
a�,
Stut
tgar
tM
embr
ana
sinus
par
a-na
salis
Bos t
auru
s L.
Muc
osa
of si
nus p
aran
asal
es fr
om th
e ca
lf H
epar
sulfu
ris co
mp.
(0
5.12
.198
9)M
embr
ana
syno
vial
isBo
s tau
rus L
.In
ner l
ayer
of t
he jo
int c
apsu
le o
f di�
eren
t jo
ints
from
the
calf
Vade
mec
um [m
entio
ned
unde
r: Sa
lix/R
hus c
omp.
]M
enisc
us a
rtic
ular
isBo
s tau
rus L
.M
enisc
us a
rtic
ular
is of
the
knee
from
cal
fM
enisc
us G
enus
/Sta
nnum
(2
5.10
.199
4)
Der
Mer
kurs
tab:
Son
der-
he�
1999
Men
iscus
gen
usBo
s tau
rus L
.M
enisc
us o
f the
kne
e fr
om th
e ca
lfM
andr
agor
a co
mp.
(0
7.04
.198
8)M
ephi
tis p
utor
ius
Mep
hitis
m
ephi
tis S
CH
REB.
Li
quid
secr
etio
n of
ana
l gla
nds f
rom
Me-
phiti
s mep
hitis
Sch
reb.
IV
AA
stat
emen
t 201
3
Mes
ence
phal
on*
Bos t
auru
s L.
Mes
ence
phal
on fr
om th
e ca
lf Va
dem
ecum
[men
tione
d un
der:
Regi
o su
bsta
ntia
e ni
grae
]
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Appendix 2.3
142
Scie
nti�
c nam
e Sc
ient
i�c n
ame o
f the
anim
alAb
brev
iate
d de
�niti
onRe
fere
nce t
o St
anda
rdEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Mes
ench
ymBo
s tau
rus L
.Em
bryo
nal c
onne
ctiv
e tis
sue
and
tissu
e pa
rts o
f the
adu
lt an
imal
. Foe
tal t
issue
s de
velo
ped
from
mes
ench
yma
with
a h
igh
mes
ench
ymal
func
tion:
ute
rus o
f the
adu
lt an
imal
; foe
tal s
lack
conn
ectiv
e tis
sue
(e.g
. fr
om a
xilla
), th
ymus
, hea
rt ti
ssue
(with
out
valv
es),
red
bone
mar
row
with
retic
ular
co
nnec
tive
tissu
e an
d sp
ongi
ous b
ones
, nu
cleu
s pul
posu
s int
erve
rteb
ralis
, mes
en-
teriu
m
Mes
ench
ym (2
5.10
.199
4)
Mes
ench
ymSu
s scr
ofa
dom
estic
a L.
List
e H
AS
(10.
2012
)M
osch
usM
osch
us
mos
chife
rus L
. Se
cret
ion
of b
ursa
from
mal
e M
osch
us
mos
chife
rus L
. Ph
. Fr.
IVA
A st
atem
ent 2
013
Muc
osa
bucc
alis
Bos t
auru
s L.
Bucc
al m
ucos
a fr
om th
e ca
lfA
BMA-
Vade
mec
um
Cyd
onia
-Sili
cea
Sirim
im
P. 1
17M
uscu
liBo
s tau
rus L
.Bo
vine
glu
teal
mus
cles
and
bic
eps m
uscl
e of
the
arm
(age
1,5
-4 y
ears
)A
BMA-
Vade
mec
um:
Mus
culi-
Auru
m S
irim
im
P. 1
78M
uscu
li gl
utae
iBo
s tau
rus L
.G
lute
al m
uscl
es fr
om th
e ca
lf IV
AA
stat
emen
t 201
3M
uscu
lus d
elto
ideu
s-Ko
mpl
exBo
s tau
rus L
.Pa
rts o
f the
Mus
culu
s del
toid
eus-
com
plex
, M
uscu
lus s
upra
spin
am, M
uscu
lus i
nfra
sp
inam
, Mus
culu
s del
toid
eus,
Mus
culu
s bi
ceps
bra
chii
and
Mus
culu
s tric
eps b
ra-
chii
from
the
calf
Der
Mer
kurs
tab:
Son
der-
he�
1999
Mus
culu
s rec
tus a
b-do
min
isBo
s tau
rus L
.M
uscu
lus r
ectu
s abd
omin
is fr
om th
e ca
lf Va
dem
ecum
: Mus
culu
s re
ctus
abd
omin
isM
uscu
lus s
oleu
s-Ko
m-
plex
Bos t
auru
s L.
Part
s of t
he M
uscu
lus s
oleu
s-Ko
mpl
ex,
Mus
culu
s sol
eus,
Mus
culu
s �bu
laris
(p
eron
aeus
) lon
gus,
Mus
culu
s gas
troc
ne-
miu
s fro
m th
e ca
lf
IVA
A st
atem
ent 2
013
Myg
ale
avic
ular
isse
e Ar
anea
avi
cula
ris
IVA
A st
atem
ent 2
013
Myg
ale
Seve
ral s
peci
es o
f the
Myg
ale
sp, �
erap
hros
a sp
, La
siodo
ra sp
Livi
ng sp
ider
ABM
A-Va
dem
ecum
H
epar
-Plu
mbu
m S
irim
im
P. 1
48
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Ap
pend
ix 2
.3
143
Scie
nti�
c nam
e Sc
ient
i�c n
ame o
f the
anim
alAb
brev
iate
d de
�niti
onRe
fere
nce t
o St
anda
rdEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Myo
card
ium
Bos t
auru
s L.
Myo
card
ium
from
the
calf
Prim
ula
com
p. (0
2.03
.199
1)N
aja
trip
udia
nsN
aja
naja
L.
Car
eful
ly d
ried
poiso
n fr
om N
aja
naja
L.
HA
B IV
AA
stat
emen
t 201
3N
ervi
inte
rcos
tale
sBo
s tau
rus L
.In
terc
osta
l Ner
ves f
rom
the
calf
Der
Mer
kurs
tab:
Son
der-
he�
1999
Ner
vus a
bduc
ens*
Bos t
auru
s L.
Ner
vus a
bduc
ens f
rom
the
calf
IVA
A st
atem
ent 2
013
Ner
vus a
cces
soriu
sBo
s tau
rus L
.N
ervu
s acc
esso
rius f
rom
the
calf
IVA
A st
atem
ent 2
013
Ner
vus f
acia
lis*
Bos t
auru
s L.
Ner
vus f
acia
lis fr
om th
e ca
lf D
er M
erku
rsta
b: S
onde
r-he
� 19
99N
ervu
s fem
oral
isBo
s tau
rus L
.N
ervu
s fem
oral
is fr
om th
e ca
lf IV
AA
stat
emen
t 201
3N
ervu
s glo
ssop
hary
n-ge
usBo
s tau
rus L
.N
ervu
s glo
ssop
hary
ngeu
s fro
m th
e ca
lf G
löck
ler,
M.:
“Ant
hrop
os-
ophi
sche
Arz
neith
erap
ie”
(Ant
hrop
osop
hic �
erap
y w
ith M
edic
inal
Pro
duct
s),
Publ
isher
Wiss
ensc
ha�l
i-ch
e Ve
rlags
gese
llsch
a�,
Stut
tgar
t N
ervu
s hyp
oglo
ssus
Bos t
auru
s L.
Ner
vus h
ypog
loss
us fr
om th
e ca
lf IV
AA
stat
emen
t 201
3N
ervu
s isc
hiad
icus
Bos t
auru
s L.
Ner
vus i
schi
adic
us fr
om th
e ca
lf N
ervu
s isc
hiad
icus
(2
5.10
.199
4)N
ervu
s isc
hiad
icus
Ory
ctol
agus
cuni
culu
s L.
Ner
vus i
schi
adic
us fr
om th
e ra
bbit
Ner
vus i
schi
adic
us
(25.
10.1
994)
Ner
vus l
aryn
geus
recu
r-re
nsBo
s tau
rus L
.N
ervu
s lar
ynge
us re
curr
ens f
rom
the
calf
Apis/
Lary
nx co
mp.
(2
5.10
.199
4)N
ervu
s lar
ynge
us
supe
rior
Bos t
auru
s L.
Ner
vus l
aryn
geus
supe
rior f
rom
the
calf
Apis/
Lary
nx co
mp.
(2
5.10
.199
4)N
ervu
s med
ianu
sBo
s tau
rus L
.N
ervu
s med
ianu
s fro
m th
e ca
lf D
er M
erku
rsta
b: S
onde
r-he
� 19
99N
ervu
s ocu
lom
otor
ius*
Bos t
auru
s L.
Ner
vus o
culo
mot
oriu
s fro
m th
e ca
lf N
ervu
s opt
icus
com
p.
(03.
07.1
992)
Ner
vus o
phta
lmic
usBo
s tau
rus L
.N
ervu
s oph
talm
icus
from
the
calf
Iris
bovi
s com
p.
(02.
03.1
991)
Ner
vus o
ptic
us*
Bos t
auru
s L.
Ner
vus o
ptic
us fr
om th
e ca
lf N
ervu
s opt
icus
com
p.
(03.
07.1
992)
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Appendix 2.3
144
Scie
nti�
c nam
e Sc
ient
i�c n
ame o
f the
anim
alAb
brev
iate
d de
�niti
onRe
fere
nce t
o St
anda
rdEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Ner
vus o
ptic
usO
ryct
olag
us cu
nicu
lus L
.N
ervu
s opt
icus
from
the
rabb
itN
ervu
s opt
icus
com
p.
(03.
07.1
992)
Ner
vus p
eron
aeus
Bos t
auru
s L.
Ner
vus p
eron
aeus
(�bu
laris
) fro
m th
e ca
lf D
er M
erku
rsta
b: S
onde
r-he
� 19
99N
ervu
s phr
enic
usBo
s tau
rus L
.N
ervu
s phr
enic
us fr
om th
e ca
lf Va
dem
ecum
: Ner
vus
phre
nicu
s N
ervu
s pud
endu
sBo
s tau
rus L
.N
ervu
s pud
endu
s fro
m th
e ca
lf IV
AA
stat
emen
t 201
3N
ervu
s rad
ialis
Bos t
auru
s L.
Ner
vus r
adia
lis fr
om th
e ca
lf IV
AA
stat
emen
t 201
3N
ervu
s sta
toac
ustic
us*
Bos t
auru
s L.
Ner
vus s
tato
acus
ticus
from
the
calf
Arn
ica/
Epip
hysis
/Plu
m-
bum
mel
litum
com
p.
(03.
07.1
992)
Ner
vus s
tato
acus
ticus
Ory
ctol
agus
cuni
culu
s L.
Ner
vus s
tato
acus
ticus
from
the
rabb
itA
rnic
a/Ep
iphy
sis/P
lum
-bu
m m
ellit
um co
mp.
(0
3.07
.199
2)N
ervu
s tib
ialis
Bos t
auru
s L.
Ner
vus t
ibia
lis fr
om th
e ca
lf IV
AA
stat
emen
t 201
3N
ervu
s trig
emin
us*
Bos t
auru
s L.
Ner
vus t
rigem
inus
from
the
calf
Ner
vus t
rigem
inus
(2
5.10
.199
4)N
ervu
s trig
emin
usO
ryct
olag
us cu
nicu
lus L
.N
ervu
s trig
emin
us fr
om th
e ra
bbit
Ner
vus t
rigem
inus
(2
5.10
.199
4)N
ervu
s tro
chle
aris*
Bos t
auru
s L.
Ner
vus t
roch
lear
is fr
om th
e ca
lf D
er M
erku
rsta
b 20
05;
58(4
): 31
0-31
5N
ervu
s uln
aris
Bos t
auru
s L.
Ner
vus u
lnar
is fr
om th
e ca
lf IV
AA
stat
emen
t 201
3N
ervu
s vag
usBo
s tau
rus L
.N
ervu
s vag
us fr
om th
e ca
lf Ap
is/La
rynx
com
p.
(25.
10.1
994)
Ner
vus v
agus
Ory
ctol
agus
cuni
culu
s L.
Ner
vus v
agus
from
the
rabb
itAp
is/La
rynx
com
p.
(25.
10.1
994)
Nod
i lym
phat
ici
Bos t
auru
s L.
Part
s of l
ymph
nod
e tis
sue
from
di�
eren
t pa
rts o
f the
bod
y fr
om th
e ca
lfD
er M
erku
rsta
b: S
onde
r-he
� 19
99N
ucle
us ru
ber*
Bos t
auru
s L.
Brai
n su
bsta
nce
from
the
Nuc
leus
rube
r fr
om th
e ca
lf D
er M
erku
rsta
b 20
05;
58(4
): 31
0-31
5O
esop
hagu
sSu
s scr
ofa
dom
estic
a L.
Oes
opha
gus f
rom
the
pig
IVA
A st
atem
ent 2
013
Oss
aSu
s scr
ofa
dom
estic
a L.
Bone
s fro
m th
e pi
g Li
ste
HA
S (1
0.20
12)
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Ap
pend
ix 2
.3
145
Scie
nti�
c nam
e Sc
ient
i�c n
ame o
f the
anim
alAb
brev
iate
d de
�niti
onRe
fere
nce t
o St
anda
rdEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Oss
aAv
es v
aria
e, e.g
. Pha
sianu
s co
lchicu
s L.
Cle
aned
and
mill
ed b
ones
from
bird
s, e.g
. Ph
asia
nus c
olch
icus
L.
List
e H
AS
(10.
2012
)
Oss
a lo
nga
Bos t
auru
s L.
Oss
a lo
nga
from
the
calf
IVA
A st
atem
ent 2
013
Oss
icul
a au
ditu
s*Bo
s tau
rus L
.Au
dito
ry b
ones
from
the
calf
IVA
A st
atem
ent 2
013
Ova
riase
e O
variu
mO
variu
mBo
s tau
rus L
.O
vary
from
the
cow
O
variu
m (2
8. S
erie
) (D
AZ
Nr.
29 v
om 2
1.07
.199
4)Pa
ncre
asBo
s tau
rus L
.Pa
ncre
as fr
om th
e ca
lf Pa
nkre
as (0
3.07
.199
2)Pa
ncre
asO
ryct
olag
us cu
nicu
lus L
.Pa
ncre
as fr
om th
e ra
bbit
Pank
reas
(03.
07.1
992)
Panc
reas
Sus s
crof
a do
mes
tica
L.Pa
ncre
as fr
om th
e pi
g Pa
nkre
as (0
3.07
.199
2)Pa
pilla
e du
oden
iSu
s scr
ofa
dom
estic
a L.
Papi
lla d
uode
ni re
gion
of t
he sm
all
inte
stin
e fr
om th
e pi
g IV
AA
stat
emen
t 201
3
Para
met
rium
Bos t
auru
s L.
Tiss
ue fr
om th
e br
oad
ligam
ent o
f the
ut
erus
from
the
cow
Ec
hina
cea/
Para
met
rium
co
mp.
(25.
10.1
994)
Para
met
rium
de
xtru
mBo
s tau
rus L
.Ti
ssue
from
the
right
bro
ad li
gam
ent o
f th
e ut
erus
from
the
cow
Der
Mer
kurs
tab:
Son
der-
he�
1999
Pars
feta
lis (p
lace
nta)
Bos t
auru
s L.
Alla
ntoc
horio
n fr
om th
e bo
vine
foet
us
Prun
us/R
osm
arin
us co
mp.
(0
2.03
.199
1)Pa
rs p
allid
a*Bo
s tau
rus L
.Pa
rts o
f th
e ba
se o
f the
bra
in fr
om th
e ca
lfIV
AA
stat
emen
t 201
3Pa
tella
Bos t
auru
s L.
Pate
lla fr
om th
e ca
lf IV
AA
stat
emen
t 201
3Pe
lvis
rena
lis (e
t Ure
ter)
Bos t
auru
s L.
Part
s of t
he P
elvi
s ren
alis
and
Ure
ter f
rom
th
e ca
lf IV
AA
stat
emen
t 201
3
Peni
sBo
s tau
rus L
.Pe
nis f
rom
the
bull
IVA
A st
atem
ent 2
013
Peric
ardi
umBo
s tau
rus L
.Pe
ricar
dium
from
the
calf
Glö
ckle
r, M
.: “A
nthr
opos
-op
hisc
he A
rzne
ither
apie”
(A
nthr
opos
ophi
c �er
apy
with
Med
icin
al P
rodu
cts)
, Pu
blish
er W
issen
scha
�li-
che
Verla
gsge
sells
cha�
, St
uttg
art 2
010
Perio
dont
ium
Bos t
auru
s L.
Part
s of t
he a
lveo
lar a
nd d
enta
ls re
gion
s fr
om th
e ca
lf Pe
riodo
ntiu
m/S
ilice
a co
mp.
(1
2.09
.199
2)
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Appendix 2.3
146
Scie
nti�
c nam
e Sc
ient
i�c n
ame o
f the
anim
alAb
brev
iate
d de
�niti
onRe
fere
nce t
o St
anda
rdEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Perio
steu
mBo
s tau
rus L
.Pe
riost
eum
from
the
calf
Alli
um ce
pa/T
endo
com
p.
(12.
09.1
992)
Perio
steu
mO
ryct
olag
us cu
nicu
lus L
.Pe
riost
eum
from
the
rabb
itA
llium
cepa
/Ten
do co
mp.
(1
2.09
.199
2)Pe
riton
aeum
Bos t
auru
s L.
Perit
onae
um fr
om th
e ca
lf Br
yoni
a/V
iscum
com
p.
(25.
10.1
994)
Perit
onae
umO
ryct
olag
us cu
nicu
lus L
.Pe
riton
aeum
from
the
rabb
itBr
yoni
a/V
iscum
com
p.
(25.
10.1
994)
Phar
ynx
Bos t
auru
s L.
Part
s fro
m th
e Ph
aryn
x di
gest
oriu
m a
nd
Phar
ynx
resp
irato
rius f
rom
the
calf
Vade
mec
um: P
hary
nx
Phys
eter
cat
odon
see
Ambr
a gr
isea
Phys
eter
m
acro
ceph
alus
see
Ambr
a gr
isea
Pia
mat
er e
ncep
hali*
Bos t
auru
s L.
Pia
mat
er e
ncep
hali
from
the
calf
IVA
A st
atem
ent 2
013
Plac
enta
Bos t
auru
s L.
Plac
ento
mas
from
the
preg
nant
cow
Pl
acen
ta/T
ropa
eolu
m
(02.
03.1
991)
Glö
ckle
r, M
.: “A
nthr
opos
-op
hisc
he A
rzne
ither
apie”
(A
nthr
opos
ophi
c �er
apy
with
Med
icin
al P
rodu
cts)
, Pu
blish
er W
issen
scha
�li-
che
Verla
gsge
sells
cha�
, St
uttg
art
Pleu
raBo
s tau
rus L
.Pl
eura
par
ieta
lis fr
om th
e ca
lf D
er M
erku
rsta
b: S
onde
r-he
� 19
99Pl
exus
bra
chia
lisBo
s tau
rus L
.Pl
exus
bra
chia
lis fr
om th
e ca
lf Va
dem
ecum
[men
tione
d un
der:
Disc
i/Rhu
s tox
ico-
dend
ron
com
p.]
Plex
us c
ardi
acus
Bos t
auru
s L.
Plex
us c
ardi
acus
from
the
calf
Vade
mec
um: P
lexu
s ca
rdia
cus
Plex
us co
elia
cus
Bos t
auru
s L.
Plex
us co
elia
cus f
rom
the
calf
Vade
mec
um: P
lexu
s co
elia
cus
Plex
us g
astr
icus
Bos t
auru
s L.
Plex
us g
astr
icus
from
the
calf
Vade
mec
um: P
lexu
s ga
stric
us
Plex
us h
aem
orrh
oida
lisBo
s tau
rus L
.Ve
nous
net
wor
k in
the
regi
on o
f the
re
ctum
from
the
calf
Vade
mec
um: P
lexu
s ha
emor
rhoi
dalis
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Ap
pend
ix 2
.3
147
Scie
nti�
c nam
e Sc
ient
i�c n
ame o
f the
anim
alAb
brev
iate
d de
�niti
onRe
fere
nce t
o St
anda
rdEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Plex
us lu
mba
lisBo
s tau
rus L
.Pl
exus
lum
balis
from
the
calf
IVA
A st
atem
ent 2
013
Plex
us p
elvi
nus
Bos t
auru
s L.
Plex
us p
elvi
nus f
rom
the
calf
Der
Mer
kurs
tab:
Son
der-
he�
1999
Plex
us p
ulm
onal
is (N
er-
vus v
agus
)Bo
s tau
rus L
.Pl
exus
pul
mon
alis
from
the
calf
Vade
mec
um: P
lexu
s pul
-m
onal
is (N
ervu
s vag
us)
Plex
us re
ctal
isse
e Pl
exus
hae
mor
rhoi
dalis
IV
AA
stat
emen
t 201
3Pl
exus
sacr
alis
Bos t
auru
s L.
Plex
us sa
cral
is fr
om th
e ca
lf D
er M
erku
rsta
b: S
onde
r-he
� 19
99Po
ns*
Bos t
auru
s L.
Pons
from
the
calf
Der
Mer
kurs
tab:
Son
der-
he�
1999
Port
io v
agin
alis
Bos t
auru
s L.
Port
io v
agin
alis
from
the
cow
IV
AA
stat
emen
t 201
3Pr
opol
isAp
is m
ellife
ra L
.Pr
opol
is Ph
. Fr.
Der
Mer
kurs
tab
2011
; 64
(4):
338
Pros
tata
Bos t
auru
s L.
Pros
tata
from
the
bull
Berb
eris/
Pros
tata
com
p.
(12.
09.1
992)
Pude
ndum
fe
min
ium
Bos t
auru
s L.
Labi
a vu
lvae
, Klit
oris
and
Gla
ndul
a
vest
ibul
aris
maj
or fr
om th
e co
w
Prun
us/R
osm
arin
us co
mp.
(0
2.03
.199
1)Pu
lmo
Bos t
auru
s L.
Lung
tiss
ue fr
om th
e ca
lf Fe
rrum
/Pul
mo
(12.
09.1
992)
Pulm
oO
ryct
olag
us cu
nicu
lus L
.Lu
ng fr
om th
e ra
bbit
Ferr
um/P
ulm
o (1
2.09
.199
2)Pu
lpa
dent
isBo
s tau
rus L
.Pu
lpa
dent
is fr
om th
e ca
lf Va
dem
ecum
: Pul
pa d
entis
Py
loru
sSu
s scr
ofa
dom
estic
a L.
Pylo
rus f
rom
the
pig
Der
Mer
kurs
tab:
Son
der-
he�
1999
Rect
umSu
s scr
ofa
dom
estic
a L.
Rect
um fr
om th
e pi
g D
er M
erku
rsta
b: S
onde
r-he
� 19
99Re
gio
subs
tant
iae
nigr
ae*
Bos t
auru
s L.
Tiss
ue fr
om th
e Su
bsta
ntia
nig
ra fr
om th
e ca
lf Va
dem
ecum
: Reg
io su
b-st
antia
e ni
grae
Rene
sBo
s tau
rus L
.K
idne
y fr
om th
e ca
lfRe
n (D
AZ
Nr.
29,
21.0
7.19
94)
Rene
sO
ryct
olag
us cu
nicu
lus L
.K
idne
y fr
om th
e ra
bbit
Ren
(DA
Z N
r. 29
, 21
.07.
1994
)
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Appendix 2.3
148
Scie
nti�
c nam
e Sc
ient
i�c n
ame o
f the
anim
alAb
brev
iate
d de
�niti
onRe
fere
nce t
o St
anda
rdEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Rene
s, re
gio
pyel
ore-
nalis
Bos t
auru
s L.
Part
s of t
issue
from
the
Pelv
is re
nalis
and
M
edul
la re
nalis
from
the
calf
IVA
A st
atem
ent 2
013
Retic
uloe
ndot
helia
l Sy
stem
Bos t
auru
s L.
Part
s fro
m th
e th
ymus
gla
nd, l
ymh
node
s, bo
ne m
arro
w, li
ver a
nd sp
leen
from
the
calf
Vade
mec
um [m
entio
ned
unde
r: Le
vico
com
p.]
Retin
a
(et C
horio
idea
)*Bo
s tau
rus L
.Pa
rts o
f the
Ret
ina
and
the
Cho
rioid
ea
from
the
calf
Retin
a (2
8. S
erie
) (D
AZ
Nr.
29 v
om 2
1.07
.199
4)Sc
lera
*Bo
s tau
rus L
.Sc
lera
from
the
calf
IVA
A st
atem
ent 2
013
Scol
open
dra
Seve
ral s
pecie
s of S
colo
pen-
dra
fam
ilyLi
ving
cent
iped
e of
Sco
lope
ndrid
eae
fa
mily
ABM
A-Va
dem
ecum
Si
nus f
acia
lis-M
ercu
rius
Sirim
im P
. 238
Sepi
a o�
cina
lis e
vol
u-m
ine
burs
ae re
c.Se
pia
o�cin
alis
L.
Fres
h se
cret
ion
from
ink
glan
d fr
om S
epia
o�
cina
lis L
.Be
rber
is/Se
pia
com
p.
(25.
10.1
994)
Sepi
a gr
uner
isSe
pia
o�cin
alis
L.
Drie
d se
cret
ion
from
ink
glan
d fr
om S
epia
o�
cina
lis L
. H
AB
Der
Mer
kurs
tab
1997
; 52
(1):
51Se
pia
o�ci
nalis
Sepi
a o�
cinal
is L.
D
ried
ink
bag
from
Sep
ia o
�ci
nalis
L.
Ph. F
r. D
er M
erku
rsta
b 19
97;
52(1
): 51
Sinu
s cav
erno
sus-
Kom
-pl
ex*
Bos t
auru
s L.
Part
s of t
he si
nus c
aver
nosu
s-Ko
mpl
ex;
Sinu
s cav
erno
sus,
Ner
vus o
ptic
us, N
ervu
s oc
ulom
otor
ius,
Ner
vus t
roch
lear
is, N
ervu
s tr
igem
inus
and
Ner
vus a
bduc
ens f
rom
the
calf
IVA
A st
atem
ent 2
013
Spon
gia
tost
aEu
spon
gia
o�
cinal
is L.
To
aste
d Eu
spon
gia
o�ci
nalis
L.
HA
B / P
h. F
r. Sp
ongi
a (0
2.03
.199
1)Va
dem
ecum
: Spo
ngia
Sym
path
icus
see
Trun
cus
sym
path
icus
Tara
ntul
a hi
span
ica
Lyco
sa h
ispan
icaW
alck
enae
r�
e w
hole
spid
er L
ycos
a ta
rant
ula
L.,
A
lloco
sa fa
sciiv
entr
is D
uf.,
or H
ogna
hi
span
ica
Wal
cken
aer
IVA
A st
atem
ent 2
013
Tend
oBo
s tau
rus L
.Te
ndo
from
the
calf
Alli
um ce
pa/T
endo
com
p.
(12.
09.1
992)
Test
a ov
iG
allu
s gal
lus d
omes
ticus
L.
Shel
l of h
en’s
eggs
Au
rum
/Pul
satil
la/
Spon
gia
com
p. (0
3.07
.199
2)
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Ap
pend
ix 2
.3
149
Scie
nti�
c nam
e Sc
ient
i�c n
ame o
f the
anim
alAb
brev
iate
d de
�niti
onRe
fere
nce t
o St
anda
rdEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Test
esBo
s tau
rus L
.Te
stes
from
the
bull
Test
es co
mp.
(2
8. S
erie
) (D
AZ
Nr.
29
vom
21.
07.1
994)
Test
esO
ryct
olag
us cu
nicu
lus L
.Te
stes
from
the
(mal
e) ra
bbit
Test
es co
mp.
(2
8. S
erie
) (D
AZ
Nr.
29
vom
21.
07.1
994)
Text
us co
nnec
tivus
Bos t
auru
s L.
Subc
utan
eous
and
inte
rmus
cula
r con
nec-
tive
tissu
e, fa
scia
, lig
amen
ts, t
endo
ns, a
s w
ell a
s mes
ente
rium
from
the
calf
Bora
go/R
enes
com
p.
(12.
09.1
992)
�al
amus
*Bo
s tau
rus L
.�
alam
us fr
om th
e ca
lf A
rnic
a/H
ypop
hysis
/Pl
umbu
m m
ellit
um co
mp.
(0
3.07
.199
2)�
alam
usO
ryct
olag
us cu
nicu
lus L
.�
alam
us fr
om th
e ra
bbit
Arn
ica/
Hyp
ophy
sis/
Plum
bum
mel
litum
com
p.
(03.
07.1
992)
�ro
mbo
cyte
sEq
uus
prze
wal
skii
f. ca
ballu
s PO
LIA
KOV
�ro
mbo
cyte
s fro
m th
e bl
ood
of th
e ho
rse
IVA
A st
atem
ent 2
013
�ym
us (G
land
ula)
Bos t
auru
s L.
�ym
us fr
om th
e ca
lf G
land
ula
�ym
us (2
5.
Serie
) (D
AZ
Nr.
29 v
om
21.0
7.19
94)
Tons
illa
phar
ynge
aBo
s tau
rus L
.To
nsill
a ph
aryn
gea
from
the
calf
IVA
A st
atem
ent 2
013
Tons
illae
pal
atin
aeBo
s tau
rus L
.To
nsill
a pa
latin
ae fr
om th
e ca
lf C
alen
dula
/Ech
inac
ea co
mp.
(0
2.03
.199
1)
Trab
ecul
um*
Bos t
auru
s L.
Trab
ecul
um fr
om th
e ca
lf Tr
abec
ulum
com
p.
(03.
07.1
992)
List
e H
AS
(10.
2012
)
Trac
hea
Bos t
auru
s L.
Trac
hea
from
the
calf
IVA
A st
atem
ent 2
013
Trac
tus d
iges
tivus
Bos t
auru
s L.
Equa
l par
ts o
f the
com
plet
e di
gest
ive
sy
stem
from
the
bovi
ne fo
etus
ABM
A-Va
dem
ecum
: Tr
actu
s dig
estiv
us-C
u-pr
um
Sirim
im P
. 257
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Appendix 2.3
150
Scie
nti�
c nam
e Sc
ient
i�c n
ame o
f the
anim
alAb
brev
iate
d de
�niti
onRe
fere
nce t
o St
anda
rdEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Trig
onum
ves
icae
et
Mus
culu
s sph
inct
erBo
s tau
rus L
.Ti
ssue
of t
he v
esic
a fr
om th
e re
gion
of t
he
Trig
onum
ves
icae
and
mus
cula
r tiss
ue
from
the
sphi
ncte
r of t
he v
esic
a fr
om th
e ca
lf
Der
Mer
kurs
tab:
Son
der-
he�
1999
Trun
cus c
ereb
ri*Bo
s tau
rus L
.Pa
rts f
rom
Hyp
otha
lam
us, �
alam
us,
Cor
pora
qua
drig
emin
a, P
ons,
Med
ulla
ob
long
ata
and
Cer
ebel
lum
from
the
calf
Hirn
stam
m/T
ritic
um (2
8.
Serie
) (D
AZ
Nr.
29 v
om
21.0
7.19
94)
Trun
cus c
oelia
cus
Bos t
auru
s L.
Art
eria
coel
iaca
(Tru
ncus
coel
iacu
s) fr
om
the
calf
IVA
A st
atem
ent 2
013
Trun
cus e
ncep
hali
Bos t
auru
s L.
Brai
n st
em fr
om th
e ca
lf IV
AA
stat
emen
t 201
3Tr
uncu
s enc
epha
liBo
s tau
rus L
.H
ypot
hala
mus
, �al
amus
, Cor
pora
qu
adrig
emin
a, P
ons,
Med
ulla
obl
onga
ta
from
the
calf
IVA
A st
atem
ent 2
013
Trun
cus s
ympa
thic
usBo
s tau
rus L
.Tr
uncu
s sym
path
icus
from
the
calf
Vade
mec
um: S
ympa
thi-
cus
Tuba
audi
tiva*
Bos t
auru
s L.
Tuba
audi
tiva
from
the
calf
Vade
mec
um [m
entio
ned
unde
r: C
avum
tym
pani
]Tu
ba u
terin
aBo
s tau
rus L
.Tu
ba u
terin
a fr
om th
e co
w
Echi
nace
a/
Para
met
rium
com
p.
(25.
10.1
994)
Tuba
ute
rina
Ory
ctol
agus
cuni
culu
s L.
Tuba
ute
rina
from
the
(fem
ale)
rabb
itEc
hina
cea/
Pa
ram
etriu
m co
mp.
(2
5.10
.199
4)Tu
nica
muc
osa
in
test
ini t
enui
sSu
s scr
ofa
do
mes
tica
L.M
ucos
a fr
om th
e di
�ere
nt re
gion
s of t
he
smal
l int
estin
e fr
om th
e pi
g IV
AA
stat
emen
t 201
3
Tuni
ca m
ucos
a na
siBo
s tau
rus L
.Tu
nica
muc
osa
nasi
from
the
calf
Bron
chi/P
lant
ago
com
p.
(12.
09.1
992)
Tu
nica
muc
osa
rect
iSu
s scr
ofa
do
mes
tica
L.Tu
nica
muc
osa
rect
i fro
m th
e pi
g IV
AA
stat
emen
t 201
3
Tuni
ca m
ucos
a ve
n-tr
icul
iSu
s scr
ofa
do
mes
tica
L.M
ucos
a fr
om th
e di
�ere
nt re
gion
s of t
he
stom
ach
from
the
pig
IVA
A st
atem
ent 2
013
Ure
ter
Bos t
auru
s L.
Ure
ter f
rom
the
calf
IVA
A st
atem
ent 2
013
Ure
thra
fem
inin
aBo
s tau
rus L
.U
reth
ra fr
om th
e fe
mal
e ca
lf D
er M
erku
rsta
b: S
onde
r-he
� 19
99
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Ap
pend
ix 2
.3
151
Scie
nti�
c nam
e Sc
ient
i�c n
ame o
f the
anim
alAb
brev
iate
d de
�niti
onRe
fere
nce t
o St
anda
rdEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Ure
thra
mas
culin
aBo
s tau
rus L
.U
reth
ra fr
om th
e m
ale
calf
Der
Mer
kurs
tab:
Son
der-
he�
1999
Ute
rus
Bos t
auru
s L.
Ute
rus f
rom
the
cow
Be
rber
is/U
teru
s com
p.
(12.
09.1
992)
Ute
rus
Ory
ctol
agus
cuni
culu
s L.
Ute
rus f
rom
the
(fem
ale)
rabb
itBe
rber
is/U
teru
s com
p.
(12.
09.1
992)
Ute
rus
Sus s
crof
a do
mes
tica
L.U
teru
s fro
m th
e pi
gBe
rber
is/U
teru
s com
p.
(12.
09.1
992)
Uve
a*Bo
s tau
rus L
.U
vea
from
the
calf
List
e H
AS
(10.
2010
: Uve
a co
mp.
)Va
gina
Bos t
auru
s L.
Vagi
na fr
om th
e co
w
IVA
A st
atem
ent 2
013
Vagi
nae
syno
vial
es
tend
inum
Bos t
auru
s L.
Tend
on sh
eath
s fro
m th
e ca
lf A
llium
cepa
/Ten
do co
mp.
(1
2.09
.199
2)Va
lva
trun
ci p
ulm
onal
isBo
s tau
rus L
.Va
lva
trun
ci p
ulm
onal
is fr
om th
e ca
lf IV
AA
stat
emen
t 201
3Va
lvul
a ao
rtae
Bos t
auru
s L.
Valv
a ao
rtae
from
the
calf
IVA
A st
atem
ent 2
013
Valv
ula
mitr
alis
Bos t
auru
s L.
Valv
a m
itral
is fr
om th
e ca
lf IV
AA
stat
emen
t 201
3Va
lvul
a tr
icus
pida
lisBo
s tau
rus L
.Va
lva
tric
uspi
dalis
from
the
calf
Der
Mer
kurs
tab:
Son
der-
he�
1999
Vena
cav
aBo
s tau
rus L
.Pa
rts o
f the
Ven
a ca
va cr
ania
lis a
nd V
ena
cava
cau
dalis
from
the
calf
IVA
A st
atem
ent 2
013
Vena
fem
oral
isBo
s tau
rus L
.Ve
na fe
mor
alis
from
the
calf
Der
Mer
kurs
tab:
Son
der-
he�
1999
Vena
por
tae
Bos t
auru
s L.
Vena
por
tae
from
the
calf
IVA
A st
atem
ent 2
013
Vena
saph
ena
mag
naBo
s tau
rus L
.Ve
na sa
phen
a m
agna
from
the
calf
Vade
mec
um: V
ena
sa-
phen
a m
agna
Ve
na ti
bial
isBo
s tau
rus L
.Ve
na ti
bial
is fr
om th
e ca
lf IV
AA
stat
emen
t 201
3Ve
ntric
ulus
Sus s
crof
a do
mes
tica
L.Ve
ntric
ulus
from
the
pig
Vade
mec
um: V
entr
icul
us
Vert
ebra
cerv
ical
is*Bo
s tau
rus L
.Ve
rteb
ra ce
rvic
alis
from
the
calf
IVA
A st
atem
ent 2
013
Vert
ebra
cocc
ygea
Bos t
auru
s L.
Vert
ebra
cocc
ygea
from
the
calf
IVA
A st
atem
ent 2
013
Vert
ebra
lum
balis
*Bo
s tau
rus L
.Ve
rteb
ra lu
mba
lis fr
om th
e ca
lf IV
AA
stat
emen
t 201
3Ve
sica
felle
aBo
s tau
rus L
.Ve
sica
felle
a fr
om th
e ca
lf Fe
rrum
/Ves
ica
felle
a (2
5.10
.199
4)
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Appendix 2.3
152
Scie
nti�
c nam
e Sc
ient
i�c n
ame o
f the
anim
alAb
brev
iate
d de
�niti
onRe
fere
nce t
o St
anda
rdEx
empl
ary r
efer
ence
for u
se in
anth
ropo
soph
ic m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Vesic
a ur
inar
iaBo
s tau
rus L
.Ve
sica
urin
aria
from
the
calf
Can
thar
is co
mp.
(0
1.07
.199
2)Ve
sica
urin
aria
Ory
ctol
agus
cuni
culu
s L.
Vesic
a ur
inar
ia fr
om th
e ra
bbit
Can
thar
is co
mp.
(0
1.07
.199
2)Ve
spa
crab
roVe
spa
crab
ro L
. Li
ve h
orne
tsH
AB
Vesp
a cr
abro
(25.
10.1
994)
Vade
mec
um: V
espa
cr
abro
Ve
spa
vulg
aris
Vesp
ula
germ
anica
Fab
ri-ci
us, V
espu
la v
ulga
ris L
. and
/or
Dol
ichov
espu
la sa
xoni
a Fa
bric
ius
Live
wor
ker w
asps
Li
ste
HA
S (1
0.20
12)
Vip
era
beru
sVi
pera
ber
us L
. Fr
eeze
drie
d ve
nom
of V
iper
a be
rus L
. N
aja
com
p. (2
5.10
.199
4)
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
153
APPENDIX 2.4
Starting materials that can be described chemically Additional Information, see p. 22
• Ap
pend
ix 2
.4
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Appendix 2.4
154
Latin
nam
e:
Ph.E
ur.,
HAB
or P
h.fr.
Trad
ition
al n
ame:
H
AB an
d/or
Ph.
fr.Ab
brev
iate
d de
�niti
on
Engl
ish N
ame P
h.Eu
r. if
appl
icab
le
Refe
renc
e to
stan
dard
Exem
plar
y ref
eren
ce fo
r use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
(dat
e)O
ther
Aci
dum
ars
enic
osum
see
Ars
enii
trio
xidu
m ap
hA
cidu
m b
enzo
icum
Aci
dum
ben
zoic
um, B
enzo
icum
ac
idum
pph
Benz
oic a
cid
Ph.E
ur.
(HA
B, P
h.fr.
)A
cidu
m b
enzo
icum
e re
sina
Benz
oic a
cid
from
Sia
m
benz
oin
HA
B
Aci
dum
citr
icum
anh
ydric
umA
cidu
m ci
tric
umC
itric
aci
d, a
nhyd
rous
Ph.E
ur. (
HA
B)A
cidu
m ci
tric
um m
onoh
ydric
umC
itric
aci
d m
onoh
ydra
tePh
.Eur
. Be
rber
is/Si
licea
com
p. (0
2.03
.199
1)A
cidu
m F
orm
icae
see
Appe
ndix
2.3
Aci
dum
form
icic
umFo
rmic
aci
dH
AB
Aci
dum
hex
achl
orop
latin
icum
Hex
achl
orop
latin
ic a
cid
HA
BPa
ncre
as/P
latin
um ch
lora
tum
com
p.
(02.
03.1
991)
Aci
dum
hyd
roch
lorid
um d
ilutu
mA
cidu
m h
ydro
chlo
ricum
Hyd
roch
loric
aci
d, d
ilute
(1
0%)
Ph.E
ur. (
HA
B)A
cidu
m h
ydro
chlo
ricum
com
p.
(02.
09.1
987)
Aci
dum
lact
icum
Aci
dum
lact
icum
Lact
ic a
cid
Ph.E
ur.
Maj
oran
a/�
uja
com
p. (0
2.03
.199
1)A
cidu
m n
itric
umA
cidu
m n
itric
um, N
itric
um
acid
um p
phN
itric
aci
dPh
.Eur
. (H
AB,
Ph.
fr.)
Mix
tura
Sta
nni c
omp.
(05.
12.1
989)
Aci
dum
pho
spho
ricum
dilu
tum
Aci
dum
pho
spho
ricum
Phos
phor
ic a
cid,
di
lute
(10%
)Ph
.Eur
. H
AB
Apis
regi
na/A
urum
com
p. (0
2.03
.199
1)
Aci
dum
pho
spho
ricum
conc
en-
trat
umA
cidu
m p
hosp
horic
um co
ncen
tra-
tum
, Pho
spho
ricum
aci
dum
pph
Phos
phor
ic a
cid,
co
ncen
trat
edPh
.Eur
. (P
h.fr.
)Ap
is re
gina
/Aur
um co
mp.
(02.
03.1
991)
Aci
dum
silic
icum
Aci
dum
silic
icum
Prec
ipita
ted
silic
on d
ioxi
deD
AB
Aci
dum
sulfu
ricum
Aci
dum
sulfu
ricum
, Sul
furic
um
acid
um p
phSu
lfuric
aci
dPh
.Eur
. (H
AB,
Ph
.fr.)
Aci
dum
tart
aric
umA
cidu
m ta
rtar
icum
Tart
aric
aci
dPh
.Eur
.A
escu
linum
Aes
culin
DA
B / H
AB
Echi
nace
a/Pr
unus
com
p. (0
4.06
.198
6)A
ethi
ops a
ntim
onia
lisse
e H
ydra
rgyr
um
stib
iato
-sul
fura
tum
Aet
hiop
s ant
imon
ialis
(02.
09.1
987)
Alu
men
Alu
men
Alu
mPh
.Eur
.M
ixtu
ra S
tann
i com
p. (0
5.12
.198
9)A
lum
en ch
rom
icum
Pota
ssiu
m ch
rom
ium
(III
) su
lfate
dod
ecah
ydra
teA
lum
iniu
m-k
aliu
m-s
ulfu
ricum
see
Alu
men
Ph.E
ur.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Ap
pend
ix 2
.4
155
Latin
nam
e:
Ph.E
ur.,
HAB
or P
h.fr.
Trad
ition
al n
ame:
H
AB an
d/or
Ph.
fr.Ab
brev
iate
d de
�niti
on
Engl
ish N
ame P
h.Eu
r. if
appl
icab
le
Refe
renc
e to
stan
dard
Exem
plar
y ref
eren
ce fo
r use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
(dat
e)O
ther
Am
mon
iae
solu
tio co
ncen
trat
aA
mm
onia
solu
tion,
co
ncen
trat
edPh
.Eur
.
Am
mon
ium
car
boni
cum
Mix
ture
of a
mm
oniu
m
hydr
ogen
car
bona
te a
nd
amm
oniu
m c
arba
mat
e of
va
ryin
g pr
opor
tions
HA
BEc
hina
cea
com
p. (0
4.06
.198
6)
Ant
imon
ium
tart
aric
umse
e K
aliu
m st
ibyl
tart
aric
umA
rgen
ti ca
rbon
asA
rgen
tum
car
boni
cum
Silv
er ca
rbon
ate,
99-1
00,5
%
Ag 2
CO
3 (s
ee A
ppen
dix
2.5,
e.g.
V
iscum
Mal
i cum
Arg
ento
)A
rgen
tum
met
allic
um,
Arg
entu
m m
etal
licum
pph
Met
allic
silv
erH
AB,
Ph.
fr.A
rgen
tum
met
allic
um (0
4.06
.198
6)
Arg
enti
nitr
asA
rgen
tum
nitr
icum
, A
rgen
tum
nitr
icum
pph
Silv
er n
itrat
ePh
.Eur
. (H
AB,
Ph.
fr.)
Arg
entu
m n
itric
um (0
4.06
.198
6)
Ars
enii
trio
xidu
m ap
hA
rsen
icum
alb
umA
rsen
ious
trio
xide
�p
Ph.E
ur.
Ars
enic
um a
lbum
(02.
09.1
987)
Auru
m ch
lora
tum
Hyd
roge
n te
trac
hlor
oaur
ate(
III)
tr
ihyd
rate
HA
BAp
is re
gina
/Aur
um co
mp.
(02.
03.1
991)
Auru
m ch
lora
tum
nat
rona
tum
see
Nat
rium
te
trac
hlor
oaur
atum
Auru
m m
etal
licum
, Au
rum
met
allic
um p
phM
etal
lic g
old
HA
B, P
h.fr.
Auru
m m
etal
licum
(04.
06.1
986)
Auru
m m
etal
licum
folia
tum
Gol
d le
afAu
rum
nat
ural
ese
e Ap
pend
ix 2
.1Au
rum
mur
iatic
um n
atro
natu
mse
e N
atriu
m
tetr
achl
oroa
urat
umAu
rum
sulfu
ratu
mM
ixtu
re o
f gol
d(I)
- and
go
ld(I
II) s
ul�d
eBa
rium
citr
icum
Bariu
m ci
trat
e he
xahy
drat
eBa
rium
/Pan
crea
s com
p. (0
2.03
.199
1)Ba
rii io
didu
mBa
rium
ioda
tum
Bariu
m io
dide
m
onoh
ydra
teH
AB
Benz
oicu
m a
cidu
m p
phse
e A
cidu
m b
enzo
icum
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Appendix 2.4
156
Latin
nam
e:
Ph.E
ur.,
HAB
or P
h.fr.
Trad
ition
al n
ame:
H
AB an
d/or
Ph.
fr.Ab
brev
iate
d de
�niti
on
Engl
ish N
ame P
h.Eu
r. if
appl
icab
le
Refe
renc
e to
stan
dard
Exem
plar
y ref
eren
ce fo
r use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
(dat
e)O
ther
Bism
utum
met
allic
umM
etal
lic b
ismut
hH
AB
Bism
utum
/Stib
ium
(12.
09.1
992)
Bism
uthu
m p
phse
e Bi
smut
um su
bnitr
as
pond
eros
usBi
smut
um su
bnitr
as p
onde
rosu
sBi
smut
um su
bnitr
icum
, Bi
smut
hum
pph
Bism
uth
subn
itrat
e, he
avy
Ph.E
ur.
(HA
B, P
h.fr.
)C
arbo
San
guin
is co
mp.
(25.
10.1
994)
Bora
xN
atriu
m te
trab
orac
ium
, Bo
rax
pph
Diso
dium
tetr
abor
ate
deca
hydr
ate
Ph.E
ur.
(HA
B, P
h.fr.
)C
alca
rea
form
icic
a
(Cal
cium
form
icic
um)
Cal
cium
form
ate,
obta
ined
fr
om C
onch
ae a
nd A
cidu
m
Form
icae
(s
ee A
ppen
dix
2.3)
Viti
s com
p. (0
4.06
.198
6)
Cal
care
a ph
osph
oric
a pp
hse
e C
alci
i hyd
roge
noph
os-
phas
dih
ydric
usC
alci
i hyd
roxi
dum
Cal
cii h
ydro
xidu
mC
alci
um h
ydro
xide
Ph.E
ur.
Cal
cii o
xidu
mFr
eshl
y bu
rnt l
ime
or
mar
ble
Cal
cii c
arbo
nas
Cal
cium
car
boni
cum
Cal
cium
car
bona
tePh
.Eur
.C
alci
i hyd
roge
noph
osph
as d
ihy-
dric
usC
alci
um p
hosp
horic
um,
Cal
care
a ph
osph
oric
a pp
hC
alci
um h
ydro
gen
ph
osph
ate
dihy
drat
ePh
.Eur
. (H
AB,
Ph.
fr.)
Cal
cium
stib
iato
-sul
fura
tum
A m
ixtu
re, p
repa
red
by
mel
ting
stib
ium
sulfu
ratu
m
nigr
um, s
ulfu
r and
conc
hae
toge
ther
HA
B
Cal
cii s
ulfa
s dih
ydric
usC
alci
um su
lfuric
um,
Cal
care
a su
lfuric
a pp
hC
alci
um su
lfate
dih
ydra
tePh
.Eur
. (H
AB,
Ph.
fr.)
d-C
amph
ora
Cam
phor
a, C
amph
ora
pph
D-C
amph
orPh
.Eur
. (H
AB,
Ph.
fr.)
Cam
phor
a (0
4.06
.198
6)
Cer
ussa
see
Plum
bum
car
boni
cum
Chi
nini
sulfa
sC
hini
num
sulfu
ricum
Qui
nine
sulfa
tePh
.Eur
. (H
AB,
Ph.
fr.)
Chl
orop
hyllu
m�
e gr
een
plan
t pig
men
t (G
reen
of l
eave
s).
Arg
entu
m/Q
uerc
us co
mp.
(04.
06.1
986)
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Ap
pend
ix 2
.4
157
Latin
nam
e:
Ph.E
ur.,
HAB
or P
h.fr.
Trad
ition
al n
ame:
H
AB an
d/or
Ph.
fr.Ab
brev
iate
d de
�niti
on
Engl
ish N
ame P
h.Eu
r. if
appl
icab
le
Refe
renc
e to
stan
dard
Exem
plar
y ref
eren
ce fo
r use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
(dat
e)O
ther
Cin
naba
risse
e H
ydra
rgyr
um su
lfura
-tu
m ru
brum
or C
inna
bar
in A
ppen
dix
2.1
Cob
altu
m m
etal
licum
Met
allic
coba
ltH
AB
Cob
altu
m m
etal
licum
(12.
09.1
992)
Cre
osot
umse
e K
reos
otum
Cop
per t
etra
mm
ine
sulp
hate
m
onoh
ydra
tePr
epar
ed fr
om co
pper
(II)
su
lfate
pen
tahy
drat
e an
d co
ncen
trat
ed a
mm
onia
so
lutio
n. S
ee A
ppen
dix
2.6
Cupr
um-R
en
Cupr
um-R
en-G
land
ula
supr
aren
alis
(12.
09.1
992)
Cupr
o-St
ibiu
mA
lloy
of 1
par
t of c
oppe
r an
d 1
part
of a
ntim
ony
Cupr
i ace
tas m
onoh
ydric
us ap
hCu
prum
ace
ticum
Cop
per(
II) a
ceta
te
mon
ohyd
rate
�p
Ph.E
ur.
(HA
B)Cu
prum
ace
ticum
(04.
06.1
986)
Cupr
um ci
tric
umC
oppe
r(II
) citr
ate
2,5
Hyd
rate
Cupr
um ap
hCu
prum
met
allic
umC
oppe
r �p
Ph.E
ur. (
HA
B)Cu
prum
met
allic
um (0
4.06
.198
6)Cu
prum
oxy
dula
tum
rubr
umC
oppe
r(I)
oxi
deCu
prum
oxy
dula
tum
rubr
um
(02.
03.1
990)
Cupr
i sul
fas p
enta
hydr
icus
Cupr
um su
lfuric
umC
oppe
r(II
) sul
fate
pe
ntah
ydra
tePh
.Eur
. (H
AB)
Cupr
um su
lfuric
um (0
2.03
.199
0)
Din
atrii
pho
spha
s dod
ecah
ydri-
cus
Nat
rium
pho
spho
ricum
, N
atru
m p
hosp
horic
um p
phD
isodi
um p
hosp
hate
do
deca
hydr
ate
Ph.E
ur.
(HA
B, P
h.fr.
)Ro
bini
a co
mp.
(12.
09.1
992)
Ferr
um ci
tric
umIr
on(I
II) c
itrat
e, co
ntai
ning
no
t les
s tha
n 18
.0 a
nd n
ot
mor
e th
an 2
0.0
per c
ent o
f Fe
(Ar 5
5.85
)Fe
rrum
glu
coni
cum
Iron
(II)
glu
cona
te
(Fer
rous
glu
cona
te)
Ferr
um/A
cidu
m ch
olal
icum
(25.
10.1
994)
Ferr
um h
ydro
xyda
tum
see
Appe
ndix
2.6
(F
erru
m h
ydro
xyda
tum
)Fe
rrum
aph
Ferr
um m
etal
licum
Iron
�p
(obt
aine
d by
re
duct
ion
or su
blim
atio
n)
Ph.E
ur. (
HA
B)Fe
rrum
met
allic
um (0
4.06
.198
6)
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Appendix 2.4
158
Latin
nam
e:
Ph.E
ur.,
HAB
or P
h.fr.
Trad
ition
al n
ame:
H
AB an
d/or
Ph.
fr.Ab
brev
iate
d de
�niti
on
Engl
ish N
ame P
h.Eu
r. if
appl
icab
le
Refe
renc
e to
stan
dard
Exem
plar
y ref
eren
ce fo
r use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
(dat
e)O
ther
Ferr
um m
etal
licum
redu
ctum
Iron
obt
aine
d by
redu
ctio
n of
the
min
eral
side
rite
(HA
B)
Ferr
um p
hosp
horic
um,
Ferr
um p
hosp
horic
um p
ph
(Fer
rosi
phos
phas
aph)
Hyd
rate
d iro
n(II
I)
phos
phat
eH
AB,
Ph.
fr.Fe
rrum
pho
spho
ricum
(04.
06.1
986)
Ferr
um se
squi
chlo
ratu
m so
lutu
m,
Ferr
um se
squi
chlo
ratu
mA
queo
us so
lutio
n of
iro
n(II
I) ch
lorid
e
hexa
hydr
ate
HA
BFe
rrum
pra
epar
atum
com
p. (D
AZ
Nr.
29,
21.0
7.19
94)
Ferr
osi s
ulfa
s des
icca
tus
Ferr
um su
lfuric
umFe
rrou
s sul
fate
, drie
dPh
.Eur
. (H
AB)
Ferr
osi s
ulfa
s hep
tahy
dric
usFe
rrou
s sul
fate
he
ptah
ydra
te
Ph.E
ur.
Ferr
um/Q
uarz
(04.
06.1
986)
Ferr
um u
stum
Com
plex
Iron
(II,
III)
oxi
de
– ob
tain
ed b
y gl
owin
g an
d fo
rgin
g m
etal
lic ir
on –
con-
tain
ing
not l
ess t
han
71.0
an
d no
t mor
e th
an 7
5.0
per
cent
of F
e (A
r 55.
85)
Ferr
um u
stum
com
p. (0
4.06
.198
6)
Ferr
um(I
II)-
kaliu
m-t
arta
ricum
Iron
(III
) pot
assiu
m ta
rtra
te
dehy
drat
e (F
erric
pot
as-
sium
tart
rate
)
Solu
tio F
erri
com
p. (2
5.10
.199
4)
Glo
noin
umse
e N
itrog
lyce
rinum
Hyd
rarg
yri d
ichl
orid
umH
ydra
rgyr
um b
ichl
orat
um,
Mer
curic
chlo
ride
Ph.E
ur. (
HA
B)H
ydra
rgyr
um b
icya
natu
mM
ercu
ry(I
I) c
yani
deH
AB
Mer
curiu
s cya
natu
s (02
.09.
1987
)H
ydra
rgyr
um b
iioda
tum
Mer
cury
(II)
iodi
deH
AB
Trab
ecul
um co
mp.
(03.
07.1
992)
Hyd
rarg
yrum
chlo
ratu
mM
ercu
rius d
ulci
s pph
Mer
cury
(I) c
hlor
ide
HA
B, P
h.fr.
Mer
curiu
s dul
cis (
05.1
2.19
89)
Hyd
rarg
yrum
met
allic
um, M
ercu
-riu
s viv
is, M
ercu
rius v
ivus
pph
Met
allic
mer
cury
HA
B, P
h.fr.
Mer
curiu
s viv
us (0
2.09
.198
7)
Hyd
rarg
yrum
nitr
icum
ox
ydul
atum
Mer
cury
(I) n
itrat
e
dihy
drat
eH
AB
Hyd
rarg
yrum
stib
iato
-sul
fura
tum
HA
B
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Ap
pend
ix 2
.4
159
Latin
nam
e:
Ph.E
ur.,
HAB
or P
h.fr.
Trad
ition
al n
ame:
H
AB an
d/or
Ph.
fr.Ab
brev
iate
d de
�niti
on
Engl
ish N
ame P
h.Eu
r. if
appl
icab
le
Refe
renc
e to
stan
dard
Exem
plar
y ref
eren
ce fo
r use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
(dat
e)O
ther
Hyd
rarg
yri s
ulfa
sM
ercu
ry(I
I) su
lfate
, 99
–100
,5%
HgS
O4,
(see
Ap
ppen
dix
2.5,
e.g.
Visc
um
Mal
i cum
Hyd
rarg
yro)
Hyd
rarg
yrum
sulfu
ratu
m n
igru
mBl
ack
Mer
cury
(II)
sul�
de
HA
BA
ethi
ops a
ntim
onia
lis (0
2.09
.198
7)H
ydra
rgyr
i sul
�dum
aph
Hyd
rarg
yrum
sulfu
ratu
m ru
brum
, C
inna
baris
, Cin
naba
ris p
phRe
d M
ercu
ry(I
I) su
l�de
Ph.E
ur.
(HA
B, P
h.fr.
)Ec
hina
cea/
Prun
us co
mp.
(04.
06.1
986)
Iodu
mJo
dum
, Iod
um p
phIo
dine
Ph.E
ur.
(HA
B, P
h.fr.
)Jo
dum
(07.
04.1
988)
Kal
ium
ars
enic
osum
pph
Pota
ssiu
m a
rsen
ite, K
As0
2Ph
.fr.
Kal
ii bi
chro
mas
aph
Kal
ium
bic
hrom
icum
Pota
ssiu
m d
ichr
omat
e �
pPh
.Eur
. (H
AB)
Kal
ium
bic
hrom
icum
(07.
04.1
988)
Kal
ii ca
rbon
asK
aliu
m c
arbo
nicu
m,
Kal
ium
car
boni
cum
pph
Pota
ssiu
m c
arbo
nate
Ph.E
ur.
(HA
B, P
h.fr.
)K
aliu
m c
arbo
nicu
m (1
2.09
.199
2)
Kal
ium
car
boni
cum
e ci
nere
Fag
iPo
tass
ium
car
bona
te,
prep
ared
from
the
ash
of b
eech
woo
d (F
agus
sil
vatic
a)
Agr
opyr
on co
mp.
(07.
04.1
988)
Kal
ii ch
lorid
umK
aliu
m ch
lora
tum
, K
aliu
m m
uria
ticum
pph
Pota
ssiu
m ch
lorid
ePh
.Eur
. (H
AB,
Ph.
fr.)
Kal
ium
-Eise
n-Ta
rtra
tse
e Fe
rrum
(III
)-ka
lium
-ta
rtar
icum
Kal
ii hy
drog
enot
artr
asPo
tass
ium
hyd
roge
n ta
rtra
tePh
.Eur
.
Kal
ii io
didu
mK
aliu
m io
datu
m,
Kal
ium
ioda
tum
pph
Pota
ssiu
m io
dide
Ph.E
ur.
(HA
B, P
h.fr.
)K
alii
nitr
asK
aliu
m n
itric
um,
Kal
ium
nitr
icum
pph
Pota
ssiu
m n
itrat
ePh
.Eur
. (H
AB,
Ph.
fr.)
Kal
ii di
hydr
ogen
opho
spha
sK
aliu
m p
hosp
horic
um,
Kal
ium
pho
spho
ricum
pph
Pota
ssiu
m d
ihyd
roge
n ph
osph
ate
Ph.E
ur.
(HA
B, P
h.fr.
)Be
rber
is/H
yper
icum
com
p. (2
5.10
.199
4)
Kal
ium
stib
ylta
rtar
icum
Pota
ssiu
m d
i-µ-
tart
rato
bis[
antim
onat
e(II
I)]
trih
ydra
te
HA
BTa
rtar
us st
ibia
tus (
02.0
9.19
87)
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Appendix 2.4
160
Latin
nam
e:
Ph.E
ur.,
HAB
or P
h.fr.
Trad
ition
al n
ame:
H
AB an
d/or
Ph.
fr.Ab
brev
iate
d de
�niti
on
Engl
ish N
ame P
h.Eu
r. if
appl
icab
le
Refe
renc
e to
stan
dard
Exem
plar
y ref
eren
ce fo
r use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
(dat
e)O
ther
Kal
ium
sulfu
ratu
m,
Hep
ar su
lfuris
kal
inum
C
rude
pot
ash,
cont
ain-
ing
a m
ixtu
re o
f mai
nly
pota
ssiu
m tr
isul�
de a
nd
pota
ssiu
m m
etab
isul�
te
(dip
otas
sium
pyr
osul
�te)
(HA
B 19
34, D
AB
6, P
h. H
elv.
VI)
)K
aliu
m su
lfura
tum
(02.
03.1
991)
Kal
ii su
lfas
Kal
ium
sulfu
ricum
, K
aliu
m su
lfuric
um p
phPo
tass
ium
sulfa
tePh
.Eur
. (H
AB,
Ph.
fr.)
Kal
ium
/Teu
criu
m co
mp.
(25.
10.1
994)
Kre
osot
umH
AB
Kre
osot
um (0
5.12
.198
9)Li
quor
nat
rii si
licic
ise
e N
atrii
silic
ici,
Liqu
orLi
thii
carb
onas
Lith
ium
car
boni
cum
, Li
thiu
m c
arbo
nicu
m p
phLi
thiu
m c
arbo
nate
Ph
.Eur
. (H
AB,
Ph.
fr.)
Mag
nesii
chlo
ridum
hex
ahyd
ri-cu
sM
agne
sium
chlo
ratu
m,
Mag
nesia
mur
iatic
a pp
hM
agne
sium
chlo
ride
he
xahy
drat
ePh
.Eur
. (H
AB,
Ph.
fr.)
Mag
nesiu
m h
ydro
xyda
tum
Mag
nesiu
m h
ydro
xide
(s
ee a
lso A
ppen
dix
2.6
e.g.
Hep
ar-M
agne
sium
)
Ph.E
ur.
Hep
ar-M
agne
sium
(03.
07.1
992)
Mag
nesiu
m m
etal
licum
Met
allic
mag
nesiu
mH
AB
Mag
nesii
hyd
roge
noph
osph
as
trih
ydric
usM
agne
sium
pho
spho
ricum
, M
agne
sia p
hosp
horic
a pp
hM
agne
sium
hyd
roge
n ph
osph
ate
trih
ydra
tePh
.Eur
. (H
AB,
Ph.
fr.)
Mag
nesiu
m p
hosp
horic
um (1
2.09
.199
2)
Mag
nesiu
m p
hosp
horic
um
acid
um 2
0%A
queo
us so
lutio
n of
mag
-ne
sium
dih
ydro
gen
phos
-ph
ate
(20
per c
ent m
/m)
Mag
nesiu
m p
hosp
horic
um a
cidu
m
(12.
09.1
992)
Mag
nesii
sulfa
s hep
tahy
dric
usM
agne
sium
sulfu
ricum
, M
agne
sia su
lfuric
a pp
hM
agne
sium
sulfa
te
hept
ahyd
rate
Ph.E
ur.
Mag
nesiu
m su
lfuric
um/O
varia
com
p.
(25.
10.1
994)
Mer
curiu
s aur
atus
Gol
d-m
ercu
ry a
lloy,
cont
aini
ng at
leas
t 32.
0 an
d no
t mor
e th
an 3
5.0
per
cent
Au
(Ar 1
96,9
7) a
nd
at le
ast 6
5.0
and
not m
ore
than
68.
0 pe
r cen
t Hg
(Ar
200,
59)
Mer
curiu
s bijo
datu
sse
e H
ydra
rgyr
um
biio
datu
mM
ercu
rius c
yana
tus
see
Hyd
rarg
yrum
bi
cyan
atum
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Ap
pend
ix 2
.4
161
Latin
nam
e:
Ph.E
ur.,
HAB
or P
h.fr.
Trad
ition
al n
ame:
H
AB an
d/or
Ph.
fr.Ab
brev
iate
d de
�niti
on
Engl
ish N
ame P
h.Eu
r. if
appl
icab
le
Refe
renc
e to
stan
dard
Exem
plar
y ref
eren
ce fo
r use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
(dat
e)O
ther
Mer
curiu
s dul
cis
see
Hyd
rarg
yrum
ch
lora
tum
Mer
curiu
s sol
ubili
s Hah
nem
anni
HA
BEc
hina
cea/
Mer
curiu
s com
p. (0
3.07
.199
2)M
ercu
rius s
ublim
atus
corr
osiv
usse
e H
ydra
rgyr
i di
chlo
ridum
Mer
curiu
s viv
usse
e H
ydra
rgyr
um
met
allic
umM
iniu
mM
iniu
m [L
ead(
II,IV
) ox
ide]
HA
BM
iniu
m (0
3.07
.199
2)
Nat
rii c
arbo
nas d
ecah
ydric
usSo
dium
car
bona
te
deca
hydr
ate
Ph.E
ur.
Nat
rii c
arbo
nas m
onoh
ydric
usN
atriu
m c
arbo
nicu
m,
Nat
rum
car
boni
cum
pph
Sodi
um c
arbo
nate
m
onoh
ydra
tePh
.Eur
. (H
AB,
Ph.
fr.)
Frag
aria
/Urt
ica
com
p. (0
3.07
.199
2)
Nat
rii ch
lorid
umN
atriu
m ch
lora
tum
, N
atru
m m
uria
ticum
pph
Sodi
um ch
lorid
ePh
.Eur
. (H
AB,
Ph.
fr.)
Nat
rium
pho
spho
ricum
, N
atru
m p
hosp
horic
um p
phse
e D
inat
rii p
hosp
has
dode
cahy
dric
usN
atrii
silic
ici,
Liqu
orLi
quor
nat
rii si
licic
iA
queo
us so
lutio
n of
so
dium
pol
ysili
cate
with
7,
5 –
8,5%
sodi
um o
xide
(N
a 2O
) and
25,
5 –
28,5
%
silic
icum
dio
xide
(SiO
2).
(See
also
App
endi
x 2.
6 e.g
. U
vea
com
p.)
DA
B 6
Berb
eris/
Silic
ea co
mp.
(02.
03.1
991)
Nat
rii su
lfas a
nhyd
ricus
Nat
rium
sulfu
ricum
, N
atru
m su
lfuric
um p
phA
nhyd
rous
sodi
um su
lfate
Ph.E
ur.
(HA
B, P
h.fr.
)Ly
copo
dium
com
p. (1
2.09
.199
2)
Nat
rium
tetr
abor
aciu
mse
e Bo
rax
Ph.E
ur.
Nat
rii te
trac
hlor
oaur
as
dihy
dric
us ap
hN
atriu
m te
trac
hlor
oaur
atum
Sodi
um te
trac
hlor
oaur
ate
dihy
drat
e �
pPh
.Eur
. (H
AB)
Nitr
icum
aci
dum
pph
see
Aci
dum
nitr
icum
Nitr
ogly
cerin
umG
lono
inum
, Glo
noin
um p
phSo
lutio
n of
gly
cero
l trin
i-tr
ate
(1 p
er ce
nt) i
n Et
hano
l 96
per
cent
HA
B, P
h.fr.
Glo
noin
um (0
7.04
.198
8)
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Appendix 2.4
162
Latin
nam
e:
Ph.E
ur.,
HAB
or P
h.fr.
Trad
ition
al n
ame:
H
AB an
d/or
Ph.
fr.Ab
brev
iate
d de
�niti
on
Engl
ish N
ame P
h.Eu
r. if
appl
icab
le
Refe
renc
e to
stan
dard
Exem
plar
y ref
eren
ce fo
r use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
(dat
e)O
ther
Petr
oleu
m re
cti�
catu
m,
Petr
oleu
m p
phPe
trol
eum
spiri
t boi
ling
betw
een
180
and
220
°C
obta
ined
by
rect
i�ca
tion
of
crud
e oi
l
HA
B, P
h.fr.
Petr
oleu
m (0
5.12
.198
9)
Phos
phor
icum
aci
dum
pph
see
Aci
dum
pho
spho
ricum
co
ncen
trat
umPh
osph
orus
Yello
w p
hosp
horu
sH
AB
Phos
phor
us (0
4.06
.198
6)Ph
osph
orus
rube
rRe
d am
orph
ous p
hosp
horu
sPh
osph
orus
met
allic
us (n
iger
)Bl
ack
met
allic
pho
spho
rus
Plat
inum
chlo
ratu
mse
e A
cidu
m
hexa
chlo
ropl
atin
icum
Plat
inum
met
allic
umM
etal
lic p
latin
HA
BPl
umbu
m a
cetic
umLe
ad(I
I) a
ceta
te tr
ihyd
rate
HA
BPl
umbu
m jo
datu
mLe
ad(I
I) io
dide
Plum
bum
met
allic
umM
etal
lic le
adH
AB
Plum
bum
met
allic
um (0
2.09
.198
7)Pl
umbu
m si
licic
umLe
ad(I
I) m
eta
silic
ate,
ob-
tain
ed b
y sm
eltin
g ce
russ
ite
and
quar
tz.
Plum
bum
silic
icum
(DA
Z N
r. 29
, 21
.07.
1994
)
Plum
bi c
arbo
nas
Plum
bum
car
boni
cum
Basic
lead
(II)
car
bona
teC
inis
Cap
sella
e co
mp.
(03.
07.1
992)
Sacc
haru
mSa
ccha
rum
Sac
char
iSu
cros
e ob
tain
ed fr
om th
e st
ems o
f Sac
char
um o
�ci
-na
rum
L.
Ph.E
ur.
Arg
entu
m/R
ohrz
ucke
r (05
.12.
1989
)
Silic
ease
e A
cidu
m si
licic
umSi
licea
collo
idal
isC
ollo
idal
silic
a, d
irect
ly
obta
ined
in th
e m
anuf
ac-
ture
of t
he �
nish
ed p
rodu
ct
by re
actio
n of
adj
uste
d am
ount
s of a
queo
us so
lu-
tions
of s
odiu
m si
licat
e an
d ci
tric
aci
d m
onoh
ydra
te.
Berb
eris/
Silic
ea co
mp.
(02.
03.1
991)
Stan
nosi
chlo
ridum
dih
ydric
umSt
anno
us ch
lorid
e di
hy-
drat
ePh
.Eur
.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Ap
pend
ix 2
.4
163
Latin
nam
e:
Ph.E
ur.,
HAB
or P
h.fr.
Trad
ition
al n
ame:
H
AB an
d/or
Ph.
fr.Ab
brev
iate
d de
�niti
on
Engl
ish N
ame P
h.Eu
r. if
appl
icab
le
Refe
renc
e to
stan
dard
Exem
plar
y ref
eren
ce fo
r use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
(dat
e)O
ther
Stan
num
hyd
roxy
datu
mTi
n(II
) hyd
roxi
de (s
ee a
lso
Appe
ndix
2.6
e.g.
Hep
ar-
Stan
num
)St
annu
m m
etal
licum
Met
allic
tin
HA
BSt
annu
m m
etal
licum
(04.
06.1
986)
Stan
num
silic
icum
Tran
sluce
nt m
elt f
rom
silic
a hy
drox
ide
and
tin(I
I,IV
) hy
drox
ide
Stib
ium
ars
enic
osum
Mix
ture
of e
qual
par
ts o
f an
tym
ony(
V)o
xide
and
ar
seni
c(II
I)ox
ide
HA
BSt
ibiu
m a
rsen
icos
um (0
2.09
.198
7)
Stib
ium
met
allic
umM
etal
lic a
ntim
ony
HA
BSt
ibiu
m m
etal
licum
(04.
06.1
986)
Stib
ium
sulfu
ratu
m au
rant
iacu
mM
ixtu
re o
f ant
imon
y(V
) su
l�de
and
sulfu
rH
AB
Stib
ium
sulfu
ratu
m au
rant
iacu
m (D
AZ
Nr.
29, 2
1.07
.199
4)St
ibiu
m su
lfura
tum
nig
rum
, A
ntim
oniu
m cr
udum
pph
Blac
k A
ntim
ony(
III)
sul�
deH
AB,
Ph.
fr.A
ethi
ops a
ntim
onia
lis (0
2.09
.198
7)
Sulfu
r aph
Sulfu
rsu
lfur �
p (s
ublim
ed su
lfur)
Ph.E
ur. (
HA
B)Su
lfur (
04.0
6.19
86)
Sulfu
r iod
idum
Sulfu
r iod
atum
Mix
ture
of 4
par
ts o
f io
dine
and
1 p
art o
f sul
fur
care
fully
mel
ted
toge
ther
(c
onta
ins 7
0–80
% I)
HA
B
Sulfu
r iod
idum
aph
Iode
et s
oufr
e (m
élan
ge d
’) pp
hM
ixtu
re o
f 4 p
arts
of
iodi
ne a
nd 1
par
t of s
ulfu
r ca
refu
lly m
elte
d to
geth
er
(con
tain
s 75–
82%
I)
Ph.fr
.
Sulfu
ricum
aci
dum
pph
see
Aci
dum
sulfu
ricum
Sulfu
r sel
enos
umM
ixtu
re o
btai
ned
by
mel
ting
1 pa
rt o
f sel
en
with
99
part
s of s
ulfu
r.Ta
rtar
us d
epur
atus
Puri�
ed ta
rtar
, mai
nly
cons
istin
g of
pot
assiu
m
hydr
ogen
tart
rate
Ta
rtar
us st
ibia
tus
see
Kal
ium
stib
ylta
rtar
icum
Tetr
amm
ine
copp
er(I
I) su
lfate
see
Cop
per t
etra
mm
ine
sulfa
te m
onoh
ydra
te
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
164
• Appendix 2.4
Latin
nam
e:
Ph.E
ur.,
HAB
or P
h.fr.
Trad
ition
al n
ame:
H
AB an
d/or
Ph.
fr.Ab
brev
iate
d de
�niti
on
Engl
ish N
ame P
h.Eu
r. if
appl
icab
le
Refe
renc
e to
stan
dard
Exem
plar
y ref
eren
ce fo
r use
in an
thro
poso
phic
med
icin
e
KC M
onog
raph
(dat
e)O
ther
Zinc
um is
oval
eria
nicu
m,
Zinc
um v
aler
iani
cum
Zinc
isov
aler
ate
dihy
drat
eH
AB
Zinc
um v
aler
iani
cum
(02.
09.1
987)
Zinc
um m
etal
licum
, Zi
ncum
met
allic
um p
phM
etal
lic zi
ncH
AB,
Ph.
fr.
Zinc
um v
aler
iani
cum
see
Zinc
um
isova
leria
nicu
m
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
165
APPENDIX 2.5
Starting material that have undergone special treatment Additional Information, see p. 22
• Ap
pend
ix 2
.5
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Appendix 2.5
166
Nam
e of t
he su
bsta
nce
Abbr
evia
ted
de�n
ition
Refe
renc
e to
stan
dard
(fo
r the
pla
nt)
Exem
plar
y ref
eren
ce fo
r use
in
anth
ropo
soph
ic m
edic
ine
Com
miss
ion
C
mon
ogra
ph (d
ate)
Oth
er
Aco
nitu
m n
apel
lus
Plum
bo c
ultu
mW
hole
fres
h pl
ants
of A
coni
tum
nap
ellu
s L.,
colle
cted
at th
e st
art o
f �ow
erin
g,
culti
vate
d ac
cord
ing
to A
PC M
etho
d 1.
1.1
(usin
g a
dilu
ted
lead
cont
aini
ng su
bsta
nce
for t
he tr
eatm
ent o
f the
soil
for t
he 1
st li
fe c
ycle
).
(HA
B)A
coni
tum
nap
el-
lus P
lum
bo c
ultu
m
(12.
09.1
992)
Atro
pa b
ella
donn
a Cu
pro
culta
Who
le fr
esh
plan
ts o
f Atr
opa
bella
-don
na L
., w
ithou
t woo
dy lo
wer
stem
sect
ions
, co
llect
ed at
the
end
of �
ower
ing,
cul
tivat
ed a
ccor
ding
to A
PC M
etho
d 1.
1.1
(usin
g a
dilu
ted
copp
er co
ntai
ning
subs
tanc
e fo
r the
trea
tmen
t of t
he so
il fo
r the
1st
life
cyc
le).
Bryo
phyl
lum
pin
natu
m
Arg
ento
cul
taFr
esh
leav
es o
f Bry
ophy
llum
pin
natu
m (L
am.)
Oke
n [S
yn. K
alan
choe
pin
nata
(Lam
.) Pe
rs.],
har
vest
ed in
the
�rst
yea
r of g
row
th, c
ultiv
ated
acc
ordi
ng to
APC
Met
hod
1.1.
1 (u
sing
a di
lute
d sil
ver c
onta
inin
g su
bsta
nce
for t
he tr
eatm
ent o
f the
soil
for t
he 1
st li
fe
cycl
e).
(HA
B)Br
yoph
yllu
m A
rgen
to
cultu
m (0
3.07
.199
2)
Bryo
phyl
lum
pin
natu
m
Mer
curio
cul
taFr
esh
leav
es o
f Bry
ophy
llum
pin
natu
m (L
am.)
Oke
n [S
yn. K
alan
choe
pin
nata
(Lam
.) Pe
rs.],
har
vest
ed in
the
�rst
yea
r of g
row
th, c
ultiv
ated
acc
ordi
ng to
APC
Met
hod
1.1.
1 (u
sing
a di
lute
d m
ercu
ry co
ntai
ning
subs
tanc
e fo
r the
trea
tmen
t of t
he so
il fo
r the
1st
lif
e cy
cle)
.
(HA
B)Br
yoph
yllu
m M
ercu
rio
cultu
m (1
2.09
.199
2)
Cha
mom
illa
recu
tita
Cupr
o cu
ltaFr
esh
unde
rgro
und
part
s of C
ham
omill
a re
cutit
a (L
.) Ra
usch
ert,
culti
vate
d ac
cord
ing
to A
PC M
etho
d 1.
1.1
(usin
g a
dilu
ted
copp
er co
ntai
ning
subs
tanc
e fo
r the
trea
tmen
t of
the
soil
for t
he 1
st li
fe c
ycle
).
Cha
mom
illa
Cupr
o
culta
, Rad
ix
(03.
07.1
992)
Che
lidon
ium
maj
us
Ferr
o cu
ltum
Fres
h rh
izom
e an
d ad
here
nt ro
ots o
f Che
lidon
ium
maj
us L
., co
llect
ed d
urin
g la
te
autu
mn
or o
n th
e ap
pear
ance
of t
he �
rst s
hoot
s, cu
ltiva
ted
acco
rdin
g to
APC
Met
hod
1.1.
1 (u
sing
a di
lute
d iro
n co
ntai
ning
subs
tanc
e fo
r the
trea
tmen
t of t
he so
il fo
r the
1s
t life
cyc
le).
(HA
B)C
helid
oniu
m F
erro
cu
ltum
(03.
07.1
992)
Cic
horiu
m in
tybu
s Pl
umbo
cul
tum
Who
le fr
esh
�ow
erin
g pl
ants
of C
icho
rium
inty
bus L
. (va
r. in
tybu
s and
/or v
ar. s
ati-
vum
DC
), cu
ltiva
ted
acco
rdin
g to
APC
Met
hod
1.1.
1 (u
sing
a di
lute
d le
ad co
ntai
ning
su
bsta
nce
for t
he tr
eatm
ent o
f the
soil
for t
he 1
st li
fe c
ycle
).
(HA
B)C
icho
rium
Plu
mbo
cu
ltum
(03.
07.1
992)
Cic
horiu
m in
tybu
s St
anno
cul
tum
Who
le fr
esh
�ow
erin
g pl
ants
of C
icho
rium
inty
bus L
. (va
r. in
tybu
s and
/or v
ar. s
ati-
vum
DC
), cu
ltiva
ted
acco
rdin
g to
APC
Met
hod
1.1.
1 (u
sing
a di
lute
d tin
cont
aini
ng
subs
tanc
e fo
r the
trea
tmen
t of t
he so
il fo
r the
1st
life
cyc
le).
(HA
B)C
icho
rium
Sta
nno
cultu
m (P
harm
.Ind.
11,
19
90)
Cic
horiu
m in
tybu
s St
anno
cul
tum
, Rad
ixFr
esh
root
of C
icho
rium
inty
bus L
. (va
r. in
tybu
s and
/or v
ar. s
ativ
um D
C),
colle
cted
at
�ow
erin
g tim
e, cu
ltiva
ted
acco
rdin
g to
APC
Met
hod
1.1.
1 (u
sing
a di
lute
d tin
con-
tain
ing
subs
tanc
e fo
r the
trea
tmen
t of t
he so
il fo
r the
1st
life
cyc
le).
Cic
horiu
m S
tann
o cu
ltum
(Pha
rm.In
d. 1
1,
1990
)C
inis
Urt
icae
Fer
ro
culta
eD
ried
and
ashe
d ae
rial p
arts
of U
rtic
a di
oica
L.,
colle
cted
at �
ower
ing
time,
culti
vate
d ac
cord
ing
to A
PC M
etho
d 1.
1.1
(usin
g a
dilu
ted
iron
cont
aini
ng su
bsta
nce
for t
he
trea
tmen
t of t
he so
il fo
r the
1st
life
cyc
le).
(Urt
ica
dioi
ca F
erro
cu
lta (0
3.07
.199
2))
Equi
setu
m a
rven
se
Silic
ea c
ultu
mFr
esh
gree
n st
erile
aer
ial p
arts
of E
quise
tum
arv
ense
L.,
culti
vate
d ac
cord
ing
to A
PC
Met
hod
1.1.
2 (u
sing
a di
lute
d sil
icat
e co
ntai
ning
subs
tanc
e fo
r the
trea
tmen
t of t
he
soil
for t
he 1
st li
fe c
ycle
).
(HA
B: E
quise
tum
ar
vens
e Rh
)Eq
uise
tum
arv
ense
Si
licea
cul
tum
(1
2.09
.199
2)
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Ap
pend
ix 2
.5
167
Nam
e of t
he su
bsta
nce
Abbr
evia
ted
de�n
ition
Refe
renc
e to
stan
dard
(fo
r the
pla
nt)
Exem
plar
y ref
eren
ce fo
r use
in
anth
ropo
soph
ic m
edic
ine
Com
miss
ion
C
mon
ogra
ph (d
ate)
Oth
er
Hyp
eric
um p
erfo
ratu
m
Auro
cul
tum
Fres
h ae
rial p
arts
of H
yper
icum
per
fora
tum
L.,
colle
cted
at �
ower
ing
time,
culti
vate
d ac
cord
ing
to A
PC M
etho
d 1.
1.1
(usin
g a
dilu
ted
gold
cont
aini
ng su
bsta
nce
for t
he
trea
tmen
t of t
he so
il fo
r the
1st
life
cyc
le).
(HA
B)H
yper
icum
Aur
o
cultu
m (0
3.07
.199
2)
Kal
anch
oe p
inna
tum
A
rgen
to c
ulta
see
Bryo
phyl
lum
pin
natu
m A
rgen
to c
ulta
Kal
anch
oe p
inna
tum
M
ercu
rio c
ulta
see
Bryo
phyl
lum
pin
natu
m M
ercu
rio c
ulta
Mel
issa
o�ci
nalis
Cu-
pro
culta
Fres
h ae
rial p
arts
of M
eliss
a o�
cina
lis L
., cu
ltiva
ted
acco
rdin
g to
APC
Met
hod
1.1.
1 (u
sing
a di
lute
d co
pper
cont
aini
ng su
bsta
nce
for t
he tr
eatm
ent o
f the
soil
for t
he 1
st
life
cycl
e).
(HA
B)M
eliss
a Cu
pro
culta
(2
5.10
.199
4)
Nas
turt
ium
o�
cina
le
Mer
curio
cul
tum
Fres
h ae
rial p
arts
of N
astu
rtiu
m o
�ci
nale
R. B
r., co
llect
ed at
�ow
erin
g tim
e, cu
lti-
vate
d ac
cord
ing
to A
PC M
etho
d 1.
1.1
(usin
g a
dilu
ted
mer
cury
cont
aini
ng su
bsta
nce
for t
he tr
eatm
ent o
f the
soil
for t
he 1
st li
fe c
ycle
).
(HA
B)N
astu
rtiu
m M
ercu
rio
cultu
m (2
5.10
.199
4)
Nic
otia
na ta
bacu
m
Cupr
o cu
ltaFr
esh
leave
s of N
icotia
na ta
bacu
m L
., cul
tivat
ed ac
cord
ing
to A
PC M
etho
d 1.
1.1
(usin
g a
dilu
ted
copp
er co
ntai
ning
subs
tanc
e for
the t
reat
men
t of t
he so
il fo
r the
1st
life c
ycle)
.(H
AB)
Taba
cum
Cup
ro
cultu
m (1
2.09
.199
2)O
enot
hera
Arg
ento
cu
ltaFr
esh
aeria
l par
ts o
f Oen
othe
ra b
ienn
is L.
, col
lect
ed at
�ow
erin
g tim
e, cu
ltiva
ted
acco
rdin
g to
APC
Met
hod
1.1.
1 (u
sing
a di
lute
d sil
ver c
onta
inin
g su
bsta
nce
for t
he
trea
tmen
t of t
he so
il fo
r the
1st
life
cyc
le).
(HA
B 19
24)
Vade
mec
um:
Oen
othe
ra
Arg
ento
cul
taPr
imul
a ve
ris A
uro
culta
Fres
h �o
wer
s of P
rimul
a ve
ris L
., cu
ltiva
ted
acco
rdin
g to
APC
Met
hod
1.1.
1 (u
sing
a di
lute
d go
ld co
ntai
ning
subs
tanc
e fo
r the
trea
tmen
t of t
he so
il fo
r the
1st
life
cyc
le).
Prim
ula
Auro
cul
ta
(25.
10.1
994)
Tara
xacu
m o
�ci
nale
St
anno
cul
tum
Who
le fr
esh
�ow
erin
g pl
ants
of T
arax
acum
o�
cina
le a
gg. F
.H. W
igg.
, cul
tivat
ed
acco
rdin
g to
APC
Met
hod
1.1.
1 (u
sing
a di
lute
d tin
cont
aini
ng su
bsta
nce
for t
he
trea
tmen
t of t
he so
il fo
r the
1st
life
cyc
le).
(HA
B)Ta
raxa
cum
Sta
nno
cultu
m (2
5.10
.199
4)
�uj
a oc
cide
ntal
is A
rgen
to c
ulta
Fres
h, le
afy,
one-
year
-old
twig
s of �
uja
occi
dent
alis
L., c
ultiv
ated
acc
ordi
ng to
APC
M
etho
d 1.
1.1
(usin
g a
dilu
ted
silve
r con
tain
ing
subs
tanc
e fo
r the
trea
tmen
t of t
he so
il fo
r the
1st
life
cyc
le).
(HA
B)�
uja
occi
dent
alis
A
rgen
to c
ulta
(1
2.09
.199
2)U
rtic
a di
oica
Fer
ro
culta
Fres
h ae
rial p
arts
of U
rtic
a di
oica
L, c
olle
cted
at �
ower
ing
time,
culti
vate
d ac
cord
ing
to A
PC M
etho
d 1.
1.1
(usin
g a
dilu
ted
iron
cont
aini
ng su
bsta
nce
for t
he tr
eatm
ent o
f th
e so
il fo
r the
1st
life
cyc
le).
Urt
ica
dioi
ca F
erro
cu
lta (0
3.07
.199
2)
Urt
ica
dioi
ca F
erro
cu
lta, C
inis
see
Cin
is U
rtic
ae F
erro
cul
tae
Urt
ica
dioi
ca F
erro
cu
lta, R
adix
Fres
h un
derg
roun
d pa
rts o
f Urt
ica
dioi
ca L
., co
llect
ed at
�ow
erin
g tim
e, cu
ltiva
ted
acco
rdin
g to
APC
Met
hod
1.1.
1 (u
sing
a di
lute
d iro
n co
ntai
ning
subs
tanc
e fo
r the
tr
eatm
ent o
f the
soil
for t
he 1
st li
fe c
ycle
).
Urt
ica
dioi
ca F
erro
cu
lta (0
3.07
.199
2)
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
168
• Appendix 2.6
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
169
APPENDIX 2.6
List of compositions Additional Information, see p. 22
• Ap
pend
ix 2
.6
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Appendix 2.6
170
Nam
e of t
he su
bsta
nce
Scie
nti�
c nam
e of
ingr
edie
nts
Prep
arat
ion
met
hod
Exem
plar
y ref
eren
ce fo
r use
in an
thro
poso
phic
m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Alk
ali c
omp.
Com
mip
hora
Jacq
. sp
ecie
s (M
yrrh
) /
Kal
ium
car
boni
cum
/ Q
uarz
/ Tr
ona
�e
min
eral
com
posit
ion
acco
rdin
g to
the
mod
el o
f Cic
horiu
m in
tybu
s, Pl
anta
to
ta, A
lkal
i com
p. is
mad
e fr
om: P
otas
sium
car
bona
te /
Tron
a / Q
uart
z and
Myr
rh.
Pota
ssiu
m c
arbo
nate
, Tro
na a
nd q
uart
z are
inte
nsiv
ely
tritu
rate
d an
d m
ixed
with
an
orga
nic b
inde
r (M
yrrh
).
Vade
mec
um:
Alk
ali c
omp.
Ani
s-Py
ritPi
mpi
nella
ani
sum
L.
/ Py
rite
/ Sac
-ch
arum
(Sac
char
um
o�ci
naru
m L
.)
1 g
Ani
s-Py
rit is
pre
pare
d fr
om: P
impi
nella
ani
sum
, Fru
ctus
0.3
3 g
/ pyr
ite 0
.33
g / s
acch
arum
0.3
3 g.
War
med
pyr
ite p
owde
r and
mel
ted
sucr
ose
(can
e su
gar)
are
th
orou
ghly
mix
ed, t
he p
owde
red
anise
ed a
dded
, with
�na
l tho
roug
h m
ixin
g. �
is fo
rmul
atio
n is
dilu
ted
with
an
equa
l am
ount
of l
acto
se m
onoh
ydra
te, g
rinde
d an
d sie
ved.
�e
resu
lting
pre
para
tion
is na
med
Ani
s-Py
rit 5
0%. �
e po
tenc
y A
nis-
Pyrit
D
1 is
prep
ared
from
2 p
arts
Ani
s-Py
rit 5
0% a
nd 8
par
ts la
ctos
e m
onoh
ydra
te.
Ani
s-Py
rit (0
4.06
.198
6)
Apis
cum
Lev
istic
oAp
is m
elli�
ca L
. /
Levi
stic
um o
�ci
nale
W
. D. J
. Koc
h
1 g
Apis
cum
Lev
istic
o Ø
(= D
1) is
pre
pare
d fr
om 0
.1 g
Api
s mel
li�ca
/ 0.
1 g
aque
-ou
s ext
ract
of L
evist
icum
, Rad
ix (d
rug
to e
xtra
ct =
4:1
). �
e be
es a
re k
illed
, com
-m
inut
ed a
nd m
ixed
with
a fr
eshl
y pr
epar
ed a
queo
us e
xtra
ct o
f Lev
istic
um, R
adix
(d
rug
to e
xtra
ct =
4:1
) and
gly
cero
l 85%
. �e
liqui
d is
furt
her p
roce
ssed
imm
edi-
atel
y.
Apis
cum
Lev
istic
o (1
2.09
.199
2)
Arg
entu
m-C
orpu
s vi
treu
mA
rgen
tum
met
al-
licum
/ C
orpu
s vi
treu
m (B
os ta
urus
L.
or O
ryct
olag
us
cuni
culu
s L.)
Fres
h ey
e ba
ll (C
orpu
s vitr
eum
) is c
lean
ed a
nd m
ixed
with
a so
lutio
n pr
epar
ed
of si
lver
nitr
ate,
conc
entr
ated
am
mon
ia so
lutio
n an
d pu
ri�ed
wat
er a
nd m
ixed
. A
�er a
dditi
on o
f a so
lutio
n of
glu
cose
mon
ohyd
rate
in p
uri�
ed w
ater
the
mix
ture
is
gent
ly w
arm
ed so
that
the
silve
r nitr
ate
is re
duce
d to
the
met
al. A
�er �
lterin
g,
the
resid
ue is
drie
d w
ith la
ctos
e m
onoh
ydra
te, b
eing
adj
uste
d to
giv
e a
�nal
silv
er
cont
ent o
f 1%
.
Arg
entu
m-C
orpu
s vit-
reum
(12.
09.1
992)
Arn
ica-
Cer
ebru
mA
rnic
a m
onta
na L
. /
Cer
ebru
m, C
er-
ebel
lum
, Tru
ncus
ce
rebr
i (Bo
s tau
rus
L. o
r Ory
ctol
agus
cu
nicu
lus L
.)
1 g
Arn
ica-
Cer
ebru
m D
1 co
ntai
ns: A
rnic
a, P
lant
a to
ta, p
ress
ed ju
ice
0.05
g/
Cer
ebru
m 0
.05
g (C
ereb
rum
= C
ereb
rum
, Cer
ebel
lum
, bra
in st
em =
2+1
+1).
�e
clea
ned
ingr
edie
nts o
f Cer
ebru
m a
re m
ixed
with
the
fres
h pr
esse
d pl
ant j
uice
of
Arn
ica
mon
tana
and
inte
nsiv
ely
tritu
rate
d. W
ater
for i
njec
tions
is a
dded
and
the
mix
ture
pot
entis
ed to
mak
e th
e D
1 po
tenc
y. �
e D
1 po
tenc
y is
furt
her p
roce
ssed
im
med
iate
ly.
Arn
ica-
Cer
ebru
m
(12.
09.1
992)
Cal
cium
silic
icum
co
mp.
Arn
ica
mon
tana
L.
/ Cal
cii o
xidu
m /
Cam
phor
a / K
alii
carb
onas
/ Q
uarz
/ Q
uerc
us ro
bur L
. an
d Q
uerc
us p
etra
ea
(Mat
t.) L
iebl
. /
Triti
cum
aes
tivum
L.
em
end
Fior
i et
Paol
.
�e
min
eral
com
posit
ion
acco
rdin
g to
the
mod
el o
f Arn
ica
mon
tana
, Rad
ix,
Cal
cium
silic
icum
com
p. is
pre
pare
d fr
om: S
ilica
te m
elt (
obta
ined
from
qua
rtz /
po
tass
ium
car
bona
te /
calc
ium
oxi
de) /
arn
ica
late
x / d
ried
wat
er-e
xtra
ct o
f Que
r-cu
s, C
orte
x / c
amph
or /
esse
ntia
l oil
from
Arn
ica
mon
tana
, Rad
ix /
fres
h w
heat
gl
uten
. �e
silic
ate
mel
t is a
dded
to a
mix
ture
of t
he A
rnic
a la
tex
and
drie
d ex
trac
t of
Que
rcus
, Cor
tex
and
tritu
rate
d. F
inal
ly th
e ca
mph
or a
nd th
erea
�er t
he e
ssen
tial
oil o
f Arn
ica
are
adde
d. �
e m
ixtu
re is
tritu
rate
d w
ell,
fres
h w
heat
glu
ten
adde
d an
d th
e w
hole
kne
aded
to m
ake
a pa
ste.
�is
is th
en d
ried,
pow
dere
d an
d di
lute
d w
ith
lact
ose
mon
ohyd
rate
. Pot
entis
atio
n ac
cord
ing
to P
h.Eu
r. 4.
1.1.
Vade
mec
um:
Cal
cium
silic
icum
co
mp.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
171
Nam
e of t
he su
bsta
nce
Scie
nti�
c nam
e of
ingr
edie
nts
Prep
arat
ion
met
hod
Exem
plar
y ref
eren
ce fo
r use
in an
thro
poso
phic
m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Car
bo B
etul
ae c
um
Met
hano
Betu
la p
endu
la R
oth
/ Met
hane
Car
bo B
etul
ae (c
harc
oal f
rom
the
birc
h) sa
tura
ted
with
met
hane
R1
(Ph.
Eur.)
is
used
: Pow
dere
d C
arbo
Bet
ulae
is h
eate
d un
der v
acuu
m. A
�er h
eatin
g an
d du
ring
cool
ing
Car
bo B
etul
ae is
satu
rate
d w
ith m
etha
ne.
Car
bo B
etul
ae c
um
Met
hano
(25.
10.1
994)
Che
lidon
ium
/ Cur
cum
a pr
aep.
Che
lidon
ium
maj
us
L. /
Curc
uma
xan-
thor
rhiz
a Ro
xb.
Che
lidon
ium
Ø (P
h.Eu
r. 1.
1.5)
Cur
cum
a xa
ntho
rrhi
za, R
hizo
ma
Ø (H
AB
19f w
ith
62%
Eth
anol
) are
mix
ed b
y dr
oppi
ng 1
par
t of t
he �
rst i
nto
1 pa
rt o
f the
rota
ting
seco
nd m
othe
r tin
ctur
e.
Che
lidon
ium
/ Cur
cum
a (0
4.06
.198
6)
Chi
netu
m a
rsen
icos
umC
inch
ona
pube
scen
s Va
hlA
rsen
ic a
cid-
boun
d al
kalo
id co
mpl
ex o
btai
ned
from
the
bark
of C
inch
ona
pube
s-ce
ns V
ahl
Chi
netu
m a
rsen
icos
um
(03.
07.1
992)
Cin
is e
fruc
tibus
Ave
nae
sativ
ae c
um M
agne
sio
phos
phor
ico
(1:1
)
Aven
a sa
tiva
L. /
Mag
nesiu
m p
hos-
phor
icum
1. C
inis
e fr
uctib
us A
vena
e sa
tivae
(ash
of t
he fr
uit o
f Ave
na sa
tiva,
oat
s): O
ats a
re
moi
sten
ed w
ith w
ater
to st
art g
erm
inat
ion,
drie
d an
d as
hed.
2.
Ash
of o
ats w
ith m
agne
sium
hyd
roge
n ph
osph
ate:
Equ
al p
arts
of a
sh o
f oat
s and
m
agne
sium
hyd
roge
n ph
osph
ate
are
mix
ed to
geth
er.
3. P
oten
tisat
ion
acco
rdin
g to
Ph.
Eur.
4.1.
1.
Mag
nesiu
m p
hosp
hori-
cum
cum
cine
re A
vena
e (0
2.03
.199
1)
Cin
is C
apse
llae
com
p.
APC
Art
emisi
a ab
sin-
thiu
m L
. / C
apse
lla
burs
a-pa
stor
is (L
.) M
ed. /
Cup
ri su
lfas
pent
ahyd
ricus
/ Fe
rros
i sul
fas d
esic
-ca
tus /
Hal
ite /
Kal
ii ca
rbon
as/ P
lan-
tago
lanc
eola
ta L
. /
Plum
bum
subc
ar-
boni
cum
(Cer
ussa
) / R
osa
cent
ifolia
L.
/ Cre
mor
Tar
tari
(Cre
am o
f Tar
tar)
�e
drie
d pl
ant m
ater
ial i
s inc
iner
ated
. �e
wat
er so
lubl
e as
h sa
lts o
btai
ned
ther
e-fr
om, p
otas
sium
car
bona
te (o
btai
ned
from
Cre
am o
f Tar
tar)
and
hal
ite a
re m
ixed
an
d ad
ded
to th
e po
wde
r-m
ixtu
re o
f cop
per s
ulfa
te a
nd fe
rrou
s sul
fate
. �is
com
-bi
ned
pow
der i
s gro
und
until
the
colo
ur ch
ange
s to
redd
ish b
row
n. In
the
next
step
w
ine
vine
gar,
in w
hich
fres
h ro
se p
etal
s hav
e be
en so
aked
, is a
dded
and
the
mix
ture
is
heat
ed a
nd m
ixed
whi
le th
e co
lour
turn
s to
pist
achi
o gr
een.
Whe
n th
e pa
sty
mas
s ge
ts m
ore
solid
, cer
ussa
is a
dded
and
hea
ting
is co
ntin
ued
until
the
mix
ture
is so
lid
and
dry.
A�e
r coo
ling
the
subs
tanc
e ob
tain
ed is
pow
dere
d.
For e
xter
nal u
se (e
.g. o
intm
ent,
gel)
an a
queo
us so
lutio
n of
the
wat
er so
lubl
e sa
lts is
us
ed a
s act
ive
subs
tanc
e: 9
par
ts o
f pur
i�ed
wat
er a
re a
dded
to 1
par
t of C
inis
Cap
-se
llae
com
p. A
PC, t
he m
ixtu
re is
agi
tate
d in
a cl
osed
cont
aine
r and
allo
wed
to st
and
at ro
om te
mpe
ratu
re fo
r at l
east
20
hour
s. �
e su
pern
atan
t is �
ltere
d. �
e re
sulti
ng
Cin
is C
apse
llae
com
p. a
queo
us so
lutio
n 10
% is
clea
r and
viri
dian
gre
en (t
urqu
oise
bl
ue to
em
eral
d gr
een)
in co
lour
and
has
to b
e pr
oces
sed
imm
edia
tely.
1
part
Cin
is C
apse
llae
com
p. a
queo
us so
lutio
n 10
% co
rres
pond
s to
0.1
part
s of
Cin
is C
apse
llae
com
p. A
PC.
Vade
mec
um 2
013:
C
inis
Cap
sella
e co
mp.
Ciss
us-O
ssa
Aves
var
iae,
e.g.
Phas
ianu
s col
chic
us
L. (O
ssae
) / C
issus
go
ngyl
odes
(Bak
.) Bu
rch.
1 g
Ciss
us-O
ssa
is pr
epar
ed fr
om: E
than
olic
ext
ract
from
: Ciss
us g
ongy
lode
s, ae
rial
root
1.5
g/ O
ssa
0.5
g. �
e bo
nes o
f par
trid
ge o
r phe
asan
t are
clea
ned,
boi
led,
drie
d,
pow
dere
d an
d m
ixed
with
equ
al p
arts
of l
acto
se m
onoh
ydra
te. T
o th
is m
ixtu
re a
dd
the
mot
her t
inct
ure
of C
issus
gon
gylo
des,
aeria
l roo
ts d
ried
(Ph.
Eur.
Met
hod
1.1.
7).
Ciss
us-O
ssa
(03.
07.1
992)
• Ap
pend
ix 2
.6
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
172
Nam
e of t
he su
bsta
nce
Scie
nti�
c nam
e of
ingr
edie
nts
Prep
arat
ion
met
hod
Exem
plar
y ref
eren
ce fo
r use
in an
thro
poso
phic
m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Com
posit
io C
icho
riiSe
e Com
posit
io M
iner
alis
cum
Myr
rha
Com
posit
io M
iner
alis
cum
Myr
rha
APC
Qua
rz /
Kal
ii ca
r-bo
nas /
Com
mip
h-or
a Ja
cob
spec
ies
(myr
rh) /
Aci
dum
ph
osph
oric
um /
Hal
it / F
ruct
osum
/ La
ctos
um m
onoh
y-dr
icum
�e
min
eral
com
posit
ion
acco
rdin
g to
the
mod
el o
f Cic
horiu
m in
tybu
s, Pl
anta
tota
, C
ompo
sitio
Cic
horii
, is p
repa
red
by m
eltin
g qu
artz
with
pot
assiu
m c
arbo
nate
. A�e
r co
olin
g, th
e pro
duct
is d
issol
ved
in w
ater
and
add
ed to
pow
dere
d m
yrrh
, sw
olle
n by
ad
ding
Spi
ritus
vin
i and
wat
er. �
en p
hosp
horic
aci
d is
adde
d, le
adin
g to
pre
cipi
ta-
tion
of si
licic
aci
d. �
e m
ixtu
re is
drie
d, si
eved
and
mix
ed w
ith h
alite
. A co
ncen
trat
-ed
aqu
eous
solu
tion
of c
aram
el o
f fru
ctos
e an
d th
en la
ctos
e m
onoh
ydra
te is
add
ed.
A�e
r dry
ing,
the
who
le m
ixtu
re is
grin
ded
to a
uni
form
pow
der.
Com
posit
io M
iner
alis
cum
Sac
char
o A
PCK
alii
carb
onas
/ Q
uarz
/ Tr
ona/
Sac-
char
um
�e
min
eral
com
posit
ion
acco
rdin
g to
the
mod
el o
f Cha
mom
illa
(Mat
ricar
ia
recu
tita
L.) R
adix
, Com
posit
io M
iner
alis
cum
Sac
char
o is
prep
ared
from
: Pot
as-
sium
car
bona
te/q
uart
z/tr
ona.
Pot
assiu
m c
arbo
nate
and
qua
rtz a
re m
elte
d to
geth
er.
�e
mel
t is d
issol
ved
in w
ater
to p
rodu
ce a
clea
r sol
utio
n, a
nd si
mul
tane
ously
with
a
solu
tion
of su
cros
e ad
ded
to a
solu
tion
of p
otas
sium
car
bona
te a
nd tr
ona.
�is
mix
ture
is im
med
iate
ly p
oten
tised
with
eth
anol
15%
to D
1.
Der
Mer
kurs
tab
2012
; 65(
1): 4
6-53
Cor
pus v
itreu
m-S
tan-
num
Cor
pus v
itreu
m
(Bos
taur
us L
. or
Ory
ctol
agus
cun
icu-
lus L
.) / S
tann
um
hydr
oxat
um
1 g
Cor
pus v
itreu
m-S
tann
um D
1 co
ntai
ns: C
orpu
s vitr
eum
0.0
8 g
/ sta
nnum
hy-
drox
ydat
um 0
.02
g. A
solu
tion
of ti
n (I
I) ch
lorid
e in
pur
i�ed
wat
er is
mix
ed w
ith a
so
lutio
n of
sodi
um c
arbo
nate
in p
uri�
ed w
ater
. �e
resu
lting
pre
cipi
tate
(sta
nnum
hy
drox
atum
) is a
dded
to fr
esh,
min
ced
corp
us v
itreu
m a
nd th
orou
ghly
mix
ed. �
e m
ixtu
re is
dilu
ted
in th
e pr
opor
tion
1:10
with
wat
er fo
r inj
ectio
ns to
mak
e th
e D
1 po
tenc
y. �
e D
1 po
tenc
y is
furt
her p
roce
ssed
imm
edia
tely.
Cor
pus v
itreu
m-S
tann
um
(12.
09.1
992)
Cupr
um-R
en-G
land
ula
supr
aren
alis
Gla
ndul
a su
prar
e-na
lis /
Rene
s (Bo
s ta
urus
L. o
r Ory
c-to
lagu
s cun
icul
us
L.) /
Tet
ram
min
e co
pper
(II)
sulfa
te
1 g
Cupr
um-R
en (=
D1)
cont
ains
: Gla
ndul
a su
prar
enal
is 0.
023
g / r
en 0
.060
g /
tetr
amm
ine
copp
er(I
I)su
lfate
0.0
17 g
. �e
fres
h, cl
eane
d an
imal
ingr
edie
nt is
mix
ed
with
a sm
all a
mou
nt o
f wat
er fo
r inj
ectio
ns a
nd te
tram
min
e co
pper
(II)
sulfa
te, a
nd
tritu
rate
d to
geth
er. A
�erw
ards
the
rest
of t
he w
ater
for i
njec
tions
is a
dded
to m
ake
the
D1
pote
ncy,
and
the
solu
tion
is po
tent
ised.
�e
D1
pote
ncy
is fu
rthe
r pro
cess
ed
imm
edia
tely.
Cupr
um-R
en-G
land
ula
supr
aren
alis
(12.
09.1
992)
Equi
setu
m c
um S
ulfu
re
tost
umEq
uise
tum
arv
ense
L.
/ Su
lfur
Equi
setu
m c
um S
ulfu
re to
stum
is p
repa
red
from
Equ
isetu
m a
rven
se, H
erba
and
su
lfur.
99 p
arts
Equ
isetu
m a
rven
se, H
erba
(drie
d, h
erba
l dru
g, co
mm
inut
ed to
a
part
icle
size
≤ 4
mm
) are
mix
ed w
ith o
ne p
art s
ulfu
r (pa
rtic
le si
ze ≤
0,0
63 m
m) a
nd
then
toas
ted
acco
rdin
g to
APC
4.1
. Hea
ting
time:
abo
ut 5
–15
min
utes
.
Equi
setu
m c
um S
ulfu
re
tost
um (0
5.12
.198
9)
Equi
setu
m li
mos
um-
Rube
llit
Equi
setu
m li
mos
um
L. (E
quise
tum
�u-
viat
ile L
.) /
Rube
llit
Fres
h ha
rves
ted
shoo
ts o
f Equ
isetu
m li
mos
um L
. (Eq
uise
tum
�uv
iatil
e L.
) are
put
in
to a
n aq
ueou
s dilu
tion
of R
ubel
lit D
6 du
ring
the
day
and
unde
r pre
senc
e of
day
lig
ht. I
n th
e ev
enin
g th
e sh
oots
are
take
n ou
t, co
mm
inut
ed a
nd e
xpre
ssed
. �e
expr
esse
d ju
ice
is m
ixed
with
an
equa
l mas
s of e
than
ol 9
6%. F
ilter
a�e
r 5 to
10
days
. �
e �l
trat
e is
Equi
setu
m li
mos
um-R
ubel
lit Ø
.
Sold
ner G
, Ste
ll-m
ann
HM
. Ind
ivi-
duel
le P
ädia
trie
, 4.
Au�a
ge, W
issen
-sc
ha�l
. Ver
l. G
es.,
Stut
tgar
t, 20
11, p
. 74
3
• Appendix 2.6
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Ap
pend
ix 2
.6
173
Nam
e of t
he su
bsta
nce
Scie
nti�
c nam
e of
ingr
edie
nts
Prep
arat
ion
met
hod
Exem
plar
y ref
eren
ce fo
r use
in an
thro
poso
phic
m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Ferr
um h
ydro
xyda
tum
Ferr
um ap
h / V
itis
vini
fera
L.
Ferr
um h
ydro
xyda
tum
is p
repa
red
from
Fer
rum
met
allic
um re
duct
um a
nd re
d w
ine
vine
gar.
Iron
that
pre
viou
sly h
as b
een
obta
ined
from
side
rite
by re
duct
ion
is co
vere
d w
ith re
d w
ine
vine
gar a
nd li
ghtly
war
med
for a
bout
14
days
. �en
the
solu
tion
is �l
tere
d, a
nd th
e re
sidue
was
hed
with
wat
er a
nd le
� to
reac
t with
air.
�
is ox
idat
ion
rele
ases
hea
t, w
here
fore
the
prep
arat
ion
has t
o be
kep
t moi
st. �
e ox
idise
d iro
n is
redu
ced
to p
owde
r.
Ferr
um h
ydro
xyda
tum
(0
2.03
.199
1)
Ferr
um p
omat
umFe
rrum
aph
/ Mal
us
dom
estic
a Bo
rkh.
1 g
of th
e D
1 co
ntai
ns: F
e 5
mg.
Sou
r app
les a
re p
ress
ed; t
he ju
ice
is m
ixed
with
Fer
-ru
m m
etal
licum
. �e
mix
ture
is le
� fo
r sev
eral
day
s and
then
war
med
to a
bout
50
°C. A
�erw
ards
the
solu
tion
is �l
tere
d an
d m
ixed
with
eth
anol
96%
.Fe
rrum
-Qua
rzFe
rros
i sul
fas d
esic
-ca
tus /
Mel
, Qua
rz
/ Vin
um (V
itis
vini
fera
L.)
A m
ixtu
re o
f fer
rous
sulfa
te, h
oney
, whi
te w
ine,
and
calc
inat
ed q
uart
z is p
repa
red
�is
mix
ture
is h
eate
d an
d dr
ied
unde
r vac
uum
.Fe
rrum
/ Q
uarz
(0
4.06
.198
6)
Ferr
um ro
satu
mFe
rrum
side
reum
/ Ro
sa ce
ntifo
lia L
.Fe
rrum
rosa
tum
is p
repa
red
from
Ros
a ce
ntifo
lia a
nd F
erru
m si
dere
um D
1. F
resh
ro
se p
etal
s are
tritu
rate
d w
ith 1
% F
erru
m si
dere
um D
1 an
d th
e am
ount
of w
ater
, ca
lcul
ated
acc
ordi
ng to
Ph.
Eur.
1.1.
6, a
nd th
en a
llow
ed to
stan
d fo
r 2-4
day
s at
15-2
00C
. �en
the
calc
ulat
ed a
mou
nt o
f eth
anol
96%
is a
dded
and
the
prep
arat
ion
cont
inue
d ac
cord
ing
to P
h.Eu
r. 1.
1.6.
�e
com
posit
ion
can
be p
oten
tised
.
Ferr
um ro
satu
m/G
raph
-ite
s (03
.07.
1992
)
Hel
lebo
rus n
iger
H
elle
boru
s nig
er L
. A
queo
us e
xtra
ct p
repa
red
from
the
fres
h pl
ant p
arts
of H
elle
boru
s nig
er L
. (Fl
os
rec.
and
Plan
ta to
ta re
c.), a
ccor
ding
to A
PC 7
.5.
Hel
lebo
rus n
iger
(0
4.06
.198
6)
Hel
lebo
rus f
oetid
us
Hel
lebo
rus f
oetid
us
L.
Aqu
eous
ext
ract
pre
pare
d fr
om th
e fr
esh
plan
t par
ts o
f Hel
lebo
rus f
oetid
us L
. (Fl
os
rec.
and
Foliu
m e
t Rad
ix re
c.) a
ccor
ding
to A
PC 7
.5.
Hep
ar-M
agne
sium
Hep
ar (B
os ta
urus
L.
or O
ryct
olag
us
cuni
culu
s L.)
/ Mag
-ne
sium
hyd
roxy
da-
tum
1 g
Hep
ar-M
agne
sium
D1
cont
ains
: Hep
ar 0
.06
g / m
agne
sium
hyd
roxy
datu
m 0
.04
g. A
solu
tion
of m
agne
sium
chlo
ride
in w
ater
is m
ixed
with
a so
lutio
n of
sodi
um
hydr
oxid
e in
wat
er. �
e re
sulti
ng p
reci
pita
te (M
agne
sium
hyd
roxy
datu
m) i
s was
hed
seve
ral t
imes
with
wat
er a
nd th
an m
ixed
with
chop
ped
piec
es o
f liv
er a
nd th
en
toge
ther
with
hon
ey, i
t is �
nely
tritu
rate
d. �
e m
ixtu
re is
mix
ed w
ith w
ater
for i
n-je
ctio
ns (P
h.Eu
r. 3.
1.2)
or g
lyce
rol 8
5% (P
h.Eu
r. 2.
1.1)
, and
pot
entis
ed to
mak
e th
e D
1 po
tenc
y. �
is D
1 po
tenc
y is
proc
esse
d im
med
iate
ly.
Hep
ar-M
agne
sium
(0
3.02
.199
2)
Hep
ar-S
tann
umH
epar
(Bos
taur
us
L. o
r Ory
ctol
agus
cu
nicu
lus L
.) / S
tan-
num
hyd
roxy
datu
m
1 g
Hep
ar-S
tann
um co
ntai
ns: H
epar
0.0
8 g
/ Sta
nnum
hyd
roxy
datu
m 0
.02
g. A
so
lutio
n of
tin
(II)
chlo
ride
in w
ater
is m
ixed
with
a so
lutio
n of
sodi
um c
arbo
nate
in
wat
er. �
e re
sulti
ng p
reci
pita
te (S
tann
um h
ydro
xyat
um) i
s was
hed
with
wat
er.
�e
resu
lting
Sta
nnum
hyd
roxy
atum
is m
ixed
with
chop
ped
piec
es o
f liv
er a
nd th
en
thor
ough
ly tr
itura
ted
with
hon
ey. �
e m
ixtu
re is
mix
ed w
ith w
ater
for i
njec
tions
(P
h. E
ur. 3
.1.2
) or g
lyce
rol 8
5% (P
h. E
ur. 2
.1.1
), an
d po
tent
ised
to m
ake
the
D1
pote
ncy.
�is
D1
pote
ncy
is pr
oces
sed
imm
edia
tely.
Hep
ar-S
tann
um
(02.
03.1
991)
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
174
Nam
e of t
he su
bsta
nce
Scie
nti�
c nam
e of
ingr
edie
nts
Prep
arat
ion
met
hod
Exem
plar
y ref
eren
ce fo
r use
in an
thro
poso
phic
m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Hep
ar su
lfuris
Ost
rea
edul
is L.
/ Su
lfur
HA
BH
epar
sulfu
ris co
mp.
(0
5.12
.198
9)K
aliu
m a
cetic
um co
mp.
Ant
imon
ite /
Cor
al-
lium
rubr
um L
. /
Cro
cus s
ativ
us L
. / K
alii
carb
onas
/ A
cetu
m V
ini d
estil
-la
tum
(Viti
s vin
ifera
L.
) / S
pirit
us e
Vin
o (V
itis v
inife
ra L
.)
Kal
ium
ace
ticum
com
p. is
pre
pare
d fr
om:
Pota
ssiu
m c
arbo
nate
/ di
still
ed re
d w
ine
vine
gar /
ant
imon
ite /
Cro
cus s
ativ
us ti
nc-
ture
(veh
icle
: spi
ritus
e v
ino)
/ sp
iritu
s e v
ino
/ Cor
alliu
m ru
brum
. Po
tass
ium
car
bona
te/d
istill
ed re
d w
ine
vine
gar/
antim
onite
/ Cro
cus s
ativ
us ti
nc-
ture
/Cor
alliu
m ru
brum
and
spiri
tus e
vin
o ar
e st
epw
ise co
mbi
ned
and
repe
ated
ly
dist
illed
. �e
resu
ltant
drie
d re
sidue
is u
sed.
Kal
ium
ace
ticum
com
p.
(03.
07.1
992)
Kal
ium
sulfu
ricum
co
mp.
Kal
ii su
lfas /
Nat
rii
sulfa
s / L
inum
usit
a-tis
simum
L.
�e
min
eral
com
posit
ion
acco
rdin
g to
the
mod
el o
f Ana
galli
s arv
ensis
, Her
ba,
Kal
ium
sulfu
ricum
com
p. is
pre
pare
d by
mix
ing
Kal
ii su
lfas a
nd N
atrii
sulfa
s and
m
akin
g a
past
e by
grin
ding
with
muc
ilage
of l
inse
ed. �
e m
ixtu
re is
drie
d, g
rinde
d,
sieve
d; a
nd �
nally
dilu
ted
with
lact
ose
mon
ohyd
rate
.
Vade
mec
um:
Kal
ium
sulfu
ricum
co
mp.
Lapi
s Can
cri p
raep
a-ra
tus
Ast
acus
ast
acus
L. /
Fl
int /
Viti
s vin
ifera
L.
Lapi
s Can
cri p
raep
arat
us is
pre
pare
d by
trea
ting
a m
ixtu
re o
f equ
al p
arts
of p
ow-
dere
d �i
nt a
nd L
apis
Can
cri w
ith d
istill
ed re
d w
ine
vine
gar.
�e
mix
ture
is �
ltere
d an
d th
e �l
trat
e di
lute
d to
10%
dry
resid
ue.
Lapi
s Can
cri -
Flin
tste
inA
stac
us a
stac
us L
. /
Flin
t / V
itis v
inife
ra
L.
1 g
Lapi
s Can
cri -
Flin
tste
in co
ntai
ns: L
apis
Can
cri 0
.5 g
/�in
t 0.5
g: F
inel
y po
wde
red
Lapi
s Can
cri a
nd �
int a
re th
orou
ghly
mix
ed w
ith sp
irito
e v
ino
and
the
slurr
y tr
eate
d w
ith w
ater
. �e
resu
ltant
dry
resid
ue is
the
subs
tanc
e.
Lapi
s Can
cri /
Flin
tste
in
(07.
04.1
988)
Mix
tura
Sta
nni c
omp.
Alu
men
/ Cu
prum
m
etal
licum
/ St
an-
num
met
allic
um /
Aci
dum
nitr
icum
(6
5 pe
r cen
tum
);
1 g
susp
ensio
n is
prep
ared
from
: 1 m
g A
lum
en /
0,00
2 m
g Cu
prum
met
allic
um /
2 m
g St
annu
m m
etal
licum
10,
4 m
g A
cidu
m n
itric
um (6
5 pe
r cen
tum
).D
er M
erku
rsta
b 20
11; 6
4(4)
: 332
-33
7
Myr
rha
com
p.Au
rum
met
allic
um
/ Bos
wel
lia sp
ecie
s /
Com
mip
hora
Jacq
. Sp
ecie
s / S
acch
arum
(S
acch
arum
o�
ci-
naru
m L
.)
1 g
Myr
rha
com
p. D
1 is
prep
ared
from
: Myr
rha
0.1
g / A
urum
met
allic
um fo
liatu
m
(gol
d le
af) 0
.001
g a
nd O
liban
um 0
.1g.
Myr
rha
and
gold
leaf
are
bou
nd to
geth
er
with
the
aid
of m
oder
ate
heat
; inc
ense
smok
e (f
rom
Olib
anum
) is p
asse
d th
roug
h th
e m
ixtu
re. �
is co
mpo
sitio
n is
stirr
ed in
to m
olte
n su
cros
e (c
ane
suga
r). A
�er
cool
ing
it is
tritu
rate
d fo
r one
hou
r by
hand
, res
ultin
g th
e po
tenc
y D
1.
Vade
mec
um: M
yr-
rha
com
p.
Ono
pord
on co
mp.
Hyo
scya
mus
nig
er
L. /
Ono
pord
um
acan
thiu
m L
. /
Prim
ula
veris
L.
A co
mbi
natio
n of
Ono
pord
um a
cant
hium
, Flo
s rec
., et
hano
l. D
iges
tio (1
:3.1
) with
0.
1-1%
Hyo
scya
mus
nig
er, H
erba
rec.
Ø a
nd P
rimul
a ve
ris, F
los r
ec.,
etha
nol.
Di-
gest
io (1
:3.1
) with
0.1
-1%
Hyo
scya
mus
nig
er, H
erba
rec.
Ø
Ono
pord
on co
mp.
(0
4.06
.198
6)
• Appendix 2.6
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
175
Nam
e of t
he su
bsta
nce
Scie
nti�
c nam
e of
ingr
edie
nts
Prep
arat
ion
met
hod
Exem
plar
y ref
eren
ce fo
r use
in an
thro
poso
phic
m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Ono
pord
on co
mp.
pr
aepa
ratu
mO
nopo
rdum
aca
n-th
ium
L. /
Hyo
-sc
yam
us n
iger
L. /
Pr
imul
a ve
ris L
.
Ono
pord
um a
cant
hium
, Flo
s rec
., et
hano
l. D
iges
tio (1
:3.1
) with
1%
Hyo
scya
mus
ni
ger,
Her
ba re
c. Ø
is d
ilute
d w
ith w
ater
(a).
Prim
ula
veris
, Flo
s rec
., et
hano
l. D
i-ge
stio
(1:3
.1) i
s dilu
ted
with
wat
er (b
). In
a sp
ecia
l equ
ipm
ent 1
par
t of t
he se
cond
m
ixtu
re (b
) is d
ropp
ed i
nto
1 pa
rt o
f the
rota
ting
mix
ture
a.
Ono
pord
on co
mp.
(0
4.06
.198
6)
Ono
pord
um a
cant
hium
, Fl
os re
c., e
than
ol.
Dig
estio
(1:3
.1) w
ith
0.1-
1% H
yosc
yam
us
nige
r, H
erba
rec.
Ø
Ono
pord
um a
can-
thiu
m L
. / H
yosc
ya-
mus
nig
er L
.
Dig
estio
pre
pare
d fr
om 1
par
t of t
he fr
esh
�ow
erhe
ads o
f Ono
pord
um a
cant
hium
L.
and
3.1
par
ts o
f eth
anol
of s
uita
ble
conc
entr
atio
n or
wat
er fo
r inj
ectio
ns a
nd th
e ad
ditio
n of
0.0
04 to
0.0
4 pa
rts (
corr
espo
ndin
g to
0.1
to 1
%) o
f Hyo
scya
mus
nig
er
L., H
erba
, mot
her t
inct
ure
( Ph.
Eur.
1.1.
3).
Ono
pord
on co
mp.
(0
4.06
.198
6)
Peat
mos
s ext
ract
com
-po
sitio
n I (
light
)So
lum
ulig
inos
um /
Aes
culu
s hip
poca
s-ta
num
L. /
Equ
ise-
tum
arv
ense
L.
98 p
arts
of p
eat m
oss e
xtra
ct in
ana
logy
to to
HA
B M
etho
d 12
c (us
ing
puri�
ed
wat
er o
nly)
, are
mix
ed w
ith e
ach
1 pa
rt o
f Aes
culu
s hip
poca
stan
um e
sem
ine
ac-
cord
ing
to H
AB
Met
hod
12m
and
Equ
isetu
m a
rven
se e
x he
rba
acco
rdin
g to
HA
B M
etho
d 12
c. �
e su
pern
atan
t liq
uid
is de
cant
ed a
nd �
ltere
d a�
er 1
0 - 1
2 w
eeks
yi
eldi
ng at
leas
t 75%
Pea
t mos
s ext
ract
com
posit
ion
I.
Solu
m u
ligin
osum
com
p.
(02.
03.1
991)
Peat
mos
s ext
ract
com
-po
sitio
n II
(dar
k)So
lum
ulig
inos
um /
Aes
culu
s hip
poca
s-ta
num
L. /
Equ
ise-
tum
arv
ense
L.
�e
rest
le�
from
the
deca
ntin
g fo
r pre
parin
g Pe
at m
oss e
xtra
ct co
mpo
sitio
n I,
(max
. 25%
) is P
eat m
oss e
xtra
ct co
mpo
sitio
n II
Solu
m u
ligin
osum
com
p.
(02.
03.1
991)
Plan
tago
lanc
eola
ta,
Foliu
m re
c., et
hano
l. D
i-ge
stio
(1:3
.1) w
ith 1
-2%
H
yosc
yam
us n
iger
, H
erba
rec.
Ø
Plan
tago
lanc
eola
ta
L. /
Hyo
scya
mus
ni
ger L
.
Dig
estio
pre
pare
d fr
om 1
par
t of t
he fr
esh
leav
es o
f Pla
ntag
o la
nceo
lata
L. a
nd 3
.1
part
s of e
than
ol o
f sui
tabl
e co
ncen
trat
ion
or w
ater
for i
njec
tions
and
the
addi
tion
of 0
.04
to 0
.08
part
s (co
rres
pond
ing
to 1
to 2
%) o
f Hyo
scya
mus
nig
er L
., H
erba
, m
othe
r tin
ctur
e (P
h. E
ur. 1
.1.3
).
Plan
tago
- Pr
imul
a cu
m
Hyo
scya
mo
(02.
09.1
987)
Plum
bum
mel
litum
Plum
bum
met
al-
licum
/ M
el /
Sac-
char
um (S
acch
arum
o�
cina
rum
L.)
Plum
bum
mel
litum
is p
repa
red
from
lead
, hon
ey a
nd c
ane
suga
r. D
epre
ssio
ns a
re
intr
oduc
ed in
to a
shee
t of l
ead,
this
is �l
led
with
hon
ey, a
nd th
e w
hole
cove
red
with
m
olte
n le
ad. A
�er c
oolin
g it
is gr
ated
, mel
ted
agai
n an
d th
en la
id o
ut a
s a sh
eet.
New
dep
ress
ions
are
intr
oduc
ed o
nce
mor
e. �
ese
are
�lle
d th
is tim
e w
ith m
olte
n su
cros
e (c
ane
suga
r) a
nd co
vere
d w
ith m
olte
n le
ad fr
om th
e �r
st le
ad-h
oney
-she
et.
A�e
r coo
ling
it is
�nel
y gr
ated
and
the
D1
pote
ncy
is pr
epar
ed b
y tr
itura
tion
with
la
ctos
e m
onoh
ydra
te. D
urin
g th
e gr
indi
ng a
nd tr
itura
tion
proc
ess t
he p
owde
r mus
t be
siev
ed.
Plum
bum
mel
litum
(0
4.06
.198
6)
Prim
ula
veris
, Flo
s rec
., et
hano
l. D
iges
tio (1
:3.1
) w
ith 0
.1-1
% H
yosc
ya-
mus
nig
er, H
erba
rec.
Ø
Prim
ula
veris
L. /
H
yosc
yam
us n
iger
L.
A d
iges
tio p
repa
red
from
1 p
art o
f the
fres
h �o
wer
s of P
rimul
a ve
ris L
. and
3.1
par
ts
of e
than
ol o
f sui
tabl
e co
ncen
trat
ion
or w
ater
for i
njec
tions
and
the
addi
tion
of 0
.004
to
0.0
4 pa
rts (
corr
espo
ndin
g to
0.1
to 1
%) o
f Hyo
scya
mus
nig
er L
., H
erba
, mot
her
tinct
ure
(Ph.
Eur
. 1.1
.3).
Ono
pord
on co
mp.
(04.
06.1
986)
• Ap
pend
ix 2
.6
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
176
Nam
e of t
he su
bsta
nce
Scie
nti�
c nam
e of
ingr
edie
nts
Prep
arat
ion
met
hod
Exem
plar
y ref
eren
ce fo
r use
in an
thro
poso
phic
m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Prim
ula
veris
, Flo
s rec
., et
hano
l. D
iges
tio (1
: 12
.35)
with
0.6
%
Hyo
scya
mus
nig
er,
Her
ba re
c. Ø
Prim
ula
veris
L. /
H
yosc
yam
us n
iger
L.
Prep
ared
by
dige
stio
acc
ordi
ng to
APC
3.8
.1 fr
om 1
par
t of t
he fr
esh
�ow
ers o
f Pr
imul
a ve
ris L
. and
12.
35 p
arts
of e
than
ol o
f sui
tabl
e co
ncen
trat
ion
and
the
addi
-tio
n of
0.0
8 pa
rts (
corr
espo
ndin
g to
0.6
%) o
f Hyo
scya
mus
nig
er L
., H
erba
, mot
her
tinct
ure
(Ph.
Eur
. 1.1
.3).
Prun
usei
sen
Prun
us sp
inos
a e
�orib
us e
t sum
-m
itatib
us fe
rm c
um
Ferr
o
Prep
ared
acc
ordi
ng to
HA
B m
etho
d 37
aPr
unus
spin
osa
cum
Fe
rro
(25.
10.1
994)
Qua
rz c
um F
erro
sul-
furic
oFe
rros
i sul
fas /
Q
uarz
/ M
el /
Viti
s vi
nife
ra L
.
5 pa
rts o
f qua
rtz a
re in
cine
rate
d to
red
heat
at 8
00 °C
and
a�e
rwar
ds c
ut in
to sm
all
piec
es. �
e qu
artz
is tr
itura
ted
with
9.1
5 pa
rts o
f fer
rous
sulfa
te. 2
0 pa
rts o
f whi
te
win
e ar
e he
ated
to b
oilin
g, a
nd a
�er c
oolin
g to
35
°C, m
ade
into
a p
aste
with
the
quar
tz a
nd fe
rrou
s sul
fate
mix
ture
. 10
part
s of h
oney
and
20
part
s of l
acto
se m
ono-
hydr
ate
are
adde
d an
d th
ey a
re m
ixed
wel
l tog
ethe
r. �
e m
ixtu
re is
pla
ced
unde
r va
cuum
and
drie
d at
a su
itabl
e m
inim
um te
mpe
ratu
re. W
hile
still
war
m, t
he to
ugh
britt
le su
bsta
nce
is tr
itura
ted
with
eno
ugh
lact
ose
mon
ohyd
rate
to m
ake
100
part
s (m
othe
r sub
stan
ce=D
1).
Que
rcus
robu
r/pe
trae
e
cort
ice
cum
Cal
cio
carb
onic
o
Que
rcus
robu
r L.,
Que
rcus
pet
raea
(M
att.)
Lie
bl.
1. C
alci
um c
arbo
nicu
m e
cine
re Q
uerc
us: o
ak b
ark
is in
cine
rate
d. �
e as
h is
susp
ende
d 1
part
in 1
0 pa
rts o
f pur
i�ed
wat
er. C
arbo
n di
oxid
e is
indu
ced
for 5
to
10 m
inut
es a
nd th
en w
arm
ed u
ntil
bubb
ling
star
ts (7
5-85
°C).
�is
tem
pera
ture
is
kept
unt
il bu
bblin
g en
ds. �
e co
oled
susp
ensio
n is
�lte
red
and
the
resid
ue d
ried
= C
alci
um c
arbo
nicu
m e
cine
re Q
uerc
us.
2. C
alci
um c
arbo
nicu
m e
cine
re Q
uerc
us so
lutu
m: 0
.1 p
art o
f Cal
cium
car
boni
cum
e
cine
re Q
uerc
us is
mix
ed w
ith 6
100
part
s of p
uri�
ed w
ater
or w
ater
for i
njec
tions
an
d bo
iled
for 5
min
utes
. �e
cool
ed so
lutio
n is
�lte
red
(for s
olut
ions
for i
njec
tion
it is
deca
nted
and
�lte
red)
. �e
resu
lt is
a sa
tura
ted
aque
ous s
olut
ion
of C
alci
um
carb
onic
um e
cine
re Q
uerc
us =
Cal
cium
car
boni
cum
e ci
nere
Que
rcus
solu
tum
. 2.
1. C
alci
um c
arbo
nicu
m e
cine
re Q
uerc
us so
lutu
m sa
ccha
ratu
m: s
yrup
pre
pare
d w
ith su
cros
e an
d C
alci
um c
arbo
nicu
m e
cine
re Q
uerc
us so
lutu
m (6
4:36
). 3.
Que
rcus
robu
r/pe
trae
e co
rtic
e cu
m C
alci
o ca
rbon
ico
solu
tion
= D
5: A
dec
oc-
tion
of o
ak b
ark
acco
rdin
g to
HA
B M
etho
d 23
a (Ø
=D1)
is p
oten
tised
to D
5 w
ith
Cal
cium
car
boni
cum
e ci
nere
Que
rcus
solu
tum
as a
veh
icle
. Ap
pend
ix: a
ccor
ding
to th
e do
sage
form
to b
e pr
oduc
ed e
ither
pot
entis
e fu
rthe
r w
ith C
alci
um c
arbo
nicu
m e
cine
re Q
uerc
us so
lutu
m (e
.g. s
olut
ion
for i
njec
tion)
or
with
Cal
cium
car
boni
cum
e ci
nere
Que
rcus
solu
tum
sacc
hara
tum
(Glo
buli
vela
ti).
Cal
cium
car
boni
cum
cu
m Q
uerc
u (0
2.03
.199
1)
Rose
neise
nRo
sa e
�or
ibus
ferm
cu
m F
erro
Prep
ared
acc
ordi
ng to
HA
B m
etho
d 37
aFe
rrum
rosa
tum
/Gra
ph-
ites (
03.0
7.19
92)
• Appendix 2.6
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
177
Nam
e of t
he su
bsta
nce
Scie
nti�
c nam
e of
ingr
edie
nts
Prep
arat
ion
met
hod
Exem
plar
y ref
eren
ce fo
r use
in an
thro
poso
phic
m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Sile
x –
Lapi
s can
cri
solu
tus
Sile
x (F
lint)
/ Kal
ii ni
tras
/ La
pis c
ancr
i / A
cetu
m V
ini d
est.
(Viti
s vin
ifera
L.)
Cal
cium
silic
ate
is pr
ecip
itate
d by
add
ing
an a
queo
us so
lutio
n of
pot
assiu
m si
licat
e (p
repa
red
from
�in
t and
pot
assiu
m n
itrat
e) to
an
aque
ous s
olut
ion
of c
alci
um
acet
ate
(pre
pare
d fr
om L
apis
Can
cri a
nd d
istill
ed re
d w
ine
vine
gar i
n se
vera
l ste
ps)
and
diss
olve
d in
dist
illed
red
win
e vi
nega
r to
give
a cl
ear s
olut
ion.
�e
solu
tion
is di
lute
d w
ith w
ater
to 1
.0%
and
then
succ
usse
d to
resu
lt th
e po
tenc
y D
2.
Vade
mec
um 2
013:
Si
lex-
Lapi
s Can
cri
solu
tus
Solu
tio a
lkal
ina
Leaf
y pl
ants
/ C
ream
of
Tar
tar
An
aque
ous s
olut
ion
prep
ared
from
the
ash
of a
spec
ial c
ompo
st. C
ompo
st p
rodu
c-tio
n pr
ocee
ds at
abo
ut 3
70C
with
gre
en p
arts
of p
lant
s, so
il an
d a
prep
arat
ion
from
ta
rtar
.
Solu
tio a
lkal
ina
(25.
10.1
994)
Solu
tio F
erri
com
p.K
alii
carb
onas
/ Fe
rrum
(III
)-K
alii-
tart
aric
um /
Sulfu
r / T
rona
/ A
cidu
m
tart
aric
um
�e
min
eral
com
posit
ion
acco
rdin
g to
the
mod
el o
f Urt
ica
dioi
ca, P
lant
a to
ta, S
o-lu
tio F
erri
com
p. is
pre
pare
d fr
om: P
otas
sium
car
bona
te /
ferr
ic p
otas
sium
tart
rate
/ s
ulfu
r / tr
ona
/ aci
dum
tart
aric
um. P
otas
sium
car
bona
te, t
rona
and
sulfu
r are
m
elte
d to
geth
er. �
e re
sulti
ng m
elt i
s diss
olve
d in
wat
er a
nd a
ltern
atel
y he
ated
and
su
bjec
ted
to a
n in
tens
ive
air-
stre
am. A
�er t
his p
roce
dure
ferr
ic p
otas
sium
tart
rate
an
d ac
idum
tart
aric
um a
re a
dded
. �e
resu
lting
solu
tion
is ex
pose
d to
the
light
.
Solu
tio F
erri
com
p.(2
5.10
.199
4)
Solu
tio S
acch
ari c
omp.
Aci
dum
sulfu
ricum
/ B
etul
a pe
ndul
a Ro
th /
Kal
ii ca
rbo-
nas /
Fer
rum
(III
)-K
aliu
m-t
arta
ricum
/ M
el /
Qua
rtz /
Tro
na
�e
min
eral
com
posit
ion
acco
rdin
g to
the
mod
el o
f Cha
mom
illa
(Mat
ricar
ia re
cu-
tita
L.),
Radi
x, S
olut
io S
acch
ari c
omp.
is p
repa
red
from
: Car
bo B
etul
ae /
pota
ssiu
m
carb
onat
e / f
erric
pot
assiu
m ta
rtra
te /
hone
y / q
uart
z / tr
ona.
Pot
assiu
m c
arbo
n-at
e, qu
artz
and
Car
bo B
etul
ae a
re m
elte
d to
geth
er. �
e m
elt i
s diss
olve
d in
wat
er
to p
rodu
ce a
clea
r sol
utio
n, to
whi
ch a
solu
tion
of p
otas
sium
car
bona
te, t
rona
and
di
lute
d su
lfuric
aci
d is
adde
d. A
�er a
dditi
on o
f fur
ther
dilu
ted
sulfu
ric a
cid,
hon
ey
and
then
ferr
ic p
otas
sium
tart
rate
are
add
ed. �
e re
sulti
ng so
lutio
n is
expo
sed
to
the
light
.
Solu
tio S
acch
ari c
omp.
(25.
10.1
994)
Solu
tio S
ilice
ae co
mp.
Kal
ii ca
rbon
as /
Mar
ble
/ Qua
rz /
Sulfu
r / T
rona
�e
min
eral
com
posit
ion
acco
rdin
g to
the
mod
el o
f Equ
isetu
m a
rven
se, H
erba
, So
lutio
Sili
ceae
com
p. is
pre
pare
d fr
om: P
otas
sium
car
bona
te /
mar
ble
/ qua
rtz /
tr
ona
and
sulfu
r. Q
uart
z and
pot
assiu
m c
arbo
nate
are
mel
ted
toge
ther
and
diss
olve
d in
wat
er. I
n a
furt
her s
tep
mar
ble,
pota
ssiu
m c
arbo
nate
and
tron
a ar
e di
ssol
ved
in w
ater
by
add-
ing
vapo
ur fr
om b
urni
ng su
lfur t
o a
seco
nd so
lutio
n. B
oth
solu
tions
are
com
bine
d un
der c
ontin
uos v
apou
r fro
m b
urni
ng su
lfur.
Air
is pa
ssed
thro
ugh
the
resu
lting
so
lutio
n fo
r sev
eral
hou
rs.
Solu
tio S
ilice
a co
mp.
(25.
10.1
994)
Stan
num
mel
litum
Stan
num
met
al-
licum
/ M
el /
Sac-
char
um (S
acch
arum
o�
cina
rum
L.)
Stan
num
mel
litum
is p
repa
red
from
tin
with
hon
ey a
nd c
ane
suga
r. D
epre
ssio
ns
are
intr
oduc
ed in
to a
shee
t of t
in, t
his i
s �lle
d w
ith h
oney
, and
the
who
le co
vere
d w
ith m
olte
n tin
. A�e
r coo
ling
it is
grat
ed, m
elte
d ag
ain
and
then
laid
out
as a
shee
t. N
ew d
epre
ssio
ns a
re in
trod
uced
onc
e m
ore.
�es
e ar
e �l
led
this
time
with
mol
ten
sucr
ose
(can
e su
gar)
and
cove
red
with
mol
ten
tin. A
�er c
oolin
g it
is �n
ely
grat
ed
and
the
D1
pote
ncy
is pr
epar
ed b
y tr
itura
tion
with
lact
ose
mon
ohyd
rate
. Dur
ing
the
grin
ding
and
tritu
ratio
n pr
oces
s the
pow
der m
ust b
e sie
ved.
Der
Mer
kurs
tab
1992
; 45(
2):
108-
12
• Ap
pend
ix 2
.6
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
178
Nam
e of t
he su
bsta
nce
Scie
nti�
c nam
e of
ingr
edie
nts
Prep
arat
ion
met
hod
Exem
plar
y ref
eren
ce fo
r use
in an
thro
poso
phic
m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Trab
ecul
um co
mp.
Aci
dum
form
icic
um
e fo
rmic
a / A
m-
mon
iae
solu
tio co
n-ce
ntra
ta 2
5% /
Cupr
i su
lfas p
enta
hydr
icus
/ H
ydra
rgyr
um
biio
datu
m /
Kal
ii io
-di
dum
/ Tr
abec
ulum
(B
os ta
urus
L.)
1 g
of T
rabe
culu
m co
mp.
(=D
1) is
pre
pare
d fr
om: 0
.1 g
Tra
becu
lum
/ 0.
1 g
acid
um
form
icic
um e
form
ica
(5%
) / 0
.005
g C
upri
sulfa
s / 0
.007
g A
mm
onia
e so
lutio
con-
cent
rata
/ 0.
03 g
Hyd
rarg
yrum
biio
datu
m /
0.02
25 g
Kal
ii io
didu
m.
Trab
ecul
um is
trea
ted
with
an
aque
ous s
olut
ion
of A
cidu
m fo
rmic
icum
e fo
rmic
a to
mak
e a
pulp
with
a sm
ooth
cons
isten
cy a
nd th
en m
ixed
with
an
amm
onia
cal
solu
tion
of co
pper
sulfa
te. �
en a
solu
tion
of m
ercu
ry (I
I) io
dide
and
pot
assiu
m
iodi
de a
nd �
nally
lact
ose
mon
ohyd
rate
is a
dded
. A�e
r dry
ing,
the
who
le m
ixtu
re is
ru
bbed
to a
uni
form
pow
der.
Trab
ecul
um co
mp.
(03.
07.1
992)
Uve
a co
mp.
Aci
dum
form
icic
um
e fo
rmic
a / A
cidu
m
asco
rbic
um /
Liqu
or n
atrii
silic
ici
/ Fer
rosi
sulfa
s /
Hyo
scya
mus
nig
er
L. /
Mag
nesiu
m
phos
phor
icum
ac
idum
/ U
vea
(Bos
ta
urus
L.)
1 g
Uve
a co
mp.
cont
ains
: Uve
a bo
vis 1
.00
g / M
agne
sium
pho
spho
ricum
aci
dum
0.
10 g
/ A
cidu
m a
scor
bicu
m 0
.10
g / F
erru
m su
lfuric
um 0
.33
g / L
iquo
r nat
rii si
-lic
ici 1
.00
g / H
yosc
yam
us n
iger
, Pla
nta
tota
Rh
Ø (H
AB,
Met
hod
21) 1
.00
g. U
vea
is tr
eate
d w
ith a
n aq
ueou
s sol
utio
n of
Aci
dum
form
icic
um e
form
ica
to m
ake
a pu
lp
with
a sm
ooth
cons
isten
cy a
nd th
en m
ixed
with
a so
lutio
n of
mag
nesiu
m p
hos-
phat
e di
hydr
ate
and
sodi
um si
licat
e. �
en a
n aq
ueou
s sol
utio
n of
ferr
ous s
ulfa
te
and
asco
rbic
aci
d ar
e ad
ded,
and
�na
lly H
yosc
yam
us, P
lant
a to
ta R
h Ø
is a
dded
. A
�er d
ryin
g, th
e su
bsta
nce
is po
wde
red.
Visc
um A
biet
is V
iscum
alb
um L
. A
queo
us e
xtra
ct p
repa
red
from
the
fres
h pl
ant o
f Visc
um a
lbum
ssp.
abi
etis
(Wi-
esb.
) Jan
ch. (
Hos
t tre
e: A
bies
alb
a M
ill.;
�r tr
ee),
prep
ared
acc
ordi
ng to
APC
7.2
.2.
Visc
um a
lbum
(04.
06.1
986)
Visc
um M
ali
Visc
um a
lbum
L.
Ferm
ente
d aq
ueou
s ext
ract
pre
pare
d fr
om th
e fr
esh
plan
t exc
ludi
ng h
aust
oriu
m
of V
iscum
alb
um ss
p. a
lbum
L. (
Hos
t tre
e: M
alus
dom
estic
a Bo
ekh.
; app
le tr
ee),
prep
ared
acc
ordi
ng to
APC
7.2
.3.
Visc
um M
ali
Visc
um a
lbum
L.
Aqu
eous
ext
ract
pre
pare
d fr
om th
e fr
esh
plan
t of V
iscum
alb
um ss
p. a
lbum
L.
(Hos
t tre
e: M
alus
dom
estic
a Bo
ekh.
; app
le tr
ee),
prep
ared
acc
ordi
ng to
APC
7.2
.2.
Visc
um M
ali c
um
Arg
ento
Visc
um a
lbum
L. /
A
rgen
ti ca
rbon
asFe
rmen
ted
aque
ous e
xtra
ct p
repa
red
from
the
fres
h pl
ant e
xclu
ding
hau
stor
ium
of
Visc
um a
lbum
ssp.
alb
um L
. (H
ost t
ree:
Mal
us d
omes
tica
Boek
h.; a
pple
tree
) with
ad
ditio
n of
silv
er c
arbo
nate
(2x1
0-5 m
g pe
r 100
mg
fres
h pl
ant),
pre
pare
d ac
cord
ing
to A
PC 7
.2.4
.
Visc
um a
lbum
c. A
rg.
(DA
Z N
r. 29
, 21.
07.1
994)
Visc
um M
ali c
um
Cupr
oV
iscum
alb
um L
. / C
upri
carb
onas
(m
alac
hite
)
Ferm
ente
d aq
ueou
s ext
ract
pre
pare
d fr
om th
e fr
esh
plan
t exc
ludi
ng h
aust
oriu
m
of V
iscum
alb
um ss
p. a
lbum
L. (
Hos
t tre
e: M
alus
dom
estic
a Bo
ekh.
; app
le tr
ee)
with
add
ition
of c
oppe
r car
bona
te (m
alac
hite
) (2x
10-5
mg
per 1
00 m
g fr
esh
plan
t),
prep
ared
acc
ordi
ng to
APC
7.2
.4.
Visc
um a
lbum
c. C
u(D
AZ
Nr.
29, 2
1.07
.199
4)
Visc
um M
ali c
um
Hyd
rarg
yro
Visc
um a
lbum
L. /
H
ydra
rgyr
i sul
fas
Ferm
ente
d aq
ueou
s ext
ract
pre
pare
d fr
om th
e fr
esh
plan
t exc
ludi
ng h
aust
oriu
m o
f V
iscum
alb
um ss
p. a
lbum
L. (
Hos
t tre
e: M
alus
dom
estic
a Bo
ekh.
; app
le tr
ee) w
ith
addi
tion
of m
ercu
ry su
lfate
(2x1
0-5 m
g pe
r 100
mg
fres
h pl
ant),
pre
pare
d ac
cord
ing
to A
PC 7
.2.4
.
Visc
um a
lbum
c. H
g(D
AZ
Nr.
29, 2
1.07
.199
4)
• Appendix 2.6
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
179
Nam
e of t
he su
bsta
nce
Scie
nti�
c nam
e of
ingr
edie
nts
Prep
arat
ion
met
hod
Exem
plar
y ref
eren
ce fo
r use
in an
thro
poso
phic
m
edic
ine
KC M
onog
raph
(dat
e)O
ther
Visc
um P
ini
Visc
um a
lbum
L.
Ferm
ente
d aq
ueou
s ext
ract
pre
pare
d fr
om th
e fr
esh
plan
t exc
ludi
ng h
aust
oriu
m o
f V
iscum
alb
um ss
p. au
stria
cum
(Wie
sb.)
Vollm
ann
(Hos
t tre
e: P
inus
sylv
estr
is L.
; pi
ne),
prep
ared
acc
ordi
ng to
APC
7.2
.3.
Visc
um a
lbum
(04.
06.1
986)
Visc
um P
ini
Visc
um a
lbum
L.
Aqu
eous
ext
ract
pre
pare
d fr
om th
e fr
esh
plan
t of V
iscum
alb
um ss
p. au
stria
cum
(W
iesb
.) Vo
llman
n (H
ost t
ree:
Pin
us sy
lves
tris
L.; p
ine)
, pre
pare
d ac
cord
ing
to A
PC
7.2.
2.V
iscum
Pin
i cum
A
rgen
toV
iscum
alb
um L
. /
Arg
enti
carb
onas
Ferm
ente
d aq
ueou
s ext
ract
pre
pare
d fr
om th
e fr
esh
plan
t exc
ludi
ng h
aust
oriu
m
of V
iscum
alb
um ss
p. au
stria
cum
(Wie
sb.)
Vollm
ann
(Hos
t tre
e: P
inus
sylv
estr
is L.
; pin
e) w
ith a
dditi
on o
f silv
er c
arbo
nate
(2x1
0-5 m
g pe
r 100
mg
fres
h pl
ant)
, pr
epar
ed a
ccor
ding
to A
PC 7
.2.4
.
Visc
um a
lbum
c. A
rg.
(DA
Z N
r. 29
, 21.
07.1
994)
Visc
um P
ini c
um C
upro
Visc
um a
lbum
L.
/ Cup
ri ca
rbon
as
(mal
achi
te)
Ferm
ente
d aq
ueou
s ext
ract
pre
pare
d fr
om th
e fr
esh
plan
t exc
ludi
ng h
aust
oriu
m o
f V
iscum
alb
um ss
p. a
lbum
L. (
Hos
t tre
e: P
inus
sylv
estr
is L.
; pin
e) w
ith a
dditi
on o
f co
pper
car
bona
te (m
alac
hite
) (2x
10-5
mg
per 1
00 m
g fr
esh
plan
t), p
repa
red
acco
rd-
ing
to A
PC 7
.2.4
.
Visc
um a
lbum
c. C
u(D
AZ
Nr.
29, 2
1.07
.199
4)
Visc
um P
ini c
um
Hyd
rarg
yro
Visc
um a
lbum
L. /
H
ydra
rgyr
i sul
fas
Ferm
ente
d aq
ueou
s ext
ract
pre
pare
d fr
om th
e fr
esh
plan
t exc
ludi
ng h
aust
oriu
m o
f V
iscum
alb
um ss
p. au
stria
cum
(Wie
sb.)
Vollm
ann
(Hos
t tre
e: P
inus
sylv
estr
is L.
; pi
ne) w
ith a
dditi
on o
f mer
cury
sulfa
te (1
0-5 m
g pe
r 100
mg
fres
h pl
ant),
pre
pare
d ac
cord
ing
to A
PC 7
.2.4
.
Visc
um a
lbum
c. H
g(D
AZ
Nr.
29, 2
1.07
.199
4)
Visc
um Q
uerc
iV
iscum
alb
um L
. Fe
rmen
ted
aque
ous e
xtra
ct p
repa
red
from
the
fres
h pl
ant e
xclu
ding
hau
stor
ium
of
Visc
um a
lbum
ssp.
alb
um L
. (H
ost t
ree:
Que
rcus
robu
r L.,
Que
rcus
pet
raea
(Mat
t.)
Lieb
l.; o
ak),
prep
ared
acc
ordi
ng to
APC
7.2
.3.
Visc
um a
lbum
(04.
06.1
986)
Visc
um Q
uerc
i cum
A
rgen
toV
iscum
alb
um L
. /
Arg
enti
carb
onas
Ferm
ente
d aq
ueou
s ext
ract
pre
pare
d fr
om th
e fr
esh
plan
t exc
ludi
ng h
aust
oriu
m o
f V
iscum
alb
um ss
p. a
lbum
L. (
Hos
t tre
e: Q
uerc
us ro
bur L
., Q
uerc
us p
etra
ea (M
att.)
Li
ebl.;
oak
) with
add
ition
of s
ilver
car
bona
te (1
0-5 m
g pe
r 100
mg
fres
h pl
ant),
pr
epar
ed a
ccor
ding
to A
PC 7
.2.4
.
Visc
um a
lbum
c. A
rg.
(DA
Z N
r. 29
, 21.
07.1
994)
Visc
um Q
uerc
i cum
Cu
pro
Visc
um a
lbum
L.
/ Cup
ri ca
rbon
as
(mal
achi
te)
Ferm
ente
d aq
ueou
s ext
ract
pre
pare
d fr
om th
e fr
esh
plan
t exc
ludi
ng h
aust
oriu
m o
f V
iscum
alb
um ss
p. a
lbum
L. (
Hos
t tre
e: Q
uerc
us ro
bur L
., Q
uerc
us p
etra
ea (M
att.)
Li
ebl.;
oak
) with
add
ition
of c
oppe
r car
bona
te (m
alac
hite
) (10
-5 m
g pe
r 100
mg
fres
h pl
ant),
pre
pare
d ac
cord
ing
to A
PC 7
.2.4
.
Visc
um a
lbum
c. C
u(D
AZ
Nr.
29, 2
1.07
.199
4)
Visc
um Q
uerc
i cum
H
ydra
rgyr
oV
iscum
alb
um L
. /
Hyd
rarg
yri s
ulfa
sFe
rmen
ted
aque
ous e
xtra
ct p
repa
red
from
the
fres
h pl
ant e
xclu
ding
hau
stor
ium
of
Visc
um a
lbum
ssp.
alb
um L
. (H
ost t
ree:
Que
rcus
robu
r L.,
Que
rcus
pet
raea
(Mat
t.)
Lieb
l.; o
ak) w
ith a
dditi
on o
f mer
cury
sulfa
te (1
0-5 m
g pe
r 100
mg
fres
h pl
ant),
pr
epar
ed a
ccor
ding
to A
PC 7
.2.4
.
Visc
um a
lbum
c. H
g(D
AZ
Nr.
29, 2
1.07
.199
4)
Visc
um U
lmi c
um
Hyd
rarg
yro
Visc
um a
lbum
L. /
H
ydra
rgyr
i sul
fas
Ferm
ente
d aq
ueou
s ext
ract
pre
pare
d fr
om th
e fr
esh
plan
t exc
ludi
ng h
aust
oriu
m o
f V
iscum
alb
um ss
p. a
lbum
L. (
Hos
t tre
e: U
lmus
cap
rinifo
lia G
led.
[Ulm
us c
ampe
s-tr
is L.
], U
lmus
gla
bra
Hud
s.; el
m) w
ith a
dditi
on o
f mer
cury
sulfa
te (1
0-5 m
g pe
r 100
m
g fr
esh
plan
t), p
repa
red
acco
rdin
g to
APC
7.2
.4.
Visc
um a
lbum
c. H
g(D
AZ
Nr.
29, 2
1.07
.199
4)
• Ap
pend
ix 2
.6
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
180
• Appendix II
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
181
APPENDIX II
Correlation table: Ph.Eur./HAB manufacturing methods used in anthroposophic pharmacy and corresponding manufacturing methods in the HPUS
• Ap
pend
ix II
• Appendix II
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
182
Ph. E
ur. /
HA
B m
etho
ds u
sed
in
anth
ropo
soph
ic p
harm
acy
Cor
resp
ondi
ng m
anuf
actu
ring
in th
e H
PUS
Ph. E
ur. M
etho
d 1.
1.1
(HA
B 1a
)Ph
. Eur
. Met
hod
1.1.
2 (H
AB
1b)
Cla
ss O
Ph. E
ur. M
etho
d 1.
1.3
(HA
B 2a
)Ph
. Eur
. Met
hod
1.1.
4 (H
AB
2b)
Cla
ss M
Ph. E
ur. M
etho
d 1.
1.5
(HA
B 3a
)Ph
. Eur
. Met
hod
1.1.
6 (H
AB
3b)
Ph. E
ur. M
etho
d 1.
1.7
(HA
B 3c
)
Cla
ss N
Ph. E
ur. M
etho
d 1.
1.8
(HA
B 4a
)C
lass
C
Ph. E
ur. M
etho
d 1.
1.9
(HA
B 4b
)C
lass
E
Ph. E
ur. M
etho
d 1.
1.10
(Ph.
fr.)
No
corr
espo
ndin
g H
PUS
met
hod
for a
ttenu
atio
ns, t
houg
h C
lass
C is
the
sam
e pr
oces
s for
the
first
step
1
Ph. E
ur. M
etho
d 1.
1.11
(Ph.
fr.)
No
corr
espo
ndin
g H
PUS
met
hod
for a
ttenu
atio
ns, t
houg
h C
lass
D is
the
sam
e pr
oces
s for
the
first
step
2
Ph. E
ur. M
etho
d 3.
1.1
(HA
B 5a
)C
lass
A o
r Cla
ss B
, dep
endi
ng o
n so
lubi
lity
Cha
ract
erist
ics o
f the
star
ting
mat
eria
l
Ph. E
ur. M
etho
d 3.
1.2
(HA
B 5b
)C
lass
A o
r Cla
ss B
, dep
endi
ng o
n so
lubi
lity
Cha
ract
erist
ics o
f the
star
ting
mat
eria
l
Ph. E
ur. M
etho
d 4.
1.1
(HA
B 6)
Cla
ss F
Ph. E
ur. M
etho
d 4.
1.2
(Ph.
fr.)
Cla
ss F
Ph. E
ur. M
etho
d 4.
2.1
(HA
B 7)
“Med
icat
ion:
Med
icat
ed P
owde
rs” a
pplie
s for
cent
esim
al, b
ut n
ot fo
r dec
imal
atte
nuat
ions
3
Ph. E
ur. M
etho
d 3.
2.1
(HA
B 8a
)Ph
. Eur
. Met
hod
3.2.
2 (H
AB
8b)
Cla
ss H
1 �
e Ph
. Eur
. Met
hod
1.1.
10 p
rodu
ces a
1:1
0 pr
epar
atio
n fr
om w
hich
the
D1
or C
1 is
mad
e. �
e H
PUS
Cla
ss C
also
pro
duce
s a 1
:10
prep
arat
ion.
But
this
is co
nsid
-er
ed th
e sa
me
as a
D1.
�us
, Ph.
Eur
. Met
hod
1.1.
10 D
1 =
HPU
S D
2. F
or th
is re
ason
, the
met
hods
do
not c
orre
spon
d.2
�e
Ph. E
ur. M
etho
d 1.
1.11
pro
duce
s a 1
:20
prep
arat
ion
from
whi
ch th
e D
1 or
C1
is m
ade.
�e
HPU
S C
lass
D a
lso p
rodu
ces a
1:2
0 pr
epar
atio
n. B
ut th
e C
lass
D
prep
arat
ion
is th
en at
tenu
ated
2 p
arts
+ 8
par
ts v
ehic
le to
pro
duce
the
D2.
�e
prep
arat
ion
by P
h. E
ur. M
etho
d 1.
1.11
is at
tenu
ated
1 p
art +
9 p
arts
veh
icle
to p
rodu
ce
the
D1.
For
this
reas
on, t
he m
etho
ds d
o no
t cor
resp
ond.
3 H
PUS
“Med
iate
d Po
wde
rs” a
re sp
eci�
ed to
be
mad
e fr
om 1
par
t liq
uid
prep
arat
ion
+ 10
0 pa
rts v
ehic
le.
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Ap
pend
ix II
183
Ph. E
ur. /
HA
B m
etho
ds u
sed
in
anth
ropo
soph
ic p
harm
acy
Cor
resp
ondi
ng m
anuf
actu
ring
in th
e H
PUS
HA
B M
etho
d 9
“Med
icat
ion:
Tab
lets”
HA
B M
etho
d 10
“Med
icat
ion:
Glo
bule
s”
HA
B M
etho
d 11
“For
ms o
f veh
icle
s for
disp
ensin
g”
HA
B M
etho
d 12
a“F
orm
s of v
ehic
les f
or d
ispen
sing”
HA
B M
etho
d 12
bC
lass
M
HA
B M
etho
d 13
“For
ms o
f veh
icle
s for
disp
ensin
g”
HA
B M
etho
d 14
“For
ms o
f veh
icle
s for
disp
ensin
g”
HA
B M
etho
d 15
“For
ms o
f veh
icle
s for
disp
ensin
g: O
phth
alm
ic S
olut
ions
”
HA
B M
etho
d 16
New
Sec
tion
39, a
nd “I
ntro
duct
ion
to th
e H
omoe
opat
hic P
harm
acop
oeia
of t
he U
nite
d St
ates
: St
atem
ent r
egar
ding
com
bina
tions
of h
omoe
opat
hic d
rugs
”H
AB
Met
hod
17“A
ttenu
atio
ns: F
ifty
Mill
esim
al S
cale
of A
ttenu
atio
n”
HA
B M
etho
d 18
a-b
Cla
ss M
, “Ti
nctu
res o
f bot
anic
al su
bsta
nces
: Inc
ubat
ion”
HA
B M
etho
ds 1
8c-e
Cla
ss N
, “Ti
nctu
res o
f bot
anic
al su
bsta
nces
: Inc
ubat
ion”
HA
B M
etho
ds 1
8fC
lass
C, “
Tinc
ture
s of b
otan
ical
subs
tanc
es: I
ncub
atio
n”
HA
B M
etho
ds 1
9a-b
Cla
ss M
, “Ti
nctu
res o
f bot
anic
al su
bsta
nces
: Dec
octio
n”
HA
B M
etho
ds 1
9c-e
Cla
ss N
, “Ti
nctu
res o
f bot
anic
al su
bsta
nces
: Dec
octio
n”
HA
B M
etho
d 19
fC
lass
C, “
Tinc
ture
s of b
otan
ical
subs
tanc
es: D
ecoc
tion”
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Appendix II
184
Ph. E
ur. /
HA
B m
etho
ds u
sed
in a
nthr
opos
ophi
c ph
arm
acy
Cor
resp
ondi
ng m
anuf
actu
ring
in th
e H
PUS
HA
B M
etho
d 20
Cla
ss C
, “Ti
nctu
res o
f bot
anic
al su
bsta
nces
: Inf
usio
n”
HA
B M
etho
d 21
Cla
ss O
, fer
men
ted
HA
B M
etho
d 22
Cla
ss P
HA
B M
etho
d 23
aC
lass
C, “
Tinc
ture
s of b
otan
ical
subs
tanc
es: D
ecoc
tion”
HA
B M
etho
d 23
bC
lass
N, “
Tinc
ture
s of b
otan
ical
subs
tanc
es: D
ecoc
tion”
HA
B M
etho
d 24
aC
lass
C, “
Tinc
ture
s of b
otan
ical
subs
tanc
es: I
nfus
ion”
HA
B M
etho
ds 3
3C
lass
P
HA
B M
etho
ds 3
4C
lass
P
HA
B M
etho
ds 3
5C
lass
P
HA
B M
etho
ds 3
6C
lass
P
Ph. E
ur. M
etho
d 5.
1.1
(HA
B 40
a)Ph
. Eur
. Met
hod
5.1.
2 (H
AB
40b)
Ph. E
ur. M
etho
d 5.
1.3
(HA
B 40
c)
No
corr
espo
ndin
g m
etho
d
Ph. E
ur. M
etho
d 2.
1.1
(HA
B 42
a)Ph
. Eur
. Met
hod
2.1.
2 (H
AB
42b)
Cla
ss L
, Met
hod
II
Ph. E
ur. M
etho
d 2.
1.3
(Ph.
fr.)
No
corr
espo
ndin
g m
etho
d
Ph. E
ur. M
etho
d 2.
2.1
(HA
B 41
a)Ph
. Eur
. Met
hod
2.2.
2 (H
AB
41b)
Ph. E
ur. M
etho
d 2.
2.3
(HA
B 41
c)Ph
. Eur
. Met
hod
2.2.
4 (H
AB
41d)
Cla
ss L
, Met
hod
II (a
ltern
ate
met
hodo
logy
)
HA
B M
etho
ds 4
5“F
orm
s of
veh
icle
s for
disp
ensin
g: N
asal
Sol
utio
ns”
HA
B M
etho
ds 5
1C
lass
P
ANTHROPOSOPHIC PHARMACEUTICAL CODEX APC 3.0
• Ap
pend
ix II
185